<SEC-DOCUMENT>0001104659-25-107349.txt : 20251106
<SEC-HEADER>0001104659-25-107349.hdr.sgml : 20251106
<ACCEPTANCE-DATETIME>20251106070020
ACCESSION NUMBER:		0001104659-25-107349
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251106
DATE AS OF CHANGE:		20251106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProQR Therapeutics N.V.
		CENTRAL INDEX KEY:			0001612940
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36622
		FILM NUMBER:		251456048

	BUSINESS ADDRESS:	
		STREET 1:		ZERNIKEDREEF 9
		CITY:			LEIDEN
		STATE:			P7
		ZIP:			2333 CK
		BUSINESS PHONE:		31 88 166 7000

	MAIL ADDRESS:	
		STREET 1:		ZERNIKEDREEF 9
		CITY:			LEIDEN
		STATE:			P7
		ZIP:			2333 CK

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ProQR Therapeutics B.V.
		DATE OF NAME CHANGE:	20140708
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>prqr-20250930x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 11/4/2025 03:07:48 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">FORM&#160;6-K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Report of Foreign Private Issuer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Rule&#160;13a-16 or 15d-16 of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">November 6, 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Commission File Number: 001-36622</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">PROQR THERAPEUTICS N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Zernikedreef 9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">2333 CK Leiden</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">The Netherlands</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Tel: +31 88 166 7000</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">(Address,&#160;Including ZIP Code, and Telephone Number,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;"> Including Area Code, of Registrant&#8217;s Principal Executive Offices)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#160;20-F or Form&#160;40-F.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">Form&#160;20-F&#160; </font><font style="font-family:'Times New Roman';font-size:12pt;">&#8999;</font><font style="font-size:12pt;">&#160; Form&#160;40-F&#160; </font><font style="font-family:'Times New Roman';font-size:12pt;">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation S-T Rule&#160;101(b)(1):&#160; </font><font style="font-family:'Times New Roman';font-size:12pt;">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation S-T Rule&#160;101(b)(7):&#160; </font><font style="font-family:'Times New Roman';font-size:12pt;">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Furnished as Exhibit 99.1 to this Report on Form 6-K are the unaudited financial statements of ProQR Therapeutics N.V. (the &#8220;Company&#8221;) for the three and nine-month periods ended September 30, 2025, and furnished as Exhibit 99.2 to this Report on Form 6-K is a press release of ProQR Therapeutics N.V. dated November 6, 2025, announcing the Company&#8217;s results for the three and nine-month periods ended September 30, 2025.&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">On November 6, 2025, the Company issued a press release titled, &#8220;ProQR Announces Third Quarter 2025 Operating and Financial Results,&#8221; announcing the Company&#8217;s results for the three and nine-month periods ended September 30, 2025 and providing a business update. A copy of this press release is attached hereto as Exhibit&#160;99.2 and is incorporated herein by reference. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">ProQR hereby incorporates by reference the information contained herein into ProQR&#8217;s registration statements on Form&#160;F-3 (File No.&#160;333-282419, File No.&#160;333-270943, File No.&#160;333-263166 and File No.&#160;333-285767).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">INDEX TO EXHIBITS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:89.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:8.79%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:1.72%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:89.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">99.1</font></p></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:12pt;" href="prqr-20250930xex99d1.htm"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Unaudited financial statements of ProQR Therapeutics N.V. for the three and nine-month periods ended September 30, 2025.</font></a></p></td></tr><tr><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">99.2</font></p></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:12pt;" href="prqr-20250930xex99d2.htm"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release of ProQR Therapeutics N.V. dated November 6, 2025, announcing the Company&#8217;s results for the three and nine-month periods ended September 30, 2025.</font></a></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">PROQR THERAPEUTICS N.V.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date: November 6, 2025</font></p></td><td style="vertical-align:bottom;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:45.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Dennis Hom</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Dennis Hom</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>prqr-20250930xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.1.0.0 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 11/4/2025 3:07:50 PM -->
<!-- iXBRL Library version: 1.0.9397.4506 -->
<!-- iXBRL Service Job ID: e7ecb113-b702-481b-ac85-304d20403e91 -->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:prqr="http://www.proqr.com/20250930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>ProQR Therapeutics N.V._2025-09-30</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="dei:EntityCentralIndexKey" id="Tc_zSjLbJXv_UGKsGIyg1Sl8Q_2_1">0001612940</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="dei:CurrentFiscalYearEndDate" id="Tc_Hs17U_KiTUWAbGefjwv2UA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="dei:DocumentFiscalYearFocus" id="Tc_lxzQgqV3jk2T4MMt8-5VBw_4_1">2025</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="dei:DocumentFiscalPeriodFocus" id="Tc_XUy2uYK_XUeMZVs26cUJPw_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="dei:AmendmentFlag" id="Tc_LOOGAOmpqUaYvPCN3O-boA_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="dei:EntityRegistrantName" id="Tc_ejJZIjULsEy8Qa81jJfomw_7_1">ProQR Therapeutics N.V.</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="dei:DocumentType" id="Tc_5PiMSMYdFUu8w54GRgDWpg_8_1">6-K</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="dei:DocumentPeriodEndDate" id="Tc_ntZAHLvz5kC47rW3vwiIqw_9_1">2025-09-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2020_To_7_1_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember__5Hj4Avi-0abIwNa79N03w" name="prqr:LeaseTerm" id="Hidden_1k_9dkbIBE6F9vmNuzcVIw">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2020_To_7_1_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember__5Hj4Avi-0abIwNa79N03w" name="prqr:LeaseTerm" id="Hidden_9sghCigMRE-91luzw8kAXw">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_12_1_2020_To_12_31_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_mQAGEX8GEkW-yeLTTQ4VGA" name="prqr:LeaseTerm" id="Hidden_zMWif57Oekmju6l1QF4dVQ">P11Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_DDyp30oG70y9MAT2AAkBnw" name="prqr:LeaseCurrentExtensionPeriodUnderOption" id="Hidden__Ne-iWIfzU6QAPw9QT7ObQ">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_flCTEjbcz066k8F4PCLrew" name="prqr:DurationOfUnderwritersOption" id="Hidden_SBfXi-xh50yWDW8Jo_eMMQ">P30D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="prqr-20250930.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_9_1_2022_To_9_30_2022_prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_prqr_PontifaxAndKreosWarrantsMember_QDqtNs1aIEi1heNwMkeeNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="prqr:IfrsClassesOfWarrantsOrRightsAxisAxis">prqr:PontifaxAndKreosWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_b5MiuBOLvkiPnH8dj15XoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:SharePurchaseAgreementWithEliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_dbgoR6vcMUqTMO3jvVhl5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_iVCbzNhSAkCnatzraPCD8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_ShelfRegistrationStatement2024Member_ng7Fbf6gFUy4vNzZAU2odA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:ShelfRegistrationStatement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_sHnEGchkcEymfM1vdGke-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_2f19mTxVb0akP73Sa_oSQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:RettSyndromeResearchTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_7_1_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember__5Hj4Avi-0abIwNa79N03w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">prqr:OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_mQAGEX8GEkW-yeLTTQ4VGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">prqr:OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_DDyp30oG70y9MAT2AAkBnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">prqr:OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_5PEUyinG3kmhHLSlPJV_1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_fkkBmmdVaESJHda3nXUU-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_SQEbr7EQSkStP6J8wDVlYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-31</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_prqr_IfrsSaleOfStockAxis_prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_PGd6rcr3S0i-F2HTv9iGJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_xZ1UKhJoMEuxAabw7b7dlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:RettSyndromeResearchTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_flCTEjbcz066k8F4PCLrew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_PoXgbyj0VEimJfqnnq8vXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_2suHy2Uqqkq-b7CLFUL2lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_YJJKCH6_f0CGHWEK670wpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_Ps4wlpTyCk-CiG6i9mnIJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">prqr:OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_pMfe7-CYZkSkMiFKJi9Z7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">prqr:OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_wm8LBrxXCkyzFCS9TM0Eaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_0tkeXgS6dkGzbdukDKq5tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:RettSyndromeResearchTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2023_To_2_28_2023_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_ifrs-full_ProductsAndServicesAxis_prqr_MilestonePaymentsMember_8ueA1NVJtEa4bfujUxBP3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">prqr:MilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GmQU-y9rwk-z-77kvpEtVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViiiBvMember_VdFaX-IgmUWXDhT8Sj91cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsViiiB.v.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViiBvMember_vOqWyc0GxkKVzCAG4aDgJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsViiB.v.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViBvMember_Eg_4tvfBoUCuq-QPluHQsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsViB.v.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsVBvMember_XAFpvyId2k2r7a7zNVEohA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsVB.v.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIxBvMember_8b6o2YoKLUWPL-vDhftrUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIxB.v.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIvBvMember_TGiLF5LfiUGZLR-qDsOFtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIvB.v.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIIncMember_ECpwoHs8RUyCW8sNiNEueg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIiiBvMember_fK1FbaT8-k-4CxcnPUyGNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIiiB.v.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIiBvMember_0sZHnPkpQUib6ZcDTeKIPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIiB.v.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIBvMember_rEz99sZOpEOeeXyEDeM7bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIB.v.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsHoldingBvMember_O8oNddjWmkC-HAijvKH37g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsHoldingB.v.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_25_2024_To_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_1SV3IDfQekeRE9nHK-mnpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:SharePurchaseAgreementWithEliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-25</xbrli:startDate><xbrli:endDate>2024-10-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_m4ViI6b7i0S1NobB07mbHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:October2024UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_dgOq00RA5UyztuNQFmTsMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_G4ICZ7yXkk65BgEHTs4AlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_-bqBRBYnMkqbwyTudO1CSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_MWf62Mctg0SEca73DdSQSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_12_2018_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_lbY8fExZj0i3II_9Pf9fhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_Jm0ycghQx06aKQaV-XaMYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_U0bIiWfTwUK2UDFOYXKvcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_uPUa2i_7MkuFypR4I9OjUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_IsxdhpKNBUWj5naxXv5zDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_z8mrJ_XS20OdmQRuFtWhnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_iwf40QnTJ0m4Vo8mAlujCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_08ltvoMrCUOhqccsXSmSpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_D3VJA-2yEka_L4CJUP1bwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_YarrowBiotechnologyMember_9ABsPfcrBEWgLl8UM2SqAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">prqr:YarrowBiotechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_yg5IGweIK0qeV0bYXpRQJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">prqr:PhoenicisTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_YarrowBiotechnologyMember_16WLvw49kkCNj0VZA6LAug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">prqr:YarrowBiotechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_Px873arFI0yxw9TbKLJcIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">prqr:PhoenicisTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_NBruH9iPUEO1qm4ppbYCPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">prqr:IfrsSellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsResearchAndDevelopmentExpenseMember_tcUIS9w0g0CCeSma1Lfl1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">prqr:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_JxIfwdbS8kWh6YPJlU9p3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">prqr:IfrsSellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsResearchAndDevelopmentExpenseMember_cdQDW243CEmqV7EBFQBmvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">prqr:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_xVLmQv70tkmTWrXUzZkHoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_asbCzlcqMkyM5w2Y3PRbqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_DsMV-YDBnUK76VIPgik0-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_VwVPNTRKjka_upzN4CwLew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_SMbLKd34R0KfHuM4rpeilg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_oQrhBR2oxUapLnyLuIArqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_0mrf-R_XY0yzUG8OnKrkDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_RJ5IIuOtWE6SDgrSyS_t2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_9QFRxe8qfUmtwOQ_FsyrEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_II-Ovg3YckajeIRdrZzZKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_YmG5mam2kU6LZGJw23cDuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_wqiJlNiVCU6R8R3Fcw6cCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_TG6NHlq740CXHuiR9mTbLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_xzfXEnJ9DEuEVu_FmD7uuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_77JK05vzLU-X-WnDU8wcDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_e5T6UVKy1ki9ZfWxfnjDhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_7CEaesH_rUeFoouKWkTtcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_4xDxWcNmjEeMIATjnOIb_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_OFftNnWG-UGZ6tREcP4ijw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AcgFrNkamkCvsd1bQi1WLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_hWA0MWK6lUqB0UHEeVamnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_EeQqadGBPU6ffQXEFmCknA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:RettSyndromeResearchTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_z_wMRuiDMEqEinzBTRrmJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_rPv_1PsZlkyKXSb6IKaW-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:RettSyndromeResearchTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_N0cWD2q4NkeY3A32UZEFqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_i0u4-QQ5ZU-UjEoLiyQsHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_g29o3Zo7Ak-Bxlwv8XcO8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ZHbkuA8ZZEC6p9HbY3sb1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_7SqLUGM3Ck68Fx8rYXnMKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqm_Oc_SVpN4d0OQM3FvR-NrfQ"><xbrli:measure>utr:sqm</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_iAZ-erTqcEibFQQvKQuMIg"><xbrli:measure>prqr:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_q_6SzVvYpE-NdnoAmmu_UA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gDmQDSG3yE2YgRihCX1JZQ_38_8" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_pJYcw-P9VUK36cFJsz2OXw_38_4" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_s4p3Rj1sNEei8rE1UMUcwg_38_6" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_TX_OmuqLh0S8PKxDqpOTOA_38_2" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_s9xCNhJU7UyUXkbd8wzU2A_39_8" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_6LEmXJeSm0qw3i_R36LS0w_39_4" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_rAltVSr5REaA_gZkXcxqmw_39_6" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_3xdgtgdroEqBdaprFuW2zw_39_2" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_8_yNxwVA80GtQtAVy9Qlig_35_8" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_dz8HPvqgH0SMB3BaCxeXZg_35_4" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_6mdFNphE1kOtUlwBgZLI_w_35_6" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_4OyBA5NKzE-knRZJUAf3Dg_35_2" toRefs="_6bcb422b_dd88_4484_a93e_66423de002bd" order="1"/></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2e404062_5ce1_4d39_86f2_424112cbd44e"></a><a id="TOC"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">PROQR THERAPEUTICS&#160;N.V.</b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;"><br/></b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">Index to Unaudited Condensed Consolidated Financial Statements</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:94.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:94.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">&#160;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">PAGE</span></p></td></tr><tr><td style="vertical-align:top;width:94.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Open Sans';font-size:9pt;" href="#Statement_of_Financial_Position"><span style="font-style:normal;font-weight:normal;">Unaudited Condensed Consolidated Statement of Financial Position at September 30, 2025 and December 31, 2024</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;">1</span></p></td></tr><tr><td style="vertical-align:top;width:94.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Open Sans';font-size:9pt;" href="#Statement_of_Profit_or_Loss_and_OCI"><span style="font-style:normal;font-weight:normal;">Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three and Nine Month Periods ended September 30, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;">2</span></p></td></tr><tr><td style="vertical-align:top;width:94.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Open Sans';font-size:9pt;" href="#Statement_of_Changes_in_Equity"><span style="font-style:normal;font-weight:normal;">Unaudited Condensed Consolidated Statement of Changes in Equity for the Nine Month Periods Ended September&#160;30, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;">3</span></p></td></tr><tr><td style="vertical-align:top;width:94.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Open Sans';font-size:9pt;" href="#Statement_of_Cash_Flows"><span style="font-style:normal;font-weight:normal;">Unaudited Condensed Consolidated Statement of Cash Flows for the Three and Nine Month Periods ended September 30, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;">4</span></p></td></tr><tr><td style="vertical-align:top;width:94.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-family:'Open Sans';font-size:9pt;" href="#NotestoUnauditedCondensedConsolidatedFin"><span style="font-style:normal;font-weight:normal;">Notes to Unaudited Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;">5</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:0pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">1</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_47b4861f_6833_4d45_ac79_7af2551ea3b2"></a><a id="Statement_of_Financial_Position"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 4pt 0pt;"><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">PROQR THERAPEUTICS N.V.</b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;"><br/></b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">Unaudited Condensed Consolidated Statement of Financial Position</b></p><a id="_f4161316_0429_45ac_a129_89fd4a989a79"></a><a id="Tc__MNAlksPX0ijh6BIN-jJJQ_1_2"></a><a id="Tc_XkZezKS3q0qM4DNbl5SGNA_1_4"></a><a id="Tc_3c5LN2aV5USnFEbXyG2iCA_2_2"></a><a id="Tc_BzLPIyuk4EKauiSNAL9QEA_2_4"></a><a id="Tc_EcFGmKxb7keN39nFGU-L3w_3_2"></a><a id="Tc_vQLxdbRwbkSDnesfFk7HSQ_3_4"></a><a id="Tc_y8oqy2z210eHLixEVl8csg_4_0"></a><a id="Tc_XQgwJq8sNUCIBKNV9lZx-g_5_0"></a><a id="Tc_uesqDNvc8Uu962k-SfSm7w_5_1"></a><a id="Tc_8wnl8_pYwkuD8JY8_mvm-g_6_0"></a><a id="Tc_ogk0Trwa9kCkZkQzbDI0Wg_6_1"></a><a id="Tc_HlIC1DlQSkaTDY1JMMHOSg_6_2"></a><a id="Tc_23_rB3_m10CdOxq4IPcGdw_6_4"></a><a id="Tc_eucj2ZHNs0q_P0G9iW67uw_7_0"></a><a id="Tc_EUM4WfmE00yfEFuCdme3sQ_9_0"></a><a id="Tc_0hrceoHiY02csDo3nB9I1w_9_1"></a><a id="Tc_mQPdZsqUjkaLcFvMXK-2Mw_10_0"></a><a id="Tc_YQPeHFpSoEe5_CTig94h2w_10_1"></a><a id="Tc_dIHsKwyN3UqnRL8Kmyby2g_11_0"></a><a id="Tc_2qNWJu1UrEymlI8GyhO1pQ_12_0"></a><a id="Tc_2X1M5CYOU0KJd8Mnu7KGrA_13_0"></a><a id="Tc_Piw_zsHHS0i6KhPOCUaFDg_15_0"></a><a id="Tc_o-hfNfUZxESY_uxaIs8x0g_16_0"></a><a id="Tc_i4YSD3mQQ0GKykI3cyxS7g_17_0"></a><a id="Tc_EWaxKZ5Mb0OWT-6_226u5g_18_0"></a><a id="Tc_l1MV1hf-ekWoEclDIbX24g_18_1"></a><a id="Tc_IFmKhXidCUq0jw3WIru7Zw_20_0"></a><a id="Tc_lNKM_Rke3kelvGqU4Q5zkA_21_0"></a><a id="Tc_-NQjosWroki1gKi6I8yBaA_21_1"></a><a id="Tc_qqgivNCvEkmTtqvuBRDzSw_21_2"></a><a id="Tc_CV8wiD1EoE6ggy5CONpu3A_21_4"></a><a id="Tc_ljPCri8k5kOZeGVSuUi2rA_22_0"></a><a id="Tc_anu8dwTiLEWEYYhO1VYbiw_22_1"></a><a id="Tc_M6zmO_oaA0q9D-mByvDqrw_23_0"></a><a id="Tc_Fcpkwc6oHEqMcbd-PhMQIg_23_1"></a><a id="Tc_26dyC2bOzUe4Tgzs9tLF-Q_24_0"></a><a id="Tc_cAqKKCicl0K-ukcx16tN0Q_26_0"></a><a id="Tc_7L-kBIlnXEmxGPvQJup5Mw_26_1"></a><a id="Tc_2ItXdaUhOUm-kcMRoFYBww_27_0"></a><a id="Tc_URhwhjYqrky1GVTSi5CAKw_27_1"></a><a id="Tc_B2236RFrqU6BNmJS8-oEMA_28_0"></a><a id="Tc_4COJ1pZkrUqIFCGGl-OR8A_28_1"></a><a id="Tc_nXapagQZB0eJVf3HNlD0ww_29_0"></a><a id="Tc_na2jxr3pKkiWHZXDm2WPRw_30_0"></a><a id="Tc_t7FVyyUt50O55r-YlwoQFA_31_0"></a><a id="Tc__yUF79s7XUmBL82sCH41vw_31_1"></a><a id="Tc_78s-CAamXESw0h0_aEZrPg_32_0"></a><a id="Tc_IrYyUGyVNEWlDhTRT_XaDA_32_1"></a><a id="Tc_YHxCQP_oZUC4grT5hn4h9w_33_0"></a><a id="Tc_dRqmaJKgZ0G29GOr9SW0Hg_34_0"></a><a id="Tc_VLiEccl41kCX8j_hOn6zpQ_36_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.32%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.31%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Property, plant and equipment</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">7</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="Tc_0pgaWSl4KUCGGVm1sBTiMg_5_2">13,018</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="Tc_Tg3x4fq8e0OYlBc9YCTiYA_5_4">14,113</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Investments in financial assets</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">17</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8212; </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_0oPXqRJjYE2cYsGEByIUTQ_7_2">13,018</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_AKdpOnCdGEGrgKl-me1Mrg_7_4">14,113</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Cash and cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">5</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_YiCxvqodUUK8GkQy5WXW2A_9_2">106,883</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_7Rhmvia_Gk2bf2N3zrk1Zg_9_4">149,408</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Prepayments and other receivables</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">6</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="prqr:PrepaymentsAndOtherReceivables" scale="3" id="Tc_85BMUdXt2EmYCZSKGewjXA_10_2">3,872</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="prqr:PrepaymentsAndOtherReceivables" scale="3" id="Tc_vBg3eucyvkqBP_WAu5VjiQ_10_4">3,747</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Other taxes</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="Tc_3k-QXim_tEuV0ZFqfy2CWQ_11_2">576</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="Tc_PNruGeuZU0SH6u1jLIYM4g_11_4">690</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_kk1LGuHUwEWvZJeSw7lkeA_12_2">111,331</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_4boPl6vnuEuUfhXK4SPfpg_12_4">153,845</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" id="Tc_qYmvhGR2OUOkq6Riw6OjUg_13_2">124,349</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" id="Tc_Z5_i61FU7E2TpcQoVc8NGw_13_4">167,958</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Equity attributable to owners of the Company</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" id="Tc_-Ur3mNlm5UmcNTKD_6QSbg_17_2">57,071</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" id="Tc_iK-pywS7MEaEPCg311a7BQ_17_4">88,560</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Total equity</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">12</b></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_lHrj6vMBME2sYjI36I-psw_18_2">57,071</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_zFO5viT5ZUa9WwsSP0GiDw_18_4">88,560</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Borrowings</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">9</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8212; </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">10</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_5WDQAtBf3EWhQL-_N8y4Bg_22_2">10,017</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_WFwAeu12r0Gh3XCnmezWIw_22_4">11,067</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Deferred income</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">11</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" scale="3" id="Tc_z4fg8Pq-KUGrMEnj4ki1Lg_23_2">24,125</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" scale="3" id="Tc_OgZ1O9P1LEif43374A6Q0Q_23_4">29,429</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_zbuIevT22UOaUsXhSGENvw_24_2">34,142</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_AkgXlbfDl0KkJQodF4PQFQ_24_4">40,496</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Borrowings</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">9</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" scale="3" id="Tc_w67wqrIAZUWlWOgV2iFvbQ_26_2">4,800</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" scale="3" id="Tc__d2yKuJGDkmiJ9H7m5iB-g_26_4">4,582</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">10</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_dBhbX5BEfUOXzEdxguPRgg_27_2">1,674</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_R4vuqgbV50KIfxLDN3T0sg_27_4">1,567</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Derivative financial instruments</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">9</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="Tc_MZajUUXzZUmtFt2OCMjk0Q_28_2">292</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="Tc_KwOKN1aDFUWgIV_c1TGITA_28_4">468</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Trade payables</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_5y9zHIbFiEKbyvPqp09g0g_29_2">305</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_r8EP-60fzECQxi2hW7nAEg_29_4">16</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Social securities and other taxes</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" scale="3" id="Tc_8hjzLiJ3mUW70ofSowyUFA_30_2">121</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" scale="3" id="Tc_8da4kROD60aTEibZBQpc6w_30_4">1,478</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Deferred income</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">11</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" scale="3" id="Tc_fWZrIG141EOK8SVtisEEHg_31_2">17,394</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" scale="3" id="Tc_DGz-IyNRA0m2wmRgqHFyzw_31_4">21,942</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="color:#262626;font-family:'Open Sans';">Other current liabilities</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">8</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_UZ20Sd6p2UeAD9Us2F10Dg_32_2">8,550</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_lZ5g5l_u4UeGdmY-8rZXzQ_32_4">8,849</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_IhHpjZNHoESudg5E85PLTg_33_2">33,136</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_L8_Mp3BwtUiincZQsADTRg_33_4">38,902</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="3" id="Tc_u9uJyYQ9YkSG3Ls23dF_MA_34_2">67,278</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="3" id="Tc_j4nsN_jJG0Cc-K-YUQdd3g_34_4">79,398</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.31%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Total equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.95%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_9tonhQf2KUKdGuTUpnBtMw_36_2">124,349</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.62%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_3xVuYuL8Gkq3WTTOhVWYpw_36_4">167,958</ix:nonFraction> </b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">2</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_376be082_155a_4b45_a991_8d2404662d1e"></a><a id="Statement_of_Profit_or_Loss_and_OCI"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">PROQR THERAPEUTICS N.V.</b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;"><br/></b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">Unaudited Condensed Consolidated Statement of Profit or Loss and </b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">Other Comprehensive Income</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><span style="font-family:'Open Sans';">(&#8364; in thousands, except share and per share data)</span></p><a id="_7ab94803_9fec_4065_b99e_fd45a9749e69"></a><a id="_91e1eb9c_c4c3_4afe_8373_dd823a7e9f00"></a><a id="Tc_nYlRSy4VGkiQpIPeZyREKg_1_2"></a><a id="Tc_2JWKjlT1SUOnQ9f6jt8hsA_1_6"></a><a id="Tc_prlDDaA6b0642_euX0VCuw_2_2"></a><a id="Tc_ovbQGAT6S0m1KFcNl-6_8Q_2_6"></a><a id="Tc_7EEYxvUWNkG2xe33zDYI7g_3_2"></a><a id="Tc_yMUO5o_tlUinK_F5-OiVFg_3_4"></a><a id="Tc_P6665x-8wkyNEpkTQtDq_A_3_6"></a><a id="Tc_isapuGeKTk6GeKbKX88iJQ_3_8"></a><a id="Tc_0oVGSOGbDkOrVqZtgVXEvg_4_2"></a><a id="Tc_XP-HDj-fJ0ycpiqSxdQbSA_4_4"></a><a id="Tc_sQc7EftBREqomzDGYJuuSg_4_6"></a><a id="Tc_ibVArPhd60-zpk698pfe7Q_4_8"></a><a id="Tc_porjke3vaEagxDziTnVwig_5_0"></a><a id="Tc_u-ZzzhEaQkuwRBpPYpdf9g_5_1"></a><a id="Tc_IusprY9VO0quiR2T2BenXg_7_0"></a><a id="Tc_hW0orhXN7Ui4OJnu6Cgd2Q_7_1"></a><a id="Tc_dSJGe-cSwkCiYpB2_6yTQA_9_0"></a><a id="Tc_q2NCYRFVMkSWp9WwbIM6XA_9_1"></a><a id="Tc_vzVfkgmARESmjBok5MpkHg_10_0"></a><a id="Tc_ALfqaBW7rE6GdkKwOZRpdw_10_1"></a><a id="Tc_qtsbINlzBU2I8Tdp5KL5rg_11_0"></a><a id="Tc__fbVFeDIFEupWkuxuC0yAw_13_0"></a><a id="Tc_lJuk2cLaREaBuHrMSLYaHw_14_0"></a><a id="Tc_mw3zqmZjck-SRKU2S2l_bQ_15_0"></a><a id="Tc_KC8HH-Sq0EuUmCUT3MziaA_17_0"></a><a id="Tc_YUgsp3HSUUiS3t7yngAB3w_18_0"></a><a id="Tc_19igoNdiGE2q994415YJRQ_18_1"></a><a id="Tc_QQYNIUbVHUqLlQucx7dKFQ_18_2"></a><a id="Tc_eYeSh9YddU6hTya4CGGWSA_18_4"></a><a id="Tc_IV2jX8rybEOtggnxUwb8Kg_20_0"></a><a id="Tc_HlM_OKDzJESizGpnPE2X4A_21_0"></a><a id="Tc_GQlgEiH3sUa8A99wK4E6ig_23_0"></a><a id="Tc_MsmbR6xduU68aiz_4gEphw_25_0"></a><a id="Tc_xiCwaxLloEaCKNSROWKhRg_26_0"></a><a id="Tc_jVNTTbvmKECH99ONhChynQ_27_0"></a><a id="Tc_djdTXEXBbUGvFSFbfTiU9w_27_2"></a><a id="Tc_1-_hdoIGdkqkDEG6eTpJhA_27_4"></a><a id="Tc_rN3fsmCJg0S2POkDmqaN_A_27_6"></a><a id="Tc_xDyC8JysaU-p32uCjRO_pg_27_8"></a><a id="Tc_CmjYR7F_VkaxglvBTiyrOg_29_0"></a><a id="Tc_UYYzxgUh1k6lplA6YTKUKQ_30_0"></a><a id="Tc_6kpcvG_EVUiOvzr735bflQ_31_0"></a><a id="Tc__SxIvr57Ukua_ao7-tnpgA_31_2"></a><a id="Tc_zsXpvgBFTU-tfqVH4Xfasg_31_4"></a><a id="Tc_okbLb8ly3ECJeVL8lkREaQ_31_6"></a><a id="Tc_m3twTNJWm0qqhrJLO8X0dg_31_8"></a><a id="Tc_6nSCqTbPuUiF4PDIbJomrQ_34_0"></a><a id="Tc_PNR2EIq5X0qIUWMMnoxH8Q_35_0"></a><a id="Tc_18WRJq_x6EGIU5JAO88IJQ_37_0"></a><a id="Tc_KbY82N5LlUmVOJvS6rlmKQ_38_0"></a><a id="Tc_XTtTGc1hNEuT0OmAVPRBIw_39_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:97.83%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.11%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:25.34%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Three&#160;month&#160;period</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:25.3%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Nine&#160;month&#160;period</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:25.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">ended&#160;September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:25.3%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">ended&#160;September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"> </b><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">&#8364;1,000</i></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">13</b></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_Cc3YEeJXAUalR-8gmHSp2Q_5_2">2,882</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_dd7twKMQBk-bP9CKLpvPdA_5_4">3,843</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_be_RpEAnkUWod96xjNMrlA_5_6">11,218</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_U6hRy0j7a0am7m1R__vcQQ_5_8">14,598</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Other income</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">14</b></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" id="Tc_QUqHLJaDK02_9SgXftNaag_7_2">33</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" id="Tc_BgLSgk3WQEW9-pNQyaXWow_7_4">138</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" id="Tc_FzP_HaBUQEu0AJi2ikSuWQ_7_6">413</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" id="Tc_rwB5KNR45k643bDeLyeiqA_7_8">504</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Research and development costs</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">15</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_U8Yt8yIFqkSDIB3pFt7tOQ_9_2">11,080</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_JFLi3ESIS0KTbAc7j3jLYg_9_4">9,414</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_kVURblW8UUaj9HPWRBULKg_9_6">34,811</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_ZoyxkFgHDUqANEWbVjGpmA_9_8">25,745</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">General and administrative costs</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">16</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_VSzYmMB8lkGZ8WKTQ_1vMQ_10_2">3,119</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_W719dD_Mmka2JP2jvU7LAg_10_4">3,283</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_J5xq8fXJB0ykZ8URO3qszQ_10_6">11,169</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_VO32mfozqEWcrZ6yINa8SQ_10_8">9,748</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Total operating costs</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OperatingExpense" scale="3" id="Tc_PmxHEnb4zUWoyOYnDXOpeQ_11_2">14,199</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OperatingExpense" scale="3" id="Tc_Ajuci-UEUUqYrozezoNJHA_11_4">12,697</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OperatingExpense" scale="3" id="Tc_4D47HJRIRk6bRB9Ve9CtbA_11_6">45,980</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OperatingExpense" scale="3" id="Tc_SYgxHEtEU0qULnU8SQC7Qw_11_8">35,493</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Operating result</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_TClTMgmf4U-IMgDrfKqFRA_13_2">11,284</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_FeHmKYhEckeKCxfZCR-u9Q_13_4">8,716</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_w-50RnqiqEa2pXCwciPM4w_13_6">34,349</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_jS5G6R15-Em_2B2ygfHpFw_13_8">20,391</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Finance income and expense</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" id="Tc_4RJW6BfpsUOWre3AF4Ao7Q_14_2">280</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" id="Tc_Omh00bfUw0-KGCE6J5L7vQ_14_4">469</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" id="Tc_yJ6A6Ulj_E69H72hJMqXvA_14_6">927</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" id="Tc_glC8gP9rlU61Z5j8ffrcAQ_14_8">1,470</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Results related to financial liabilities measured at fair value through profit or loss</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" sign="-" scale="3" id="Tc_vjjvkpFio0uxlaeWHhUj8Q_15_2">2</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="3" id="Tc_arzRHAKL_02UJrm1xtYw3g_15_4">139</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="3" id="Tc_wmz19EesYkOHKpR1M7e8AA_15_6">176</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="3" id="Tc_55OOLg8cnUiGiM_OINca1g_15_8">266</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Result before corporate income taxes</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_FBEf4oZGek69C0itCrez-g_17_2">11,006</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_0fshqAQID0-OH6gOkJ5CJA_17_4">8,108</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_uliJsEgDIk2wHH4mINVc3A_17_6">33,246</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_T04kNAqHukCKVi5hErT6jQ_17_8">18,655</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Income taxes</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">18</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Tc_2l0sEDnexEWCyUCgZsPmdg_18_6">18</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Tc_WceuaASur0uA3zHb9R1GsQ_18_8">197</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Result for the period</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_Fbob8BPeV0eawfpmjEJcGw_20_2">11,006</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_GXAtEFN8yEa22vI2D92fYg_20_4">8,108</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_xw5dvWGGS0iDZqnkJ9b-rQ_20_6">33,264</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_N2io_dhaE0GPM0sfXJsa3g_20_8">18,458</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Other comprehensive income (foreign exchange differences on foreign operation)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_aZ5SkRnQYkGHaBjGKmkAHw_21_2">23</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_NqlZanWDn0K61Tm2rP5jBg_21_4">377</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_zRgBO2xCRUu34uxsg6fXEQ_21_6">1,076</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_L4Rt_upC8UaOg1tMNi6neA_21_8">101</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Total comprehensive income </b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_iyhiw44JF0epZcOZthxV1w_23_2">11,029</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_wkrEwP_qi0C1yyVW8MGnjQ_23_4">8,485</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_KF50k3XnRUy4KXefB9G_cA_23_6">34,340</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_aIkLipgoq0CrlhrOZSHc5A_23_8">18,559</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Result attributable to</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Owners of the Company</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" sign="-" scale="3" id="Tc_PAJK4pi4RkOlTdlepCzoEA_26_2">11,006</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" sign="-" scale="3" id="Tc_uIQDrLB8jUuj5hBTk_574Q_26_4">8,108</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" sign="-" scale="3" id="Tc_AgqYYsb-FUulg0YyHGvWeQ_26_6">33,264</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" sign="-" scale="3" id="Tc_aKt9qMMDE0-vKF_jt7_C-Q_26_8">18,458</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Non-controlling interests</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_7T_IDaGZNkeYySp8XkZ7Sg_28_2">11,006</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_DFGobGCEcEy2zPWevbJ_Ww_28_4">8,108</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_CK2szqKB_k238v-bkYGNvQ_28_6">33,264</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_0monkrYtsECmiQ-Y5eVJJA_28_8">18,458</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Total comprehensive income attributable to</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Owners of the Company</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" sign="-" scale="3" id="Tc_EXXErGI56kmdxXd0Q2MwXw_30_2">11,029</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" sign="-" scale="3" id="Tc_kvQyNv6mTkyIKiaOFj8Hcg_30_4">8,485</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" sign="-" scale="3" id="Tc__yC6XH-ddk659Iman2hvaw_30_6">34,340</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" sign="-" scale="3" id="Tc_ZTEG0gBXvUa0kW4DkiAf-Q_30_8">18,559</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Non-controlling interests</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_uFfcqbUvjU6HNj7_GNMY4g_32_2">11,029</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_WLfKNDfzQEmD2312dbUzqw_32_4">8,485</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_wSytm9UPL024WWnqbay-Iw_32_6">34,340</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_5WV_Y-6jGEKyr0BttWyJIw_32_8">18,559</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Share information</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Weighted average number of shares outstanding</span><sup style="color:#262626;font-family:'Open Sans';font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Tc_4OyBA5NKzE-knRZJUAf3Dg_35_2"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="Tc_4OyBA5NKzE-knRZJUAf3Dg_35_2_2">105,344,996</ix:nonFraction></ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Tc_dz8HPvqgH0SMB3BaCxeXZg_35_4"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="Tc_dz8HPvqgH0SMB3BaCxeXZg_35_4_2">81,682,296</ix:nonFraction></ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Tc_6mdFNphE1kOtUlwBgZLI_w_35_6"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="Tc_6mdFNphE1kOtUlwBgZLI_w_35_6_2">105,328,752</ix:nonFraction></ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Tc_8_yNxwVA80GtQtAVy9Qlig_35_8"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="Tc_8_yNxwVA80GtQtAVy9Qlig_35_8_2">81,639,533</ix:nonFraction></ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Earnings per share attributable to owners of the Company (Euro per share)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Basic loss per share</span><sup style="color:#262626;font-family:'Open Sans';font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_TX_OmuqLh0S8PKxDqpOTOA_38_2">0.10</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_pJYcw-P9VUK36cFJsz2OXw_38_4">0.10</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_s4p3Rj1sNEei8rE1UMUcwg_38_6">0.32</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_gDmQDSG3yE2YgRihCX1JZQ_38_8">0.23</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:45.11%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Diluted loss per share</span><sup style="color:#262626;font-family:'Open Sans';font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_3xdgtgdroEqBdaprFuW2zw_39_2">0.10</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_6LEmXJeSm0qw3i_R36LS0w_39_4">0.10</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_rAltVSr5REaA_gZkXcxqmw_39_6">0.32</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.92%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_s9xCNhJU7UyUXkbd8wzU2A_39_8">0.23</ix:nonFraction>)</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:justify;margin:0pt 0pt 5pt 0pt;"><span style="font-family:'Open Sans';">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</span></p><a id="_4ab627b6_df97_4a7e_98e8_efb5ea7d2325"></a><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="color:#262626;font-family:'Open Sans';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><ix:footnote xml:lang="en-US" id="_6bcb422b_dd88_4484_a93e_66423de002bd"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:normal;font-weight:normal;">For these periods the potential exercise of share options is not included in the diluted earnings per share as the Company was loss-making. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal</span><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:normal;font-weight:normal;">. </span></ix:footnote></td></tr></table><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">3</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c4908448_4c4e_4002_86b1_c0b420c00da1"></a><a id="Statement_of_Changes_in_Equity"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 4pt 0pt;"><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">PROQR THERAPEUTICS N.V.</b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;"><br/></b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">Unaudited Condensed Consolidated Statement of Changes in Equity</b></p><a id="_e4d94a25_603b_473e_8b37_6c1bf369e564"></a><a id="Tc_CT-aM_EQsU6mjhoIjO2DXQ_1_2"></a><a id="Tc_uW7-geDkpU6NplV2y5Ud9w_2_2"></a><a id="Tc_xGS4SLRR6EyoW5L7csDsCg_2_4"></a><a id="Tc_Ppp60H_0zEWfw_zrNJCCCA_2_6"></a><a id="Tc_1nJaV5z5Q0aEPhIUZk2t3g_2_8"></a><a id="Tc_wi2Qu9ZKP0yVaMx0dvyKGw_2_10"></a><a id="Tc_2YGpw-xp_EyMa36vVCkptA_2_12"></a><a id="Tc_z88WlMrs6EWAX35ajogvdQ_2_14"></a><a id="Tc_aaCRwlF6lk6GJ-v-KMi3lg_3_4"></a><a id="Tc__LK0p8TYZUSEbrTGIrweWg_3_6"></a><a id="Tc_E-z2kMsVqkWqyyBs5GBqaw_3_8"></a><a id="Tc_TazZwk_bbEGgM0n6NkYlkA_3_10"></a><a id="Tc_yxLZ-pEwKk2Uhmc77JrpSQ_3_12"></a><a id="Tc_6Mt5s1ZY1EmIJgIwpIICcA_3_14"></a><a id="Tc_PC8WeM5Vh0qoanKyWnQYiQ_4_0"></a><a id="Tc_DjQuFvlmN0mli0vshs33Yg_5_0"></a><a id="Tc_bl5u60ySIk2N71xhzFTANQ_5_2"></a><a id="Tc_E6-0c0hxPkO2lNNarpUf_w_5_4"></a><a id="Tc_Tg2gyL80Gky_Yquvv7Jjvw_5_6"></a><a id="Tc_SUHNhZ8mVUu0LzVhD3SYnw_5_8"></a><a id="Tc_htko5RSXakqnV6d-ZwvuGQ_5_10"></a><a id="Tc_8lb6zkZ1jky70mDX1Jsj8g_6_0"></a><a id="Tc_dsLiTEV9lE6b4HIzRI7UTQ_6_2"></a><a id="Tc_DEDxBVM1Z0urGxeCIliONg_6_4"></a><a id="Tc_0hQRPA6K50uNAaSMUMuy6g_6_6"></a><a id="Tc_qUP9VANpIkGwci6gZcjeuA_6_8"></a><a id="Tc_XPpUfG1LzEO-uKdrn7yP6A_6_12"></a><a id="Tc_ifb2knfBeEqj6xJUg4Anzg_7_0"></a><a id="Tc_MD8l-oDOCke5Kuo4Q2ZKJg_7_2"></a><a id="Tc_AO4nFD4K80yQGRnJvLOnRA_7_4"></a><a id="Tc_TwOXLkDke0aFsKueMc6RhA_7_6"></a><a id="Tc_dIpT7homokygNmO8eq12bA_7_10"></a><a id="Tc_FiPEhiWErEmQiMTT0jGklw_7_12"></a><a id="Tc_OXn4QU-7akCJhFbhuwo2rQ_8_0"></a><a id="Tc_lvEwkvIDbECusfR9OnYx1g_8_4"></a><a id="Tc_SW7l15HHO02Fqa3JyRwu6A_8_6"></a><a id="Tc_azulW_plkkOd56U9VLmxbw_8_8"></a><a id="Tc__Gozp_fn3EuVlvNWXWaMeg_8_10"></a><a id="Tc_tJ9V0wrmoEy9kvKCt653aw_8_12"></a><a id="Tc_I1d6bA5W9EubhUZnmPSnkg_8_14"></a><a id="Tc__EhY-Hb-oUWzXtTft1nxSw_9_0"></a><a id="Tc_q7W0BPHeV06aWRT_ff-z2Q_9_2"></a><a id="Tc_fM67vswR00OHor35-8Yu1g_9_4"></a><a id="Tc_DcdwQzJPeU6htScP0o7NBg_9_6"></a><a id="Tc_qI41GHewIk-ZoKQyHWHGtg_9_10"></a><a id="Tc_3-ehaCLaikGOV1Z11vRmDg_9_14"></a><a id="Tc_9434SXus1EqG6LoNB0xDzQ_10_0"></a><a id="Tc_SvAJKFwLpUabOfW8GZ05fA_10_4"></a><a id="Tc_Rm-gfDq-_kyv1m2My8e_ug_10_10"></a><a id="Tc_DNj1xhr20E2ikL6zmgM8nQ_12_0"></a><a id="Tc_rj_K0fwCFUaw4Dsc3AMKlg_14_0"></a><a id="Tc_NEHcI2yReUqdK5ZOCVMI4w_15_0"></a><a id="Tc_IPsEKozJk0ag7yv8x2k2sA_15_2"></a><a id="Tc__ezCa-yg7UK_CxSqcG3-oA_15_4"></a><a id="Tc_6m_sha1raESbIZsz6wyHGA_15_6"></a><a id="Tc_Cm7KV-AObEaR6Ud62deBVg_15_8"></a><a id="Tc_gMMb71URu06LzVZzB3FDWw_15_10"></a><a id="Tc_zL5wZEKDqUWpgIZMT14Ewg_16_0"></a><a id="Tc_zfhJ_sQGI0aJC0rkz8fxMQ_16_2"></a><a id="Tc_DAXW9vT-iEq2iLI5jZkAQQ_16_4"></a><a id="Tc_OHY84kH0BkGUYSULbQdPyw_16_6"></a><a id="Tc_oOspkEZURkSbbnkPPKh0Bw_16_8"></a><a id="Tc_9I_3bPLR4USigsIinBfSAQ_16_12"></a><a id="Tc_elmEfW2ZPk2W4mMARjoi0Q_17_0"></a><a id="Tc_jYXTxUIOaUyIT_PwA4YxGA_17_2"></a><a id="Tc_dPIzrCp4-kyxATEfpVumuA_17_4"></a><a id="Tc_1e91PB0vVEajWtkTCA1poQ_17_6"></a><a id="Tc_Op8OrOnodku0faeo0RzTAw_17_10"></a><a id="Tc_iIEEeXMAaEi0ciXskuk18w_17_12"></a><a id="Tc_YhnJa3opnk-5BpiyycgdiA_18_0"></a><a id="Tc_Wun5N5n4MkSpvtAP0LZ4-Q_18_4"></a><a id="Tc_q2uw0OYYS0-CSB3Mn4HrSQ_18_6"></a><a id="Tc_R7ZxK4Q0cEyCjMyR6q-Emg_18_8"></a><a id="Tc_um0jvFBja0uME9V-qjIfgA_18_10"></a><a id="Tc_sobgpCm-gky5F7Ass2pPsA_18_12"></a><a id="Tc_TZZWYQ0PUEyGcrJ23gCmfg_18_14"></a><a id="Tc_jsoIO3baK0CreAUL2IYLxw_19_0"></a><a id="Tc_EgVSesGb7kSnbTBOd9ZVZg_19_2"></a><a id="Tc_poKYRfQCeUuErkQ9Ztu9Xg_19_4"></a><a id="Tc_VstHzGtxi0-tqqKjG2D-kg_19_6"></a><a id="Tc_qo30k0zDU0660In0DkgWpA_19_10"></a><a id="Tc_vX-ThD4pEkCGjdzstxaAcA_19_14"></a><a id="Tc_JsxLeMWV1UiPBzu9kKArtw_20_0"></a><a id="Tc_RcZZHWbOs0CjlUalbhyj2A_20_4"></a><a id="Tc_mo7aUFKyVEWA6637G1I-Aw_20_10"></a><a id="Tc_EqHEuyJqhUqR-otn9T0ECg_22_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.8%;border-bottom:1px solid #464646;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:normal;width:72.08%;border-bottom:1px solid #464646;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Attributable&#160;to&#160;owners&#160;of&#160;the&#160;Company</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.8%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:8.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Number</b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><br/></b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">of shares</b></p></td><td style="vertical-align:top;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Share</b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><br/></b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Capital</b></p></td><td style="vertical-align:top;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Share</b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><br/></b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Premium</b></p></td><td style="vertical-align:top;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Equity</b><b style="color:#262626;font-family:'Calibri','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;">&#160;</b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">settled</b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><br/></b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Employee</b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><br/></b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Benefit</b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><br/></b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Reserve</b></p></td><td style="vertical-align:top;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Translation</b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><br/></b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Reserve</b></p></td><td style="vertical-align:top;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Accumulated</b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><br/></b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Deficit</b></p></td><td style="vertical-align:top;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Total</b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><br/></b><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-size:8.5pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">&#8364;1,000</i></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Balance at January 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:8.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AcgFrNkamkCvsd1bQi1WLA" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="Tc_Z_57e2awz0GwZjT9pXw4Wg_4_2">84,248,384</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AcgFrNkamkCvsd1bQi1WLA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_noOSBe3LRk-_RDE8Pb48nA_4_4">3,370</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_e5T6UVKy1ki9ZfWxfnjDhQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_Ajh4IBsFBEi1-XMJV02uPA_4_6">412,894</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_4xDxWcNmjEeMIATjnOIb_A" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_I7cYIVejqUCS8Ga-AxQZTA_4_8">25,159</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_OFftNnWG-UGZ6tREcP4ijw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_KMIChVf7ykOBIs7BwBuh1w_4_10">817</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_7CEaesH_rUeFoouKWkTtcA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_bc2RjtMIW0Cf-Z1XJSsmYg_4_12">400,850</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2023_7SqLUGM3Ck68Fx8rYXnMKQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_DqX7B3N8xUmsFYIXwdWL6Q_4_14">41,390</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Result for the period</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_08ltvoMrCUOhqccsXSmSpg" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_1gGHV1VXtke2It3WsVaY_A_5_12">18,458</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_K3VirHnyWESgPU-G8sc9IA_5_14">18,458</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Other comprehensive income</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_G4ICZ7yXkk65BgEHTs4AlQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_Wb7LfKJQPkqwatnfuG-78w_6_10">101</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_Zassv3eoLE-jcLeMEAO3NA_6_14">101</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Recognition of share-based payments</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_D3VJA-2yEka_L4CJUP1bwA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_AeN0i3Dhw067cvny-ujjew_7_8">1,976</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_oUO5rbqmIEaJTtlOcES5Rw_7_14">1,976</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Treasury shares transferred</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_fkkBmmdVaESJHda3nXUU-Q" decimals="INF" format="ixt:num-dot-decimal" name="prqr:TreasurySharesTransferred" scale="0" id="Tc_lwqoaCo270qKOQum_HQd3g_8_2">329,675</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#8212; </b></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Share options lapsed</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_D3VJA-2yEka_L4CJUP1bwA" decimals="-3" format="ixt:num-dot-decimal" name="prqr:SharesOptionsLapsed" sign="-" scale="3" id="Tc_R7qKPkU1B0aC54ETrCQO6A_9_8">994</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_08ltvoMrCUOhqccsXSmSpg" decimals="-3" format="ixt:num-dot-decimal" name="prqr:SharesOptionsLapsed" scale="3" id="Tc_MppEoaShukyeNudqi7Flow_9_12">994</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#8212; </b></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Share options exercised / RSUs vested</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_fkkBmmdVaESJHda3nXUU-Q" decimals="INF" format="ixt:num-dot-decimal" name="prqr:IfrsStockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_6NMfn5oufUWZFokvxR0PDw_10_2">328,597</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_iwf40QnTJ0m4Vo8mAlujCg" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_RhuIOZlPPkCgNNpldFVXTg_10_6">175</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_D3VJA-2yEka_L4CJUP1bwA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" sign="-" scale="3" id="Tc_sO-C2uhOBUex46Vgwhc1ow_10_8">291</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_08ltvoMrCUOhqccsXSmSpg" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_8I7lgYwYo0qjTuL506h7tA_10_12">291</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_lMnfIn9NPEiI-WxaX_CKyg_10_14">175</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Balance at September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:8.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_77JK05vzLU-X-WnDU8wcDA" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="Tc_EcccmfoJIUaaz8HLrcIj6A_12_2">84,247,306</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_77JK05vzLU-X-WnDU8wcDA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_s-_k-fLot0ySpPZfkxSe3w_12_4">3,370</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_YmG5mam2kU6LZGJw23cDuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_sN3uXoAeJki662GtRYnnqA_12_6">413,069</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_TG6NHlq740CXHuiR9mTbLA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_G7QYwa-d8kiz3CXJlKLocw_12_8">25,850</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_xzfXEnJ9DEuEVu_FmD7uuA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_9RhFOnxbwUGkISz5GeFH_g_12_10">716</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_wqiJlNiVCU6R8R3Fcw6cCw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_isu9TQ9t50mp9ee90dibYA_12_12">418,023</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2024_g29o3Zo7Ak-Bxlwv8XcO8g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_6GC607AdEEqQ4uXjKbEr8A_12_14">24,982</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Balance at January 1, 2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:8.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_II-Ovg3YckajeIRdrZzZKA" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="Tc_IsJdKx4AjEmIn5CYVayA_g_14_2">107,710,916</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_II-Ovg3YckajeIRdrZzZKA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_KHDUW3aj4EaswcIuO8btoA_14_4">4,308</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_oQrhBR2oxUapLnyLuIArqg" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_Hi_V-eRjxE6Xj8Xq3IuFJA_14_6">483,812</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_RJ5IIuOtWE6SDgrSyS_t2g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_Kr1f73HkNU6_iC0BP4tKsw_14_8">26,248</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_9QFRxe8qfUmtwOQ_FsyrEw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_-R-rtAcv4Ue4wvblOhY6sw_14_10">1,350</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_0mrf-R_XY0yzUG8OnKrkDA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_d-bS-u-hmUGiMbtRApwlfg_14_12">427,158</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_m1CaNRjuOUyuEjjOejWj1A_14_14">88,560</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Result for the period</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_IsxdhpKNBUWj5naxXv5zDQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_aEEWz-MCe0GqUwCxKxFQ6Q_15_12">33,264</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_55_2SiQfgkqfNwGfqPnKAA_15_14">33,264</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Other comprehensive income</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_dgOq00RA5UyztuNQFmTsMA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_zBFtWaRwvUm4JF9CC9a7qA_16_10">1,076</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_sbr0DeN80EmseUbuM3Bq6A_16_14">1,076</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Recognition of share-based payments</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_z8mrJ_XS20OdmQRuFtWhnw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_j0WMrC_p0kigNbafg804dQ_17_8">2,784</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_xR4xIssSKEe0GNFTugnXYA_17_14">2,784</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Treasury shares transferred</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_5PEUyinG3kmhHLSlPJV_1Q" decimals="INF" format="ixt:num-dot-decimal" name="prqr:TreasurySharesTransferred" scale="0" id="Tc_H3pI2EEWWUOIXl8W9ZXcmA_18_2">132,665</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Share options lapsed</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_z8mrJ_XS20OdmQRuFtWhnw" decimals="-3" format="ixt:num-dot-decimal" name="prqr:SharesOptionsLapsed" sign="-" scale="3" id="Tc_cVTgn849v0WETI_uO-QJkA_19_8">1,532</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_IsxdhpKNBUWj5naxXv5zDQ" decimals="-3" format="ixt:num-dot-decimal" name="prqr:SharesOptionsLapsed" scale="3" id="Tc_0zEoPZgfZUmD4dw7l4zDHg_19_12">1,532</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">Share options exercised / RSUs vested</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_5PEUyinG3kmhHLSlPJV_1Q" decimals="INF" format="ixt:num-dot-decimal" name="prqr:IfrsStockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_s_ZHz4JJlkWcOlfCbUkL1A_20_2">132,665</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_uPUa2i_7MkuFypR4I9OjUQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_GQjxM-OcpEqW3zvgGqLhDw_20_6">67</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_z8mrJ_XS20OdmQRuFtWhnw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" sign="-" scale="3" id="Tc_Sw-ULm6PmkKyylOHCN5CtA_20_8">184</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_IsxdhpKNBUWj5naxXv5zDQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_-PVpgZlCf0umq6BZCWpJnQ_20_12">184</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_8YEc9hMKQ0-eyF-sD6yB1g_20_14">67</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.8%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Balance at September&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:8.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_SMbLKd34R0KfHuM4rpeilg" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="Tc_hrI1NYrPXESaSYzsAR_S8g_22_2">107,710,916</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.36%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_SMbLKd34R0KfHuM4rpeilg" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_h5cJcFuf-EysTCoKpmtW5g_22_4">4,308</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_xVLmQv70tkmTWrXUzZkHoA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_kdcMiVA3Q06STSKzMhFJlQ_22_6">483,879</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_DsMV-YDBnUK76VIPgik0-A" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_5NaWM1uVHEaoZUKQ30oIOg_22_8">27,316</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_VwVPNTRKjka_upzN4CwLew" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_BzRMRYutUUu1X0uxp69GVw_22_10">274</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.35%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_asbCzlcqMkyM5w2Y3PRbqQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_Ih0wzP6wdk2btbVKwU-Z8A_22_12">458,706</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.09%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.34%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" id="Tc_5rKGSly6X0e2_xD2P6jBIw_22_14">57,071</ix:nonFraction> </b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';font-size:1pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">4</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_96e7f0d1_9e70_4690_9a74_aef654b51015"></a><a id="Statement_of_Cash_Flows"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 2pt 0pt;"><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">PROQR THERAPEUTICS N.V.</b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;"><br/></b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">Unaudited Condensed Consolidated Statement of Cash Flows</b></p><a id="_c96c0ba0_a8b9_4710_8763_e8f240b5d8f6"></a><a id="Tc_L58DbTOxuUK1bmxpdrziQg_1_2"></a><a id="Tc_Cc3UCe8JzEa9vsFhh4TQJg_1_6"></a><a id="Tc_IO8dY5PLKEauGLrt44cFhw_2_2"></a><a id="Tc_AfwVk-QMBUmU4D2C9w6PJA_2_6"></a><a id="Tc_OMONmI6f3kCxmwtUfkKj5A_3_2"></a><a id="Tc_fz_gVOyTJU-KP0BvXq3-HQ_3_4"></a><a id="Tc_pED66NFb5UWjTd5h-3Q5PQ_3_6"></a><a id="Tc_H8PFs-JJFk61tAX8qW3pyw_3_8"></a><a id="Tc_3K508NTaM0O-FvgKbnXfmg_4_2"></a><a id="Tc_SqcClDk5mEOfx9wpd67rPQ_4_4"></a><a id="Tc_-pwsqul62EOqVm0tKZYEpA_4_6"></a><a id="Tc_USpaiCNc3E2LW_fODFKnaA_4_8"></a><a id="Tc_zOL5EDtGgE-d8OX-W_3DdA_5_0"></a><a id="Tc_0JdG3gFpJUKr8oaoeq_gAQ_6_0"></a><a id="Tc_JQgLwZ5zMUSrg5IQDt_8aA_7_0"></a><a id="Tc_MIN0y3iPDUOTJA-ZC_jgjQ_8_0"></a><a id="Tc_u6pXzLGtF0qaJBycdamMZw_8_1"></a><a id="Tc_D-jcBjbh30eQ89EfbV2bjQ_8_4"></a><a id="Tc_1AKVmQVIw02oN1CiDJbbrw_8_8"></a><a id="Tc_Rt3lyOo7RkyYdzcpx21vDQ_9_0"></a><a id="Tc_7T3YCWl52E2e0-Rq_taZBQ_10_0"></a><a id="Tc_xHIn9Mt_kUuutgLWVzuf6Q_10_1"></a><a id="Tc_bw611FvWkketJIMm6Js-Ug_11_0"></a><a id="Tc_YBBesLe8p0GhRDRR8nQ5IQ_12_0"></a><a id="Tc_6mDvUShDLUav2VosELNk4Q_13_0"></a><a id="Tc_4NS5oc9D0ESceP7MA_agqA_13_1"></a><a id="Tc_rx73StfUUU6mI01rNSgHYA_13_2"></a><a id="Tc_IXhraTfO90eGn-Ggf3Atow_13_4"></a><a id="Tc_wP-6LnJFd0y27gmPJsb8Kg_15_0"></a><a id="Tc_lI6isQ-JQUCKNsFGyQidTA_16_0"></a><a id="Tc_Kwn3eMo9O0u3NkbqObsG2Q_18_0"></a><a id="Tc_OClGfVULLEmpJKje40Z-Sw_18_2"></a><a id="Tc_CA7-TEdYJ0GMYD-6OkcH2Q_19_0"></a><a id="Tc_or14ZUUWbUekkXSA9UeVRA_20_0"></a><a id="Tc_7nYXG0PqyUCabomDystblw_22_0"></a><a id="Tc_wjlo9jE5T02wqTqEa5Dd1A_24_0"></a><a id="Tc_ErY6bLWqpkiQL8prs8zH6w_25_0"></a><a id="Tc_MdDw850nCEiB3BVe19KB9w_25_2"></a><a id="Tc_rREWO6b6TEyXDEbDHlM3tA_25_4"></a><a id="Tc_9FW4WlzUZE63mCRBDyj0zw_25_6"></a><a id="Tc_gjIr5Q-Ls02ulwLi0aXSBA_26_0"></a><a id="Tc_DcALAqhMzUGYmYHVMVjg-g_26_2"></a><a id="Tc_UnYt9mvvyE2vfGa6G_N2aQ_26_6"></a><a id="Tc_lLArIe7n9EapZ_rimRfK5w_27_0"></a><a id="Tc_LFUNpIV0gke04-qKIysqCw_29_0"></a><a id="Tc_1Ity7iKMrUex-iUQYTsymg_31_0"></a><a id="Tc_uyd9ReZW5kKvXGCgfDqkEw_32_0"></a><a id="Tc_zdRCYycn-kW7xBva-PTGaQ_32_1"></a><a id="Tc_lubS73k9EUm1nV7jOdBiAg_32_2"></a><a id="Tc_RuiUkEg-RUqx-PB7U1ko3g_33_0"></a><a id="Tc_2CC87GRywEeE6YhpbY0Kow_33_1"></a><a id="Tc_qFRIf8u6-EGUKIahHAd_MA_35_0"></a><a id="Tc_TpfYKMEQQEa8e_wUOcYGZg_37_0"></a><a id="Tc_k1QWoh8BcEyJRWlzDEGrDg_39_0"></a><a id="Tc_OKA3FoQYz0igqL-TQVOeXQ_40_0"></a><a id="Tc_0OtBtJoxhEy5fg9PyhvmSg_40_1"></a><a id="Tc_PuGiINg58UKY1M-E4_NIsQ_42_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.93%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.73%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:26.49%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Three&#160;month&#160;period&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:26.38%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Nine&#160;month&#160;period&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.73%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:26.49%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:26.38%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"> </b><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:italic;">,000</i></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Cash flows from operating activities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Net result</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_IhKsaek9MUuo57ezvYN-zw_6_2">11,006</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_1QQ1GkW4CEC87DHmgEoOVw_6_4">8,108</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_m5AxFLmsjkKTEgsx_2j0Aw_6_6">33,264</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_VGSfDBnVH0eqXq6AB3Ge3Q_6_8">18,458</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Adjustments for:</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; Other income</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">14</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="prqr:AdjustmentsForOtherIncome" scale="3" id="Tc_wCsSkKA7o0ewd_jf6-g6Ew_8_2">33</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="prqr:AdjustmentsForOtherIncome" scale="3" id="Tc_pOFlcDCQGU-wIGo4irl3WA_8_6">413</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; Depreciation</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" id="Tc_HsB4Yxtb6U-uYSOL1qdaYg_9_2">671</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" id="Tc_0cSkb2Jv7E6lOBCNcGxXMg_9_4">688</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" id="Tc_vqMzi4VOCkyqoDzpwHjrRg_9_6">2,024</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" id="Tc_ShqhEJjC5kyxxOyyrHW6Ww_9_8">2,090</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:7.5pt;">12</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_UhHMA9xyvEqCPuOqBzwAKg_10_2">1,117</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_8s7g_4n3eEK7aGvRmt5Zeg_10_4">612</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_swX6S0vfMUe_ZmGAnLK04w_10_6">2,784</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_40qnARF6X0OVrrHiCNQITg_10_8">1,976</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; Financial income and expenses</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" id="Tc_IU53EKpWkUCSEEwzoTrvBg_11_2">280</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" id="Tc_IhZWXtKTMEqILBCvzcoK0w_11_4">469</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" id="Tc_G48UjV1qoEG_HtuCCe-r5Q_11_6">927</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" id="Tc_ZRec2vwmYku2DEmvkkp7kA_11_8">1,470</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; Results related to financial liabilities measured at fair value through profit or loss</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFairValueGainsLosses" scale="3" id="Tc_m7qgut8-ZUGRUwxMOQJkBg_12_2">2</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFairValueGainsLosses" sign="-" scale="3" id="Tc_-VxsJrNwIEG3TmVCSDKo5w_12_4">139</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFairValueGainsLosses" sign="-" scale="3" id="Tc_X-O3bxpyjEumYiQDb229FA_12_6">176</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFairValueGainsLosses" sign="-" scale="3" id="Tc_tSmtD7-yJEm-TDit628pjw_12_8">266</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; Income tax expenses</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">18</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncomeTaxExpense" scale="3" id="Tc_EjT904MGU0edMlkXaYW2Cg_13_6">18</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncomeTaxExpense" sign="-" scale="3" id="Tc_fOo7lO-SkECVSjp3yp374w_13_8">197</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Changes in working capital</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="Tc_KQp8KUC0tUityvbNBcezXg_15_2">3,074</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" sign="-" scale="3" id="Tc_YBQF8G28a0ig7YfdPTJMAw_15_4">1,117</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="Tc_usBO4SBq6E260Wfj49TqIA_15_6">10,974</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="Tc_okDZb3SjaUWrqBS29Eeqsw_15_8">12,721</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;">Cash used in operations</i></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperations" sign="-" scale="3" id="Tc_PUU_K6Ply0agZfjQ24-A4A_16_2">12,603</ix:nonFraction>)</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperations" sign="-" scale="3" id="Tc_AoHUWWe7qUKo5mVnApdH8w_16_4">6,299</ix:nonFraction>)</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperations" sign="-" scale="3" id="Tc_hHvoFrifz0CuJlgUIYjusw_16_6">40,928</ix:nonFraction>)</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperations" sign="-" scale="3" id="Tc__SkHCE3zIkeRBkTcfoxe2w_16_8">29,046</ix:nonFraction>)</i></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Corporate income tax received / (paid)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" sign="-" scale="3" id="Tc_-IQg7xbKp06nGwHnn4tzJg_18_4">1</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" scale="3" id="Tc_furFCQcvt0y8TOP3PMBofw_18_6">18</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" sign="-" scale="3" id="Tc_qe-AHTguTkmsTL5DBT9ALQ_18_8">197</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Interest received</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="Tc_iJqNhWyizkaXCqPwm-NMyg_19_2">519</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="Tc_4lhTUjCmrkyuCzig5PgAZw_19_4">860</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="Tc_afD9b_1DRUKSxrvFrOiu4g_19_6">1,924</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="Tc_Le_WxfLzyEu0M0_rD8k6Cg_19_8">2,402</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Interest paid</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_C-6MdZJwL0OOKGupQEsOsw_20_2">151</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_TuHOnD1yCE2NWjecIFI5Hg_20_4">219</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_J4kSvC_LFkSN0qRRhrsslA_20_6">412</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_XnysXJ2dGE-oE2jpZwTpOA_20_8">598</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">Net cash used in operating activities</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_UsDuY_KP30SKRAYekSwGaQ_22_2">12,235</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_S-yyfWda30y9bOgNk2BuYw_22_4">5,657</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_xhmO-wdPeEO2ZBfhtEQzaA_22_6">39,434</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_sSmVjy0mdkGoQscYntsvXw_22_8">27,045</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Cash flow from investing activities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Increase in financial asset - current</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="3" id="Tc_miAaBzlAMUaesKynVEiokA_25_8">17,000</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Decrease in financial asset - current</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="3" id="Tc_kdpVHv47rEecL0qQEm83lg_26_4">17,000</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="3" id="Tc_tsbAUHCsJ0Sy0f6_7o2gTw_26_8">17,000</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Purchases of property, plant and equipment</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_E5GLhWfeS0aVi986_D2YNg_27_2">169</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_KY6ai4MQvUGe3Ij4NSfkXw_27_4">286</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_IEoKMlEy006KqtgAX-9fYA_27_6">494</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_KQ0ccQymZ0KiuadyNx05JQ_27_8">1,285</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">Net cash (used in) / generated by investing activities</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_H35S8fJEk0y8eL8lNu0-ng_29_2">169</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="Tc_lsS_yTWCb02jkdmXZhffqQ_29_4">16,714</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_EEWVU0oiKESPtC9-KyvCbA_29_6">494</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_cN3QEiRgkkqRRzXRTlGa8A_29_8">1,285</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Cash flow from financing activities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Proceeds from exercise of share options</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">12</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#8212; </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="Tc_jILzXyvxw0SUA9IfOrlEQw_32_4">1</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="Tc_5ssSshEvu02ivC0aK8-FWg_32_6">67</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="Tc_AfIhGXHoT0WICTYj3ZaaUw_32_8">175</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Repayment of lease liability</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">10</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_BRSz4XUz0ka_dfhyOfhdIg_33_2">444</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_OA0fTb3uC06ky6YW73lCDw_33_4">454</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_CnVPB3SOOEqleh2WIRfbbw_33_6">1,304</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_o0YhTijGpU-V1QMji4VYPA_33_8">1,329</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">Net cash used in financing activities</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" sign="-" scale="3" id="Tc_AzbukifYRESHbUfxQGcTPg_35_2">444</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" sign="-" scale="3" id="Tc_vT_BJGEqB0GDbolBLHBhhQ_35_4">453</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" sign="-" scale="3" id="Tc_Il_65MclHUudq-pgEhsKkw_35_6">1,237</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-style:italic;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" sign="-" scale="3" id="Tc_aaPJlzt9WE2PIih6hQeH0Q_35_8">1,154</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Net (decrease) / increase in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_pEgR_dmdI0-rHcYeDj5VkQ_37_2">12,848</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" id="Tc_pNsm8E_ArUmdsdqgaalNqQ_37_4">10,604</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_a0CJVrCETEyRsoehOo6qKw_37_6">41,165</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_CSgTBmSKnUy2poopYbXD5w_37_8">29,484</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Currency effect cash and cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_3djnP4fU0EON4Dno96n9fQ_39_2">34</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_Ac3dVEmo_UqmiKfomWA7WQ_39_4">173</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_DV8i4mMlJUaLZOW-5JrTdg_39_6">1,360</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">(<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_dWTixVZD-Eukv7zShVMwIg_39_8">40</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">Cash and cash equivalents, at beginning of the period</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">5</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_6_30_2025_i0u4-QQ5ZU-UjEoLiyQsHw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_UkI9YNi0FkC8DwklGJNiJw_40_2">119,765</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_6_30_2024_ZHbkuA8ZZEC6p9HbY3sb1w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_KKldtCjEUEWbfrw_J2s2Aw_40_4">78,970</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_lS0MFWoTq02CvzpMClo17g_40_6">149,408</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 1.8pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2023_7SqLUGM3Ck68Fx8rYXnMKQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_-hZvpzqtc0CNiR27QIqX2A_40_8">118,925</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:6.5pt;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:42.73%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;">Cash and cash equivalents at the end of the period</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.57%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_w11-nWDPkkazz5OjXx5_og_42_2">106,883</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2024_g29o3Zo7Ak-Bxlwv8XcO8g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_pzTADizJ1k2NUdHKC5fIhA_42_4">89,401</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_ayTatYf16k-ScXCYOAWAEQ_42_6">106,883</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.45%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.46%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-size:7.5pt;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2024_g29o3Zo7Ak-Bxlwv8XcO8g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_7cR-1YrPRUCYRa3PYNyH8A_42_8">89,401</ix:nonFraction> </b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';font-size:7.5pt;">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">5</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f86020dc_02e0_4c01_9208_a1e68859b214"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">PROQR THERAPEUTICS&#160;N.V.</b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;"><br/></b><b style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;">Notes&#160;to Unaudited Condensed Consolidated Financial Statements</b></p><a id="NotestoUnauditedCondensedConsolidatedFin"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="prqr:DisclosureOfGeneralInformationExplanatory" id="Tb_wWzC2AkKMkmRvMSxJo9Igg" continuedAt="Tb_wWzC2AkKMkmRvMSxJo9Igg_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">1. General Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">ProQR Therapeutics N.V., or &#8220;ProQR&#8221; or the &#8220;Company&#8221;, is a biotechnology company domiciled in the Netherlands that primarily focuses on the discovery and development of novel therapeutic medicines.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Since September 18, 2014, the Company&#8217;s ordinary shares have been listed on Nasdaq. They are currently trading at Nasdaq Capital Market under ticker symbol PRQR. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company was incorporated in the Netherlands, on February&#160;21, 2012 (Chamber of Commerce no. 54600790) and was reorganized from a private company with limited liability to a public company with limited liability on September&#160;23, 2014. The Company has its statutory seat in Leiden, the Netherlands. The address of its headquarters and registered office is Zernikedreef 9, 2333 CK Leiden, the Netherlands.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-family:'Open Sans';">ProQR Therapeutics N.V. is the ultimate parent company of the following entities:</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics Holding B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsHoldingBvMember_O8oNddjWmkC-HAijvKH37g" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr__xTuVq-8T0OkTFXa1vflZg">100</ix:nonFraction>%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics I B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIBvMember_rEz99sZOpEOeeXyEDeM7bQ" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr_9mm9jNR9j0-l7uA3fYjdNg">100</ix:nonFraction>%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics II B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIiBvMember_0sZHnPkpQUib6ZcDTeKIPA" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr_bx0wu18qckqxpgBwn_rBew">100</ix:nonFraction>%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics III B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIiiBvMember_fK1FbaT8-k-4CxcnPUyGNw" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr_lL4qnBJYwEamL8_w0AYa1Q">100</ix:nonFraction>%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics IV B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIvBvMember_TGiLF5LfiUGZLR-qDsOFtQ" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr_1k2uohSVA0GGkxCKPiGd_Q">100</ix:nonFraction>%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics V B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsVBvMember_XAFpvyId2k2r7a7zNVEohA" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr_I9A9RmOfsEekFfiayHKiuQ">100</ix:nonFraction>%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics VI B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViBvMember_Eg_4tvfBoUCuq-QPluHQsQ" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr_tWke656V2E-rBYfnM4XcTA">100</ix:nonFraction>%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics VII B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViiBvMember_vOqWyc0GxkKVzCAG4aDgJQ" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr_XgeWOQAZDky0-SQGt9KSMw">100</ix:nonFraction>%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics VIII B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViiiBvMember_VdFaX-IgmUWXDhT8Sj91cg" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr_LemBnAFMy06cBShKVxXvTQ">100</ix:nonFraction>%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics IX B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIxBvMember_8b6o2YoKLUWPL-vDhftrUQ" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr_ta2cSAbmaU6QGZFVZdCtAw">100</ix:nonFraction>%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics I&#160;Inc. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIIncMember_ECpwoHs8RUyCW8sNiNEueg" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr_U9KoLsaF-UG3bNBQq025SQ">100</ix:nonFraction>%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">)</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">ProQR Therapeutics N.V. is also statutory director of Stichting Bewaarneming Aandelen ProQR (&#8220;ESOP Foundation&#8221;) and has full control over this entity. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">As used in these condensed consolidated financial statements, unless the context indicates otherwise, all references to &#8220;ProQR&#8221; or the &#8220;Company&#8221; refer to ProQR Therapeutics N.V. including its subsidiaries and the ESOP Foundation.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">6</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_wWzC2AkKMkmRvMSxJo9Igg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="Tb_4VcKChri-kOXA66XYSvUiA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2. Significant Accounting Policies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">These interim condensed consolidated financial statements for the three and nine month periods ended September 30, 2025, have been prepared in accordance with IAS 34 Interim Financial Statements. They should be read in conjunction with the Company&#8217;s annual financial statements for the year ended December 31, 2024. These interim condensed consolidated financial statements do not include all information required for a complete set of financial statements prepared in accordance with IFRS Standards. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company&#8217;s financial position and performance since the last annual financial statements. In the opinion of management, all events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period are disclosed in these interim condensed consolidated financial statements. The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those applied in the preparation of the Company&#8217;s annual financial statements for the year ended December 31, 2024. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">During the nine month period ended September 30, 2024, the Company invested in financial assets in the form of a deposit with an original maturity of longer than three months but shorter than twelve months which are measured at amortized cost as they give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. The deposit matured on September 30, 2024.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company&#8217;s financial results have varied substantially, and are expected to continue to vary, from period to period. The Company believes that its ordinary activities are not linked to any particular seasonal factors.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The management of ProQR has, upon preparing and finalizing these interim condensed consolidated financial statements, assessed the Company&#8217;s ability to fund its operations for a period of at least one year after the date of signing these interim condensed consolidated financial statements. Management expects the Company to continue as a going concern based on its existing funding, taking into account the Company&#8217;s current cash position and the projected cash flows based on the activities under execution on the basis of ProQR&#8217;s business plan and budget. Thus, we continue to adopt the going concern basis of accounting in preparing the interim condensed consolidated financial statements.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The carrying amount of all financial assets and financial liabilities is a reasonable approximation of the fair value and therefore, information about the fair values of each class has not been disclosed.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company operates in </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_segment_iAZ-erTqcEibFQQvKQuMIg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="INF" format="ixt-sec:numwordsen" name="prqr:IfrsNumberOfReportableSegments" scale="0" id="Narr_lRm-LsImMkqi8Eg027mqdg">one</ix:nonFraction></span><span style="font-family:'Open Sans';"> reportable segment, which comprises the discovery and development of innovative, RNA based therapeutics.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations" id="Tb_3ZMAXfmTMkObXgmRjXSewA" continuedAt="Tb_3ZMAXfmTMkObXgmRjXSewA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">3. Adoption of New and Revised International Financial Reporting Standards</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">New Standards and Interpretations, which became effective as of January&#160;1, 2025, did not have a material impact on our condensed consolidated financial statements.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">7</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_3ZMAXfmTMkObXgmRjXSewA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="Tb_M7TfTwmnnkC06e7mvY9rAA" continuedAt="Tb_M7TfTwmnnkC06e7mvY9rAA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">4. Critical Accounting Estimates and Judgements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In the application of the Company&#8217;s accounting policies, management is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Open Sans';">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The significant judgements made by management in applying the Company&#8217;s accounting policies and the key sources of estimation uncertainty were the same as those described in the Company&#8217;s annual financial statements for the year ended December 31, 2024.</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="Tb_RfU_Fsdc20OWzTokcX7_UA" continuedAt="Tb_RfU_Fsdc20OWzTokcX7_UA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Open Sans';font-style:italic;">(i) Revenue recognition for the Eli Lilly and Company research and collaboration agreement</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">a. Identification of the performance obligations</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">As further described in Note 13 the identification of the performance obligations for the Company&#8217;s original research and collaboration agreement with Eli Lilly and Company (&#8220;Lilly&#8221;), and the amended and restated research and collaboration agreement (collectively, the &#8220;Collaboration agreement&#8221;) involves significant judgement.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">A key judgement was made in determining that the license granted to Lilly is not distinct from the associated research and development (&#8220;R&amp;D&#8221;) services, due to the lack of stand-alone value of the license without the Company&#8217;s involvement and the significant interdependencies between the license and the R&amp;D services to be provided by the Company. As a result, the license and the R&amp;D services are accounted for together as a single combined performance obligation consisting of multiple activities that are not distinct.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">b. Determining the timing of satisfaction of performance obligations</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">As further described in Note 13, before the handover of a compound to Lilly, the Company recognizes revenue over time, using an input method that estimates the satisfaction of the performance obligation as the percentage of labor hours incurred compared to the total estimated labor hours required to complete the promised services. As the Company&#8217;s estimate of the total labor hours required is dependent on the evolution of the research and development activities, it may be subject to change. If the progression and/or outcome of certain research and development activities would be different from the assumptions that were made during the preparation of these financial statements, this could lead to material adjustments to the total estimated labor hours, which might result in a reallocation of revenue between current and future periods. Our total deferred revenue balance related to this Lilly performance obligation amounts to &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_z_wMRuiDMEqEinzBTRrmJA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DeferredIncomeIncludingContractLiabilities" scale="0" id="Narr_VOVheS1Qh02s7WDUqe1OqA">41,492,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> at September 30, 2025 (December 31, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_N0cWD2q4NkeY3A32UZEFqg" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DeferredIncomeIncludingContractLiabilities" scale="0" id="Narr_3Uyr96w3A0yM-y17vmJrNw">50,930,000</ix:nonFraction></span><span style="font-family:'Open Sans';">).</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">c. Determining the transaction price</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company applied judgement to determine whether the equity investments made by Lilly in ProQR are part of the transaction price for the Collaboration agreement. The Company concluded that the differences between the prices that Lilly paid for the shares and the ProQR stock closing prices on the days of entering into the equity investment agreements arose because of the Company&#8217;s existing obligations to deliver research and development services to Lilly under the terms of the Collaboration agreement. Therefore, the above differences between the closing share prices on the agreement effective dates and the equity investment prices paid by Lilly are considered to be part of the transaction price of the contract and are initially allocated to deferred revenue.</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">8</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_M7TfTwmnnkC06e7mvY9rAA_cont1"><ix:continuation id="Tb_RfU_Fsdc20OWzTokcX7_UA_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The contract also includes variable consideration, but no variable consideration was included in the initial transaction price at the inception, as it was not highly probable that a significant reversal in the amount of cumulative revenue recognized would not occur. The Company includes such variable consideration in the transaction price when the uncertainty associated with the variable consideration is resolved. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Collaboration agreement includes variable consideration in the form of development milestones, commercial milestones, and sales-based royalties based on the level of sales. As further described in Note 13, during 2025, the Company achieved development milestones during the ProQR research program under the agreement, which were added to the transaction price and recognized partially as revenue during 2025 based on the status of completion (satisfied part) of the single combined performance obligation.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="Tb_lHv1HCh5iU2OpXOwcNcC-Q" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><i style="font-family:'Open Sans';font-style:italic;">(ii) Research and development expenditures</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Research expenditures are reflected in the income statement. Development expenses are currently also reflected in the income statement because the criteria for capitalization are not met. At each balance sheet date, the Company estimates the level of service performed by the vendors and the associated costs incurred for the services performed.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Although we do not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period.</span></p></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="Tb_ChgAjryzyECElOtwsik-mQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">5. Cash and Cash Equivalents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">At September 30, 2025, the Company&#8217;s cash and cash equivalents were &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Narr_CDQCzr5pyUC3BoGvweVStA">106,883,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> compared to &#8364;</span><span style="font-family:'Open Sans';">&#160;<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Narr_n65XTa3lQ06GJ4PqRN6CsA">149,408,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> at December&#160;31, 2024. The cash balances are held at banks with investment grade credit ratings. Short-term credit ratings must be rated A-1/P-1/F1 at a minimum by at least one of the Nationally Recognized Statistical Rating Organizations (&#8220;NRSROs&#8221;) specifically Moody&#8217;s, Standard &amp; Poor&#8217;s or Fitch. The cash at banks is at full disposal of the Company. Included in cash and cash equivalents are deposits fixed for at most 3-month periods at a time.</span></p></ix:nonNumeric><a id="Tc_GEG53cDmbkKGcIXsGeTxgg_1_2"></a><a id="Tc_PpzqeDbs_Uutb9S8DfjaZA_1_4"></a><a id="Tc_ObTRGK84QUuOK8q_5cehGg_2_2"></a><a id="Tc_app_w8M5KU2hont6kSrGRw_2_4"></a><a id="Tc_AlgJWcsfh0K2DY1RsXY8UA_3_2"></a><a id="Tc_cFE1CCwe9E-fNElZ3vEseA_3_4"></a><a id="Tc_499fUFCWgU6Tcu0y2vRhjw_4_0"></a><a id="Tc_ikNnmevdWk-G0ab4Wb-vTA_5_0"></a><a id="Tc_0AlaZaJ9HkuPuTPNCIa70w_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory" id="Tb_DwP1V_FtU0K_fG7PpoIgAw" continuedAt="Tb_DwP1V_FtU0K_fG7PpoIgAw_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.55;margin:0pt 0pt 4pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">6. Prepayments and Other Receivables</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="prqr:DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock" id="Tb_5FzAFasx5E6vBTT8QyuM4g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td></tr><tr><td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Prepayments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"> <ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Prepayments" scale="3" id="Tc_BBpTqlIuS0eIcu378-yRJQ_4_2">1,903</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Prepayments" scale="3" id="Tc_mWDsJV4HwEirpjb1_kzQew_4_4">2,410</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">Other receivables</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"> <ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" id="Tc_PygbQL_qpUSYltYiiJgtDQ_5_2">1,467</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" id="Tc_1OEiaaxHaEKOvbvVzKhhLg_5_4">835</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">Accrued income from Rett Syndrome Research Trust</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"> <ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AccruedIncomeIncludingContractAssets" scale="3" id="Tc_2J5jBjjt60-ebFVQLXvG5Q_6_2">502</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AccruedIncomeIncludingContractAssets" scale="3" id="Tc_6y-wzenrv0Ogv2_KuN_a2A_6_4">502</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.52%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="prqr:PrepaymentsAndOtherReceivables" scale="3" id="Tc_FQj9U1yRtUif5Xp9-pfTDw_7_2">3,872</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="prqr:PrepaymentsAndOtherReceivables" scale="3" id="Tc_H16DXKHYvkW1VsXtvJwWUA_7_4">3,747</ix:nonFraction> </b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">All receivables are considered short-term and due within one year. At September 30, 2025 and December 31, 2024 prepayments consisted principally of payments made by the Company for services not yet provided by vendors. At September 30, 2025 other receivables consisted principally of amounts receivable from research collaboration partners, accrued income and deposits. At December 31, 2024 other receivables consisted principally of accrued grant income and deposits. As at September 30, 2025 and December 31, 2024 the accrued grant income relating to Rett Syndrome Research Trust (&#8220;RSRT&#8221;) includes the initial fair value of the warrants issued to RSRT that was accounted for as a reduction of the transaction price. The RSRT agreement is described in Note 14. Other Income.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">9</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_DwP1V_FtU0K_fG7PpoIgAw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="Tb_aJUY1185c0yicVx68Rupmg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.55;margin:0pt 0pt 4pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">7. Property, Plant and Equipment</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">At September 30, 2025, and December 31, 2024, property plant and equipment consisted of buildings and leasehold improvements, laboratory equipment and other assets. Buildings and leasehold improvements include a right-of-use asset relating to the lease of our Leiden office and laboratory space, with a carrying amount of &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_Ps4wlpTyCk-CiG6i9mnIJg" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="0" id="Narr_DkL2cj1yZkGTbVZfYBCMag">10,448,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> at September&#160;30,&#160;2025 (December 31, 2024: &#8364;</span><span style="font-family:'Open Sans';">&#160;<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_pMfe7-CYZkSkMiFKJi9Z7Q" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="0" id="Narr_gaZdwmjC60e792oYazRriQ">11,433,000</ix:nonFraction></span><span style="font-family:'Open Sans';">).</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory" id="Tb_q4ptrGKyckeBrWjw31JzYQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.55;margin:0pt 0pt 4pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">8. Other Current Liabilities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">At September 30, 2025, other current liabilities amount to &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" id="Narr_8IyuMVPts02cln8TCxOGuQ">8,550,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> (December 31, 2024:&#160;&#8364; </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" id="Narr_-nn-5-b_pEyRELgVmiXNCQ">8,849,000</ix:nonFraction></span><span style="font-family:'Open Sans';">). At September 30, 2025 and December&#160;31, 2024, other current liabilities consisted principally of accruals for services provided by vendors not yet billed, payroll related accruals and other miscellaneous liabilities.</span></p></ix:nonNumeric><a id="Tc_PdSRJXzRP0e_COyfq-nWag_1_2"></a><a id="Tc_poFiQrqhgEuPGL7wyXOFLQ_1_4"></a><a id="Tc_q-0EIxKNkUix59RVsrkdqQ_2_2"></a><a id="Tc_FiPboxDgm06a7sYh96zJWQ_2_4"></a><a id="Tc_I5zMPxZv202ABV-5ybmJfg_3_2"></a><a id="Tc_2ijfohZftEqo1nKxDbzfeQ_3_4"></a><a id="Tc_vCNv-OWVKkmmFs97ZIaAww_4_0"></a><a id="Tc_ltJDj1w-V0Gbzi6m55g5pA_5_0"></a><a id="Tc_V0UiVExH3EyULV_tvbN4tA_7_0"></a><a id="Tc_yjYcA-JA5ESC_DDP4ftLVA_8_0"></a><a id="Tc_amKM9t43bka-u5a2uanptA_9_0"></a><a id="Tc_air8K8xlx0yCxQD-XQ2T6w_9_2"></a><a id="Tc_L6TJITF40EidQXzOpp6S8A_9_4"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfBorrowingsExplanatory" id="Tb_jMkQc_PXPk-jTqIFcy701A" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">9</b><b style="font-family:'Open Sans';font-weight:bold;">. Borrowings</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" id="Tb_d9-2gdHIAkC6zR7jKi00Yw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.39151382%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.78%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.62%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"> </b><span style="font-family:'Open Sans';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Innovation credit</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_Jm0ycghQx06aKQaV-XaMYg" decimals="-3" format="ixt:num-dot-decimal" name="prqr:BorrowingsExcludingAccruedInterest" scale="3" id="Tc_pU_mLJN_9EyUELoSWJXCOQ_4_2">2,899</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_U0bIiWfTwUK2UDFOYXKvcg" decimals="-3" format="ixt:num-dot-decimal" name="prqr:BorrowingsExcludingAccruedInterest" scale="3" id="Tc_nrsCRAzqi0-s8MgXRT6yKw_4_4">2,899</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Accrued interest on innovation credit</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_Jm0ycghQx06aKQaV-XaMYg" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPayable" scale="3" id="Tc_keiNtv9s4E6YeEqBTWVYPw_5_2">1,901</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_U0bIiWfTwUK2UDFOYXKvcg" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPayable" scale="3" id="Tc_FhiqUVNRSUiYYRMWPhWcgg_5_4">1,683</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">Total borrowings</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Borrowings" scale="3" id="Tc_UzMtNS93lkeMuaQSysapQg_7_2">4,800</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Borrowings" scale="3" id="Tc_Bt7fgqU85kWeojlonQL6yA_7_4">4,582</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Current portion</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" scale="3" id="Tc_wdRqE2Eef0O7uTHtcVfHqg_8_2">4,800</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" scale="3" id="Tc_tZqb77hm1kalkhTVVNwtMQ_8_4">4,582</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">Total non-current borrowings</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">&#8212; </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">&#8212; </b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In December 2018, ProQR was awarded an Innovation credit for the sepofarsen program. Amounts were drawn under this facility from 2018 through 2022. The credit of &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_10_12_2018_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_lbY8fExZj0i3II_9Pf9fhw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NotionalAmount" scale="0" id="Narr_1V4qG17pJUi1ZfhbYqZLvw">3,907,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> was used to conduct the Phase 2/3 clinical study and efforts to obtain regulatory and ethical market approval (New Drug Applications (&#8220;NDA&#8221;) / Marketing Authorization Applications (&#8220;MAA&#8221;)) of sepofarsen for LCA10. In the fourth quarter of 2023, ProQR made a partial repayment of the principal, amounting to &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_10_1_2023_To_12_31_2023_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_wm8LBrxXCkyzFCS9TM0Eaw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="0" id="Narr_Mi2-VXmMF0Sz5oHTk-Jgkw">1,008,000</ix:nonFraction></span><span style="font-family:'Open Sans';">. The remaining amount payable of &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_6_30_2025_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_PoXgbyj0VEimJfqnnq8vXw" decimals="-3" format="ixt:num-dot-decimal" name="prqr:CurrentBorrowingsExcludingAccruedInterest" scale="0" id="Narr_VFYPTbGozEWwAu3T2MbN5w">2,899,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> is recognized under current borrowings as at September 30, 2025 and December 31, 2024.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In December 2023, ProQR received a waiver for the remaining balance of the Innovation credit including accrued interest. As a result, the repayment of the total loan of &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_2suHy2Uqqkq-b7CLFUL2lg" decimals="-3" format="ixt:num-dot-decimal" name="prqr:ConditionalWaiverOfDebtTotal" scale="0" id="Narr_Ll1Nd4RN_0uncXx6JshItw">4,292,000</ix:nonFraction></span><span style="font-family:'Open Sans';">, including accrued interest, could be waived if conditions are met, subject to annual review. In January 2025, the waiver for the principal and interest was again extended until December 31, 2025.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;">In September 2022, ProQR extinguished its debt with Pontifax and Kreos by repaying all outstanding principal amounts. However, the Pontifax&#8217; and Kreos&#8217; warrants, classified as derivative financial instruments on the balance sheet, remain in place until their </span><ix:nonNumeric contextRef="Duration_9_1_2022_To_9_30_2022_prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_prqr_PontifaxAndKreosWarrantsMember_QDqtNs1aIEi1heNwMkeeNg" format="ixt-sec:durwordsen" name="prqr:WarrantsEconomicLifetime" id="Narr_okaQb4dpRkmceeuaur0azA"><span style="font-family:'Open Sans';font-size:9pt;">five-year</span></ix:nonNumeric><span style="font-family:'Open Sans';font-size:9pt;"> economic life expires in 2025 and 2026. These warrants are accounted for as embedded derivatives and were recognized separately from the host contract as derivative financial liabilities at fair value through profit or loss. During Q3 2025, the original Pontifax warrants expiring in July 2025 and the Kreos warrants expiring in August 2025 expired and were derecognized. </span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfLeasesExplanatory" id="Tb_gN9OWDFK60G1FTtDxBmJ9A" continuedAt="Tb_gN9OWDFK60G1FTtDxBmJ9A_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">10. Lease Liabilities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">At September 30, 2025 and December 31, 2024, lease liabilities primarily consisted of the Company&#8217;s lease of office and laboratory facilities at Zernikedreef in Leiden, the Netherlands. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Open Sans';">The Company leases office and laboratory facilities of </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_sqm_Oc_SVpN4d0OQM3FvR-NrfQ" contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_Ps4wlpTyCk-CiG6i9mnIJg" decimals="0" format="ixt:num-dot-decimal" name="prqr:AreaOfPropertyUnderLease" scale="0" id="Narr_vX-H8cAKYUWzkT74Q5izcw">4,818</ix:nonFraction></span><span style="font-family:'Open Sans';"> square meters at Zernikedreef in Leiden, the Netherlands, where our headquarters and our laboratories are located. The current lease agreement for these facilities terminates </span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">10</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gN9OWDFK60G1FTtDxBmJ9A_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">on June 30, 2031. The lease agreement contains no significant dismantling requirements. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;">The initial </span><span style="-sec-ix-hidden:Hidden_1k_9dkbIBE6F9vmNuzcVIw;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">10-year</span></span><span style="font-family:'Open Sans';font-size:9pt;"> lease agreement for the Leiden office and laboratory facilities was accounted for as of commencement date July 1, 2020. This </span><span style="-sec-ix-hidden:Hidden_9sghCigMRE-91luzw8kAXw;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">10-year</span></span><span style="font-family:'Open Sans';font-size:9pt;"> period was extended by </span><ix:nonNumeric contextRef="Duration_12_1_2020_To_12_31_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_mQAGEX8GEkW-yeLTTQ4VGA" format="ixt-sec:durwordsen" name="prqr:LeaseExtensionTerm" id="Narr_B4DRHiXTR06onj0Q0qdXvQ"><span style="font-family:'Open Sans';font-size:9pt;">1 year</span></ix:nonNumeric><span style="font-family:'Open Sans';font-size:9pt;"> to an </span><span style="-sec-ix-hidden:Hidden_zMWif57Oekmju6l1QF4dVQ;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">11-year</span></span><span style="font-family:'Open Sans';font-size:9pt;"> period in December 2020. The lease contract may be extended for subsequent </span><span style="-sec-ix-hidden:Hidden__Ne-iWIfzU6QAPw9QT7ObQ;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">5-year</span></span><span style="font-family:'Open Sans';font-size:9pt;"> periods. As the Company is not reasonably certain to exercise these extension options, these are not included in the lease term. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The carrying amount of the right-of-use asset is disclosed in Note 7.</span></p></ix:continuation><a id="Tc_out0rg1gTU618HWzBbqn3A_1_2"></a><a id="Tc_ETCC-tHea0K8rRN9O1eIGQ_1_4"></a><a id="Tc_ZDWMdHtaRk--6BIEWv9llQ_2_2"></a><a id="Tc_T56iHnX1YEen-W65ZJNREA_2_4"></a><a id="Tc_pWVIVZpsikmayrPdN7LA3w_3_2"></a><a id="Tc_2_FXeMR5MEal0_a77vMrsA_3_4"></a><a id="Tc_W8melKXJ9E2KzyiBfhjNyA_4_0"></a><a id="Tc_u-FJjJfjOkOIE5hxScDfzg_5_0"></a><a id="Tc_fKMmJAPukEilIVNH8PqoxA_6_0"></a><a id="Tc_qO3v9_DCcECB0zTMQ1fRCQ_8_0"></a><a id="Tc_yiUVu5Aq-U2azhlaGfUkow_9_0"></a><a id="Tc_Z0Wo43CjmUqkGp9Qv0wdZQ_11_0"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfDeferredIncomeExplanatory" id="Tb_fLg2hUh7eUOmf1w4HbQ71w" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">11. Deferred Income</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The following table summarizes details of deferred income at September 30, 2025 and December 31, 2024. The nature of the deferred income is described in Note 13 and 14.</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="prqr:ScheduleOfDeferredIncomeTableTextBlock" id="Tb_rRV0BxIlCE-pVGS08tAslA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">Payments from Eli Lilly and Company</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_z_wMRuiDMEqEinzBTRrmJA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" scale="3" id="Tc_ijR2YHA9wUm9TVlbkJWn3A_4_2">17,367</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_N0cWD2q4NkeY3A32UZEFqg" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" scale="3" id="Tc_MlZ8js4Ns0KirngWbvs27Q_4_4">21,501</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">Payments from Rett Syndrome Research Trust</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_EeQqadGBPU6ffQXEFmCknA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" scale="3" id="Tc_ZFjOrvA0NkWPjVzkIhm6JQ_5_2">27</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_rPv_1PsZlkyKXSb6IKaW-A" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" scale="3" id="Tc_PXu582gMHUysNzHfHojVOg_5_4">441</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Current deferred income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" scale="3" id="Tc_0BJltPkgGUeNVtj0WIkVqg_6_2">17,394</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" scale="3" id="Tc_tWvKzUmbHkq4HWgWoY9QoQ_6_4">21,942</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">Payments from Eli Lilly and Company</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_z_wMRuiDMEqEinzBTRrmJA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" scale="3" id="Tc_KcrTIq2O5ESNOtMwoSMRsg_8_2">24,125</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_N0cWD2q4NkeY3A32UZEFqg" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" scale="3" id="Tc_dgxwrtPto0aTu_sXXOOyVA_8_4">29,429</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Non-current deferred income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" scale="3" id="Tc_41H9ajUsA0igU4Yu_qIeUg_9_2">24,125</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" scale="3" id="Tc_6LrKfxvD_0S_kkcZw4lb_A_9_4">29,429</ix:nonFraction> </b></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.7%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Total deferred income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DeferredIncomeIncludingContractLiabilities" scale="3" id="Tc_ODxF5HgCD0q4dDxCmmfWnA_11_2">41,519</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DeferredIncomeIncludingContractLiabilities" scale="3" id="Tc_Mw5HUlJkuUWta-RcoQQ0vw_11_4">51,371</ix:nonFraction> </b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><span style="color:#ffffff;font-family:'Open Sans';">c</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="Tb_cyDyVCgfcUG6oNFak0LbrA" continuedAt="Tb_cyDyVCgfcUG6oNFak0LbrA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">12. Shareholders&#8217; Equity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The authorized share capital of the Company amounting to &#8364;</span><span style="font-family:'Open Sans';"> <ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt:num-dot-decimal" name="prqr:AuthorizedShareCapitalValue" scale="0" id="Narr_diUxTsC5yk69Vd9CrL2pOg">13,600,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> consists of </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_MWf62Mctg0SEca73DdSQSA" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr_7uN0ZbqfsEqUn0yiFqvDFQ">170,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> ordinary shares and </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_-bqBRBYnMkqbwyTudO1CSg" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr_AzPCc2C8oky3V_7aK_5Utg">170,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> preference shares with a par value of &#8364;</span><span style="font-family:'Open Sans';"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_Vod3mhiWN0KAgmuIusZn-g">0.04</ix:nonFraction></span><span style="font-family:'Open Sans';">&#160;per share. At September 30, 2025, </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_MWf62Mctg0SEca73DdSQSA" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_0wEDROJwOkmEi7Me7tLOCg">107,710,916</ix:nonFraction></span><span style="font-family:'Open Sans';"> ordinary shares were issued, </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_MWf62Mctg0SEca73DdSQSA" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" id="Narr_2TxHfKrTWEiNfX54bhZUYQ">105,345,192</ix:nonFraction></span><span style="font-family:'Open Sans';"> ordinary shares were fully paid and </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_MWf62Mctg0SEca73DdSQSA" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" scale="0" id="Narr_GEZ3W7N8i0Ge4NGuGC9Gfg">2,365,724</ix:nonFraction></span><span style="font-family:'Open Sans';"> ordinary shares were held by the Company as treasury shares (December 31, 2024: </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="As_Of_12_31_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_YJJKCH6_f0CGHWEK670wpw" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" scale="0" id="Narr_yhHCpl3Gykq3hzFPsbcUBQ">2,498,389</ix:nonFraction></span><span style="font-family:'Open Sans';">).</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In September 2024, the Company filed a shelf registration statement on Form F-3, which permitted: (a) the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_ShelfRegistrationStatement2024Member_ng7Fbf6gFUy4vNzZAU2odA" decimals="INF" format="ixt:num-dot-decimal" name="prqr:MaximumOfferingPriceInShelfRegistrationStatement" scale="0" id="Narr_n-EEwDtggkqxVW7vr6w-_Q">300,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> of its ordinary shares, warrants and/or units; and (b) as part of the $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_ShelfRegistrationStatement2024Member_ng7Fbf6gFUy4vNzZAU2odA" decimals="INF" format="ixt:num-dot-decimal" name="prqr:MaximumOfferingPriceInShelfRegistrationStatement" scale="0" id="Narr_rb_n4I7qdE2aiVRnogItuQ">300,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';">, the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_sHnEGchkcEymfM1vdGke-g" decimals="INF" format="ixt:num-dot-decimal" name="prqr:MaximumOfferingPriceInShelfRegistrationStatement" scale="0" id="Narr_yQ6AK1Lx-EufAkBBuiaf3g">75,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> of its ordinary shares that may be issued and sold under a sales agreement (the &#8220;sales agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) in one or more at-the-market (&#8220;ATM&#8221;) offerings. The Company will pay Cantor a commission equal to </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_sHnEGchkcEymfM1vdGke-g" decimals="2" format="ixt:num-dot-decimal" name="prqr:PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement" scale="-2" id="Narr_0J2QTWp1vk6nyp9wdcnJiQ">3</ix:nonFraction>%</span><span style="font-family:'Open Sans';"> of the gross proceeds of the sales price of all ordinary shares sold through it as sales agent under the sale agreement. As of September 30, 2025, </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_1_1_2024_To_12_31_2024_prqr_IfrsSaleOfStockAxis_prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_PGd6rcr3S0i-F2HTv9iGJg" decimals="INF" format="ixt-sec:numwordsen" name="prqr:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_CeV78P9rq0KA1OMCZ9ZWXQ">no</ix:nonFraction></span><span style="font-family:'Open Sans';"> shares have been issued pursuant to this ATM facility.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;">In October 2024, the Company consummated an underwritten public offering of </span><span style="font-family:'Open Sans';font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA" decimals="INF" format="ixt:num-dot-decimal" name="prqr:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_55jRqgcBrkqJvBTM0VLoOg">18,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';font-size:9pt;"> ordinary shares (the &#8220;offering&#8221;) at a public offering price of $&#160;</span><span style="font-family:'Open Sans';font-size:9pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q_6SzVvYpE-NdnoAmmu_UA" contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA" decimals="2" format="ixt:num-dot-decimal" name="prqr:IfrsSaleOfStockPricePerShare" scale="0" id="Narr_5TV9dKK-OkK4JQSdynBT5Q">3.50</ix:nonFraction></span><span style="font-family:'Open Sans';font-size:9pt;"> per share (the &#8220;public offering price&#8221;). In addition, the Company granted the underwriters a </span><span style="-sec-ix-hidden:Hidden_SBfXi-xh50yWDW8Jo_eMMQ;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">30-day</span></span><span style="font-family:'Open Sans';font-size:9pt;"> option to purchase up to </span><span style="font-family:'Open Sans';font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="As_Of_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_dbgoR6vcMUqTMO3jvVhl5g" decimals="INF" format="ixt:num-dot-decimal" name="prqr:NumberOfSharesCallableForOptionsIssued" scale="0" id="Narr_STqEDCfXaEuJlRjcCVkl6g">2,700,000</ix:nonFraction></span><span style="font-family:'Open Sans';font-size:9pt;"> additional ordinary shares at the public offering price, less underwriting discounts and commissions. The option was partially exercised on October 31, 2024, resulting in the issuance of </span><span style="font-family:'Open Sans';font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_10_31_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_SQEbr7EQSkStP6J8wDVlYQ" decimals="INF" format="ixt:num-dot-decimal" name="prqr:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_SbiJHTTzyEaQE-uDVbtxqQ">1,940,072</ix:nonFraction></span><span style="font-family:'Open Sans';font-size:9pt;"> shares. The gross proceeds from the Offering and subsequent partial exercise of the underwriters&#8217; option, amounted to $&#160;</span><span style="font-family:'Open Sans';font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="Narr_AnXN3GFZ_0m2IeGJOeyURA">69,790,000</ix:nonFraction></span><span style="font-family:'Open Sans';font-size:9pt;"> (&#8364;&#160;</span><span style="font-family:'Open Sans';font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="Narr_1ZxUpkhnVE6Snc19GyGbCg">64,600,000</ix:nonFraction></span><span style="font-family:'Open Sans';font-size:9pt;">) while the transaction costs amounted to approximately &#8364;&#160;</span><span style="font-family:'Open Sans';font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="0" id="Narr_VTno_8wWx0KsBpGdq7YsZQ">4,365,000</ix:nonFraction></span><span style="font-family:'Open Sans';font-size:9pt;">, resulting in net proceeds of approximately &#8364;&#160;</span><span style="font-family:'Open Sans';font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA" decimals="-3" format="ixt:num-dot-decimal" name="prqr:NetProceedsFromIssuingShares" scale="0" id="Narr_mhEr6BpOpEerF6VrGjTMHA">60,235,000</ix:nonFraction></span><span style="font-family:'Open Sans';font-size:9pt;">.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">11</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_cyDyVCgfcUG6oNFak0LbrA_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Concurrently with the Offering, the Company entered into a share purchase agreement with Lilly in a separately negotiated transaction (the &#8220;concurrent private placement&#8221;), pursuant to which the Company agreed to offer and sell, and Lilly agreed to purchase, </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_10_25_2024_To_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_1SV3IDfQekeRE9nHK-mnpw" decimals="INF" format="ixt:num-dot-decimal" name="prqr:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_-_b786Sy9k2SwPjnLv_0OA">3,523,538</ix:nonFraction></span><span style="font-family:'Open Sans';"> ordinary shares at a price per share equal to the public offering price, for total gross proceeds of approximately $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="Duration_10_25_2024_To_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_1SV3IDfQekeRE9nHK-mnpw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="Narr_vwJqSs5UZU2wMeiq8wqZAA">12,300,000</ix:nonFraction></span><span style="font-family:'Open Sans';">, subject to a purchase price cap of $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="As_Of_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_b5MiuBOLvkiPnH8dj15XoQ" decimals="INF" format="ixt:num-dot-decimal" name="prqr:PurchasePriceCapSharePurchaseAgreement" scale="0" id="Narr_380FeGJDA0Kogow3Y5Gh0A">15,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';">, the consummation of the Offering and the satisfaction of other customary closing conditions. The proceeds of $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="Duration_10_25_2024_To_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_1SV3IDfQekeRE9nHK-mnpw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="Narr_Q27qrXEFNUKbMb5duVf89w">12,300,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> (&#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_10_25_2024_To_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_1SV3IDfQekeRE9nHK-mnpw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="Narr_GRD9dVc0mkCnNlm7dXHuNA">11,400,000</ix:nonFraction></span><span style="font-family:'Open Sans';">) from the concurrent private placement were received on October 25, 2024. The ordinary shares purchased in the concurrent private placement are not subject to any underwriting discounts or commissions.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Open Sans';font-style:italic;">Translation reserve</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Open Sans';font-style:italic;">Share options</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company operates an equity-settled share-based compensation plan, which was introduced in 2013. Options and Restricted Stock Units (&#8220;RSUs&#8221;) may be granted to employees, members of the Board and consultants. The compensation expenses included in operating costs for this plan in the nine month period ended September 30, 2025 were &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" id="Narr_lCbwnsJ_y0-p1Hiiekyx7g">2,784,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> (nine month period ended September 30, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" id="Narr_S-L7AOC3gkWTRRyWV9ToVg">1,976,000</ix:nonFraction></span><span style="font-family:'Open Sans';">), of which &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_NBruH9iPUEO1qm4ppbYCPA" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" id="Narr_0I6pAeW_hEqZc8w1a6OgKw">1,952,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> was recorded in general and administrative costs (nine month period ended September 30, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_JxIfwdbS8kWh6YPJlU9p3w" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" id="Narr_xD0rA6EYyECnO1AJMli6Qg">1,559,000</ix:nonFraction></span><span style="font-family:'Open Sans';">) and &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsResearchAndDevelopmentExpenseMember_tcUIS9w0g0CCeSma1Lfl1Q" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" id="Narr_g7KNz4-r2k-CgX_cQ_xRRg">832,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> was recorded in research and development costs (nine month period ended September 30, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsResearchAndDevelopmentExpenseMember_cdQDW243CEmqV7EBFQBmvQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" id="Narr_E-KwUP1dxkSNPeE2hH7Qbw">417,000</ix:nonFraction></span><span style="font-family:'Open Sans';">).</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfRevenueExplanatory" id="Tb_eLS7qS-_sU-oZvJsYdQmHg" continuedAt="Tb_eLS7qS-_sU-oZvJsYdQmHg_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">13. Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Open Sans';font-style:italic;">Eli Lilly and Company collaboration</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In September 2021, the Company entered into a global licensing and research collaboration with Lilly focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR and Lilly will use ProQR&#8217;s proprietary Axiomer</span><span style="font-size:11pt;">&#8482;</span><span style="font-family:'Open Sans';"> RNA editing platform to progress new drug targets toward clinical development and commercialization.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Under the terms of the agreement, ProQR received an upfront payment and equity consideration, and is eligible to receive milestone payments and royalties on the net sales of any resulting products. In September 2021, the Company issued </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_9_1_2021_To_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_m4ViI6b7i0S1NobB07mbHQ" decimals="INF" format="ixt:num-dot-decimal" name="prqr:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Wo5xoSEZBEKdHJtr9OZ3yA">3,989,976</ix:nonFraction></span><span style="font-family:'Open Sans';"> shares to Lilly, resulting in gross proceeds of </span><span style="font-family:'Open Sans';">$&#160;<ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="Duration_9_1_2021_To_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_m4ViI6b7i0S1NobB07mbHQ" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="Narr_NgIapWR0nEi525SfM3bkRw">30,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> (&#8364;</span><span style="font-family:'Open Sans';">&#160;<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_9_1_2021_To_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_m4ViI6b7i0S1NobB07mbHQ" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="Narr_L8qhLvtr1E6PCoaPd2ekYg">25,270,000</ix:nonFraction></span><span style="font-family:'Open Sans';">). These shares were issued at a premium of $ </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="As_Of_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_hWA0MWK6lUqB0UHEeVamnw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DeferredIncomeIncludingContractLiabilities" scale="0" id="Narr_Xt8xNRYywUSmjTWnPAxtpg">2,429,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> (&#8364; </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_hWA0MWK6lUqB0UHEeVamnw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DeferredIncomeIncludingContractLiabilities" scale="0" id="Narr_x25xtSRj-Uad8_I8xky5Ew">2,047,000</ix:nonFraction></span><span style="font-family:'Open Sans';">), which was determined to be part of the transaction price and as such was initially recognized as deferred revenue. An up-front payment of $</span><span style="font-family:'Open Sans';">&#160;<ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="Duration_10_1_2021_To_10_31_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GmQU-y9rwk-z-77kvpEtVw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices" scale="0" id="Narr_34lOyA_BsEWsPhppx9HLnA">20,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> (&#8364; </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_10_1_2021_To_10_31_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GmQU-y9rwk-z-77kvpEtVw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices" scale="0" id="Narr_wuPYktp-dUO9HHH7ps_rvQ">16,849,000</ix:nonFraction></span><span style="font-family:'Open Sans';">) was received in October 2021.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In December 2022, the Company and Lilly amended their research and collaboration agreement described above, which expanded the collaboration. Under the amended and restated research and collaboration agreement, Lilly will gain access to additional targets in the central nervous system (&#8220;CNS&#8221;) and peripheral nervous system (&#8220;PNS&#8221;) with ProQR&#8217;s Axiomer platform.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">As described under Note 12, pursuant to the amended and restated agreement, the Company issued </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA" contextRef="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g" decimals="INF" format="ixt:num-dot-decimal" name="prqr:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_5AdN7w_p1UimFpNPHKo3hQ">9,381,586</ix:nonFraction></span><span style="font-family:'Open Sans';"> shares to Lilly in December 2022, resulting in gross proceeds of $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="Narr_1u4QR43Xfk-gwBDdlEweKQ">15,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> (&#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="Narr_6Pg85B_yr0KKLMGnwiwdKw">14,122,000</ix:nonFraction></span><span style="font-family:'Open Sans';">). These shares were issued at a discount of $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g" decimals="-3" format="ixt:num-dot-decimal" name="prqr:DiscountOnIssueOfShares" scale="0" id="Narr_oCLhZz3-jkuklcw7b4lQHQ">480,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> (&#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g" decimals="-3" format="ixt:num-dot-decimal" name="prqr:DiscountOnIssueOfShares" scale="0" id="Narr_CZUAuQjwvk22VCkI9jImYA">451,000</ix:nonFraction></span><span style="font-family:'Open Sans';">), which is accounted for as a reduction of the transaction price. In February 2023, ProQR also received an upfront payment of $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="Duration_2_1_2023_To_2_28_2023_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_ifrs-full_ProductsAndServicesAxis_prqr_MilestonePaymentsMember_8ueA1NVJtEa4bfujUxBP3g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices" scale="0" id="Narr_oj-Edp89uECsk0Nv1XsAUA">60,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> (&#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_2_1_2023_To_2_28_2023_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_ifrs-full_ProductsAndServicesAxis_prqr_MilestonePaymentsMember_8ueA1NVJtEa4bfujUxBP3g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices" scale="0" id="Narr_KdZjxwqm5kCXQ0LuX_3nTw">56,412,000</ix:nonFraction></span><span style="font-family:'Open Sans';">). Lilly has the ability to exercise an option to further expand the partnership for a consideration of $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_z_wMRuiDMEqEinzBTRrmJA" decimals="-3" format="ixt:num-dot-decimal" name="prqr:AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership" scale="0" id="Narr_9bsWcbRyq0S7I1QG6PHAYA">50,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';">.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">12</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_eLS7qS-_sU-oZvJsYdQmHg_cont1" continuedAt="Tb_eLS7qS-_sU-oZvJsYdQmHg_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">With regard to the original and amended and restated research and collaboration agreements with Lilly, the Company concluded as follows:</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">The amended and restated research and collaboration agreement is accounted for as a separate contract under IFRS 15 given the group of promises to be delivered are distinct and are priced commensurate with stand-alone selling prices.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">For each of the agreements, the company identified </span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_iVCbzNhSAkCnatzraPCD8A" decimals="INF" format="ixt-sec:numwordsen" name="prqr:NumberOfPerformanceObligationsInCollaborationAgreement" scale="0" id="Narr_FdrWjPocPEq8gxjHxFGIfg">one</ix:nonFraction></span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"> performance obligation under IFRS 15, for the transfer of a license combined with the performance of research and development activities. The Company concluded that the license is not capable of being distinct and is not distinct in the context of the contract. ProQR&#8217;s services are evaluated as predominant at inception of the contract and the compounds resulting from the collaboration do not represent a series of distinct promises because they were not predetermined at the inception of the contract and can be terminated or replaced at the discretion of Lilly subject to the terms and conditions of the Collaboration agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">The transaction price of the agreement includes fixed components, consisting of an up-front fee and an equity component (premium or discount). The agreement also contains variable parts, notably milestones, which are included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Development milestone payments to be reached during the ProQR research program will only be included to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the milestones is subsequently resolved. Sales-based milestones and sales-based royalties will be included as the underlying sales occur.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">Initially, the Company recognizes revenue over time, using an input method that estimates the satisfaction of the performance obligation as the percentage of labor hours incurred compared to the total estimated labor hours required to complete the promised services.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">After the handover of a compound to Lilly:</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">The variable consideration for development milestones to be reached during the Lilly R&amp;D activities is linked to a separable right to use the license which comes into existence for each successful compound transferred to Lilly. This license is a separate performance obligation and revenue will be recognized at a point in time when the development milestone for a license is achieved and the variable constraint is resolved. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">The variable consideration for commercial milestones is linked to a separable right to use the license which comes into existence for each successful compound transferred to Lilly. This license is a separate performance obligation and will be recognized at a point in time when the commercial milestone for a license is achieved and the variable constraint is resolved. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">For sales-based royalties, the license is the predominant item to which the royalty relates. The sales-based royalties will be recognized after the handover of the compound to Lilly (after completion of the initial performance obligation) and once the respective sale level occurs. &#160; </span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Open Sans';">During the nine month period ended September 30, 2025, the Company reached milestones amounting to $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_iVCbzNhSAkCnatzraPCD8A" decimals="0" format="ixt:num-dot-decimal" name="prqr:ValueOfMilestonesReachedDuringPeriod" scale="0" id="Narr_DvIe6MLwK0WiiNytDTFkkw">2,000,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> (&#8364; </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_iVCbzNhSAkCnatzraPCD8A" decimals="-3" format="ixt:num-dot-decimal" name="prqr:ValueOfMilestonesReachedDuringPeriod" scale="0" id="Narr_g2K4h_Be0kijqu0ZG3aoDA">1,781,000</ix:nonFraction></span><span style="font-family:'Open Sans';">) under the agreement, which was added to the transaction price and recognized partially as revenue during the nine month period ended September 30, 2025.</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">13</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_eLS7qS-_sU-oZvJsYdQmHg_cont2"></ix:continuation><a id="Tc_0CCg7bhggESep8-SWQRsQw_1_2"></a><a id="Tc_W53CHgqSbkujWDcQsgMl-A_2_2"></a><a id="Tc_MYbMRb3H_kaNy78oPUmdyg_3_2"></a><a id="Tc_gmGiPqZGyUSz72Z3CTaziw_3_4"></a><a id="Tc_OnMHcSe4l06Z9GiVJlfNUg_4_2"></a><a id="Tc_3lx4YJfS1UOK35AoNEb1cA_4_4"></a><a id="Tc_TOKQrT0TDECYaApZ3NEVgQ_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory" id="Tb_wwGOATHyvk2mVmhBljkd_w" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">14. Other Income</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="prqr:DisclosureOfOtherIncomeTableTextBlockExplanatory" id="Tb_-jqs_D44rkacgzYirbNi7g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.34%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">Nine month period </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.34%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"> </b><span style="font-family:'Open Sans';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">Grant income</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="prqr:IfrsRevenueFromGrants" scale="3" id="Tc_8mrcAopUCUOkw3GvMGC1TQ_6_2">413</ix:nonFraction> </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="prqr:IfrsRevenueFromGrants" scale="3" id="Tc_hiC1asDPVUWYP8zNbGBPSg_6_4">504</ix:nonFraction> </span></p></td></tr><tr><td style="vertical-align:top;width:70.69%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" id="Tc_L4yBsUrBcESPvjgnzkrGug_7_2">413</ix:nonFraction> </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" id="Tc_lQiDjFZ6VEamixM29S5dkw_7_4">504</ix:nonFraction> </b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In January, 2024, the Company entered into an agreement with the RSRT that focuses on the design and development of editing oligonucleotides (&#8220;EONs&#8221;) using the Company&#8217;s Axiomer technology platform targeting the transcription factor Methyl CpG binding protein 2 (&#8220;MECP2&#8221;) and correcting mutations of interest. Under the agreement, RSRT awarded the Company up to &#8364;</span><span style="font-family:'Open Sans';">&#160;<ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_1_31_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_2f19mTxVb0akP73Sa_oSQg" decimals="-3" format="ixt:num-dot-decimal" name="prqr:MaximumGrantReceivableForInitialPhaseOfProject" scale="0" id="Narr_Pd2JSR1Y90Ohn-8uIu150w">1,015,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> as a research grant for the initial phase of the project that was received during 2024. Of this grant &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_xZ1UKhJoMEuxAabw7b7dlQ" decimals="-3" format="ixt:num-dot-decimal" name="prqr:IfrsRevenueFromGrants" scale="0" id="Narr_G7v4UxFhnUyZ5x2IEnhIWA">504,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> was recognized as Other Income during the nine month period ended September 30, 2024, and &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_0tkeXgS6dkGzbdukDKq5tg" decimals="-3" format="ixt:num-dot-decimal" name="prqr:IfrsRevenueFromGrants" scale="0" id="Narr_NspaL1-THU6-a-e8FyMsTA">413,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> recognized as Other Income for the nine month period ended September 30, 2025. The balance was recorded as Deferred Income in 2024 and 2025.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In December 2024, the Company expanded partnership with RSRT to include an additional $&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg" contextRef="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_rPv_1PsZlkyKXSb6IKaW-A" decimals="-3" format="ixt:num-dot-decimal" name="prqr:MaximumGrantReceivableForAdditionalPhaseOfProject" scale="0" id="Narr_grHHc4_3NkyGfwyi9vDA8A">8,150,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> in funding from the RSRT to support the advancement of the selected candidates into clinical trials. As at September 30, 2025 </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_0tkeXgS6dkGzbdukDKq5tg" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices" scale="0" id="Narr_WF5G3671_kq0FlZ5ryggGw">no</ix:nonFraction></span><span style="font-family:'Open Sans';"> amounts have been received under this agreement and the work has not yet commenced.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Grants are recognized in other income in the same period in which the related R&amp;D costs are recognized.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory" id="Tb_ogn-uM3jPEG91xi1hm-Qxw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">15. Research and Development Costs</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Research and development costs amount to &#8364; </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" id="Narr_T6ADJSRJvECvtgkQ6Z8upw">34,811,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> for the nine month period ended September 30, 2025 (nine month period ended September 30, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" id="Narr_L0e6-2Xq-ki6z8zyH9MMLQ">25,745,000</ix:nonFraction></span><span style="font-family:'Open Sans';">) and are comprised of allocated employee costs including share-based payments, the costs of materials and laboratory consumables, outsourced activities, license and intellectual property costs and other allocated costs. Research and development costs increased compared to the same period in the prior year, mainly due to the Company&#8217;s increased outsourced research and development activities in the nine month period of 2025 and increased full time employee equivalents (&#8220;FTE&#8221;).</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory" id="Tb_A8iuq0q9aUSp8CRhvNiRog" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">16. General and Administrative Costs</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">General and administrative costs amount to &#8364; </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" id="Narr__9p3mzCUJUW6pDAysBJWuQ">11,169,000</ix:nonFraction></span><span style="font-family:'Open Sans';"> for the nine month period ended September 30, 2025 (nine month period ended September 30, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" id="Narr__yVvzMKGkU-TvvRSQe11FA">9,748,000</ix:nonFraction></span><span style="font-family:'Open Sans';">).</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="Tb_Iw4TdkoweEOFGXdS8vm_LA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">17. Investments in Financial Assets</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Investment in financial assets consist of the Company&#8217;s investment in Phoenicis Therapeutics Inc. (&#8220;Phoenicis&#8221;) and Yarrow Biotechnology Inc. (&#8220;Yarrow&#8221;).</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">ProQR holds a </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_yg5IGweIK0qeV0bYXpRQJg" decimals="3" format="ixt:num-dot-decimal" name="prqr:ProportionOfOwnershipInterest" scale="-2" id="Narr_GDt9Ptcu_UC_Dzuf7EH1Dg">3.9</ix:nonFraction>%</span><span style="font-family:'Open Sans';"> interest in Phoenicis. As at September 30, 2025, the investment amounts to &#8364;</span><span style="font-family:'Open Sans';"> <ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_yg5IGweIK0qeV0bYXpRQJg" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="0" id="Narr_vZgd1BBmBky1npntl0K-Ew">nil</ix:nonFraction></span><span style="font-family:'Open Sans';"> (December 31, 2024: &#8364;</span><span style="font-family:'Open Sans';"> <ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_Px873arFI0yxw9TbKLJcIw" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="0" id="Narr_JFmMboMN-kO74Ap3CYzi5w">nil</ix:nonFraction></span><span style="font-family:'Open Sans';">). Phoenicis discontinued its research and development operational activities during the quarter ended September 30, 2024. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">ProQR holds a </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q" contextRef="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_YarrowBiotechnologyMember_9ABsPfcrBEWgLl8UM2SqAg" decimals="3" format="ixt:num-dot-decimal" name="prqr:ProportionOfOwnershipInterest" scale="-2" id="Narr_nVhn6JQfF0GkeSg8Z54jYA">5.1</ix:nonFraction>%</span><span style="font-family:'Open Sans';"> interest in Yarrow. As at September 30, 2025, the fair value of the Yarrow financial asset amounted to &#8364;</span><span style="font-family:'Open Sans';"> <ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_YarrowBiotechnologyMember_9ABsPfcrBEWgLl8UM2SqAg" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="0" id="Narr_gvVuCS3ViEKm1W4XveuSQA">nil</ix:nonFraction></span><span style="font-family:'Open Sans';"> (December 31, 2024: &#8364;</span><span style="font-family:'Open Sans';"> <ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_YarrowBiotechnologyMember_16WLvw49kkCNj0VZA6LAug" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="0" id="Narr_8lfTSC9R_kSpnOI4QlF50g">nil</ix:nonFraction></span><span style="font-family:'Open Sans';">).</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><span style="color:#00aaa1;">PAGE </span><span style="color:#00aaa1;">14</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;min-height:14.0pt;text-align:right;margin:0pt;">Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="Tb_6-OOO6rwjUqCmcsL9s4Cfw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">18</b><b style="font-family:'Open Sans';font-weight:bold;">. Income Taxes</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The current income tax liability amounts to &#8364; </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:CurrentTaxLiabilities" scale="0" id="Narr_lANLZen4u0ir-NUGFxI-QA">nil</ix:nonFraction></span><span style="font-family:'Open Sans';"> at September 30, 2025 (December 31, 2024: &#8364; </span><span style="font-family:'Open Sans';"><ix:nonFraction unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg" contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:CurrentTaxLiabilities" scale="0" id="Narr_dEowfBrv4E-HTsJnITmTUw">nil</ix:nonFraction></span><span style="font-family:'Open Sans';">). No significant temporary differences exist between accounting and tax results. Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which are uncertain. Accordingly, the Company has not yet recognized any deferred tax asset related to operating losses.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Tax losses in the Netherlands may be carried forward indefinitely. However, the offset of losses will be limited in a given year against the first &#8364; 1 million of taxable profit. For taxable profit in excess of this amount, losses may only be offset up to 50% of this excess. In addition, unused non-deductible interest expenses may be carried forward indefinitely. However, the offset will be limited in a given year against the higher of 20% of adjusted taxable profit or &#8364; 1.0 million of interest income.</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="Tb_uaVzvgbVSEqM-9ULQjgPUg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">19. Related-Party Transactions</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company does not have any transactions with related parties other than compensation to its Board members.</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="Tb_zyHFT-3H_kOjnmH5Nl52Ow" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">20. Events After Balance Sheet Date</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">None.</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;visibility:hidden;background:#ffff00;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>prqr-20250930xex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 11/4/2025 03:07:49 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:13.14%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="color:#ff0000;font-family:'Franklin Gothic Medium';font-size:9pt;letter-spacing:1pt;min-height:17.0pt;text-align:right;text-indent:0pt;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;letter-spacing:0pt;text-transform:none;">Exhibit</b><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;letter-spacing:0pt;"> 99.2</b></p><p style="color:#23a49b;font-family:'DIN Offc Pro Black';font-size:24pt;line-height:28pt;margin:0pt 0pt 28pt 0pt;">ProQR Announces Third Quarter 2025 Operating and Financial Results</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:17.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;">Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseases</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:17.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;">Initiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagement data from all cohorts in H1 2026</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:17.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8364; 106.9 million cash and cash equivalents as of end Q3 &#8211; providing runway into         mid-2027</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., November 6, 2025 &#8211; ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer</font><font style="color:#262626;font-size:11pt;">&#8482;</font><font style="font-size:11pt;"> RNA editing technology platform, today reported its financial and operating results for the third quarter ended September 30, 2025, and provided a business update.</font></p><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:11pt;">&#8220;Last month we achieved an important milestone with the CTA authorization and are initiating our first-in-human study for AX-0810, marking a significant step forward for both this program and our Axiomer RNA editing platform,&#8221; said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. &#8220;This study represents the first clinical evaluation of an Axiomer editing oligonucleotide and positions us to deliver initial safety and PK data before year-end, followed by target engagement data in the first half of 2026. Supported by our strong cash position providing runway into mid-2027, we continue to advance our broader pipeline, platform, and partnership activities, executing on our strategy to deliver transformative RNA editing therapies for diseases with high unmet need.&#8221;</font></p><p style="font-family:'Open Sans';font-size:10pt;font-style:italic;font-weight:bold;line-height:17pt;padding-left:36pt;text-indent:-36pt;margin:17pt 0pt 6pt 0pt;"><b style="color:#333333;font-size:13pt;font-style:normal;font-weight:bold;">Recent Progress</b><a name="_Hlk70330146"></a><a name="_Hlk132726567"></a><b style="color:#333333;font-size:13pt;font-style:normal;font-weight:bold;"> and Anticipated Upcoming Events</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:17.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#262626;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;">In November, the Company hosted a </font><b style="color:#23a49b;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">virtual analyst and investor event&#160;focused&#160;on AX-0810</b><font style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;">, highlighting the Phase 1 trial design and target engagement/biomarker strategy.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:17.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#262626;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:bold;">AX-0810</b><font style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;"> uses Axiomer&#8217;s ability to modulate protein function by targeting NTCP for the treatment of cholestatic diseases. In October </font><b style="color:#23a49b;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">AX-0810 received CTA authorization</b><b style="color:#23a49b;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:bold;"> </b><font style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;">and a first-in-human (FIH) Phase 1 study is being initiated in healthy volunteers. Initial safety, tolerability, and PK data for Cohort 1 is expected toward the end of 2025 with target engagement data for all healthy volunteer cohorts in the first half of 2026. In parallel, </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:13.14%;margin-top:30pt;page-break-after:always;width:76.51%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:13.14%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:17.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#262626;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;">activities are underway to include a patient cohort in this FIH following completion of the healthy volunteer cohorts.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:17.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#262626;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;">Beyond AX-0810, ProQR&#8217;s Axiomer pipeline demonstrates the broad potential of RNA editing across three key applications &#8211; modulate, correct, and protect &#8211; with updates expected across these earlier-stage programs in the coming months.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#262626;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:bold;">AX-2402</b><font style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;"> applies Axiomer RNA editing to correct disease-causing mutations, targeting the R270X nonsense mutation in MECP2 to restore normal protein function for the treatment of Rett syndrome. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#262626;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:bold;">AX-2911</b><font style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;"> leverages Axiomer&#8217;s ability to modulate protein activity by editing the I148M mutation in PNPLA3, the strongest known genetic risk factor for fatty liver disease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#262626;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:bold;">AX-1412</b><font style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;"> demonstrates Axiomer&#8217;s protective application, mimicking a naturally occurring B4GALT1 variant associated with significantly reduced cardiovascular risk.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:17.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;">In October, the Company presented at the </font><b style="color:#23a49b;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Oligonucleotide Therapeutics Society (OTS)&#160;Annual Meeting</b><font style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;"> in Budapest, highlighting applications of its Axiomer RNA editing platform technology.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:17.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#262626;font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#262626;font-family:'Open Sans';font-size:11pt;font-style:normal;font-weight:normal;">ProQR continues to execute on partnership with Eli Lilly and Company (Lilly), with potential data updates and milestone income from the ongoing collaboration.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Open Sans';font-size:10pt;font-style:italic;font-weight:bold;line-height:17pt;padding-left:36pt;text-indent:-36pt;margin:17pt 0pt 6pt 0pt;"><b style="color:#333333;font-size:13pt;font-style:normal;font-weight:bold;">Financial Highlights</b></p><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">At September 30, 2025, ProQR held cash and cash equivalents of approximately &#8364; 106.9 million, compared to &#8364; 149.4 million at December 31, 2024. </font></p><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Net cash used in operating activities during the nine-month period ended September 30, 2025 was &#8364; 39.4 million, compared to &#8364; 27.0 million used for the same period last year.</font> <font style="font-size:11pt;">During the first nine months of 2025, the Company achieved certain milestones in the collaboration agreement with Eli Lilly amounting to $2.0 million (</font>~<font style="font-size:11pt;">&#8364; 1.8 million). </font></p><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Research and development (R&amp;D) costs were &#8364; 34.8 million for the nine month period ended September 30, 2025 compared to &#8364; 25.7 million for the same period last year.</font></p><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">General and administrative costs were &#8364; 11.2 million for the nine month period ended September 30, 2025 compared to &#8364; 9.7 million for the same period in 2024.</font></p><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Net loss for the nine month period ended September 30, 2025 was &#8364; 33.3 million, or &#8364; 0.32 per diluted share, compared to &#8364; 18.5 million, or &#8364; 0.23 per diluted share, for the same period last year. For further financial information for the period ended September 30, 2025, please refer to the Q3 financial report 6-K filing.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:13.14%;margin-top:30pt;page-break-after:always;width:76.51%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:13.14%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Open Sans';font-size:10pt;font-style:italic;font-weight:bold;line-height:17pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;"><b style="color:#333333;font-size:13pt;font-style:normal;font-weight:bold;">About Axiomer&#8482;</b></p><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">ProQR is pioneering a next-generation RNA base editing technology called Axiomer&#8482;, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer&#8482; &#8220;Editing Oligonucleotides&#8221;, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer&#8482; EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA &#8211; an Inosine is translated as a Guanosine (G) &#8211; correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.</font></p><p style="font-family:'Open Sans';font-size:10pt;font-style:italic;font-weight:bold;line-height:17pt;padding-left:36pt;text-indent:-36pt;margin:17pt 0pt 6pt 0pt;"><b style="color:#333333;font-size:13pt;font-style:normal;font-weight:bold;">About ProQR</b></p><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer&#8482;, which uses a cell&#8217;s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.</font></p><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Learn more about ProQR at </font><b style="color:#23a49b;font-size:11pt;font-weight:bold;">www.proqr.com</b><font style="font-size:11pt;">.</font></p><p style="font-family:'Open Sans';font-size:10pt;font-style:italic;font-weight:bold;line-height:17pt;padding-left:36pt;text-indent:-36pt;margin:17pt 0pt 6pt 0pt;"><b style="color:#333333;font-size:13pt;font-style:normal;font-weight:bold;">Forward Looking Statements </b></p><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="white-space:pre-wrap;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#8220;continue,&#8221; &quot;anticipate,&quot; &quot;believe,&quot; &quot;could,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;goal,&quot; &quot;intend,&quot; &quot;look forward to&quot;, &quot;may,&quot; &quot;plan,&quot; &quot;potential,&quot; &quot;predict,&quot; &quot;project,&quot; &quot;should,&quot; &quot;will,&quot; &quot;would&quot; and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our business, technology, strategy, preclinical and clinical model data, our initial pipeline targets and the upcoming strategic priorities and milestones related thereto, the continued advancement of our lead development pipeline programs, including ongoing and planned clinical trials, the planned Phase 1 clinical study of for AX-0810 in NTCP for cholestatic diseases, including the planned trial design, implementation and initiation in the Netherlands, and our ability to recruit for and complete a Phase 1 clinical trial for AX-0810 in healthy volunteers; expectations regarding the safety and therapeutic benefits of AX-0810, including the planned dosing levels and their efficacy; the anticipated timing of initial Phase 1 clinical data for our lead program, AX-0810,  and other programs, the continued development and advancement of our Axiomer platform, the therapeutic potential of our Axiomer RNA editing oligonucleotides and product candidates, the timing, progress and results of our preclinical studies and other development and pipeline activities, including the release of data </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:13.14%;margin-top:30pt;page-break-after:always;width:76.51%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:13.14%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="white-space:pre-wrap;">related thereto, our patent estate, including our anticipated strength and our continued investment in it, as well as the timing of our clinical development, the potential of our technologies and product candidates, the collaboration with Lilly and the intended benefits thereof, including timing for data updates, potential milestones, exercise of an option to expand targets and the receipt of an opt-in payment, our ability to selectively form new partnerships and enter into future collaborations, and our financial position and cash-runway. Forward-looking statements are based on management&#39;s beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market, economic sanctions and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical events and conflicts, high inflation, rising interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:13.14%;margin-top:30pt;page-break-after:always;width:76.51%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:13.14%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Open Sans';font-size:10pt;font-style:italic;font-weight:bold;line-height:17pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;"><b style="color:#333333;font-size:13pt;font-style:normal;font-weight:bold;">ProQR Therapeutics N.V.</b></p><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans bold';font-size:11pt;font-weight:bold;">Investor and media contact:</b><font style="color:#262626;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="color:#262626;font-size:11pt;">Sarah Kiely</font><font style="color:#262626;font-size:11pt;"><br></font><font style="color:#262626;font-size:11pt;">ProQR Therapeutics N.V.</font><font style="color:#262626;font-size:11pt;"><br></font><font style="color:#262626;font-size:11pt;">T: +1 617 599 6228</font><font style="color:#262626;font-size:11pt;"><br></font><b style="color:#23a49b;font-size:11pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">skiely@proqr.com</b><font style="color:#262626;font-size:11pt;"><br></font><font style="color:#262626;font-size:11pt;">or</font></p><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt;"><b style="color:#262626;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;">Investor contact:</b></p><p style="font-family:'Open Sans';font-size:10pt;min-height:17.0pt;margin:0pt;"><font style="color:#262626;font-size:11pt;">Peter Kelleher</font><font style="color:#262626;font-size:11pt;"><br></font><font style="color:#262626;font-size:11pt;">LifeSci Advisors</font><font style="color:#262626;font-size:11pt;"><br></font><font style="color:#262626;font-size:11pt;">T: +1 617 430 7579</font><font style="font-size:11pt;"><br></font><b style="color:#23a49b;font-size:11pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">pkelleher@lifesciadvisors.com</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:13.14%;margin-top:30pt;page-break-after:always;width:76.51%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:13.14%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="color:#262626;font-family:'Open Sans';font-size:13pt;font-weight:bold;line-height:17pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Financial Tables</b></p><p style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;line-height:1.19;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PROQR THERAPEUTICS N.V.</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Unaudited Condensed Consolidated Statement of Financial Position</b><a name="Statement_of_Financial_Position"></a></p><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.91%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">&#8364;1</font><i style="color:#262626;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">&#8364;1</font><i style="color:#262626;font-style:italic;">,000</i></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Property, plant and equipment</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">13,018 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">14,113 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Investments in financial assets</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">&#8212; </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 6pt;"><b style="color:#262626;font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">13,018 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">14,113 </b></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Cash and cash equivalents</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">106,883 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">149,408 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Prepayments and other receivables</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">3,872 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">3,747 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Other taxes</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">576 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">690 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 6pt;"><b style="color:#262626;font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">111,331 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">153,845 </b></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">124,349 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">167,958 </b></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-weight:bold;">Equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Equity attributable to owners of the Company</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">57,071 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">88,560 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-weight:bold;">Total equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">57,071 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">88,560 </b></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Borrowings</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">&#8212; </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Lease liabilities</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">10,017 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">11,067 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Deferred income</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">24,125 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">29,429 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 6pt;"><b style="color:#262626;font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">34,142 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">40,496 </b></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Borrowings</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">4,800 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">4,582 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Lease liabilities</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">1,674 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">1,567 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Derivative financial instruments</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">292 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">468 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Trade payables</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">305 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">16 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Social securities and other taxes</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">121 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">1,478 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Deferred income</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">17,394 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">21,942 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 12pt;"><font style="color:#262626;">Other current liabilities</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">8,550 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="color:#262626;">8,849 </font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt 0pt 0pt 6pt;"><b style="color:#262626;font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">33,136 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">38,902 </b></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">67,278 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">79,398 </b></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.91%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-weight:bold;">Total equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">124,349 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-weight:bold;">167,958 </b></p></td></tr></table></div><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:13.14%;margin-top:30pt;page-break-after:always;width:76.51%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:13.14%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;line-height:17pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PROQR THERAPEUTICS N.V.</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income </b><a name="Statement_of_Profit_or_Loss_and_OCI"></a></p><p style="font-family:'Open Sans';font-size:9pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">(&#8364; in thousands, except share and per share data)</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.69%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#ffffff;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.54%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Three&#160;month&#160;period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.54%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Nine&#160;month&#160;period</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#ffffff;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.54%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">ended&#160;September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#ffffff;font-size:7.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.54%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">ended&#160;September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;"> </b><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#ffffff;font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#ffffff;font-size:7.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">2,882 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">3,843 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">11,218 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">14,598 </b></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Other income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">33 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">138 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">413 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">504 </b></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Research and development costs</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(11,080)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(9,414)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(34,811)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(25,745)</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">General and administrative costs</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(3,119)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(3,283)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(11,169)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(9,748)</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Total operating costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(14,199)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(12,697)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(45,980)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(35,493)</b></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Operating result</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(11,284)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(8,716)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(34,349)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(20,391)</b></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Finance income and expense</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">280 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">469 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">927 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">1,470 </font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Results related to financial liabilities measured at fair value through profit or loss</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(2)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">139 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">176 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">266 </font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Result before corporate income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(11,006)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(8,108)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(33,246)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(18,655)</b></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Income taxes</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(18)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">197 </font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Result for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(11,006)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(8,108)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(33,264)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(18,458)</b></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Other comprehensive income (foreign exchange differences on foreign operation)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(23)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(377)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(1,076)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(101)</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Total comprehensive income </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(11,029)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(8,485)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(34,340)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(18,559)</b></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Result attributable to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Owners of the Company</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(11,006)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(8,108)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(33,264)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(18,458)</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Non-controlling interests</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(11,006)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(8,108)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(33,264)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(18,458)</b></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Total comprehensive income attributable to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Owners of the Company</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(11,029)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(8,485)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(34,340)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(18,559)</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Non-controlling interests</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(11,029)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(8,485)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(34,340)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(18,559)</b></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Share information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Weighted average number of shares outstanding</font><sup style="color:#262626;font-size:5.62pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">105,344,996 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">81,682,296 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">105,328,752 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">81,639,533 </font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Earnings per share attributable to owners of the Company (Euro per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Basic loss per share</font><sup style="color:#262626;font-size:5.62pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(0.10)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(0.10)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(0.32)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(0.23)</font></p></td></tr><tr><td style="vertical-align:top;width:41.69%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Diluted loss per share</font><sup style="color:#262626;font-size:5.62pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(0.10)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(0.10)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(0.32)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(0.23)</font></p></td></tr></table></div><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Open Sans';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#262626;font-family:'Open Sans';font-size:7.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="color:#262626;font-family:'Open Sans';font-size:7.5pt;font-style:normal;font-weight:normal;">For these periods the potential exercise of share options is not included in the diluted earnings per share as the Company was loss-making. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal.</font></td></tr></table><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;line-height:1.37;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:13.14%;margin-top:30pt;page-break-after:always;width:76.51%;border-width:0;"><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;line-height:17pt;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PROQR THERAPEUTICS N.V.</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Unaudited Condensed Consolidated Statement of Changes in Equity</b><a name="Statement_of_Changes_in_Equity"></a></p><p style="font-family:'Open Sans';font-size:11.5pt;font-weight:bold;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';line-height:17pt;margin-bottom:3pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.68%;border-bottom:1px solid #464646;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#ffffff;font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:70.02%;border-bottom:1px solid #464646;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Attributable&#160;to&#160;owners&#160;of&#160;the&#160;Company</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.68%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#ffffff;font-size:8.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Number</b><b style="color:#262626;font-size:7.5pt;font-weight:bold;"><br></b><b style="color:#262626;font-size:7.5pt;font-weight:bold;">of shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#ffffff;font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Share</b><b style="color:#262626;font-size:7.5pt;font-weight:bold;"><br></b><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Capital</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#ffffff;font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Share</b><b style="color:#262626;font-size:7.5pt;font-weight:bold;"><br></b><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Premium</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#ffffff;font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Equity</b><b style="color:#262626;font-family:'Calibri','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;">&#160;</b><b style="color:#262626;font-size:7.5pt;font-weight:bold;">settled</b><b style="color:#262626;font-size:7.5pt;font-weight:bold;"><br></b><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Employee</b><b style="color:#262626;font-size:7.5pt;font-weight:bold;"><br></b><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Benefit</b><b style="color:#262626;font-size:7.5pt;font-weight:bold;"><br></b><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Reserve</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#ffffff;font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Translation</b><b style="color:#262626;font-size:7.5pt;font-weight:bold;"><br></b><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Reserve</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#ffffff;font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Accumulated</b><b style="color:#262626;font-size:7.5pt;font-weight:bold;"><br></b><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Deficit</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#ffffff;font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Total</b><b style="color:#262626;font-size:7.5pt;font-weight:bold;"><br></b><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><i style="color:#262626;font-size:8.5pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;font-weight:bold;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Balance at January 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:8.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">84,248,384 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">3,370 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">412,894 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">25,159 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">817 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(400,850)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">41,390 </b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Result for the period</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(18,458)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(18,458)</b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Other comprehensive income</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(101)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(101)</b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Recognition of share-based payments</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">1,976 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">1,976 </b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Treasury shares transferred</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(329,675)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">&#8212; </b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Share options lapsed</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(994)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">994 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">&#8212; </b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Share options exercised / RSUs vested</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">328,597 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">175 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(291)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">291 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">175 </b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Balance at September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:8.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">84,247,306 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">3,370 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">413,069 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">25,850 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">716 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(418,023)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">24,982 </b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Balance at January 1, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:8.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">107,710,916 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">4,308 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">483,812 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">26,248 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">1,350 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(427,158)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">88,560 </b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Result for the period</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(33,264)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(33,264)</b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Other comprehensive income</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;white-space:pre-wrap;"> (1,076)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(1,076)</b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Recognition of share-based payments</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">2,784 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">2,784 </b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Treasury shares transferred</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(132,665)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">&#8212; </b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Share options lapsed</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(1,532)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">1,532 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">&#8212; </b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">Share options exercised / RSUs vested</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">132,665 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">67 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">(184)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">184 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">67 </b></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:8.5pt;">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.68%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">Balance at September&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:8pt;line-height:1.37;margin:0pt;"><b style="color:#262626;font-size:8.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">107,710,916 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">4,308 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">483,879 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">27,316 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">274 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">(458,706)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="color:#262626;font-size:7.5pt;font-weight:bold;">57,071 </b></p></td></tr></table></div><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;font-weight:bold;line-height:1.37;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8%;margin-right:8%;margin-top:30pt;page-break-after:always;width:84%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Open Sans';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.55;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11.5pt;font-style:normal;font-weight:bold;">PROQR THERAPEUTICS N.V.</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11.5pt;font-style:normal;font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11.5pt;font-style:normal;font-weight:bold;">Unaudited Condensed Consolidated Statement of Cash Flows</b><a name="Statement_of_Cash_Flows"></a></p><p style="font-family:'Open Sans';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11.5pt;font-style:normal;line-height:1.37;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.76%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#ffffff;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.61%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Three&#160;month&#160;period&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#ffffff;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.61%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Nine&#160;month&#160;period&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.76%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#ffffff;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.61%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="color:#ffffff;font-size:7.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.61%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;"> </b><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="color:#ffffff;font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#ffffff;font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#262626;font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="color:#262626;font-size:7.5pt;">&#8364;1</font><i style="color:#262626;font-size:7.5pt;font-style:italic;">,000</i></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash flows from operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Net result</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(11,006)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(8,108)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(33,264)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(18,458)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Adjustments for:</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">&#8212; Other income</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(33)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(413)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">&#8212; </font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">&#8212; Depreciation</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">671 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">688 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">2,024 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">2,090 </font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">&#8212; Share-based compensation</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="color:#262626;font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">1,117 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">612 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">2,784 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">1,976 </font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">&#8212; Financial income and expenses</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(280)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(469)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(927)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(1,470)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">&#8212; Results related to financial liabilities measured at fair value through profit or loss</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">2 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(139)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(176)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(266)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">&#8212; Income tax expenses</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">18 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(197)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Changes in working capital</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(3,074)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">1,117 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(10,974)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(12,721)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><i style="font-size:7.5pt;font-style:italic;">Cash used in operations</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><i style="font-size:7.5pt;font-style:italic;">(12,603)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><i style="font-size:7.5pt;font-style:italic;">(6,299)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><i style="font-size:7.5pt;font-style:italic;">(40,928)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><i style="font-size:7.5pt;font-style:italic;">(29,046)</i></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Corporate income tax received / (paid)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">1 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(18)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">197 </font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Interest received</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">519 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">860 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">1,924 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">2,402 </font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Interest paid</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(151)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(219)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(412)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(598)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:43.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">Net cash used in operating activities</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">(12,235)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">(5,657)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">(39,434)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">(27,045)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash flow from investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Increase in financial asset - current</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(17,000)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Decrease in financial asset - current</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">17,000 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">17,000 </font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Purchases of property, plant and equipment</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(169)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(286)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(494)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(1,285)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">Net cash (used in) / generated by investing activities</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">(169)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">16,714 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">(494)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">(1,285)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash flow from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Proceeds from exercise of share options</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">&#8212; </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">1 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">67 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">175 </font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Repayment of lease liability</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(444)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(454)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(1,304)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(1,329)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">Net cash used in financing activities</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">(444)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">(453)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">(1,237)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;font-weight:bold;">(1,154)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Net (decrease) / increase in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(12,848)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">10,604 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(41,165)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(29,484)</b></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Currency effect cash and cash equivalents</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(34)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(173)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(1,360)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">(40)</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;">Cash and cash equivalents, at beginning of the period</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">119,765 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">78,970 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">149,408 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><font style="font-size:7.5pt;">118,925 </font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:6pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:6.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:6pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:6.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:6pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:6.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:6pt;line-height:1.37;text-align:right;margin:0pt;"><font style="font-size:6.5pt;">&#160;&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:43.76%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash and cash equivalents at the end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">106,883 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">89,401 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">106,883 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Open Sans';font-size:7pt;line-height:1.37;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">89,401 </b></p></td></tr></table></div><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Open Sans';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#8dc5c1;font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>prqr-20250930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/4/2025 3:07:58 PM-->
<!--Modified on: 11/4/2025 3:07:58 PM-->
<xsd:schema targetNamespace="http://www.proqr.com/20250930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:prqr="http://www.proqr.com/20250930" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition" id="StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition">
        <link:definition>00100 - Statement - Unaudited Condensed Consolidated Statement of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/StatementConsolidatedStatementOfProfitOrLossAndComprehensiveIncomeCalc2Imported" id="StatementConsolidatedStatementOfProfitOrLossAndComprehensiveIncomeCalc2Imported">
        <link:definition>00200 - Statement - Consolidated Statement of Profit or Loss and Comprehensive Income - calc2 (Imported)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome" id="StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome">
        <link:definition>00200 - Statement - Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows" id="StatementUnauditedCondensedConsolidatedStatementOfCashFlows">
        <link:definition>00400 - Statement - Unaudited Condensed Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails" id="DisclosurePrepaymentsAndOtherReceivablesDetails">
        <link:definition>40601 - Disclosure - Prepayments and Other Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureBorrowingsDetails" id="DisclosureBorrowingsDetails">
        <link:definition>40901 - Disclosure - Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureOtherIncomeDetails" id="DisclosureOtherIncomeDetails">
        <link:definition>41401 - Disclosure - Other Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity" id="StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity">
        <link:definition>00300 - Statement - Unaudited Condensed Consolidated Statement of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureGeneralInformationDetails" id="DisclosureGeneralInformationDetails">
        <link:definition>40101 - Disclosure - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails" id="DisclosureGeneralInformationRevisionOfComparativeFiguresDetails">
        <link:definition>40102 - Disclosure - General Information - Revision of comparative figures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails" id="DisclosureCriticalAccountingEstimatesAndJudgementsDetails">
        <link:definition>40401 - Disclosure - Critical Accounting Estimates and Judgements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails" id="DisclosurePropertyPlantAndEquipmentDetails">
        <link:definition>40701 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails" id="DisclosureLeaseLiabilitiesDetails">
        <link:definition>41001 - Disclosure - Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureDeferredIncomeDetails" id="DisclosureDeferredIncomeDetails">
        <link:definition>41101 - Disclosure - Deferred Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails" id="DisclosureShareholdersEquityShareCapitalDetails">
        <link:definition>41201 - Disclosure - Shareholders' Equity - Share capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails" id="DisclosureShareholdersEquitySaleOfSharesDetails">
        <link:definition>41202 - Disclosure - Shareholders' Equity - Sale of shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails" id="DisclosureShareholdersEquityShareOptionsDetails">
        <link:definition>41203 - Disclosure - Shareholders' Equity - Share options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureRevenueDetails" id="DisclosureRevenueDetails">
        <link:definition>41301 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails" id="DisclosureOtherIncomeNarrativeDetails">
        <link:definition>41402 - Disclosure - Other Income - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails" id="DisclosureInvestmentsInFinancialAssetsDetails">
        <link:definition>41701 - Disclosure - Investments in Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureGeneralInformation" id="DisclosureGeneralInformation">
        <link:definition>10101 - Disclosure - General Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureAdoptionOfNewAndRevisedInternationalFinancialReportingStandards" id="DisclosureAdoptionOfNewAndRevisedInternationalFinancialReportingStandards">
        <link:definition>10301 - Disclosure - Adoption of New and Revised International Financial Reporting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgments" id="DisclosureCriticalAccountingEstimatesAndJudgments">
        <link:definition>10401 - Disclosure - Critical Accounting Estimates and Judgments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureCashAndCashEquivalents" id="DisclosureCashAndCashEquivalents">
        <link:definition>10501 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivables" id="DisclosurePrepaymentsAndOtherReceivables">
        <link:definition>10601 - Disclosure - Prepayments and Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosurePropertyPlantAndEquipment" id="DisclosurePropertyPlantAndEquipment">
        <link:definition>10701 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureOtherCurrentLiabilities" id="DisclosureOtherCurrentLiabilities">
        <link:definition>10801 - Disclosure - Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureBorrowings" id="DisclosureBorrowings">
        <link:definition>10901 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureLeaseLiabilities" id="DisclosureLeaseLiabilities">
        <link:definition>11001 - Disclosure - Lease Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureDeferredIncome" id="DisclosureDeferredIncome">
        <link:definition>11101 - Disclosure - Deferred Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureShareholdersEquity" id="DisclosureShareholdersEquity">
        <link:definition>11201 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>11301 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureOtherIncome" id="DisclosureOtherIncome">
        <link:definition>11401 - Disclosure - Other Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureResearchAndDevelopmentCosts" id="DisclosureResearchAndDevelopmentCosts">
        <link:definition>11501 - Disclosure - Research and Development Costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCosts" id="DisclosureGeneralAndAdministrativeCosts">
        <link:definition>11601 - Disclosure - General and Administrative Costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssets" id="DisclosureInvestmentsInFinancialAssets">
        <link:definition>11701 - Disclosure - Investments in Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11801 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11901 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureEventsAfterBalanceSheetDate" id="DisclosureEventsAfterBalanceSheetDate">
        <link:definition>12001 - Disclosure - Events After Balance Sheet Date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesTables" id="DisclosurePrepaymentsAndOtherReceivablesTables">
        <link:definition>30603 - Disclosure - Prepayments and Other Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureBorrowingsTables" id="DisclosureBorrowingsTables">
        <link:definition>30903 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureDeferredIncomeTables" id="DisclosureDeferredIncomeTables">
        <link:definition>31103 - Disclosure - Deferred Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureOtherIncomeTables" id="DisclosureOtherIncomeTables">
        <link:definition>31403 - Disclosure - Other Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureCashAndCashEquivalentsDetails" id="DisclosureCashAndCashEquivalentsDetails">
        <link:definition>40501 - Disclosure - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureOtherCurrentLiabiltiesDetails" id="DisclosureOtherCurrentLiabiltiesDetails">
        <link:definition>40801 - Disclosure - Other Current Liabilties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureResearchAndDevelopmentCostsDetails" id="DisclosureResearchAndDevelopmentCostsDetails">
        <link:definition>41501 - Disclosure - Research and Development Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCostsDetails" id="DisclosureGeneralAndAdministrativeCostsDetails">
        <link:definition>41601 - Disclosure - General and Administrative Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41801 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="prqr-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="prqr-20250930_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="prqr-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="prqr-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.proqr.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xsd:import namespace="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="prqr_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfOtherIncomeTableTextBlockExplanatory" id="prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsRevenueFromGrants" id="prqr_IfrsRevenueFromGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IfrsOtherIncomeAbstract" id="prqr_IfrsOtherIncomeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaymentsAndOtherReceivables" id="prqr_PrepaymentsAndOtherReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="GeneralInformationAbstract" id="prqr_GeneralInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProqrTherapeuticsHoldingB.v.Member" id="prqr_ProqrTherapeuticsHoldingB.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProqrTherapeuticsIB.v.Member" id="prqr_ProqrTherapeuticsIB.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProqrTherapeuticsIiB.v.Member" id="prqr_ProqrTherapeuticsIiB.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProqrTherapeuticsIiiB.v.Member" id="prqr_ProqrTherapeuticsIiiB.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProqrTherapeuticsIvB.v.Member" id="prqr_ProqrTherapeuticsIvB.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProqrTherapeuticsViB.v.Member" id="prqr_ProqrTherapeuticsViB.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProqrTherapeuticsViiB.v.Member" id="prqr_ProqrTherapeuticsViiB.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProqrTherapeuticsViiiB.v.Member" id="prqr_ProqrTherapeuticsViiiB.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProqrTherapeuticsIxB.v.Member" id="prqr_ProqrTherapeuticsIxB.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProqrTherapeuticsIInc.Member" id="prqr_ProqrTherapeuticsIInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfGeneralInformationExplanatory" id="prqr_DisclosureOfGeneralInformationExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaturityGroupingsAxis" id="prqr_MaturityGroupingsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaturityGroupingsDomain" id="prqr_MaturityGroupingsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaymentsAndOtherReceivablesAbstract" id="prqr_PrepaymentsAndOtherReceivablesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock" id="prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AuthorizedShareCapitalValue" id="prqr_AuthorizedShareCapitalValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IfrsSubsidiarySaleOfStockAxis" id="prqr_IfrsSubsidiarySaleOfStockAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockNameOfTransactionDomain" id="prqr_IfrsSaleOfStockNameOfTransactionDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsNumberOfReportableSegments" id="prqr_IfrsNumberOfReportableSegments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsScenarioAxis" id="prqr_IfrsScenarioAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsScenarioUnspecifiedDomain" id="prqr_IfrsScenarioUnspecifiedDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherIncomeTable" id="prqr_OtherIncomeTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherIncomeLineItems" id="prqr_OtherIncomeLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsStockIssuedDuringPeriodSharesNewIssues" id="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InnovationCreditMember" id="prqr_InnovationCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SharesOptionsLapsed" id="prqr_SharesOptionsLapsed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsAccountingPoliciesAbstract" id="prqr_IfrsAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConditionalWaiverOfDebtTotal" id="prqr_ConditionalWaiverOfDebtTotal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IfrsSaleOfStockPricePerShare" id="prqr_IfrsSaleOfStockPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSubsequentEventsAxis" id="prqr_IfrsSubsequentEventsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSubsequentEventsDomain" id="prqr_IfrsSubsequentEventsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AreaOfPropertyUnderLease" id="prqr_AreaOfPropertyUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="IfrsResearchAndDevelopmentExpenseMember" id="prqr_IfrsResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSellingGeneralAndAdministrativeExpensesMember" id="prqr_IfrsSellingGeneralAndAdministrativeExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OfficeAndLaboratoryFacilityMember" id="prqr_OfficeAndLaboratoryFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PhoenicisTherapeuticsIncMember" id="prqr_PhoenicisTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TreasurySharesTransferred" id="prqr_TreasurySharesTransferred" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsStockIssuedDuringPeriodSharesStockOptionsExercised" id="prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsForOtherIncome" id="prqr_AdjustmentsForOtherIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ProqrTherapeuticsVB.v.Member" id="prqr_ProqrTherapeuticsVB.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="YarrowBiotechnologyMember" id="prqr_YarrowBiotechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCounterpartyNameAxis" id="prqr_IfrsCounterpartyNameAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsRepurchaseAgreementCounterpartyNameDomain" id="prqr_IfrsRepurchaseAgreementCounterpartyNameDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockAxis" id="prqr_IfrsSaleOfStockAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockDomain" id="prqr_IfrsSaleOfStockDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EliLillyAndCompanyMember" id="prqr_EliLillyAndCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsBalanceSheetLocationAxis" id="prqr_IfrsBalanceSheetLocationAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsBalanceSheetLocationDomain" id="prqr_IfrsBalanceSheetLocationDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProportionOfOwnershipInterest" id="prqr_ProportionOfOwnershipInterest" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="IfrsStatementScenarioAxis" id="prqr_IfrsStatementScenarioAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScenarioDomain" id="prqr_ScenarioDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InvestmentsInFinancialAssetsAbstract" id="prqr_InvestmentsInFinancialAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable" id="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems" id="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredIncomeAbstract" id="prqr_DeferredIncomeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfDeferredIncomeTableTextBlock" id="prqr_ScheduleOfDeferredIncomeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantsEconomicLifetime" id="prqr_WarrantsEconomicLifetime" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DiscountOnIssueOfShares" id="prqr_DiscountOnIssueOfShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" id="prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" id="prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership" id="prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OtherCurrentLiabilitiesAbstract" id="prqr_OtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfPerformanceObligationsInCollaborationAgreement" id="prqr_NumberOfPerformanceObligationsInCollaborationAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsClassesOfWarrantsOrRightsAxisAxis" id="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassesOfWarrantsOrRightsDomain" id="prqr_ClassesOfWarrantsOrRightsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PontifaxAndKreosWarrantsMember" id="prqr_PontifaxAndKreosWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" id="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LeaseTerm" id="prqr_LeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LeaseExtensionTerm" id="prqr_LeaseExtensionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LeaseCurrentExtensionPeriodUnderOption" id="prqr_LeaseCurrentExtensionPeriodUnderOption" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShelfRegistrationStatement2024Member" id="prqr_ShelfRegistrationStatement2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumOfferingPriceInShelfRegistrationStatement" id="prqr_MaximumOfferingPriceInShelfRegistrationStatement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember" id="prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement" id="prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="RettSyndromeResearchTrustMember" id="prqr_RettSyndromeResearchTrustMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentCostsAbstract" id="prqr_ResearchAndDevelopmentCostsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="October2024UnderwrittenPublicOfferingMember" id="prqr_October2024UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember" id="prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DurationOfUnderwritersOption" id="prqr_DurationOfUnderwritersOption" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfSharesCallableForOptionsIssued" id="prqr_NumberOfSharesCallableForOptionsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NetProceedsFromIssuingShares" id="prqr_NetProceedsFromIssuingShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PurchasePriceCapSharePurchaseAgreement" id="prqr_PurchasePriceCapSharePurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SharePurchaseAgreementWithEliLillyAndCompanyMember" id="prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePaymentsMember" id="prqr_MilestonePaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumGrantReceivableForInitialPhaseOfProject" id="prqr_MaximumGrantReceivableForInitialPhaseOfProject" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MaximumGrantReceivableForAdditionalPhaseOfProject" id="prqr_MaximumGrantReceivableForAdditionalPhaseOfProject" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BorrowingsExcludingAccruedInterest" id="prqr_BorrowingsExcludingAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CurrentBorrowingsExcludingAccruedInterest" id="prqr_CurrentBorrowingsExcludingAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ValueOfMilestonesReachedDuringPeriod" id="prqr_ValueOfMilestonesReachedDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>prqr-20250930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/4/2025 3:07:58 PM-->
<!--Modified on: 11/4/2025 3:07:58 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition" roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#StatementConsolidatedStatementOfProfitOrLossAndComprehensiveIncomeCalc2Imported" roleURI="http://www.proqr.com/role/StatementConsolidatedStatementOfProfitOrLossAndComprehensiveIncomeCalc2Imported" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome" roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#StatementUnauditedCondensedConsolidatedStatementOfCashFlows" roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosurePrepaymentsAndOtherReceivablesDetails" roleURI="http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureBorrowingsDetails" roleURI="http://www.proqr.com/role/DisclosureBorrowingsDetails" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureOtherIncomeDetails" roleURI="http://www.proqr.com/role/DisclosureOtherIncomeDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition" xlink:type="extended" xlink:title="00100 - Statement - Unaudited Condensed Consolidated Statement of Financial Position">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_CurrentAssets_638978656764944680" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PrepaymentsAndOtherReceivables" xlink:label="prqr_PrepaymentsAndOtherReceivables_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638978656764944680" xlink:to="prqr_PrepaymentsAndOtherReceivables_638978656764944680" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638978656764944680" xlink:to="ifrs-full_CashAndCashEquivalents_638978656764944680" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638978656764944680" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_638978656764944680" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_NoncurrentAssets_638978656764944680" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638978656764944680" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638978656764944680" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="EquityAndLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Equity_638978656764944680" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Equity_638978656764944680" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_638978656764944680" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Liabilities_638978656764944680" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638978656764944680" xlink:to="ifrs-full_NoncurrentLiabilities_638978656764944680" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638978656764944680" xlink:to="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_638978656764944680" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638978656764944680" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_638978656764944680" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638978656764944680" xlink:to="ifrs-full_CurrentLiabilities_638978656764944680" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638978656764944680" xlink:to="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_638978656764944680" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638978656764944680" xlink:to="ifrs-full_CurrentLeaseLiabilities_638978656764944680" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638978656764944680" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities_638978656764944680" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638978656764944680" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638978656764944680" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638978656764944680" xlink:to="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_638978656764944680" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:label="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638978656764944680" xlink:to="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_638978656764944680" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638978656764944680" xlink:to="ifrs-full_OtherCurrentLiabilities_638978656764944680" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.proqr.com/role/StatementConsolidatedStatementOfProfitOrLossAndComprehensiveIncomeCalc2Imported" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statement of Profit or Loss and Comprehensive Income - calc2 (Imported)">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_638978656764944680" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_638978656764944680" order="1" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome" xlink:type="extended" xlink:title="00200 - Statement - Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss_638978656764944680" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638978656764944680" xlink:to="ifrs-full_ProfitLossBeforeTax_638978656764944680" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638978656764944680" xlink:to="ifrs-full_FinanceIncomeCost_638978656764944680" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638978656764944680" xlink:to="ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_638978656764944680" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638978656764944680" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638978656764944680" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638978656764944680" xlink:to="ifrs-full_OperatingExpense_638978656764944680" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense_638978656764944680" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638978656764944680" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638978656764944680" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense_638978656764944680" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638978656764944680" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638978656764944680" xlink:to="ifrs-full_OtherIncome_638978656765101365" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638978656764944680" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638978656765101365" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638978656764944680" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638978656765101365" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638978656765101365" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Unaudited Condensed Consolidated Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638978656765101365" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638978656765101365" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638978656765101365" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638978656765101365" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_638978656765101365" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638978656765101365" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638978656765101365" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638978656765101365" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_638978656765101365" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_638978656765101365" xlink:to="ifrs-full_ProfitLoss_638978656765101365" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_638978656765101365" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_638978656765101365" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_638978656765101365" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638978656765101365" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AdjustmentsForOtherIncome" xlink:label="prqr_AdjustmentsForOtherIncome_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_638978656765101365" xlink:to="prqr_AdjustmentsForOtherIncome_638978656765101365" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_638978656765101365" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_638978656765101365" order="5" use="optional" weight="-1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_638978656765101365" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_638978656765101365" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_638978656765101365" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_638978656765101365" order="7" use="optional" weight="-1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_638978656765101365" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses_638978656765101365" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638978656765101365" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638978656765101365" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_638978656765101365" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638978656765101365" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638978656765101365" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638978656765101365" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_638978656765101365" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638978656765101365" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638978656765101365" xlink:to="ifrs-full_ProceedsFromIssuingShares_638978656765101365" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638978656765101365" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_638978656765101365" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638978656765101365" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638978656765101365" order="3" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Prepayments and Other Receivables (Details)">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PrepaymentsAndOtherReceivables" xlink:label="PrepaymentsAndOtherReceivables" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Prepayments" xlink:label="ifrs-full_Prepayments_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaymentsAndOtherReceivables" xlink:to="ifrs-full_Prepayments_638978656765101365" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaymentsAndOtherReceivables" xlink:to="ifrs-full_OtherReceivables_638978656765101365" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccruedIncomeIncludingContractAssets" xlink:label="ifrs-full_AccruedIncomeIncludingContractAssets_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaymentsAndOtherReceivables" xlink:to="ifrs-full_AccruedIncomeIncludingContractAssets_638978656765101365" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.proqr.com/role/DisclosureBorrowingsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Borrowings (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_638978656765101365" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.proqr.com/role/DisclosureOtherIncomeDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Other Income (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome" xlink:label="OtherIncome" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsRevenueFromGrants" xlink:label="prqr_IfrsRevenueFromGrants_638978656765101365" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OtherIncome" xlink:to="prqr_IfrsRevenueFromGrants_638978656765101365" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>prqr-20250930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/4/2025 3:07:58 PM-->
<!--Modified on: 11/4/2025 3:07:58 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity" roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureGeneralInformationDetails" roleURI="http://www.proqr.com/role/DisclosureGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureGeneralInformationRevisionOfComparativeFiguresDetails" roleURI="http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureCriticalAccountingEstimatesAndJudgementsDetails" roleURI="http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosurePropertyPlantAndEquipmentDetails" roleURI="http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureBorrowingsDetails" roleURI="http://www.proqr.com/role/DisclosureBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureLeaseLiabilitiesDetails" roleURI="http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureDeferredIncomeDetails" roleURI="http://www.proqr.com/role/DisclosureDeferredIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureShareholdersEquityShareCapitalDetails" roleURI="http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureShareholdersEquitySaleOfSharesDetails" roleURI="http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureShareholdersEquityShareOptionsDetails" roleURI="http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureRevenueDetails" roleURI="http://www.proqr.com/role/DisclosureRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureOtherIncomeNarrativeDetails" roleURI="http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureInvestmentsInFinancialAssetsDetails" roleURI="http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.proqr.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="prqr-20250930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.proqr.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis To dei_EntityDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:title="ifrs-full_ComponentsOfEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:title="ifrs-full_EquityMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ComponentsOfEquityAxis To ifrs-full_EquityMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:title="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:title="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CategoriesOfRelatedPartiesAxis To ifrs-full_EntitysTotalForRelatedPartiesMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:title="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:title="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SignificantInvestmentsInSubsidiariesAxis To ifrs-full_EntitysTotalForSubsidiariesMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:title="ifrs-full_SignificantInvestmentsInAssociatesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:title="ifrs-full_EntitysTotalForAssociatesMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SignificantInvestmentsInAssociatesAxis To ifrs-full_EntitysTotalForAssociatesMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="ifrs-full_InitiallyAppliedIFRSsAxis" xlink:title="ifrs-full_InitiallyAppliedIFRSsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsDomain" xlink:label="ifrs-full_InitiallyAppliedIFRSsDomain" xlink:title="ifrs-full_InitiallyAppliedIFRSsMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_InitiallyAppliedIFRSsAxis" xlink:to="ifrs-full_InitiallyAppliedIFRSsDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_InitiallyAppliedIFRSsAxis To ifrs-full_InitiallyAppliedIFRSsMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:title="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:title="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis To ifrs-full_IntangibleAssetsOtherThanGoodwillMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:title="ifrs-full_PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis To ifrs-full_PropertyPlantAndEquipmentMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:title="ifrs-full_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain" xlink:title="ifrs-full_RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_RangeAxis To ifrs-full_RangesMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MaturityGroupingsAxis" xlink:label="prqr_MaturityGroupingsAxis" xlink:title="prqr_MaturityGroupingsAxis" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MaturityGroupingsDomain" xlink:label="prqr_MaturityGroupingsDomain" xlink:title="prqr_MaturityGroupingsDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="prqr_MaturityGroupingsAxis" xlink:to="prqr_MaturityGroupingsDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:prqr_MaturityGroupingsAxis To prqr_MaturityGroupingsDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:title="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" xlink:title="ifrs-full_CarryingAmountMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis To ifrs-full_CarryingAmountMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:title="prqr_IfrsIncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:title="prqr_IfrsIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:prqr_IfrsIncomeStatementLocationAxis To prqr_IfrsIncomeStatementLocationDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:title="ifrs-full_GeographicalAreasAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:title="ifrs-full_GeographicalAreasMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_GeographicalAreasAxis To ifrs-full_GeographicalAreasMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xlink:title="ifrs-full_BorrowingsByNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain" xlink:label="ifrs-full_BorrowingsByNameDomain" xlink:title="ifrs-full_BorrowingsByNameMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_BorrowingsByNameAxis To ifrs-full_BorrowingsByNameMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:title="ifrs-full_ClassesOfAssetsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="ifrs-full_ClassesOfAssetsDomain" xlink:title="ifrs-full_ClassesOfAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfAssetsAxis To ifrs-full_ClassesOfAssetsMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:title="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:title="ifrs-full_ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfShareCapitalAxis To ifrs-full_ClassesOfShareCapitalMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSubsidiarySaleOfStockAxis" xlink:label="prqr_IfrsSubsidiarySaleOfStockAxis" xlink:title="prqr_IfrsSubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockNameOfTransactionDomain" xlink:label="prqr_IfrsSaleOfStockNameOfTransactionDomain" xlink:title="prqr_IfrsSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="prqr_IfrsSubsidiarySaleOfStockAxis" xlink:to="prqr_IfrsSaleOfStockNameOfTransactionDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:prqr_IfrsSubsidiarySaleOfStockAxis To prqr_IfrsSaleOfStockNameOfTransactionDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsCounterpartyNameAxis" xlink:label="prqr_IfrsCounterpartyNameAxis" xlink:title="prqr_IfrsCounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsRepurchaseAgreementCounterpartyNameDomain" xlink:label="prqr_IfrsRepurchaseAgreementCounterpartyNameDomain" xlink:title="prqr_IfrsRepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="prqr_IfrsCounterpartyNameAxis" xlink:to="prqr_IfrsRepurchaseAgreementCounterpartyNameDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:prqr_IfrsCounterpartyNameAxis To prqr_IfrsRepurchaseAgreementCounterpartyNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockAxis" xlink:label="prqr_IfrsSaleOfStockAxis" xlink:title="prqr_IfrsSaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockDomain" xlink:label="prqr_IfrsSaleOfStockDomain" xlink:title="prqr_IfrsSaleOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="prqr_IfrsSaleOfStockAxis" xlink:to="prqr_IfrsSaleOfStockDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:prqr_IfrsSaleOfStockAxis To prqr_IfrsSaleOfStockDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:title="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:title="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfSharebasedPaymentArrangementsAxis To ifrs-full_SharebasedPaymentArrangementsMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:title="ifrs-full_CounterpartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain" xlink:title="ifrs-full_CounterpartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CounterpartiesAxis To ifrs-full_CounterpartiesMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" xlink:title="ifrs-full_ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain" xlink:label="ifrs-full_ProductsAndServicesDomain" xlink:title="ifrs-full_ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ProductsAndServicesAxis To ifrs-full_ProductsAndServicesMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsBalanceSheetLocationAxis" xlink:label="prqr_IfrsBalanceSheetLocationAxis" xlink:title="prqr_IfrsBalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsBalanceSheetLocationDomain" xlink:label="prqr_IfrsBalanceSheetLocationDomain" xlink:title="prqr_IfrsBalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="prqr_IfrsBalanceSheetLocationAxis" xlink:to="prqr_IfrsBalanceSheetLocationDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:prqr_IfrsBalanceSheetLocationAxis To prqr_IfrsBalanceSheetLocationDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis" xlink:title="ifrs-full_TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfContractsDomain" xlink:label="ifrs-full_TypesOfContractsDomain" xlink:title="ifrs-full_TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfContractsAxis To ifrs-full_TypesOfContractsMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:title="srt_CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis To srt_RepurchaseAgreementCounterpartyNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:title="ifrs-full_ClassesOfFinancialAssetsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:title="ifrs-full_FinancialAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfFinancialAssetsAxis To ifrs-full_FinancialAssetsMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:title="srt_EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis To srt_EquityMethodInvesteeNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsScenarioAxis" xlink:label="prqr_IfrsScenarioAxis" xlink:title="prqr_IfrsScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsScenarioUnspecifiedDomain" xlink:label="prqr_IfrsScenarioUnspecifiedDomain" xlink:title="prqr_IfrsScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="prqr_IfrsScenarioAxis" xlink:to="prqr_IfrsScenarioUnspecifiedDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:prqr_IfrsScenarioAxis To prqr_IfrsScenarioUnspecifiedDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:title="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:title="ifrs-full_NonadjustingEventsMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_NonadjustingEventsAfterReportingPeriodAxis To ifrs-full_NonadjustingEventsMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:title="ifrs-full_ItemsOfContingentLiabilitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ItemsOfContingentLiabilitiesDomain" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesDomain" xlink:title="ifrs-full_ItemsOfContingentLiabilitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ItemsOfContingentLiabilitiesDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ItemsOfContingentLiabilitiesAxis To ifrs-full_ItemsOfContingentLiabilitiesMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:title="ifrs-full_MaturityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain" xlink:title="ifrs-full_AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_MaturityAxis To ifrs-full_AggregatedTimeBandsMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:title="srt_OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:title="srt_OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis To srt_OwnershipDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSubsequentEventsAxis" xlink:label="prqr_IfrsSubsequentEventsAxis" xlink:title="prqr_IfrsSubsequentEventsAxis" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSubsequentEventsDomain" xlink:label="prqr_IfrsSubsequentEventsDomain" xlink:title="prqr_IfrsSubsequentEventsDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="prqr_IfrsSubsequentEventsAxis" xlink:to="prqr_IfrsSubsequentEventsDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:prqr_IfrsSubsequentEventsAxis To prqr_IfrsSubsequentEventsDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:title="srt_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:title="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis To srt_ScenarioUnspecifiedDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis" xlink:title="ifrs-full_NewIFRSsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NewIFRSsDomain" xlink:label="ifrs-full_NewIFRSsDomain" xlink:title="ifrs-full_NewIFRSsMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_NewIFRSsAxis To ifrs-full_NewIFRSsMember" order="1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsStatementScenarioAxis" xlink:label="prqr_IfrsStatementScenarioAxis" xlink:title="prqr_IfrsStatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ScenarioDomain" xlink:label="prqr_ScenarioDomain" xlink:title="prqr_ScenarioDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="prqr_IfrsStatementScenarioAxis" xlink:to="prqr_ScenarioDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:prqr_IfrsStatementScenarioAxis To prqr_ScenarioDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis_1" xlink:title="ifrs-full_TypesOfInterestRatesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain_1" xlink:title="ifrs-full_InterestRateTypesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfInterestRatesAxis_1" xlink:to="ifrs-full_TypesOfInterestRatesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfInterestRatesAxis_1 To ifrs-full_InterestRateTypesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PastDueStatusAxis" xlink:label="ifrs-full_PastDueStatusAxis_1" xlink:title="ifrs-full_PastDueStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PastDueStatusDomain" xlink:label="ifrs-full_PastDueStatusDomain_1" xlink:title="ifrs-full_PastDueStatusMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_PastDueStatusAxis_1" xlink:to="ifrs-full_PastDueStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_PastDueStatusAxis_1 To ifrs-full_PastDueStatusMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_1" xlink:title="ifrs-full_ClassesOfFinancialLiabilitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesDomain_1" xlink:title="ifrs-full_FinancialLiabilitiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis_1" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfFinancialLiabilitiesAxis_1 To ifrs-full_FinancialLiabilitiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_1" xlink:title="prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_1" xlink:title="prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_1" xlink:to="prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_1 To prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_1" xlink:title="srt_CurrencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_1" xlink:title="currency_AllCurrenciesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CurrencyAxis_1" xlink:to="currency_AllCurrenciesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CurrencyAxis_1 To currency_AllCurrenciesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis_1" xlink:title="ifrs-full_TypesOfRisksAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain_1" xlink:title="ifrs-full_TypesOfRisksMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfRisksAxis_1" xlink:to="ifrs-full_TypesOfRisksDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfRisksAxis_1 To ifrs-full_TypesOfRisksMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1" xlink:title="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_1" xlink:title="ifrs-full_RestatedMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1" xlink:to="ifrs-full_RestatedMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1 To ifrs-full_RestatedMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_1" xlink:title="ifrs-full_CategoriesOfFinancialAssetsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="ifrs-full_CategoriesOfFinancialAssetsDomain_1" xlink:title="ifrs-full_FinancialAssetsCategoryMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis_1" xlink:to="ifrs-full_CategoriesOfFinancialAssetsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CategoriesOfFinancialAssetsAxis_1 To ifrs-full_FinancialAssetsCategoryMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_1" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1 To ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsClassesOfWarrantsOrRightsAxisAxis" xlink:label="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_1" xlink:title="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ClassesOfWarrantsOrRightsDomain" xlink:label="prqr_ClassesOfWarrantsOrRightsDomain_1" xlink:title="prqr_ClassesOfWarrantsOrRightsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_1" xlink:to="prqr_ClassesOfWarrantsOrRightsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_1 To prqr_ClassesOfWarrantsOrRightsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_1" xlink:title="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain" xlink:label="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain_1" xlink:title="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_1" xlink:to="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_1 To ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity" xlink:type="extended" xlink:title="00300 - Statement - Unaudited Condensed Consolidated Statement of Changes in Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_SharePremiumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_TreasurySharesTransferred" xlink:label="prqr_TreasurySharesTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="prqr_TreasurySharesTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_SharesOptionsLapsed" xlink:label="prqr_SharesOptionsLapsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="prqr_SharesOptionsLapsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureGeneralInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsHoldingB.v.Member" xlink:label="prqr_ProqrTherapeuticsHoldingB.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="prqr_ProqrTherapeuticsHoldingB.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIB.v.Member" xlink:label="prqr_ProqrTherapeuticsIB.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="prqr_ProqrTherapeuticsIB.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIiB.v.Member" xlink:label="prqr_ProqrTherapeuticsIiB.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="prqr_ProqrTherapeuticsIiB.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIiiB.v.Member" xlink:label="prqr_ProqrTherapeuticsIiiB.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="prqr_ProqrTherapeuticsIiiB.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIvB.v.Member" xlink:label="prqr_ProqrTherapeuticsIvB.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="prqr_ProqrTherapeuticsIvB.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsVB.v.Member" xlink:label="prqr_ProqrTherapeuticsVB.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="prqr_ProqrTherapeuticsVB.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsViB.v.Member" xlink:label="prqr_ProqrTherapeuticsViB.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="prqr_ProqrTherapeuticsViB.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsViiB.v.Member" xlink:label="prqr_ProqrTherapeuticsViiB.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="prqr_ProqrTherapeuticsViiB.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsViiiB.v.Member" xlink:label="prqr_ProqrTherapeuticsViiiB.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="prqr_ProqrTherapeuticsViiiB.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIxB.v.Member" xlink:label="prqr_ProqrTherapeuticsIxB.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="prqr_ProqrTherapeuticsIxB.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIInc.Member" xlink:label="prqr_ProqrTherapeuticsIInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="prqr_ProqrTherapeuticsIInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails" xlink:type="extended" xlink:title="40102 - Disclosure - General Information - Revision of comparative figures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_DeferredIncomeIncludingContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Critical Accounting Estimates and Judgements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_CounterpartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_EliLillyAndCompanyMember" xlink:label="prqr_EliLillyAndCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="prqr_EliLillyAndCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DeferredIncomeIncludingContractLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Property, Plant and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" xlink:label="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_RightofuseAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureBorrowingsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain" xlink:label="ifrs-full_BorrowingsByNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_InnovationCreditMember" xlink:label="prqr_InnovationCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameDomain" xlink:to="prqr_InnovationCreditMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsClassesOfWarrantsOrRightsAxisAxis" xlink:label="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ClassesOfWarrantsOrRightsDomain" xlink:label="prqr_ClassesOfWarrantsOrRightsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis" xlink:to="prqr_ClassesOfWarrantsOrRightsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PontifaxAndKreosWarrantsMember" xlink:label="prqr_PontifaxAndKreosWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="prqr_ClassesOfWarrantsOrRightsDomain" xlink:to="prqr_PontifaxAndKreosWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_Borrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_BorrowingsExcludingAccruedInterest" xlink:label="prqr_BorrowingsExcludingAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="prqr_BorrowingsExcludingAccruedInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPayable" xlink:label="ifrs-full_InterestPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_InterestPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_CurrentBorrowingsExcludingAccruedInterest" xlink:label="prqr_CurrentBorrowingsExcludingAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="prqr_CurrentBorrowingsExcludingAccruedInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_WarrantsEconomicLifetime" xlink:label="prqr_WarrantsEconomicLifetime" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="prqr_WarrantsEconomicLifetime" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ConditionalWaiverOfDebtTotal" xlink:label="prqr_ConditionalWaiverOfDebtTotal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="prqr_ConditionalWaiverOfDebtTotal" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OfficeAndLaboratoryFacilityMember" xlink:label="prqr_OfficeAndLaboratoryFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="prqr_OfficeAndLaboratoryFacilityMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" xlink:label="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="prqr_OfficeAndLaboratoryFacilityMember" xlink:to="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AreaOfPropertyUnderLease" xlink:label="prqr_AreaOfPropertyUnderLease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="prqr_AreaOfPropertyUnderLease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_LeaseTerm" xlink:label="prqr_LeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="prqr_LeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_LeaseExtensionTerm" xlink:label="prqr_LeaseExtensionTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="prqr_LeaseExtensionTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_LeaseCurrentExtensionPeriodUnderOption" xlink:label="prqr_LeaseCurrentExtensionPeriodUnderOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="prqr_LeaseCurrentExtensionPeriodUnderOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_RightofuseAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureDeferredIncomeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Deferred Income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_CounterpartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_EliLillyAndCompanyMember" xlink:label="prqr_EliLillyAndCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="prqr_EliLillyAndCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_RettSyndromeResearchTrustMember" xlink:label="prqr_RettSyndromeResearchTrustMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="prqr_RettSyndromeResearchTrustMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:label="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DeferredIncomeIncludingContractLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Shareholders' Equity - Share capital (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_PreferenceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_CounterpartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_EliLillyAndCompanyMember" xlink:label="prqr_EliLillyAndCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="prqr_EliLillyAndCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AuthorizedShareCapitalValue" xlink:label="prqr_AuthorizedShareCapitalValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="prqr_AuthorizedShareCapitalValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Shareholders' Equity - Sale of shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockAxis" xlink:label="prqr_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="prqr_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockDomain" xlink:label="prqr_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="prqr_IfrsSaleOfStockAxis" xlink:to="prqr_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ShelfRegistrationStatement2024Member" xlink:label="prqr_ShelfRegistrationStatement2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="prqr_IfrsSaleOfStockDomain" xlink:to="prqr_ShelfRegistrationStatement2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember" xlink:label="prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="prqr_ShelfRegistrationStatement2024Member" xlink:to="prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_October2024UnderwrittenPublicOfferingMember" xlink:label="prqr_October2024UnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="prqr_ShelfRegistrationStatement2024Member" xlink:to="prqr_October2024UnderwrittenPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember" xlink:label="prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="prqr_October2024UnderwrittenPublicOfferingMember" xlink:to="prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember" xlink:label="prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="prqr_ShelfRegistrationStatement2024Member" xlink:to="prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MaximumOfferingPriceInShelfRegistrationStatement" xlink:label="prqr_MaximumOfferingPriceInShelfRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="prqr_MaximumOfferingPriceInShelfRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement" xlink:label="prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockPricePerShare" xlink:label="prqr_IfrsSaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="prqr_IfrsSaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DurationOfUnderwritersOption" xlink:label="prqr_DurationOfUnderwritersOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="prqr_DurationOfUnderwritersOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_NumberOfSharesCallableForOptionsIssued" xlink:label="prqr_NumberOfSharesCallableForOptionsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="prqr_NumberOfSharesCallableForOptionsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_PaymentsForShareIssueCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_NetProceedsFromIssuingShares" xlink:label="prqr_NetProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="prqr_NetProceedsFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PurchasePriceCapSharePurchaseAgreement" xlink:label="prqr_PurchasePriceCapSharePurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="prqr_PurchasePriceCapSharePurchaseAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Shareholders' Equity - Share options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSellingGeneralAndAdministrativeExpensesMember" xlink:label="prqr_IfrsSellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="prqr_IfrsSellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsResearchAndDevelopmentExpenseMember" xlink:label="prqr_IfrsResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="prqr_IfrsResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_CounterpartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_EliLillyAndCompanyMember" xlink:label="prqr_EliLillyAndCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="prqr_EliLillyAndCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain" xlink:label="ifrs-full_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MilestonePaymentsMember" xlink:label="prqr_MilestonePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesDomain" xlink:to="prqr_MilestonePaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DeferredIncomeIncludingContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DiscountOnIssueOfShares" xlink:label="prqr_DiscountOnIssueOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="prqr_DiscountOnIssueOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership" xlink:label="prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_NumberOfPerformanceObligationsInCollaborationAgreement" xlink:label="prqr_NumberOfPerformanceObligationsInCollaborationAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="prqr_NumberOfPerformanceObligationsInCollaborationAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ValueOfMilestonesReachedDuringPeriod" xlink:label="prqr_ValueOfMilestonesReachedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="prqr_ValueOfMilestonesReachedDuringPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Other Income - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OtherIncomeTable" xlink:label="prqr_OtherIncomeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="prqr_OtherIncomeTable" xlink:to="ifrs-full_CounterpartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_RettSyndromeResearchTrustMember" xlink:label="prqr_RettSyndromeResearchTrustMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="prqr_RettSyndromeResearchTrustMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OtherIncomeLineItems" xlink:label="prqr_OtherIncomeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="prqr_OtherIncomeLineItems" xlink:to="prqr_OtherIncomeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsRevenueFromGrants" xlink:label="prqr_IfrsRevenueFromGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="prqr_OtherIncomeLineItems" xlink:to="prqr_IfrsRevenueFromGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MaximumGrantReceivableForInitialPhaseOfProject" xlink:label="prqr_MaximumGrantReceivableForInitialPhaseOfProject" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="prqr_OtherIncomeLineItems" xlink:to="prqr_MaximumGrantReceivableForInitialPhaseOfProject" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MaximumGrantReceivableForAdditionalPhaseOfProject" xlink:label="prqr_MaximumGrantReceivableForAdditionalPhaseOfProject" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="prqr_OtherIncomeLineItems" xlink:to="prqr_MaximumGrantReceivableForAdditionalPhaseOfProject" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_WarrantsEconomicLifetime" xlink:label="prqr_WarrantsEconomicLifetime" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="prqr_OtherIncomeLineItems" xlink:to="prqr_WarrantsEconomicLifetime" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="prqr_OtherIncomeLineItems" xlink:to="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Investments in Financial Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable" xlink:label="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable" xlink:to="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain" xlink:label="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PhoenicisTherapeuticsIncMember" xlink:label="prqr_PhoenicisTherapeuticsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain" xlink:to="prqr_PhoenicisTherapeuticsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_YarrowBiotechnologyMember" xlink:label="prqr_YarrowBiotechnologyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain" xlink:to="prqr_YarrowBiotechnologyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems" xlink:label="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems" xlink:to="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProportionOfOwnershipInterest" xlink:label="prqr_ProportionOfOwnershipInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems" xlink:to="prqr_ProportionOfOwnershipInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>prqr-20250930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/4/2025 3:07:58 PM-->
<!--Modified on: 11/4/2025 3:07:58 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DocumentAndEntityInformationAbstract" xlink:label="prqr_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_DocumentAndEntityInformationAbstract" xlink:to="prqr_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited Condensed Consolidated Statement of Financial Position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment including right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, at beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PrepaymentsAndOtherReceivables" xlink:label="prqr_PrepaymentsAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_PrepaymentsAndOtherReceivables" xlink:to="prqr_PrepaymentsAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_PrepaymentsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables that represent amounts paid for goods and services before they have been delivered and other receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_PrepaymentsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="prqr_PrepaymentsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Prepayments and Other Receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current receivables from taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity attributable to owners of parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity attributable to owners of the Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="ifrs-full_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xlink:to="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current deferred income including non-current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current deferred income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current borrowings and current portion of non-current borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current derivative financial liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current payables on social security and taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Social securities and other taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:label="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:to="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current deferred income including current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current deferred income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from contracts with customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating result</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income and expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains (losses) on financial liabilities at fair value through profit or loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Results related to financial liabilities measured at fair value through profit or loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Result before corporate income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income), continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Result for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Result for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net result</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, exchange differences on translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (foreign exchange differences on foreign operation)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss), attributable to [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Result attributable to</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss), attributable to owners of parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Owners of the Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income attributable to</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income, attributable to owners of parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Owners of the Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average ordinary shares and adjusted weighted average ordinary shares [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of shares outstanding (basic)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of shares outstanding (diluted)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share attributable to owners of the Company (Euro per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited Condensed Consolidated Statement of Changes in Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ComponentsOfEquityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Premium</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Settled Employee Benefit Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Settled Employee Benefit Reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Translation Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Translation Reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statement of Changes in Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through share-based payment transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognition of share-based payments</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_TreasurySharesTransferred" xlink:label="prqr_TreasurySharesTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_TreasurySharesTransferred" xlink:to="prqr_TreasurySharesTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_TreasurySharesTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of treasury shares transferred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_TreasurySharesTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="prqr_TreasurySharesTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares transferred (in shares)</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_SharesOptionsLapsed" xlink:label="prqr_SharesOptionsLapsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_SharesOptionsLapsed" xlink:to="prqr_SharesOptionsLapsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_SharesOptionsLapsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity resulting from share options lapsing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_SharesOptionsLapsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Options Lapsed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_SharesOptionsLapsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share options lapsed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through exercise of options, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares options exercised / RSUs vested</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period through the exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share options exercised / RSUs vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited Condensed Consolidated Statement of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile profit (loss) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for:</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AdjustmentsForOtherIncome" xlink:label="prqr_AdjustmentsForOtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_AdjustmentsForOtherIncome" xlink:to="prqr_AdjustmentsForOtherIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_AdjustmentsForOtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for other income to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_AdjustmentsForOtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="prqr_AdjustmentsForOtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial income and expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for fair value losses (gains)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Results related to financial liabilities measured at fair value through profit or loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in working capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash used in operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid (refund), classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate income tax received / (paid)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of financial instruments, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in financial asset - current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sales or maturity of financial instruments, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in financial asset - current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) / generated by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of shares, net of transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of share options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of lease liabilities, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (decrease) / increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency effect cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_GeneralInformationAbstract" xlink:label="prqr_GeneralInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_GeneralInformationAbstract" xlink:to="prqr_GeneralInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_GeneralInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_GeneralInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General Information</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfGeneralInformationExplanatory" xlink:label="prqr_DisclosureOfGeneralInformationExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_DisclosureOfGeneralInformationExplanatory" xlink:to="prqr_DisclosureOfGeneralInformationExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_DisclosureOfGeneralInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of general information about the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_DisclosureOfGeneralInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of General Information Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_DisclosureOfGeneralInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General Information</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsAccountingPoliciesAbstract" xlink:label="prqr_IfrsAccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsAccountingPoliciesAbstract" xlink:to="prqr_IfrsAccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsAccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n.a.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsAccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of material accounting policy information [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adoption of New and Revised International Financial Reporting Standards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of initial application of standards or interpretations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adoption of New and Revised International Financial Reporting Standards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Critical Accounting Estimates and Judgments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting judgements and estimates [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Critical Accounting Estimates and Judgments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of cash and cash equivalents [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PrepaymentsAndOtherReceivablesAbstract" xlink:label="prqr_PrepaymentsAndOtherReceivablesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_PrepaymentsAndOtherReceivablesAbstract" xlink:to="prqr_PrepaymentsAndOtherReceivablesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_PrepaymentsAndOtherReceivablesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_PrepaymentsAndOtherReceivablesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments and Other Receivables.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of prepayments and other assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments and Other Receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of property, plant and equipment [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OtherCurrentLiabilitiesAbstract" xlink:label="prqr_OtherCurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_OtherCurrentLiabilitiesAbstract" xlink:to="prqr_OtherCurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_OtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_OtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other current liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_BorrowingsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:to="ifrs-full_DisclosureOfBorrowingsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of borrowings [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liabilities.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of leases [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liabilities</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DeferredIncomeAbstract" xlink:label="prqr_DeferredIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_DeferredIncomeAbstract" xlink:to="prqr_DeferredIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_DeferredIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_DeferredIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDeferredIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDeferredIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfDeferredIncomeExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of deferred income [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsOtherIncomeAbstract" xlink:label="prqr_IfrsOtherIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsOtherIncomeAbstract" xlink:to="prqr_IfrsOtherIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsOtherIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsOtherIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other operating income [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ResearchAndDevelopmentCostsAbstract" xlink:label="prqr_ResearchAndDevelopmentCostsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ResearchAndDevelopmentCostsAbstract" xlink:to="prqr_ResearchAndDevelopmentCostsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ResearchAndDevelopmentCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ResearchAndDevelopmentCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of general and administrative expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Costs</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_InvestmentsInFinancialAssetsAbstract" xlink:label="prqr_InvestmentsInFinancialAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_InvestmentsInFinancialAssetsAbstract" xlink:to="prqr_InvestmentsInFinancialAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_InvestmentsInFinancialAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_InvestmentsInFinancialAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in Financial Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in Financial Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related-Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related-Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Events After Balance Sheet Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Events After Balance Sheet Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for recognition of revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenditures</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock" xlink:label="prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock" xlink:to="prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of prepayments and other receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Prepayments And Other Receivables [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of prepayments and other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of borrowings</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ScheduleOfDeferredIncomeTableTextBlock" xlink:label="prqr_ScheduleOfDeferredIncomeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ScheduleOfDeferredIncomeTableTextBlock" xlink:to="prqr_ScheduleOfDeferredIncomeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ScheduleOfDeferredIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of deferred income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ScheduleOfDeferredIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Income [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ScheduleOfDeferredIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of deferred income</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory" xlink:label="prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory" xlink:to="prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of other income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Other Income Table Text Block Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of subsidiaries [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiaries [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiaries [domain]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsHoldingB.v.Member" xlink:label="prqr_ProqrTherapeuticsHoldingB.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProqrTherapeuticsHoldingB.v.Member" xlink:to="prqr_ProqrTherapeuticsHoldingB.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProqrTherapeuticsHoldingB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics Holding B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProqrTherapeuticsHoldingB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics Holding B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ProqrTherapeuticsHoldingB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics Holding B.V.</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIB.v.Member" xlink:label="prqr_ProqrTherapeuticsIB.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProqrTherapeuticsIB.v.Member" xlink:to="prqr_ProqrTherapeuticsIB.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProqrTherapeuticsIB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics I B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProqrTherapeuticsIB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics I B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ProqrTherapeuticsIB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics I B.V.</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIiB.v.Member" xlink:label="prqr_ProqrTherapeuticsIiB.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProqrTherapeuticsIiB.v.Member" xlink:to="prqr_ProqrTherapeuticsIiB.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProqrTherapeuticsIiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics II B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProqrTherapeuticsIiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics II B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ProqrTherapeuticsIiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics II B.V.</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIiiB.v.Member" xlink:label="prqr_ProqrTherapeuticsIiiB.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProqrTherapeuticsIiiB.v.Member" xlink:to="prqr_ProqrTherapeuticsIiiB.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProqrTherapeuticsIiiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics III B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProqrTherapeuticsIiiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics III B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ProqrTherapeuticsIiiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics III B.V.</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIvB.v.Member" xlink:label="prqr_ProqrTherapeuticsIvB.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProqrTherapeuticsIvB.v.Member" xlink:to="prqr_ProqrTherapeuticsIvB.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProqrTherapeuticsIvB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics IV B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProqrTherapeuticsIvB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics IV B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ProqrTherapeuticsIvB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics IV B.V.</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsVB.v.Member" xlink:label="prqr_ProqrTherapeuticsVB.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProqrTherapeuticsVB.v.Member" xlink:to="prqr_ProqrTherapeuticsVB.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProqrTherapeuticsVB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics V B.V. [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProqrTherapeuticsVB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics V B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ProqrTherapeuticsVB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics V B.V.</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsViB.v.Member" xlink:label="prqr_ProqrTherapeuticsViB.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProqrTherapeuticsViB.v.Member" xlink:to="prqr_ProqrTherapeuticsViB.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProqrTherapeuticsViB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics VI B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProqrTherapeuticsViB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics VI B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ProqrTherapeuticsViB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics VI B.V.</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsViiB.v.Member" xlink:label="prqr_ProqrTherapeuticsViiB.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProqrTherapeuticsViiB.v.Member" xlink:to="prqr_ProqrTherapeuticsViiB.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProqrTherapeuticsViiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics VII B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProqrTherapeuticsViiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics VII B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ProqrTherapeuticsViiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics VII B.V.</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsViiiB.v.Member" xlink:label="prqr_ProqrTherapeuticsViiiB.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProqrTherapeuticsViiiB.v.Member" xlink:to="prqr_ProqrTherapeuticsViiiB.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProqrTherapeuticsViiiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics VIII B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProqrTherapeuticsViiiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics VIII B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ProqrTherapeuticsViiiB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics VIII B.V.</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIxB.v.Member" xlink:label="prqr_ProqrTherapeuticsIxB.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProqrTherapeuticsIxB.v.Member" xlink:to="prqr_ProqrTherapeuticsIxB.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProqrTherapeuticsIxB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics IX B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProqrTherapeuticsIxB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics IX B.V. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ProqrTherapeuticsIxB.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics IX B.V.</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIInc.Member" xlink:label="prqr_ProqrTherapeuticsIInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProqrTherapeuticsIInc.Member" xlink:to="prqr_ProqrTherapeuticsIInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProqrTherapeuticsIInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics I Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProqrTherapeuticsIInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics I Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ProqrTherapeuticsIInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ProQR Therapeutics I Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of subsidiaries [line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest in subsidiary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:to="ifrs-full_DeferredIncomeIncludingContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income including contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsNumberOfReportableSegments" xlink:label="prqr_IfrsNumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsNumberOfReportableSegments" xlink:to="prqr_IfrsNumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsNumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsNumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_IfrsNumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparties [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="ifrs-full_CounterpartiesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparties [domain]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_EliLillyAndCompanyMember" xlink:label="prqr_EliLillyAndCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_EliLillyAndCompanyMember" xlink:to="prqr_EliLillyAndCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_EliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eli Lilly and Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_EliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eli Lilly and Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Prepayments" xlink:label="ifrs-full_Prepayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Prepayments" xlink:to="ifrs-full_Prepayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Prepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccruedIncomeIncludingContractAssets" xlink:label="ifrs-full_AccruedIncomeIncludingContractAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccruedIncomeIncludingContractAssets" xlink:to="ifrs-full_AccruedIncomeIncludingContractAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccruedIncomeIncludingContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued income including contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccruedIncomeIncludingContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued income from Rett Syndrome Research Trust</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of property, plant and equipment [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of property, plant and equipment [domain]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" xlink:label="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" xlink:to="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents the office and laboratory facilities at Zernikedreef in Leiden, the Netherlands.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and laboratory facilities at Zernikedreef in Leiden, the Netherlands [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and laboratory facilities at Zernikedreef in Leiden, the Netherlands</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain" xlink:label="ifrs-full_BorrowingsByNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameDomain" xlink:to="ifrs-full_BorrowingsByNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [domain]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_InnovationCreditMember" xlink:label="prqr_InnovationCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_InnovationCreditMember" xlink:to="prqr_InnovationCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_InnovationCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to innovation credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_InnovationCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innovation credit</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsClassesOfWarrantsOrRightsAxisAxis" xlink:label="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis" xlink:to="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes Of Warrants Or Rights Axis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Classes Of Warrants Or Rights Axis [Axis]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ClassesOfWarrantsOrRightsDomain" xlink:label="prqr_ClassesOfWarrantsOrRightsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ClassesOfWarrantsOrRightsDomain" xlink:to="prqr_ClassesOfWarrantsOrRightsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ClassesOfWarrantsOrRightsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of warrants or rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ClassesOfWarrantsOrRightsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of warrants or rights [Domain]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PontifaxAndKreosWarrantsMember" xlink:label="prqr_PontifaxAndKreosWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_PontifaxAndKreosWarrantsMember" xlink:to="prqr_PontifaxAndKreosWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_PontifaxAndKreosWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents the Pontifax and Kreos warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_PontifaxAndKreosWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pontifax and Kreos warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_PontifaxAndKreosWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pontifax and Kreos warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_Borrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total borrowings</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_BorrowingsExcludingAccruedInterest" xlink:label="prqr_BorrowingsExcludingAccruedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_BorrowingsExcludingAccruedInterest" xlink:to="prqr_BorrowingsExcludingAccruedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_BorrowingsExcludingAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings excluding accrued interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_BorrowingsExcludingAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings excluding accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPayable" xlink:label="ifrs-full_InterestPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPayable" xlink:to="ifrs-full_InterestPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_CurrentBorrowingsExcludingAccruedInterest" xlink:label="prqr_CurrentBorrowingsExcludingAccruedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_CurrentBorrowingsExcludingAccruedInterest" xlink:to="prqr_CurrentBorrowingsExcludingAccruedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_CurrentBorrowingsExcludingAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current borrowings excluding accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_CurrentBorrowingsExcludingAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current borrowings excluding accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotionalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of borrowings</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_WarrantsEconomicLifetime" xlink:label="prqr_WarrantsEconomicLifetime" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_WarrantsEconomicLifetime" xlink:to="prqr_WarrantsEconomicLifetime_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_WarrantsEconomicLifetime_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, economic lifetime</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_WarrantsEconomicLifetime_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, economic lifetime</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_WarrantsEconomicLifetime_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, economic lifetime</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ConditionalWaiverOfDebtTotal" xlink:label="prqr_ConditionalWaiverOfDebtTotal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ConditionalWaiverOfDebtTotal" xlink:to="prqr_ConditionalWaiverOfDebtTotal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ConditionalWaiverOfDebtTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The total amount of debt including interest can be waived up on satisfying the conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ConditionalWaiverOfDebtTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conditional Waiver of Debt, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ConditionalWaiverOfDebtTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total conditional waiver of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [table]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OfficeAndLaboratoryFacilityMember" xlink:label="prqr_OfficeAndLaboratoryFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_OfficeAndLaboratoryFacilityMember" xlink:to="prqr_OfficeAndLaboratoryFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_OfficeAndLaboratoryFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for office and laboratory space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_OfficeAndLaboratoryFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and Laboratory Facility [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [line items]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AreaOfPropertyUnderLease" xlink:label="prqr_AreaOfPropertyUnderLease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_AreaOfPropertyUnderLease" xlink:to="prqr_AreaOfPropertyUnderLease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_AreaOfPropertyUnderLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of property under lease as per lease terms.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_AreaOfPropertyUnderLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area Of Property Under Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_AreaOfPropertyUnderLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area under lease</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_LeaseTerm" xlink:label="prqr_LeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_LeaseTerm" xlink:to="prqr_LeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_LeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_LeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_LeaseExtensionTerm" xlink:label="prqr_LeaseExtensionTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_LeaseExtensionTerm" xlink:to="prqr_LeaseExtensionTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_LeaseExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease extension term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_LeaseExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease extension term</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_LeaseCurrentExtensionPeriodUnderOption" xlink:label="prqr_LeaseCurrentExtensionPeriodUnderOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_LeaseCurrentExtensionPeriodUnderOption" xlink:to="prqr_LeaseCurrentExtensionPeriodUnderOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_LeaseCurrentExtensionPeriodUnderOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, current extension period under option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_LeaseCurrentExtensionPeriodUnderOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, current extension period under option</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_RettSyndromeResearchTrustMember" xlink:label="prqr_RettSyndromeResearchTrustMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_RettSyndromeResearchTrustMember" xlink:to="prqr_RettSyndromeResearchTrustMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_RettSyndromeResearchTrustMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rett Syndrome Research Trust [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_RettSyndromeResearchTrustMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rett Syndrome Research Trust [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_RettSyndromeResearchTrustMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rett Syndrome Research Trust</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of share capital [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of share capital [domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreferenceSharesMember" xlink:to="ifrs-full_PreferenceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders Equity</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AuthorizedShareCapitalValue" xlink:label="prqr_AuthorizedShareCapitalValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_AuthorizedShareCapitalValue" xlink:to="prqr_AuthorizedShareCapitalValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_AuthorizedShareCapitalValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of authorized share capital value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_AuthorizedShareCapitalValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized share capital value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_AuthorizedShareCapitalValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized share capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued and fully paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued and fully paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares in entity held by entity or by its subsidiaries or associates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:to="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock shares issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of ordinary shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockAxis" xlink:label="prqr_IfrsSaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsSaleOfStockAxis" xlink:to="prqr_IfrsSaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsSaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by type of sale of the entity's stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsSaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockDomain" xlink:label="prqr_IfrsSaleOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsSaleOfStockDomain" xlink:to="prqr_IfrsSaleOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ShelfRegistrationStatement2024Member" xlink:label="prqr_ShelfRegistrationStatement2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ShelfRegistrationStatement2024Member" xlink:to="prqr_ShelfRegistrationStatement2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ShelfRegistrationStatement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents the 2024 shelf registration statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ShelfRegistrationStatement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf registration statement, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_ShelfRegistrationStatement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 shelf registration statement</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember" xlink:label="prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember" xlink:to="prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents at the market offerings with Cantor Fitzgerald and Co under the shelf registration statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the market offerings with Cantor Fitzgerald and Co under shelf registration statement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the market offerings with Cantor Fitzgerald and Co under shelf registration statement</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_October2024UnderwrittenPublicOfferingMember" xlink:label="prqr_October2024UnderwrittenPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_October2024UnderwrittenPublicOfferingMember" xlink:to="prqr_October2024UnderwrittenPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_October2024UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents the October 2024 underwritten public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_October2024UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">October 2024 underwritten public offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_October2024UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">October 2024 underwritten public offering</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember" xlink:label="prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember" xlink:to="prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents the underwriters' option in connection to the October 2024 underwritten public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters' option in connection to October 2024 underwritten public offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters' option in connection to October 2024 underwritten public offering</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember" xlink:label="prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember" xlink:to="prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents the share purchase agreement with Eli Lilly and Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share purchase agreement with Eli Lilly and Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share purchase agreement with Eli Lilly and Company</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MaximumOfferingPriceInShelfRegistrationStatement" xlink:label="prqr_MaximumOfferingPriceInShelfRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_MaximumOfferingPriceInShelfRegistrationStatement" xlink:to="prqr_MaximumOfferingPriceInShelfRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_MaximumOfferingPriceInShelfRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum offering price in shelf registration statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_MaximumOfferingPriceInShelfRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum offering price in shelf registration statement</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement" xlink:label="prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement" xlink:to="prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of commission payable for gross proceeds from sales agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of commission payable for gross proceeds from sales agreement</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockPricePerShare" xlink:label="prqr_IfrsSaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsSaleOfStockPricePerShare" xlink:to="prqr_IfrsSaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsSaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share amount received for each share of common stock issued or sold in the stock transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsSaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Sale Of Stock Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_IfrsSaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DurationOfUnderwritersOption" xlink:label="prqr_DurationOfUnderwritersOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_DurationOfUnderwritersOption" xlink:to="prqr_DurationOfUnderwritersOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_DurationOfUnderwritersOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Duration of underwriters' option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_DurationOfUnderwritersOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Duration of underwriters' option</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_NumberOfSharesCallableForOptionsIssued" xlink:label="prqr_NumberOfSharesCallableForOptionsIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_NumberOfSharesCallableForOptionsIssued" xlink:to="prqr_NumberOfSharesCallableForOptionsIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_NumberOfSharesCallableForOptionsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares callable for options issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_NumberOfSharesCallableForOptionsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares callable for options issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for share issue costs</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_NetProceedsFromIssuingShares" xlink:label="prqr_NetProceedsFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_NetProceedsFromIssuingShares" xlink:to="prqr_NetProceedsFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_NetProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_NetProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuing shares</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PurchasePriceCapSharePurchaseAgreement" xlink:label="prqr_PurchasePriceCapSharePurchaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_PurchasePriceCapSharePurchaseAgreement" xlink:to="prqr_PurchasePriceCapSharePurchaseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_PurchasePriceCapSharePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price cap, share purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_PurchasePriceCapSharePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price cap, share purchase agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Attribution of expenses by nature to their function [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Attribution of expenses by nature to their function [domain]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSellingGeneralAndAdministrativeExpensesMember" xlink:label="prqr_IfrsSellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsSellingGeneralAndAdministrativeExpensesMember" xlink:to="prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing selling, general and administrative expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS General and administrative costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative costs</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsResearchAndDevelopmentExpenseMember" xlink:label="prqr_IfrsResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsResearchAndDevelopmentExpenseMember" xlink:to="prqr_IfrsResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption in which the reported facts about research and development expense have been included.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from equity-settled share-based payment transactions in which goods or services received did not qualify for recognition as assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-settled share based payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain" xlink:label="ifrs-full_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesDomain" xlink:to="ifrs-full_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [domain]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MilestonePaymentsMember" xlink:label="prqr_MilestonePaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_MilestonePaymentsMember" xlink:to="prqr_MilestonePaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_MilestonePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_MilestonePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_MilestonePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DiscountOnIssueOfShares" xlink:label="prqr_DiscountOnIssueOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_DiscountOnIssueOfShares" xlink:to="prqr_DiscountOnIssueOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_DiscountOnIssueOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of discount on issue of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_DiscountOnIssueOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount on Issue of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_DiscountOnIssueOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount on shares issued</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership" xlink:label="prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership" xlink:to="prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional consideration to be received if counterparty exercises option to expand partnership</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional consideration to be received if counterparty exercises option to expand partnership</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_NumberOfPerformanceObligationsInCollaborationAgreement" xlink:label="prqr_NumberOfPerformanceObligationsInCollaborationAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_NumberOfPerformanceObligationsInCollaborationAgreement" xlink:to="prqr_NumberOfPerformanceObligationsInCollaborationAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_NumberOfPerformanceObligationsInCollaborationAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of performance obligations in collaboration agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_NumberOfPerformanceObligationsInCollaborationAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of performance obligations in collaboration agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:to="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts from sales of goods and rendering of services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ValueOfMilestonesReachedDuringPeriod" xlink:label="prqr_ValueOfMilestonesReachedDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ValueOfMilestonesReachedDuringPeriod" xlink:to="prqr_ValueOfMilestonesReachedDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ValueOfMilestonesReachedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of milestones reached during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ValueOfMilestonesReachedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of milestones reached during the period</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsRevenueFromGrants" xlink:label="prqr_IfrsRevenueFromGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_IfrsRevenueFromGrants" xlink:to="prqr_IfrsRevenueFromGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_IfrsRevenueFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_IfrsRevenueFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Revenue From Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_IfrsRevenueFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OtherIncomeTable" xlink:label="prqr_OtherIncomeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_OtherIncomeTable" xlink:to="prqr_OtherIncomeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_OtherIncomeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about components of other income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_OtherIncomeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income [Table]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OtherIncomeLineItems" xlink:label="prqr_OtherIncomeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_OtherIncomeLineItems" xlink:to="prqr_OtherIncomeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_OtherIncomeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_OtherIncomeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income [Line Items]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MaximumGrantReceivableForInitialPhaseOfProject" xlink:label="prqr_MaximumGrantReceivableForInitialPhaseOfProject" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_MaximumGrantReceivableForInitialPhaseOfProject" xlink:to="prqr_MaximumGrantReceivableForInitialPhaseOfProject_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_MaximumGrantReceivableForInitialPhaseOfProject_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum grant receivable for the initial phase of the project.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_MaximumGrantReceivableForInitialPhaseOfProject_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum grant receivable for the initial phase of the project</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MaximumGrantReceivableForAdditionalPhaseOfProject" xlink:label="prqr_MaximumGrantReceivableForAdditionalPhaseOfProject" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_MaximumGrantReceivableForAdditionalPhaseOfProject" xlink:to="prqr_MaximumGrantReceivableForAdditionalPhaseOfProject_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_MaximumGrantReceivableForAdditionalPhaseOfProject_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum grant receivable for additional phase of the project.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_MaximumGrantReceivableForAdditionalPhaseOfProject_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum grant receivable for additional phase of the project</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable" xlink:label="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable" xlink:to="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to investment in financial asset and gain on disposal of associate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Investment in Financial Asset and Gain on Disposal of Associate [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in equity instruments designated at fair value through other comprehensive income [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain" xlink:label="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain" xlink:to="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in equity instruments designated at fair value through other comprehensive income [domain]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PhoenicisTherapeuticsIncMember" xlink:label="prqr_PhoenicisTherapeuticsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_PhoenicisTherapeuticsIncMember" xlink:to="prqr_PhoenicisTherapeuticsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_PhoenicisTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Phoenicis Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_PhoenicisTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phoenicis Therapeutics Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prqr_PhoenicisTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phoenicis Therapeutics Inc.</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_YarrowBiotechnologyMember" xlink:label="prqr_YarrowBiotechnologyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_YarrowBiotechnologyMember" xlink:to="prqr_YarrowBiotechnologyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_YarrowBiotechnologyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Yarrow Biotechnology.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_YarrowBiotechnologyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Yarrow Biotechnology, Inc</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems" xlink:label="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems" xlink:to="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent investment in financial asset and gain on disposal of associate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Investment in Financial Asset and Gain on Disposal of Associate [Line items]</label>
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProportionOfOwnershipInterest" xlink:label="prqr_ProportionOfOwnershipInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prqr_ProportionOfOwnershipInterest" xlink:to="prqr_ProportionOfOwnershipInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prqr_ProportionOfOwnershipInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The proportion of ownership interest that the entity holds in another entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prqr_ProportionOfOwnershipInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets at fair value through other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax liabilities</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>prqr-20250930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/4/2025 3:07:58 PM-->
<!--Modified on: 11/4/2025 3:07:58 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.proqr.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition" roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome" roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity" roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#StatementUnauditedCondensedConsolidatedStatementOfCashFlows" roleURI="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureGeneralInformation" roleURI="http://www.proqr.com/role/DisclosureGeneralInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.proqr.com/role/DisclosureSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureAdoptionOfNewAndRevisedInternationalFinancialReportingStandards" roleURI="http://www.proqr.com/role/DisclosureAdoptionOfNewAndRevisedInternationalFinancialReportingStandards" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureCriticalAccountingEstimatesAndJudgments" roleURI="http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureCashAndCashEquivalents" roleURI="http://www.proqr.com/role/DisclosureCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosurePrepaymentsAndOtherReceivables" roleURI="http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosurePropertyPlantAndEquipment" roleURI="http://www.proqr.com/role/DisclosurePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureOtherCurrentLiabilities" roleURI="http://www.proqr.com/role/DisclosureOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureBorrowings" roleURI="http://www.proqr.com/role/DisclosureBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureLeaseLiabilities" roleURI="http://www.proqr.com/role/DisclosureLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureDeferredIncome" roleURI="http://www.proqr.com/role/DisclosureDeferredIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureShareholdersEquity" roleURI="http://www.proqr.com/role/DisclosureShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureRevenue" roleURI="http://www.proqr.com/role/DisclosureRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureOtherIncome" roleURI="http://www.proqr.com/role/DisclosureOtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureResearchAndDevelopmentCosts" roleURI="http://www.proqr.com/role/DisclosureResearchAndDevelopmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureGeneralAndAdministrativeCosts" roleURI="http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureInvestmentsInFinancialAssets" roleURI="http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureIncomeTaxes" roleURI="http://www.proqr.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.proqr.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureEventsAfterBalanceSheetDate" roleURI="http://www.proqr.com/role/DisclosureEventsAfterBalanceSheetDate" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosurePrepaymentsAndOtherReceivablesTables" roleURI="http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureBorrowingsTables" roleURI="http://www.proqr.com/role/DisclosureBorrowingsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureDeferredIncomeTables" roleURI="http://www.proqr.com/role/DisclosureDeferredIncomeTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureOtherIncomeTables" roleURI="http://www.proqr.com/role/DisclosureOtherIncomeTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureGeneralInformationDetails" roleURI="http://www.proqr.com/role/DisclosureGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureGeneralInformationRevisionOfComparativeFiguresDetails" roleURI="http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureCriticalAccountingEstimatesAndJudgementsDetails" roleURI="http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureCashAndCashEquivalentsDetails" roleURI="http://www.proqr.com/role/DisclosureCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosurePrepaymentsAndOtherReceivablesDetails" roleURI="http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosurePropertyPlantAndEquipmentDetails" roleURI="http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureOtherCurrentLiabiltiesDetails" roleURI="http://www.proqr.com/role/DisclosureOtherCurrentLiabiltiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureBorrowingsDetails" roleURI="http://www.proqr.com/role/DisclosureBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureLeaseLiabilitiesDetails" roleURI="http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureDeferredIncomeDetails" roleURI="http://www.proqr.com/role/DisclosureDeferredIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureShareholdersEquityShareCapitalDetails" roleURI="http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureShareholdersEquitySaleOfSharesDetails" roleURI="http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureShareholdersEquityShareOptionsDetails" roleURI="http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureRevenueDetails" roleURI="http://www.proqr.com/role/DisclosureRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureOtherIncomeDetails" roleURI="http://www.proqr.com/role/DisclosureOtherIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureOtherIncomeNarrativeDetails" roleURI="http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureResearchAndDevelopmentCostsDetails" roleURI="http://www.proqr.com/role/DisclosureResearchAndDevelopmentCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureGeneralAndAdministrativeCostsDetails" roleURI="http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureInvestmentsInFinancialAssetsDetails" roleURI="http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prqr-20250930.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.proqr.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.proqr.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638978656765258067" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638978656765258067" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638978656765258067" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638978656765258067" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_638978656765258067" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638978656765258067" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638978656765258067" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638978656765258067" order="8" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition" xlink:type="extended" xlink:title="00100 - Statement - Unaudited Condensed Consolidated Statement of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638978656765258067" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638978656765258067" xlink:to="ifrs-full_NoncurrentAssets_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638978656765258067" xlink:to="ifrs-full_CashAndCashEquivalents_638978656765258067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PrepaymentsAndOtherReceivables" xlink:label="prqr_PrepaymentsAndOtherReceivables_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638978656765258067" xlink:to="prqr_PrepaymentsAndOtherReceivables_638978656765258067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638978656765258067" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_638978656765258067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638978656765258067" xlink:to="ifrs-full_CurrentAssets_638978656765258067" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638978656765258067" xlink:to="ifrs-full_Assets_638978656765258067" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_EquityAbstract_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638978656765258067" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638978656765258067" xlink:to="ifrs-full_Equity_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="ifrs-full_LiabilitiesAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_LiabilitiesAbstract_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_NoncurrentLiabilities_638978656765258067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_638978656765258067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_CurrentLeaseLiabilities_638978656765258067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities_638978656765258067" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638978656765258067" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_638978656765258067" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:label="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_638978656765258067" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_OtherCurrentLiabilities_638978656765258067" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_CurrentLiabilities_638978656765258067" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_Liabilities_638978656765258067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638978656765258067" xlink:to="ifrs-full_EquityAndLiabilities_638978656765258067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome" xlink:type="extended" xlink:title="00200 - Statement - Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="StatementOfComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherIncome_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638978656765258067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638978656765258067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OperatingExpense_638978656765258067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638978656765258067" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_FinanceIncomeCost_638978656765258067" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_638978656765258067" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax_638978656765258067" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638978656765258067" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLoss_638978656765258067" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638978656765258067" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome_638978656765258067" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_638978656765258067" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract_638978656765258067" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_6389786567652580671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract_638978656765258067" xlink:to="ifrs-full_ProfitLoss_6389786567652580671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToAbstract_638978656765258067" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToAbstract_638978656765258067" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_6389786567652580671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToAbstract_638978656765258067" xlink:to="ifrs-full_ComprehensiveIncome_6389786567652580671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_638978656765258067" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_638978656765258067" xlink:to="ifrs-full_WeightedAverageShares_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_638978656765258067" xlink:to="ifrs-full_AdjustedWeightedAverageShares_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_638978656765258067" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract_638978656765258067" xlink:to="ifrs-full_BasicEarningsLossPerShare_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract_638978656765258067" xlink:to="ifrs-full_DilutedEarningsLossPerShare_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity" xlink:type="extended" xlink:title="00300 - Statement - Unaudited Condensed Consolidated Statement of Changes in Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="StatementOfChangesInEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_638978656765258067" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638978656765258067" xlink:to="ifrs-full_ComponentsOfEquityAxis_638978656765258067" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638978656765258067" xlink:to="ifrs-full_IssuedCapitalMember_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638978656765258067" xlink:to="ifrs-full_SharePremiumMember_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638978656765258067" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_638978656765258067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638978656765258067" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_638978656765258067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638978656765258067" xlink:to="ifrs-full_RetainedEarningsMember_638978656765258067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638978656765258067" xlink:to="ifrs-full_ComponentsOfEquityDomain_638978656765258067" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638978656765258067" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" xlink:to="ifrs-full_Equity_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" xlink:to="ifrs-full_NumberOfSharesOutstanding_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" xlink:to="ifrs-full_ProfitLoss_638978656765258067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" xlink:to="ifrs-full_OtherComprehensiveIncome_638978656765258067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_638978656765258067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_TreasurySharesTransferred" xlink:label="prqr_TreasurySharesTransferred_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" xlink:to="prqr_TreasurySharesTransferred_638978656765258067" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_SharesOptionsLapsed" xlink:label="prqr_SharesOptionsLapsed_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" xlink:to="prqr_SharesOptionsLapsed_638978656765258067" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_638978656765258067" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" xlink:to="prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised_638978656765258067" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_6389786567652580671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" xlink:to="ifrs-full_Equity_6389786567652580671" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_6389786567652580671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765258067" xlink:to="ifrs-full_NumberOfSharesOutstanding_6389786567652580671" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Unaudited Condensed Consolidated Statement of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638978656765258067" xlink:to="ifrs-full_ProfitLoss_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638978656765258067" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AdjustmentsForOtherIncome" xlink:label="prqr_AdjustmentsForOtherIncome_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="prqr_AdjustmentsForOtherIncome_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638978656765258067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_638978656765258067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses_638978656765258067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_638978656765258067" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_638978656765258067" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_638978656765258067" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_638978656765258067" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638978656765258067" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638978656765258067" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638978656765258067" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638978656765258067" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638978656765258067" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638978656765258067" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638978656765258067" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638978656765258067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638978656765258067" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638978656765258067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638978656765258067" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638978656765258067" xlink:to="ifrs-full_ProceedsFromIssuingShares_638978656765258067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638978656765258067" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_638978656765258067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638978656765258067" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638978656765258067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638978656765258067" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638978656765258067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638978656765258067" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638978656765258067" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638978656765258067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_CashAndCashEquivalents_638978656765258067" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638978656765258067" xlink:to="ifrs-full_CashAndCashEquivalents_638978656765414696" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureGeneralInformation" xlink:type="extended" xlink:title="10101 - Disclosure - General Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_GeneralInformationAbstract" xlink:label="GeneralInformationAbstract" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfGeneralInformationExplanatory" xlink:label="prqr_DisclosureOfGeneralInformationExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralInformationAbstract" xlink:to="prqr_DisclosureOfGeneralInformationExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsAccountingPoliciesAbstract" xlink:label="IfrsAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureAdoptionOfNewAndRevisedInternationalFinancialReportingStandards" xlink:type="extended" xlink:title="10301 - Disclosure - Adoption of New and Revised International Financial Reporting Standards" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:label="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgments" xlink:type="extended" xlink:title="10401 - Disclosure - Critical Accounting Estimates and Judgments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="DisclosureOfChangesInAccountingEstimatesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureCashAndCashEquivalents" xlink:type="extended" xlink:title="10501 - Disclosure - Cash and Cash Equivalents" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivables" xlink:type="extended" xlink:title="10601 - Disclosure - Prepayments and Other Receivables" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PrepaymentsAndOtherReceivablesAbstract" xlink:label="PrepaymentsAndOtherReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentsAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosurePropertyPlantAndEquipment" xlink:type="extended" xlink:title="10701 - Disclosure - Property, Plant and Equipment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureOtherCurrentLiabilities" xlink:type="extended" xlink:title="10801 - Disclosure - Other Current Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OtherCurrentLiabilitiesAbstract" xlink:label="prqr_OtherCurrentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureBorrowings" xlink:type="extended" xlink:title="10901 - Disclosure - Borrowings" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="BorrowingsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfBorrowingsExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureLeaseLiabilities" xlink:type="extended" xlink:title="11001 - Disclosure - Lease Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureDeferredIncome" xlink:type="extended" xlink:title="11101 - Disclosure - Deferred Income" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DeferredIncomeAbstract" xlink:label="prqr_DeferredIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDeferredIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_DeferredIncomeAbstract" xlink:to="ifrs-full_DisclosureOfDeferredIncomeExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureShareholdersEquity" xlink:type="extended" xlink:title="11201 - Disclosure - Shareholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="11301 - Disclosure - Revenue" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureOtherIncome" xlink:type="extended" xlink:title="11401 - Disclosure - Other Income" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsOtherIncomeAbstract" xlink:label="IfrsOtherIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherIncomeAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureResearchAndDevelopmentCosts" xlink:type="extended" xlink:title="11501 - Disclosure - Research and Development Costs" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ResearchAndDevelopmentCostsAbstract" xlink:label="prqr_ResearchAndDevelopmentCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_ResearchAndDevelopmentCostsAbstract" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCosts" xlink:type="extended" xlink:title="11601 - Disclosure - General and Administrative Costs" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="SellingGeneralAndAdministrativeExpenseAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssets" xlink:type="extended" xlink:title="11701 - Disclosure - Investments in Financial Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_InvestmentsInFinancialAssetsAbstract" xlink:label="prqr_InvestmentsInFinancialAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_InvestmentsInFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11801 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11901 - Disclosure - Related-Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureEventsAfterBalanceSheetDate" xlink:type="extended" xlink:title="12001 - Disclosure - Events After Balance Sheet Date" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsAccountingPoliciesAbstract" xlink:label="IfrsAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_638978656765414696" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Prepayments and Other Receivables (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PrepaymentsAndOtherReceivablesAbstract" xlink:label="PrepaymentsAndOtherReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock" xlink:label="prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentsAndOtherReceivablesAbstract" xlink:to="prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureBorrowingsTables" xlink:type="extended" xlink:title="30903 - Disclosure - Borrowings (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="BorrowingsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureDeferredIncomeTables" xlink:type="extended" xlink:title="31103 - Disclosure - Deferred Income (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DeferredIncomeAbstract" xlink:label="prqr_DeferredIncomeAbstract_1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ScheduleOfDeferredIncomeTableTextBlock" xlink:label="prqr_ScheduleOfDeferredIncomeTableTextBlock_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_DeferredIncomeAbstract_1" xlink:to="prqr_ScheduleOfDeferredIncomeTableTextBlock_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureOtherIncomeTables" xlink:type="extended" xlink:title="31403 - Disclosure - Other Income (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsOtherIncomeAbstract" xlink:label="IfrsOtherIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory" xlink:label="prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherIncomeAbstract" xlink:to="prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureGeneralInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_GeneralInformationAbstract" xlink:label="GeneralInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralInformationAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638978656765414696" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638978656765414696" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638978656765414696" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638978656765414696" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsHoldingB.v.Member" xlink:label="prqr_ProqrTherapeuticsHoldingB.v.Member_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" xlink:to="prqr_ProqrTherapeuticsHoldingB.v.Member_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIB.v.Member" xlink:label="prqr_ProqrTherapeuticsIB.v.Member_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" xlink:to="prqr_ProqrTherapeuticsIB.v.Member_638978656765414696" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIiB.v.Member" xlink:label="prqr_ProqrTherapeuticsIiB.v.Member_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" xlink:to="prqr_ProqrTherapeuticsIiB.v.Member_638978656765414696" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIiiB.v.Member" xlink:label="prqr_ProqrTherapeuticsIiiB.v.Member_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" xlink:to="prqr_ProqrTherapeuticsIiiB.v.Member_638978656765414696" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIvB.v.Member" xlink:label="prqr_ProqrTherapeuticsIvB.v.Member_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" xlink:to="prqr_ProqrTherapeuticsIvB.v.Member_638978656765414696" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsVB.v.Member" xlink:label="prqr_ProqrTherapeuticsVB.v.Member_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" xlink:to="prqr_ProqrTherapeuticsVB.v.Member_638978656765414696" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsViB.v.Member" xlink:label="prqr_ProqrTherapeuticsViB.v.Member_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" xlink:to="prqr_ProqrTherapeuticsViB.v.Member_638978656765414696" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsViiB.v.Member" xlink:label="prqr_ProqrTherapeuticsViiB.v.Member_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" xlink:to="prqr_ProqrTherapeuticsViiB.v.Member_638978656765414696" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsViiiB.v.Member" xlink:label="prqr_ProqrTherapeuticsViiiB.v.Member_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" xlink:to="prqr_ProqrTherapeuticsViiiB.v.Member_638978656765414696" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIxB.v.Member" xlink:label="prqr_ProqrTherapeuticsIxB.v.Member_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" xlink:to="prqr_ProqrTherapeuticsIxB.v.Member_638978656765414696" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProqrTherapeuticsIInc.Member" xlink:label="prqr_ProqrTherapeuticsIInc.Member_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesDomain_638978656765414696" xlink:to="prqr_ProqrTherapeuticsIInc.Member_638978656765414696" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638978656765414696" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638978656765414696" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638978656765414696" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_638978656765414696" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails" xlink:type="extended" xlink:title="40102 - Disclosure - General Information - Revision of comparative figures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_GeneralInformationAbstract" xlink:label="prqr_GeneralInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_GeneralInformationAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638978656765414696" xlink:to="ifrs-full_ComponentsOfEquityAxis_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638978656765414696" xlink:to="ifrs-full_ComponentsOfEquityDomain_638978656765414696" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain_638978656765414696" xlink:to="ifrs-full_RetainedEarningsMember_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638978656765414696" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_638978656765414696" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765414696" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765414696" xlink:to="ifrs-full_DeferredIncomeIncludingContractLiabilities_638978656765414696" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765414696" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638978656765414696" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765414696" xlink:to="ifrs-full_ProfitLoss_638978656765414696" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765414696" xlink:to="ifrs-full_Equity_638978656765414696" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638978656765414696" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_638978656765414696" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsAccountingPoliciesAbstract" xlink:label="IfrsAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsNumberOfReportableSegments" xlink:label="prqr_IfrsNumberOfReportableSegments_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsAccountingPoliciesAbstract" xlink:to="prqr_IfrsNumberOfReportableSegments_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Critical Accounting Estimates and Judgements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_638978656765414696" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765414696" xlink:to="ifrs-full_CounterpartiesAxis_638978656765414696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis_638978656765414696" xlink:to="ifrs-full_CounterpartiesDomain_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_EliLillyAndCompanyMember" xlink:label="prqr_EliLillyAndCompanyMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain_638978656765495044" xlink:to="prqr_EliLillyAndCompanyMember_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765414696" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="ifrs-full_DeferredIncomeIncludingContractLiabilities_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Cash and Cash Equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Prepayments and Other Receivables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PrepaymentsAndOtherReceivablesAbstract" xlink:label="PrepaymentsAndOtherReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Prepayments" xlink:label="ifrs-full_Prepayments_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentsAndOtherReceivablesAbstract" xlink:to="ifrs-full_Prepayments_638978656765495044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentsAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherReceivables_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccruedIncomeIncludingContractAssets" xlink:label="ifrs-full_AccruedIncomeIncludingContractAssets_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentsAndOtherReceivablesAbstract" xlink:to="ifrs-full_AccruedIncomeIncludingContractAssets_638978656765495044" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PrepaymentsAndOtherReceivables" xlink:label="prqr_PrepaymentsAndOtherReceivables_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentsAndOtherReceivablesAbstract" xlink:to="prqr_PrepaymentsAndOtherReceivables_638978656765495044" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Property, Plant and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638978656765495044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638978656765495044" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638978656765495044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638978656765495044" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_638978656765495044" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" xlink:label="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_638978656765495044" xlink:to="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638978656765495044" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638978656765495044" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_6389786567654950441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638978656765495044" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_6389786567654950441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638978656765495044" xlink:to="ifrs-full_RightofuseAssets_638978656765495044" order="3" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureOtherCurrentLiabiltiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Other Current Liabilties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OtherCurrentLiabilitiesAbstract" xlink:label="prqr_OtherCurrentLiabilitiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_OtherCurrentLiabilitiesAbstract_1" xlink:to="ifrs-full_OtherCurrentLiabilities_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureBorrowingsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="BorrowingsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638978656765495044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638978656765495044" xlink:to="ifrs-full_BorrowingsByNameAxis_638978656765495044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain" xlink:label="ifrs-full_BorrowingsByNameDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638978656765495044" xlink:to="ifrs-full_BorrowingsByNameDomain_638978656765495044" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_InnovationCreditMember" xlink:label="prqr_InnovationCreditMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameDomain_638978656765495044" xlink:to="prqr_InnovationCreditMember_638978656765495044" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsClassesOfWarrantsOrRightsAxisAxis" xlink:label="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638978656765495044" xlink:to="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ClassesOfWarrantsOrRightsDomain" xlink:label="prqr_ClassesOfWarrantsOrRightsDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_638978656765495044" xlink:to="prqr_ClassesOfWarrantsOrRightsDomain_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PontifaxAndKreosWarrantsMember" xlink:label="prqr_PontifaxAndKreosWarrantsMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_ClassesOfWarrantsOrRightsDomain_638978656765495044" xlink:to="prqr_PontifaxAndKreosWarrantsMember_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638978656765495044" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638978656765495044" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638978656765495044" xlink:to="ifrs-full_Borrowings_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_BorrowingsExcludingAccruedInterest" xlink:label="prqr_BorrowingsExcludingAccruedInterest_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638978656765495044" xlink:to="prqr_BorrowingsExcludingAccruedInterest_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPayable" xlink:label="ifrs-full_InterestPayable_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638978656765495044" xlink:to="ifrs-full_InterestPayable_638978656765495044" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638978656765495044" xlink:to="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_638978656765495044" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_CurrentBorrowingsExcludingAccruedInterest" xlink:label="prqr_CurrentBorrowingsExcludingAccruedInterest_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638978656765495044" xlink:to="prqr_CurrentBorrowingsExcludingAccruedInterest_638978656765495044" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638978656765495044" xlink:to="ifrs-full_NotionalAmount_638978656765495044" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638978656765495044" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638978656765495044" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_WarrantsEconomicLifetime" xlink:label="prqr_WarrantsEconomicLifetime_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638978656765495044" xlink:to="prqr_WarrantsEconomicLifetime_638978656765495044" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ConditionalWaiverOfDebtTotal" xlink:label="prqr_ConditionalWaiverOfDebtTotal_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638978656765495044" xlink:to="prqr_ConditionalWaiverOfDebtTotal_638978656765495044" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_638978656765495044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_638978656765495044" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638978656765495044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638978656765495044" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_638978656765495044" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OfficeAndLaboratoryFacilityMember" xlink:label="prqr_OfficeAndLaboratoryFacilityMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_638978656765495044" xlink:to="prqr_OfficeAndLaboratoryFacilityMember_638978656765495044" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember" xlink:label="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_OfficeAndLaboratoryFacilityMember_638978656765495044" xlink:to="prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_638978656765495044" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_638978656765495044" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AreaOfPropertyUnderLease" xlink:label="prqr_AreaOfPropertyUnderLease_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_638978656765495044" xlink:to="prqr_AreaOfPropertyUnderLease_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_LeaseTerm" xlink:label="prqr_LeaseTerm_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_638978656765495044" xlink:to="prqr_LeaseTerm_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_LeaseExtensionTerm" xlink:label="prqr_LeaseExtensionTerm_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_638978656765495044" xlink:to="prqr_LeaseExtensionTerm_638978656765495044" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_LeaseCurrentExtensionPeriodUnderOption" xlink:label="prqr_LeaseCurrentExtensionPeriodUnderOption_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_638978656765495044" xlink:to="prqr_LeaseCurrentExtensionPeriodUnderOption_638978656765495044" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_638978656765495044" xlink:to="ifrs-full_RightofuseAssets_638978656765495044" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureDeferredIncomeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Deferred Income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DeferredIncomeAbstract" xlink:label="prqr_DeferredIncomeAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_DeferredIncomeAbstract_4" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765495044" xlink:to="ifrs-full_CounterpartiesAxis_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis_638978656765495044" xlink:to="ifrs-full_CounterpartiesDomain_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_EliLillyAndCompanyMember" xlink:label="prqr_EliLillyAndCompanyMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain_638978656765495044" xlink:to="prqr_EliLillyAndCompanyMember_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_RettSyndromeResearchTrustMember" xlink:label="prqr_RettSyndromeResearchTrustMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain_638978656765495044" xlink:to="prqr_RettSyndromeResearchTrustMember_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765495044" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:label="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="ifrs-full_DeferredIncomeIncludingContractLiabilities_638978656765495044" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Shareholders' Equity - Share capital (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638978656765495044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638978656765495044" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_638978656765495044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_638978656765495044" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_638978656765495044" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalDomain_638978656765495044" xlink:to="ifrs-full_OrdinarySharesMember_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalDomain_638978656765495044" xlink:to="ifrs-full_PreferenceSharesMember_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638978656765495044" xlink:to="ifrs-full_CounterpartiesAxis_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis_638978656765495044" xlink:to="ifrs-full_CounterpartiesDomain_638978656765495044" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_EliLillyAndCompanyMember" xlink:label="prqr_EliLillyAndCompanyMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain_638978656765495044" xlink:to="prqr_EliLillyAndCompanyMember_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638978656765495044" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="ifrs-full_NumberOfSharesOutstanding_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AuthorizedShareCapitalValue" xlink:label="prqr_AuthorizedShareCapitalValue_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="prqr_AuthorizedShareCapitalValue_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_6389786567654950441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="ifrs-full_NumberOfSharesOutstanding_6389786567654950441" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="ifrs-full_NumberOfSharesIssued_638978656765495044" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="ifrs-full_NumberOfSharesAuthorised_638978656765495044" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="ifrs-full_ParValuePerShare_638978656765495044" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_638978656765495044" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_638978656765495044" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues_638978656765495044" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Shareholders' Equity - Sale of shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockAxis" xlink:label="prqr_IfrsSaleOfStockAxis_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638978656765495044" xlink:to="prqr_IfrsSaleOfStockAxis_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockDomain" xlink:label="prqr_IfrsSaleOfStockDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_IfrsSaleOfStockAxis_638978656765495044" xlink:to="prqr_IfrsSaleOfStockDomain_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ShelfRegistrationStatement2024Member" xlink:label="prqr_ShelfRegistrationStatement2024Member_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_IfrsSaleOfStockDomain_638978656765495044" xlink:to="prqr_ShelfRegistrationStatement2024Member_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember" xlink:label="prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_ShelfRegistrationStatement2024Member_638978656765495044" xlink:to="prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_October2024UnderwrittenPublicOfferingMember" xlink:label="prqr_October2024UnderwrittenPublicOfferingMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_ShelfRegistrationStatement2024Member_638978656765495044" xlink:to="prqr_October2024UnderwrittenPublicOfferingMember_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember" xlink:label="prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_October2024UnderwrittenPublicOfferingMember_638978656765495044" xlink:to="prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember" xlink:label="prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_ShelfRegistrationStatement2024Member_638978656765495044" xlink:to="prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_638978656765495044" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638978656765495044" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MaximumOfferingPriceInShelfRegistrationStatement" xlink:label="prqr_MaximumOfferingPriceInShelfRegistrationStatement_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="prqr_MaximumOfferingPriceInShelfRegistrationStatement_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement" xlink:label="prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues_638978656765495044" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSaleOfStockPricePerShare" xlink:label="prqr_IfrsSaleOfStockPricePerShare_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="prqr_IfrsSaleOfStockPricePerShare_638978656765495044" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DurationOfUnderwritersOption" xlink:label="prqr_DurationOfUnderwritersOption_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="prqr_DurationOfUnderwritersOption_638978656765495044" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_NumberOfSharesCallableForOptionsIssued" xlink:label="prqr_NumberOfSharesCallableForOptionsIssued_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="prqr_NumberOfSharesCallableForOptionsIssued_638978656765495044" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="ifrs-full_ProceedsFromIssuingShares_638978656765495044" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="ifrs-full_PaymentsForShareIssueCosts_638978656765495044" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_NetProceedsFromIssuingShares" xlink:label="prqr_NetProceedsFromIssuingShares_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="prqr_NetProceedsFromIssuingShares_638978656765495044" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PurchasePriceCapSharePurchaseAgreement" xlink:label="prqr_PurchasePriceCapSharePurchaseAgreement_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638978656765495044" xlink:to="prqr_PurchasePriceCapSharePurchaseAgreement_638978656765495044" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Shareholders' Equity - Share options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_2" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638978656765495044" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638978656765495044" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsSellingGeneralAndAdministrativeExpensesMember" xlink:label="prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_638978656765495044" xlink:to="prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsResearchAndDevelopmentExpenseMember" xlink:label="prqr_IfrsResearchAndDevelopmentExpenseMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_638978656765495044" xlink:to="prqr_IfrsResearchAndDevelopmentExpenseMember_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638978656765495044" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638978656765495044" xlink:to="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765495044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765495044" xlink:to="ifrs-full_CounterpartiesAxis_638978656765495044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis_638978656765495044" xlink:to="ifrs-full_CounterpartiesDomain_638978656765495044" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_EliLillyAndCompanyMember" xlink:label="prqr_EliLillyAndCompanyMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain_638978656765495044" xlink:to="prqr_EliLillyAndCompanyMember_638978656765495044" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765495044" xlink:to="ifrs-full_ProductsAndServicesAxis_638978656765495044" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain" xlink:label="ifrs-full_ProductsAndServicesDomain_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_638978656765495044" xlink:to="ifrs-full_ProductsAndServicesDomain_638978656765495044" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MilestonePaymentsMember" xlink:label="prqr_MilestonePaymentsMember_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesDomain_638978656765495044" xlink:to="prqr_MilestonePaymentsMember_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638978656765495044" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_DeferredIncomeIncludingContractLiabilities_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="ifrs-full_DeferredIncomeIncludingContractLiabilities_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="prqr_IfrsStockIssuedDuringPeriodSharesNewIssues_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="ifrs-full_NumberOfSharesIssued_638978656765495044" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="ifrs-full_ProceedsFromIssuingShares_638978656765495044" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DiscountOnIssueOfShares" xlink:label="prqr_DiscountOnIssueOfShares_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="prqr_DiscountOnIssueOfShares_638978656765495044" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership" xlink:label="prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership_638978656765495044" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_NumberOfPerformanceObligationsInCollaborationAgreement" xlink:label="prqr_NumberOfPerformanceObligationsInCollaborationAgreement_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="prqr_NumberOfPerformanceObligationsInCollaborationAgreement_638978656765495044" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_638978656765495044" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ValueOfMilestonesReachedDuringPeriod" xlink:label="prqr_ValueOfMilestonesReachedDuringPeriod_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638978656765495044" xlink:to="prqr_ValueOfMilestonesReachedDuringPeriod_638978656765495044" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureOtherIncomeDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Other Income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsOtherIncomeAbstract" xlink:label="IfrsOtherIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsRevenueFromGrants" xlink:label="prqr_IfrsRevenueFromGrants_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherIncomeAbstract" xlink:to="prqr_IfrsRevenueFromGrants_638978656765495044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome_638978656765495044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherIncomeAbstract" xlink:to="ifrs-full_OtherIncome_638978656765495044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Other Income - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsOtherIncomeAbstract" xlink:label="IfrsOtherIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OtherIncomeTable" xlink:label="prqr_OtherIncomeTable_638978656765575553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherIncomeAbstract" xlink:to="prqr_OtherIncomeTable_638978656765575553" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_OtherIncomeTable_638978656765575553" xlink:to="ifrs-full_CounterpartiesAxis_638978656765576638" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis_638978656765576638" xlink:to="ifrs-full_CounterpartiesDomain_638978656765576638" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_RettSyndromeResearchTrustMember" xlink:label="prqr_RettSyndromeResearchTrustMember_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain_638978656765576638" xlink:to="prqr_RettSyndromeResearchTrustMember_638978656765576638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_OtherIncomeLineItems" xlink:label="prqr_OtherIncomeLineItems_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_OtherIncomeTable_638978656765575553" xlink:to="prqr_OtherIncomeLineItems_638978656765576638" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_IfrsRevenueFromGrants" xlink:label="prqr_IfrsRevenueFromGrants_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_OtherIncomeLineItems_638978656765576638" xlink:to="prqr_IfrsRevenueFromGrants_638978656765576638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MaximumGrantReceivableForInitialPhaseOfProject" xlink:label="prqr_MaximumGrantReceivableForInitialPhaseOfProject_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_OtherIncomeLineItems_638978656765576638" xlink:to="prqr_MaximumGrantReceivableForInitialPhaseOfProject_638978656765576638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_MaximumGrantReceivableForAdditionalPhaseOfProject" xlink:label="prqr_MaximumGrantReceivableForAdditionalPhaseOfProject_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_OtherIncomeLineItems_638978656765576638" xlink:to="prqr_MaximumGrantReceivableForAdditionalPhaseOfProject_638978656765576638" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_WarrantsEconomicLifetime" xlink:label="prqr_WarrantsEconomicLifetime_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_OtherIncomeLineItems_638978656765576638" xlink:to="prqr_WarrantsEconomicLifetime_638978656765576638" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_OtherIncomeLineItems_638978656765576638" xlink:to="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_638978656765576638" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureResearchAndDevelopmentCostsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Research and Development Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ResearchAndDevelopmentCostsAbstract" xlink:label="prqr_ResearchAndDevelopmentCostsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_ResearchAndDevelopmentCostsAbstract_1" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638978656765576638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCostsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - General and Administrative Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="SellingGeneralAndAdministrativeExpenseAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638978656765576638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Investments in Financial Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_InvestmentsInFinancialAssetsAbstract" xlink:label="prqr_InvestmentsInFinancialAssetsAbstract_3" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable" xlink:label="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_InvestmentsInFinancialAssetsAbstract_3" xlink:to="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable_638978656765576638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable_638978656765576638" xlink:to="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_638978656765576638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain" xlink:label="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_638978656765576638" xlink:to="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain_638978656765576638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_PhoenicisTherapeuticsIncMember" xlink:label="prqr_PhoenicisTherapeuticsIncMember_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain_638978656765576638" xlink:to="prqr_PhoenicisTherapeuticsIncMember_638978656765576638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_YarrowBiotechnologyMember" xlink:label="prqr_YarrowBiotechnologyMember_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain_638978656765576638" xlink:to="prqr_YarrowBiotechnologyMember_638978656765576638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems" xlink:label="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable_638978656765576638" xlink:to="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems_638978656765576638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prqr-20250930.xsd#prqr_ProportionOfOwnershipInterest" xlink:label="prqr_ProportionOfOwnershipInterest_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems_638978656765576638" xlink:to="prqr_ProportionOfOwnershipInterest_638978656765576638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems_638978656765576638" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_638978656765576638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.proqr.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_1" xlink:to="ifrs-full_CurrentTaxLiabilities_638978656765576638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638978656765576638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_1" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638978656765576638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ProQR Therapeutics N.V.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001612940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statement of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment</a></td>
<td class="nump">&#8364; 13,018<span></span>
</td>
<td class="nump">&#8364; 14,113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">13,018<span></span>
</td>
<td class="nump">14,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">106,883<span></span>
</td>
<td class="nump">149,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_PrepaymentsAndOtherReceivables', window );">Prepayments and other receivables</a></td>
<td class="nump">3,872<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax', window );">Other taxes</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">111,331<span></span>
</td>
<td class="nump">153,845<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">124,349<span></span>
</td>
<td class="nump">167,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to owners of the Company</a></td>
<td class="nump">57,071<span></span>
</td>
<td class="nump">88,560<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">57,071<span></span>
</td>
<td class="nump">88,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">10,017<span></span>
</td>
<td class="nump">11,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities', window );">Deferred income</a></td>
<td class="nump">24,125<span></span>
</td>
<td class="nump">29,429<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">34,142<span></span>
</td>
<td class="nump">40,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Borrowings</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">4,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,674<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Derivative financial instruments</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade payables</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Social securities and other taxes</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities', window );">Deferred income</a></td>
<td class="nump">17,394<span></span>
</td>
<td class="nump">21,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">8,550<span></span>
</td>
<td class="nump">8,849<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">33,136<span></span>
</td>
<td class="nump">38,902<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">67,278<span></span>
</td>
<td class="nump">79,398<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 124,349<span></span>
</td>
<td class="nump">&#8364; 167,958<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current deferred income including non-current contract liabilities. [Refer: Deferred income including contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_PrepaymentsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_PrepaymentsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 2,882<span></span>
</td>
<td class="nump">&#8364; 3,843<span></span>
</td>
<td class="nump">&#8364; 11,218<span></span>
</td>
<td class="nump">&#8364; 14,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,080)<span></span>
</td>
<td class="num">(9,414)<span></span>
</td>
<td class="num">(34,811)<span></span>
</td>
<td class="num">(25,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,119)<span></span>
</td>
<td class="num">(3,283)<span></span>
</td>
<td class="num">(11,169)<span></span>
</td>
<td class="num">(9,748)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,199)<span></span>
</td>
<td class="num">(12,697)<span></span>
</td>
<td class="num">(45,980)<span></span>
</td>
<td class="num">(35,493)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,284)<span></span>
</td>
<td class="num">(8,716)<span></span>
</td>
<td class="num">(34,349)<span></span>
</td>
<td class="num">(20,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income and expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">280<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="nump">927<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Results related to financial liabilities measured at fair value through profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Result before corporate income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,006)<span></span>
</td>
<td class="num">(8,108)<span></span>
</td>
<td class="num">(33,246)<span></span>
</td>
<td class="num">(18,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,006)<span></span>
</td>
<td class="num">(8,108)<span></span>
</td>
<td class="num">(33,264)<span></span>
</td>
<td class="num">(18,458)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Other comprehensive income (foreign exchange differences on foreign operation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(377)<span></span>
</td>
<td class="num">(1,076)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,029)<span></span>
</td>
<td class="num">(8,485)<span></span>
</td>
<td class="num">(34,340)<span></span>
</td>
<td class="num">(18,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Result attributable to</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,006)<span></span>
</td>
<td class="num">(8,108)<span></span>
</td>
<td class="num">(33,264)<span></span>
</td>
<td class="num">(18,458)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,006)<span></span>
</td>
<td class="num">(8,108)<span></span>
</td>
<td class="num">(33,264)<span></span>
</td>
<td class="num">(18,458)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Total comprehensive income attributable to</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,029)<span></span>
</td>
<td class="num">(8,485)<span></span>
</td>
<td class="num">(34,340)<span></span>
</td>
<td class="num">(18,559)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (11,029)<span></span>
</td>
<td class="num">&#8364; (8,485)<span></span>
</td>
<td class="num">&#8364; (34,340)<span></span>
</td>
<td class="num">&#8364; (18,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract', window );"><strong>Share information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares outstanding (basic)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">105,344,996<span></span>
</td>
<td class="nump">81,682,296<span></span>
</td>
<td class="nump">105,328,752<span></span>
</td>
<td class="nump">81,639,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares outstanding (diluted)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">105,344,996<span></span>
</td>
<td class="nump">81,682,296<span></span>
</td>
<td class="nump">105,328,752<span></span>
</td>
<td class="nump">81,639,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share attributable to owners of the Company (Euro per share)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (0.1)<span></span>
</td>
<td class="num">&#8364; (0.1)<span></span>
</td>
<td class="num">&#8364; (0.32)<span></span>
</td>
<td class="num">&#8364; (0.23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (0.1)<span></span>
</td>
<td class="num">&#8364; (0.1)<span></span>
</td>
<td class="num">&#8364; (0.32)<span></span>
</td>
<td class="num">&#8364; (0.23)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:normal;font-weight:normal;">For these periods the potential exercise of share options is not included in the diluted earnings per share as the Company was loss-making. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal</span><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:normal;font-weight:normal;">. </span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 56<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_56_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 56<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_56_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2025-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statement of Changes in Equity - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Share Premium</div></th>
<th class="th"><div>Equity Settled Employee Benefit Reserve</div></th>
<th class="th"><div>Translation Reserve</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at beginning of period at Dec. 31, 2023</a></td>
<td class="nump">&#8364; 3,370<span></span>
</td>
<td class="nump">&#8364; 412,894<span></span>
</td>
<td class="nump">&#8364; 25,159<span></span>
</td>
<td class="nump">&#8364; 817<span></span>
</td>
<td class="num">&#8364; (400,850)<span></span>
</td>
<td class="nump">&#8364; 41,390<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">84,248,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,458)<span></span>
</td>
<td class="num">(18,458)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Recognition of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_TreasurySharesTransferred', window );">Treasury shares transferred (in shares)</a></td>
<td class="num">(329,675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_SharesOptionsLapsed', window );">Share options lapsed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Shares options exercised / RSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="num">(291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share options exercised / RSUs vested (in shares)</a></td>
<td class="nump">328,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end of period at Sep. 30, 2024</a></td>
<td class="nump">&#8364; 3,370<span></span>
</td>
<td class="nump">413,069<span></span>
</td>
<td class="nump">25,850<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="num">(418,023)<span></span>
</td>
<td class="nump">24,982<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance at end of period (in shares) at Sep. 30, 2024</a></td>
<td class="nump">84,247,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at beginning of period at Dec. 31, 2024</a></td>
<td class="nump">&#8364; 4,308<span></span>
</td>
<td class="nump">483,812<span></span>
</td>
<td class="nump">26,248<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
<td class="num">(427,158)<span></span>
</td>
<td class="nump">88,560<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2024</a></td>
<td class="nump">107,710,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,264)<span></span>
</td>
<td class="num">(33,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Recognition of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_TreasurySharesTransferred', window );">Treasury shares transferred (in shares)</a></td>
<td class="num">(132,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_SharesOptionsLapsed', window );">Share options lapsed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Shares options exercised / RSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share options exercised / RSUs vested (in shares)</a></td>
<td class="nump">132,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end of period at Sep. 30, 2025</a></td>
<td class="nump">&#8364; 4,308<span></span>
</td>
<td class="nump">&#8364; 483,879<span></span>
</td>
<td class="nump">&#8364; 27,316<span></span>
</td>
<td class="nump">&#8364; 274<span></span>
</td>
<td class="num">&#8364; (458,706)<span></span>
</td>
<td class="nump">&#8364; 57,071<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance at end of period (in shares) at Sep. 30, 2025</a></td>
<td class="nump">107,710,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period through the exercise of options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_SharesOptionsLapsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share options lapsing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_SharesOptionsLapsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_TreasurySharesTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares transferred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_TreasurySharesTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statement of Cash Flows - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net result</a></td>
<td class="num">&#8364; (11,006)<span></span>
</td>
<td class="num">&#8364; (8,108)<span></span>
</td>
<td class="num">&#8364; (33,264)<span></span>
</td>
<td class="num">&#8364; (18,458)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_AdjustmentsForOtherIncome', window );">Other income</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation</a></td>
<td class="nump">671<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="nump">2,024<span></span>
</td>
<td class="nump">2,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">2,784<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Financial income and expenses</a></td>
<td class="num">(280)<span></span>
</td>
<td class="num">(469)<span></span>
</td>
<td class="num">(927)<span></span>
</td>
<td class="num">(1,470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFairValueGainsLosses', window );">Results related to financial liabilities measured at fair value through profit or loss</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncomeTaxExpense', window );">Income tax expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Changes in working capital</a></td>
<td class="num">(3,074)<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="num">(10,974)<span></span>
</td>
<td class="num">(12,721)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operations</a></td>
<td class="num">(12,603)<span></span>
</td>
<td class="num">(6,299)<span></span>
</td>
<td class="num">(40,928)<span></span>
</td>
<td class="num">(29,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Corporate income tax received / (paid)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">1,924<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(151)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,235)<span></span>
</td>
<td class="num">(5,657)<span></span>
</td>
<td class="num">(39,434)<span></span>
</td>
<td class="num">(27,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Increase in financial asset - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Decrease in financial asset - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="num">(494)<span></span>
</td>
<td class="num">(1,285)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash (used in) / generated by investing activities</a></td>
<td class="num">(169)<span></span>
</td>
<td class="nump">16,714<span></span>
</td>
<td class="num">(494)<span></span>
</td>
<td class="num">(1,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liability</a></td>
<td class="num">(444)<span></span>
</td>
<td class="num">(454)<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
<td class="num">(1,329)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(444)<span></span>
</td>
<td class="num">(453)<span></span>
</td>
<td class="num">(1,237)<span></span>
</td>
<td class="num">(1,154)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net (decrease) / increase in cash and cash equivalents</a></td>
<td class="num">(12,848)<span></span>
</td>
<td class="nump">10,604<span></span>
</td>
<td class="num">(41,165)<span></span>
</td>
<td class="num">(29,484)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Currency effect cash and cash equivalents</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="num">(1,360)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, at beginning of the period</a></td>
<td class="nump">119,765<span></span>
</td>
<td class="nump">78,970<span></span>
</td>
<td class="nump">149,408<span></span>
</td>
<td class="nump">118,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">&#8364; 106,883<span></span>
</td>
<td class="nump">&#8364; 89,401<span></span>
</td>
<td class="nump">&#8364; 106,883<span></span>
</td>
<td class="nump">&#8364; 89,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFairValueGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFairValueGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_AdjustmentsForOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for other income to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_AdjustmentsForOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_GeneralInformationAbstract', window );"><strong>General Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_DisclosureOfGeneralInformationExplanatory', window );">General Information</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">1. General Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">ProQR Therapeutics N.V., or &#8220;ProQR&#8221; or the &#8220;Company&#8221;, is a biotechnology company domiciled in the Netherlands that primarily focuses on the discovery and development of novel therapeutic medicines.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Since September 18, 2014, the Company&#8217;s ordinary shares have been listed on Nasdaq. They are currently trading at Nasdaq Capital Market under ticker symbol PRQR. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company was incorporated in the Netherlands, on February&#160;21, 2012 (Chamber of Commerce no. 54600790) and was reorganized from a private company with limited liability to a public company with limited liability on September&#160;23, 2014. The Company has its statutory seat in Leiden, the Netherlands. The address of its headquarters and registered office is Zernikedreef 9, 2333 CK Leiden, the Netherlands.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-family:'Open Sans';">ProQR Therapeutics N.V. is the ultimate parent company of the following entities:</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics Holding B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">100%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics I B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">100%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics II B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">100%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics III B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">100%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics IV B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">100%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics V B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">100%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics VI B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">100%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics VII B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">100%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics VIII B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">100%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics IX B.V. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">100%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">ProQR Therapeutics I&#160;Inc. (</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">100%</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">)</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">ProQR Therapeutics N.V. is also statutory director of Stichting Bewaarneming Aandelen ProQR (&#8220;ESOP Foundation&#8221;) and has full control over this entity. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">As used in these condensed consolidated financial statements, unless the context indicates otherwise, all references to &#8220;ProQR&#8221; or the &#8220;Company&#8221; refer to ProQR Therapeutics N.V. including its subsidiaries and the ESOP Foundation.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_DisclosureOfGeneralInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of general information about the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_DisclosureOfGeneralInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_GeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_GeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2. Significant Accounting Policies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">These interim condensed consolidated financial statements for the three and nine month periods ended September 30, 2025, have been prepared in accordance with IAS 34 Interim Financial Statements. They should be read in conjunction with the Company&#8217;s annual financial statements for the year ended December 31, 2024. These interim condensed consolidated financial statements do not include all information required for a complete set of financial statements prepared in accordance with IFRS Standards. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company&#8217;s financial position and performance since the last annual financial statements. In the opinion of management, all events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period are disclosed in these interim condensed consolidated financial statements. The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those applied in the preparation of the Company&#8217;s annual financial statements for the year ended December 31, 2024. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">During the nine month period ended September 30, 2024, the Company invested in financial assets in the form of a deposit with an original maturity of longer than three months but shorter than twelve months which are measured at amortized cost as they give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. The deposit matured on September 30, 2024.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company&#8217;s financial results have varied substantially, and are expected to continue to vary, from period to period. The Company believes that its ordinary activities are not linked to any particular seasonal factors.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The management of ProQR has, upon preparing and finalizing these interim condensed consolidated financial statements, assessed the Company&#8217;s ability to fund its operations for a period of at least one year after the date of signing these interim condensed consolidated financial statements. Management expects the Company to continue as a going concern based on its existing funding, taking into account the Company&#8217;s current cash position and the projected cash flows based on the activities under execution on the basis of ProQR&#8217;s business plan and budget. Thus, we continue to adopt the going concern basis of accounting in preparing the interim condensed consolidated financial statements.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The carrying amount of all financial assets and financial liabilities is a reasonable approximation of the fair value and therefore, information about the fair values of each class has not been disclosed.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company operates in </span><span style="font-family:'Open Sans';">one</span><span style="font-family:'Open Sans';"> reportable segment, which comprises the discovery and development of innovative, RNA based therapeutics.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 176<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_176&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n.a.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Adoption of New and Revised International Financial Reporting Standards<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract', window );"><strong>Adoption of New and Revised International Financial Reporting Standards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">Adoption of New and Revised International Financial Reporting Standards</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">3. Adoption of New and Revised International Financial Reporting Standards</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">New Standards and Interpretations, which became effective as of January&#160;1, 2025, did not have a material impact on our condensed consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 178<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_178&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 178<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_178&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Estimates and Judgments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Critical Accounting Estimates and Judgments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Critical Accounting Estimates and Judgments</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">4. Critical Accounting Estimates and Judgements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In the application of the Company&#8217;s accounting policies, management is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Open Sans';">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The significant judgements made by management in applying the Company&#8217;s accounting policies and the key sources of estimation uncertainty were the same as those described in the Company&#8217;s annual financial statements for the year ended December 31, 2024.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Open Sans';font-style:italic;">(i) Revenue recognition for the Eli Lilly and Company research and collaboration agreement</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">a. Identification of the performance obligations</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">As further described in Note 13 the identification of the performance obligations for the Company&#8217;s original research and collaboration agreement with Eli Lilly and Company (&#8220;Lilly&#8221;), and the amended and restated research and collaboration agreement (collectively, the &#8220;Collaboration agreement&#8221;) involves significant judgement.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">A key judgement was made in determining that the license granted to Lilly is not distinct from the associated research and development (&#8220;R&amp;D&#8221;) services, due to the lack of stand-alone value of the license without the Company&#8217;s involvement and the significant interdependencies between the license and the R&amp;D services to be provided by the Company. As a result, the license and the R&amp;D services are accounted for together as a single combined performance obligation consisting of multiple activities that are not distinct.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">b. Determining the timing of satisfaction of performance obligations</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">As further described in Note 13, before the handover of a compound to Lilly, the Company recognizes revenue over time, using an input method that estimates the satisfaction of the performance obligation as the percentage of labor hours incurred compared to the total estimated labor hours required to complete the promised services. As the Company&#8217;s estimate of the total labor hours required is dependent on the evolution of the research and development activities, it may be subject to change. If the progression and/or outcome of certain research and development activities would be different from the assumptions that were made during the preparation of these financial statements, this could lead to material adjustments to the total estimated labor hours, which might result in a reallocation of revenue between current and future periods. Our total deferred revenue balance related to this Lilly performance obligation amounts to &#8364;&#160;</span><span style="font-family:'Open Sans';">41,492,000</span><span style="font-family:'Open Sans';"> at September 30, 2025 (December 31, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';">50,930,000</span><span style="font-family:'Open Sans';">).</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">c. Determining the transaction price</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company applied judgement to determine whether the equity investments made by Lilly in ProQR are part of the transaction price for the Collaboration agreement. The Company concluded that the differences between the prices that Lilly paid for the shares and the ProQR stock closing prices on the days of entering into the equity investment agreements arose because of the Company&#8217;s existing obligations to deliver research and development services to Lilly under the terms of the Collaboration agreement. Therefore, the above differences between the closing share prices on the agreement effective dates and the equity investment prices paid by Lilly are considered to be part of the transaction price of the contract and are initially allocated to deferred revenue.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The contract also includes variable consideration, but no variable consideration was included in the initial transaction price at the inception, as it was not highly probable that a significant reversal in the amount of cumulative revenue recognized would not occur. The Company includes such variable consideration in the transaction price when the uncertainty associated with the variable consideration is resolved. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Collaboration agreement includes variable consideration in the form of development milestones, commercial milestones, and sales-based royalties based on the level of sales. As further described in Note 13, during 2025, the Company achieved development milestones during the ProQR research program under the agreement, which were added to the transaction price and recognized partially as revenue during 2025 based on the status of completion (satisfied part) of the single combined performance obligation.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><i style="font-family:'Open Sans';font-style:italic;">(ii) Research and development expenditures</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Research expenditures are reflected in the income statement. Development expenses are currently also reflected in the income statement because the criteria for capitalization are not met. At each balance sheet date, the Company estimates the level of service performed by the vendors and the associated costs incurred for the services performed.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Although we do not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">5. Cash and Cash Equivalents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">At September 30, 2025, the Company&#8217;s cash and cash equivalents were &#8364;&#160;</span><span style="font-family:'Open Sans';">106,883,000</span><span style="font-family:'Open Sans';"> compared to &#8364;</span><span style="font-family:'Open Sans';">&#160;149,408,000</span><span style="font-family:'Open Sans';"> at December&#160;31, 2024. The cash balances are held at banks with investment grade credit ratings. Short-term credit ratings must be rated A-1/P-1/F1 at a minimum by at least one of the Nationally Recognized Statistical Rating Organizations (&#8220;NRSROs&#8221;) specifically Moody&#8217;s, Standard &amp; Poor&#8217;s or Fitch. The cash at banks is at full disposal of the Company. Included in cash and cash equivalents are deposits fixed for at most 3-month periods at a time.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayments and Other Receivables<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_PrepaymentsAndOtherReceivablesAbstract', window );"><strong>Prepayments and Other Receivables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory', window );">Prepayments and Other Receivables</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.55;margin:0pt 0pt 4pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">6. Prepayments and Other Receivables</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td></tr><tr><td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Prepayments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"> 1,903</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">2,410 </span></p></td></tr><tr><td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">Other receivables</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"> 1,467</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">835 </span></p></td></tr><tr><td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">Accrued income from Rett Syndrome Research Trust</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"> 502</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">502 </span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.52%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">3,872 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">3,747 </b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">All receivables are considered short-term and due within one year. At September 30, 2025 and December 31, 2024 prepayments consisted principally of payments made by the Company for services not yet provided by vendors. At September 30, 2025 other receivables consisted principally of amounts receivable from research collaboration partners, accrued income and deposits. At December 31, 2024 other receivables consisted principally of accrued grant income and deposits. As at September 30, 2025 and December 31, 2024 the accrued grant income relating to Rett Syndrome Research Trust (&#8220;RSRT&#8221;) includes the initial fair value of the warrants issued to RSRT that was accounted for as a reduction of the transaction price. The RSRT agreement is described in Note 14. Other Income.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_PrepaymentsAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_PrepaymentsAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.55;margin:0pt 0pt 4pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">7. Property, Plant and Equipment</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">At September 30, 2025, and December 31, 2024, property plant and equipment consisted of buildings and leasehold improvements, laboratory equipment and other assets. Buildings and leasehold improvements include a right-of-use asset relating to the lease of our Leiden office and laboratory space, with a carrying amount of &#8364;&#160;</span><span style="font-family:'Open Sans';">10,448,000</span><span style="font-family:'Open Sans';"> at September&#160;30,&#160;2025 (December 31, 2024: &#8364;</span><span style="font-family:'Open Sans';">&#160;11,433,000</span><span style="font-family:'Open Sans';">).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_OtherCurrentLiabilitiesAbstract', window );"><strong>Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory', window );">Other Current Liabilities</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.55;margin:0pt 0pt 4pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">8. Other Current Liabilities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">At September 30, 2025, other current liabilities amount to &#8364;&#160;</span><span style="font-family:'Open Sans';">8,550,000</span><span style="font-family:'Open Sans';"> (December 31, 2024:&#160;&#8364; </span><span style="font-family:'Open Sans';">8,849,000</span><span style="font-family:'Open Sans';">). At September 30, 2025 and December&#160;31, 2024, other current liabilities consisted principally of accruals for services provided by vendors not yet billed, payroll related accruals and other miscellaneous liabilities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current liabilities. [Refer: Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_OtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_OtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBorrowingsExplanatory', window );">Borrowings</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">9</b><b style="font-family:'Open Sans';font-weight:bold;">. Borrowings</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.39151382%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.78%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.62%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"> </b><span style="font-family:'Open Sans';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Innovation credit</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">2,899 </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">2,899 </span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Accrued interest on innovation credit</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">1,901 </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">1,683 </span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">Total borrowings</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">4,800 </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">4,582 </b></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Current portion</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">4,800 </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">4,582 </span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">Total non-current borrowings</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">&#8212; </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">&#8212; </b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In December 2018, ProQR was awarded an Innovation credit for the sepofarsen program. Amounts were drawn under this facility from 2018 through 2022. The credit of &#8364;&#160;</span><span style="font-family:'Open Sans';">3,907,000</span><span style="font-family:'Open Sans';"> was used to conduct the Phase 2/3 clinical study and efforts to obtain regulatory and ethical market approval (New Drug Applications (&#8220;NDA&#8221;) / Marketing Authorization Applications (&#8220;MAA&#8221;)) of sepofarsen for LCA10. In the fourth quarter of 2023, ProQR made a partial repayment of the principal, amounting to &#8364;&#160;</span><span style="font-family:'Open Sans';">1,008,000</span><span style="font-family:'Open Sans';">. The remaining amount payable of &#8364;&#160;</span><span style="font-family:'Open Sans';">2,899,000</span><span style="font-family:'Open Sans';"> is recognized under current borrowings as at September 30, 2025 and December 31, 2024.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In December 2023, ProQR received a waiver for the remaining balance of the Innovation credit including accrued interest. As a result, the repayment of the total loan of &#8364;&#160;</span><span style="font-family:'Open Sans';">4,292,000</span><span style="font-family:'Open Sans';">, including accrued interest, could be waived if conditions are met, subject to annual review. In January 2025, the waiver for the principal and interest was again extended until December 31, 2025.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;">In September 2022, ProQR extinguished its debt with Pontifax and Kreos by repaying all outstanding principal amounts. However, the Pontifax&#8217; and Kreos&#8217; warrants, classified as derivative financial instruments on the balance sheet, remain in place until their </span><span style="font-family:'Open Sans';font-size:9pt;">five-year</span><span style="font-family:'Open Sans';font-size:9pt;"> economic life expires in 2025 and 2026. These warrants are accounted for as embedded derivatives and were recognized separately from the host contract as derivative financial liabilities at fair value through profit or loss. During Q3 2025, the original Pontifax warrants expiring in July 2025 and the Kreos warrants expiring in August 2025 expired and were derecognized. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Lease Liabilities.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Lease Liabilities</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">10. Lease Liabilities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">At September 30, 2025 and December 31, 2024, lease liabilities primarily consisted of the Company&#8217;s lease of office and laboratory facilities at Zernikedreef in Leiden, the Netherlands. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Open Sans';">The Company leases office and laboratory facilities of </span><span style="font-family:'Open Sans';">4,818</span><span style="font-family:'Open Sans';"> square meters at Zernikedreef in Leiden, the Netherlands, where our headquarters and our laboratories are located. The current lease agreement for these facilities terminates </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">on June 30, 2031. The lease agreement contains no significant dismantling requirements. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;">The initial </span><span style="-sec-ix-hidden:Hidden_1k_9dkbIBE6F9vmNuzcVIw;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">10-year</span></span><span style="font-family:'Open Sans';font-size:9pt;"> lease agreement for the Leiden office and laboratory facilities was accounted for as of commencement date July 1, 2020. This </span><span style="-sec-ix-hidden:Hidden_9sghCigMRE-91luzw8kAXw;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">10-year</span></span><span style="font-family:'Open Sans';font-size:9pt;"> period was extended by </span><span style="font-family:'Open Sans';font-size:9pt;">1 year</span><span style="font-family:'Open Sans';font-size:9pt;"> to an </span><span style="-sec-ix-hidden:Hidden_zMWif57Oekmju6l1QF4dVQ;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">11-year</span></span><span style="font-family:'Open Sans';font-size:9pt;"> period in December 2020. The lease contract may be extended for subsequent </span><span style="-sec-ix-hidden:Hidden__Ne-iWIfzU6QAPw9QT7ObQ;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">5-year</span></span><span style="font-family:'Open Sans';font-size:9pt;"> periods. As the Company is not reasonably certain to exercise these extension options, these are not included in the lease term. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The carrying amount of the right-of-use asset is disclosed in Note 7.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_DeferredIncomeAbstract', window );"><strong>Deferred Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDeferredIncomeExplanatory', window );">Deferred Income</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">11. Deferred Income</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The following table summarizes details of deferred income at September 30, 2025 and December 31, 2024. The nature of the deferred income is described in Note 13 and 14.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">Payments from Eli Lilly and Company</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">17,367 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">21,501 </span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">Payments from Rett Syndrome Research Trust</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">27 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">441 </span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Current deferred income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">17,394 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">21,942 </b></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">Payments from Eli Lilly and Company</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">24,125 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">29,429 </span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Non-current deferred income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">24,125 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">29,429 </b></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.7%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Total deferred income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">41,519 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">51,371 </b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><span style="color:#ffffff;font-family:'Open Sans';">c</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDeferredIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred income. [Refer: Deferred income including contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDeferredIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_DeferredIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_DeferredIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Shareholders' Equity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">12. Shareholders&#8217; Equity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The authorized share capital of the Company amounting to &#8364;</span><span style="font-family:'Open Sans';"> 13,600,000</span><span style="font-family:'Open Sans';"> consists of </span><span style="font-family:'Open Sans';">170,000,000</span><span style="font-family:'Open Sans';"> ordinary shares and </span><span style="font-family:'Open Sans';">170,000,000</span><span style="font-family:'Open Sans';"> preference shares with a par value of &#8364;</span><span style="font-family:'Open Sans';"> 0.04</span><span style="font-family:'Open Sans';">&#160;per share. At September 30, 2025, </span><span style="font-family:'Open Sans';">107,710,916</span><span style="font-family:'Open Sans';"> ordinary shares were issued, </span><span style="font-family:'Open Sans';">105,345,192</span><span style="font-family:'Open Sans';"> ordinary shares were fully paid and </span><span style="font-family:'Open Sans';">2,365,724</span><span style="font-family:'Open Sans';"> ordinary shares were held by the Company as treasury shares (December 31, 2024: </span><span style="font-family:'Open Sans';">2,498,389</span><span style="font-family:'Open Sans';">).</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In September 2024, the Company filed a shelf registration statement on Form F-3, which permitted: (a) the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $&#160;</span><span style="font-family:'Open Sans';">300,000,000</span><span style="font-family:'Open Sans';"> of its ordinary shares, warrants and/or units; and (b) as part of the $&#160;</span><span style="font-family:'Open Sans';">300,000,000</span><span style="font-family:'Open Sans';">, the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $&#160;</span><span style="font-family:'Open Sans';">75,000,000</span><span style="font-family:'Open Sans';"> of its ordinary shares that may be issued and sold under a sales agreement (the &#8220;sales agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) in one or more at-the-market (&#8220;ATM&#8221;) offerings. The Company will pay Cantor a commission equal to </span><span style="font-family:'Open Sans';">3%</span><span style="font-family:'Open Sans';"> of the gross proceeds of the sales price of all ordinary shares sold through it as sales agent under the sale agreement. As of September 30, 2025, </span><span style="font-family:'Open Sans';">no</span><span style="font-family:'Open Sans';"> shares have been issued pursuant to this ATM facility.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;">In October 2024, the Company consummated an underwritten public offering of </span><span style="font-family:'Open Sans';font-size:9pt;">18,000,000</span><span style="font-family:'Open Sans';font-size:9pt;"> ordinary shares (the &#8220;offering&#8221;) at a public offering price of $&#160;</span><span style="font-family:'Open Sans';font-size:9pt;">3.50</span><span style="font-family:'Open Sans';font-size:9pt;"> per share (the &#8220;public offering price&#8221;). In addition, the Company granted the underwriters a </span><span style="-sec-ix-hidden:Hidden_SBfXi-xh50yWDW8Jo_eMMQ;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">30-day</span></span><span style="font-family:'Open Sans';font-size:9pt;"> option to purchase up to </span><span style="font-family:'Open Sans';font-size:9pt;">2,700,000</span><span style="font-family:'Open Sans';font-size:9pt;"> additional ordinary shares at the public offering price, less underwriting discounts and commissions. The option was partially exercised on October 31, 2024, resulting in the issuance of </span><span style="font-family:'Open Sans';font-size:9pt;">1,940,072</span><span style="font-family:'Open Sans';font-size:9pt;"> shares. The gross proceeds from the Offering and subsequent partial exercise of the underwriters&#8217; option, amounted to $&#160;</span><span style="font-family:'Open Sans';font-size:9pt;">69,790,000</span><span style="font-family:'Open Sans';font-size:9pt;"> (&#8364;&#160;</span><span style="font-family:'Open Sans';font-size:9pt;">64,600,000</span><span style="font-family:'Open Sans';font-size:9pt;">) while the transaction costs amounted to approximately &#8364;&#160;</span><span style="font-family:'Open Sans';font-size:9pt;">4,365,000</span><span style="font-family:'Open Sans';font-size:9pt;">, resulting in net proceeds of approximately &#8364;&#160;</span><span style="font-family:'Open Sans';font-size:9pt;">60,235,000</span><span style="font-family:'Open Sans';font-size:9pt;">.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Concurrently with the Offering, the Company entered into a share purchase agreement with Lilly in a separately negotiated transaction (the &#8220;concurrent private placement&#8221;), pursuant to which the Company agreed to offer and sell, and Lilly agreed to purchase, </span><span style="font-family:'Open Sans';">3,523,538</span><span style="font-family:'Open Sans';"> ordinary shares at a price per share equal to the public offering price, for total gross proceeds of approximately $&#160;</span><span style="font-family:'Open Sans';">12,300,000</span><span style="font-family:'Open Sans';">, subject to a purchase price cap of $&#160;</span><span style="font-family:'Open Sans';">15,000,000</span><span style="font-family:'Open Sans';">, the consummation of the Offering and the satisfaction of other customary closing conditions. The proceeds of $&#160;</span><span style="font-family:'Open Sans';">12,300,000</span><span style="font-family:'Open Sans';"> (&#8364;&#160;</span><span style="font-family:'Open Sans';">11,400,000</span><span style="font-family:'Open Sans';">) from the concurrent private placement were received on October 25, 2024. The ordinary shares purchased in the concurrent private placement are not subject to any underwriting discounts or commissions.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Open Sans';font-style:italic;">Translation reserve</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Open Sans';font-style:italic;">Share options</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company operates an equity-settled share-based compensation plan, which was introduced in 2013. Options and Restricted Stock Units (&#8220;RSUs&#8221;) may be granted to employees, members of the Board and consultants. The compensation expenses included in operating costs for this plan in the nine month period ended September 30, 2025 were &#8364;&#160;</span><span style="font-family:'Open Sans';">2,784,000</span><span style="font-family:'Open Sans';"> (nine month period ended September 30, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';">1,976,000</span><span style="font-family:'Open Sans';">), of which &#8364;&#160;</span><span style="font-family:'Open Sans';">1,952,000</span><span style="font-family:'Open Sans';"> was recorded in general and administrative costs (nine month period ended September 30, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';">1,559,000</span><span style="font-family:'Open Sans';">) and &#8364;&#160;</span><span style="font-family:'Open Sans';">832,000</span><span style="font-family:'Open Sans';"> was recorded in research and development costs (nine month period ended September 30, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';">417,000</span><span style="font-family:'Open Sans';">).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">13. Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Open Sans';font-style:italic;">Eli Lilly and Company collaboration</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In September 2021, the Company entered into a global licensing and research collaboration with Lilly focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR and Lilly will use ProQR&#8217;s proprietary Axiomer</span><span style="font-size:11pt;">&#8482;</span><span style="font-family:'Open Sans';"> RNA editing platform to progress new drug targets toward clinical development and commercialization.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Under the terms of the agreement, ProQR received an upfront payment and equity consideration, and is eligible to receive milestone payments and royalties on the net sales of any resulting products. In September 2021, the Company issued </span><span style="font-family:'Open Sans';">3,989,976</span><span style="font-family:'Open Sans';"> shares to Lilly, resulting in gross proceeds of </span><span style="font-family:'Open Sans';">$&#160;30,000,000</span><span style="font-family:'Open Sans';"> (&#8364;</span><span style="font-family:'Open Sans';">&#160;25,270,000</span><span style="font-family:'Open Sans';">). These shares were issued at a premium of $ </span><span style="font-family:'Open Sans';">2,429,000</span><span style="font-family:'Open Sans';"> (&#8364; </span><span style="font-family:'Open Sans';">2,047,000</span><span style="font-family:'Open Sans';">), which was determined to be part of the transaction price and as such was initially recognized as deferred revenue. An up-front payment of $</span><span style="font-family:'Open Sans';">&#160;20,000,000</span><span style="font-family:'Open Sans';"> (&#8364; </span><span style="font-family:'Open Sans';">16,849,000</span><span style="font-family:'Open Sans';">) was received in October 2021.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In December 2022, the Company and Lilly amended their research and collaboration agreement described above, which expanded the collaboration. Under the amended and restated research and collaboration agreement, Lilly will gain access to additional targets in the central nervous system (&#8220;CNS&#8221;) and peripheral nervous system (&#8220;PNS&#8221;) with ProQR&#8217;s Axiomer platform.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">As described under Note 12, pursuant to the amended and restated agreement, the Company issued </span><span style="font-family:'Open Sans';">9,381,586</span><span style="font-family:'Open Sans';"> shares to Lilly in December 2022, resulting in gross proceeds of $&#160;</span><span style="font-family:'Open Sans';">15,000,000</span><span style="font-family:'Open Sans';"> (&#8364;&#160;</span><span style="font-family:'Open Sans';">14,122,000</span><span style="font-family:'Open Sans';">). These shares were issued at a discount of $&#160;</span><span style="font-family:'Open Sans';">480,000</span><span style="font-family:'Open Sans';"> (&#8364;&#160;</span><span style="font-family:'Open Sans';">451,000</span><span style="font-family:'Open Sans';">), which is accounted for as a reduction of the transaction price. In February 2023, ProQR also received an upfront payment of $&#160;</span><span style="font-family:'Open Sans';">60,000,000</span><span style="font-family:'Open Sans';"> (&#8364;&#160;</span><span style="font-family:'Open Sans';">56,412,000</span><span style="font-family:'Open Sans';">). Lilly has the ability to exercise an option to further expand the partnership for a consideration of $&#160;</span><span style="font-family:'Open Sans';">50,000,000</span><span style="font-family:'Open Sans';">.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">With regard to the original and amended and restated research and collaboration agreements with Lilly, the Company concluded as follows:</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">The amended and restated research and collaboration agreement is accounted for as a separate contract under IFRS 15 given the group of promises to be delivered are distinct and are priced commensurate with stand-alone selling prices.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">For each of the agreements, the company identified </span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">one</span><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"> performance obligation under IFRS 15, for the transfer of a license combined with the performance of research and development activities. The Company concluded that the license is not capable of being distinct and is not distinct in the context of the contract. ProQR&#8217;s services are evaluated as predominant at inception of the contract and the compounds resulting from the collaboration do not represent a series of distinct promises because they were not predetermined at the inception of the contract and can be terminated or replaced at the discretion of Lilly subject to the terms and conditions of the Collaboration agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">The transaction price of the agreement includes fixed components, consisting of an up-front fee and an equity component (premium or discount). The agreement also contains variable parts, notably milestones, which are included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Development milestone payments to be reached during the ProQR research program will only be included to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the milestones is subsequently resolved. Sales-based milestones and sales-based royalties will be included as the underlying sales occur.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">Initially, the Company recognizes revenue over time, using an input method that estimates the satisfaction of the performance obligation as the percentage of labor hours incurred compared to the total estimated labor hours required to complete the promised services.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">After the handover of a compound to Lilly:</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">The variable consideration for development milestones to be reached during the Lilly R&amp;D activities is linked to a separable right to use the license which comes into existence for each successful compound transferred to Lilly. This license is a separate performance obligation and revenue will be recognized at a point in time when the development milestone for a license is achieved and the variable constraint is resolved. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">The variable consideration for commercial milestones is linked to a separable right to use the license which comes into existence for each successful compound transferred to Lilly. This license is a separate performance obligation and will be recognized at a point in time when the commercial milestone for a license is achieved and the variable constraint is resolved. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;">For sales-based royalties, the license is the predominant item to which the royalty relates. The sales-based royalties will be recognized after the handover of the compound to Lilly (after completion of the initial performance obligation) and once the respective sale level occurs. &#160; </span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Open Sans';">During the nine month period ended September 30, 2025, the Company reached milestones amounting to $&#160;</span><span style="font-family:'Open Sans';">2,000,000</span><span style="font-family:'Open Sans';"> (&#8364; </span><span style="font-family:'Open Sans';">1,781,000</span><span style="font-family:'Open Sans';">) under the agreement, which was added to the transaction price and recognized partially as revenue during the nine month period ended September 30, 2025.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">Other Income</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">14. Other Income</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.34%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">Nine month period </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.34%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"> </b><span style="font-family:'Open Sans';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">Grant income</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">413 </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">504 </span></p></td></tr><tr><td style="vertical-align:top;width:70.69%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">413 </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">504 </b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In January, 2024, the Company entered into an agreement with the RSRT that focuses on the design and development of editing oligonucleotides (&#8220;EONs&#8221;) using the Company&#8217;s Axiomer technology platform targeting the transcription factor Methyl CpG binding protein 2 (&#8220;MECP2&#8221;) and correcting mutations of interest. Under the agreement, RSRT awarded the Company up to &#8364;</span><span style="font-family:'Open Sans';">&#160;1,015,000</span><span style="font-family:'Open Sans';"> as a research grant for the initial phase of the project that was received during 2024. Of this grant &#8364;&#160;</span><span style="font-family:'Open Sans';">504,000</span><span style="font-family:'Open Sans';"> was recognized as Other Income during the nine month period ended September 30, 2024, and &#8364;&#160;</span><span style="font-family:'Open Sans';">413,000</span><span style="font-family:'Open Sans';"> recognized as Other Income for the nine month period ended September 30, 2025. The balance was recorded as Deferred Income in 2024 and 2025.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">In December 2024, the Company expanded partnership with RSRT to include an additional $&#160;</span><span style="font-family:'Open Sans';">8,150,000</span><span style="font-family:'Open Sans';"> in funding from the RSRT to support the advancement of the selected candidates into clinical trials. As at September 30, 2025 </span><span style="font-family:'Open Sans';">no</span><span style="font-family:'Open Sans';"> amounts have been received under this agreement and the work has not yet commenced.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Grants are recognized in other income in the same period in which the related R&amp;D costs are recognized.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Costs<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_ResearchAndDevelopmentCostsAbstract', window );"><strong>Research and Development Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">15. Research and Development Costs</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Research and development costs amount to &#8364; </span><span style="font-family:'Open Sans';">34,811,000</span><span style="font-family:'Open Sans';"> for the nine month period ended September 30, 2025 (nine month period ended September 30, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';">25,745,000</span><span style="font-family:'Open Sans';">) and are comprised of allocated employee costs including share-based payments, the costs of materials and laboratory consumables, outsourced activities, license and intellectual property costs and other allocated costs. Research and development costs increased compared to the same period in the prior year, mainly due to the Company&#8217;s increased outsourced research and development activities in the nine month period of 2025 and increased full time employee equivalents (&#8220;FTE&#8221;).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_ResearchAndDevelopmentCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_ResearchAndDevelopmentCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Costs<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory', window );">General and Administrative Costs</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">16. General and Administrative Costs</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">General and administrative costs amount to &#8364; </span><span style="font-family:'Open Sans';">11,169,000</span><span style="font-family:'Open Sans';"> for the nine month period ended September 30, 2025 (nine month period ended September 30, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';">9,748,000</span><span style="font-family:'Open Sans';">).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Financial Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_InvestmentsInFinancialAssetsAbstract', window );"><strong>Investments in Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Investments in Financial Assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">17. Investments in Financial Assets</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Investment in financial assets consist of the Company&#8217;s investment in Phoenicis Therapeutics Inc. (&#8220;Phoenicis&#8221;) and Yarrow Biotechnology Inc. (&#8220;Yarrow&#8221;).</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">ProQR holds a </span><span style="font-family:'Open Sans';">3.9%</span><span style="font-family:'Open Sans';"> interest in Phoenicis. As at September 30, 2025, the investment amounts to &#8364;</span><span style="font-family:'Open Sans';"> nil</span><span style="font-family:'Open Sans';"> (December 31, 2024: &#8364;</span><span style="font-family:'Open Sans';"> nil</span><span style="font-family:'Open Sans';">). Phoenicis discontinued its research and development operational activities during the quarter ended September 30, 2024. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">ProQR holds a </span><span style="font-family:'Open Sans';">5.1%</span><span style="font-family:'Open Sans';"> interest in Yarrow. As at September 30, 2025, the fair value of the Yarrow financial asset amounted to &#8364;</span><span style="font-family:'Open Sans';"> nil</span><span style="font-family:'Open Sans';"> (December 31, 2024: &#8364;</span><span style="font-family:'Open Sans';"> nil</span><span style="font-family:'Open Sans';">).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_InvestmentsInFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments in financial assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_InvestmentsInFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">18</b><b style="font-family:'Open Sans';font-weight:bold;">. Income Taxes</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The current income tax liability amounts to &#8364; </span><span style="font-family:'Open Sans';">nil</span><span style="font-family:'Open Sans';"> at September 30, 2025 (December 31, 2024: &#8364; </span><span style="font-family:'Open Sans';">nil</span><span style="font-family:'Open Sans';">). No significant temporary differences exist between accounting and tax results. Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which are uncertain. Accordingly, the Company has not yet recognized any deferred tax asset related to operating losses.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Tax losses in the Netherlands may be carried forward indefinitely. However, the offset of losses will be limited in a given year against the first &#8364; 1 million of taxable profit. For taxable profit in excess of this amount, losses may only be offset up to 50% of this excess. In addition, unused non-deductible interest expenses may be carried forward indefinitely. However, the offset will be limited in a given year against the higher of 20% of adjusted taxable profit or &#8364; 1.0 million of interest income.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related-Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related-Party Transactions</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">19. Related-Party Transactions</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company does not have any transactions with related parties other than compensation to its Board members.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events After Balance Sheet Date<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Events After Balance Sheet Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events After Balance Sheet Date</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">20. Events After Balance Sheet Date</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">None.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Open Sans';font-style:italic;">(i) Revenue recognition for the Eli Lilly and Company research and collaboration agreement</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">a. Identification of the performance obligations</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">As further described in Note 13 the identification of the performance obligations for the Company&#8217;s original research and collaboration agreement with Eli Lilly and Company (&#8220;Lilly&#8221;), and the amended and restated research and collaboration agreement (collectively, the &#8220;Collaboration agreement&#8221;) involves significant judgement.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">A key judgement was made in determining that the license granted to Lilly is not distinct from the associated research and development (&#8220;R&amp;D&#8221;) services, due to the lack of stand-alone value of the license without the Company&#8217;s involvement and the significant interdependencies between the license and the R&amp;D services to be provided by the Company. As a result, the license and the R&amp;D services are accounted for together as a single combined performance obligation consisting of multiple activities that are not distinct.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">b. Determining the timing of satisfaction of performance obligations</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">As further described in Note 13, before the handover of a compound to Lilly, the Company recognizes revenue over time, using an input method that estimates the satisfaction of the performance obligation as the percentage of labor hours incurred compared to the total estimated labor hours required to complete the promised services. As the Company&#8217;s estimate of the total labor hours required is dependent on the evolution of the research and development activities, it may be subject to change. If the progression and/or outcome of certain research and development activities would be different from the assumptions that were made during the preparation of these financial statements, this could lead to material adjustments to the total estimated labor hours, which might result in a reallocation of revenue between current and future periods. Our total deferred revenue balance related to this Lilly performance obligation amounts to &#8364;&#160;</span><span style="font-family:'Open Sans';">41,492,000</span><span style="font-family:'Open Sans';"> at September 30, 2025 (December 31, 2024: &#8364;&#160;</span><span style="font-family:'Open Sans';">50,930,000</span><span style="font-family:'Open Sans';">).</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">c. Determining the transaction price</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Company applied judgement to determine whether the equity investments made by Lilly in ProQR are part of the transaction price for the Collaboration agreement. The Company concluded that the differences between the prices that Lilly paid for the shares and the ProQR stock closing prices on the days of entering into the equity investment agreements arose because of the Company&#8217;s existing obligations to deliver research and development services to Lilly under the terms of the Collaboration agreement. Therefore, the above differences between the closing share prices on the agreement effective dates and the equity investment prices paid by Lilly are considered to be part of the transaction price of the contract and are initially allocated to deferred revenue.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The contract also includes variable consideration, but no variable consideration was included in the initial transaction price at the inception, as it was not highly probable that a significant reversal in the amount of cumulative revenue recognized would not occur. The Company includes such variable consideration in the transaction price when the uncertainty associated with the variable consideration is resolved. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">The Collaboration agreement includes variable consideration in the form of development milestones, commercial milestones, and sales-based royalties based on the level of sales. As further described in Note 13, during 2025, the Company achieved development milestones during the ProQR research program under the agreement, which were added to the transaction price and recognized partially as revenue during 2025 based on the status of completion (satisfied part) of the single combined performance obligation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development expenditures</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><i style="font-family:'Open Sans';font-style:italic;">(ii) Research and development expenditures</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Research expenditures are reflected in the income statement. Development expenses are currently also reflected in the income statement because the criteria for capitalization are not met. At each balance sheet date, the Company estimates the level of service performed by the vendors and the associated costs incurred for the services performed.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Open Sans';">Although we do not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n.a.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayments and Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_PrepaymentsAndOtherReceivablesAbstract', window );"><strong>Prepayments and Other Receivables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock', window );">Schedule of prepayments and other receivables</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td></tr><tr><td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Prepayments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"> 1,903</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">2,410 </span></p></td></tr><tr><td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">Other receivables</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"> 1,467</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">835 </span></p></td></tr><tr><td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">Accrued income from Rett Syndrome Research Trust</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';"> 502</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">502 </span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.52%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">3,872 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">3,747 </b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of prepayments and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_PrepaymentsAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_PrepaymentsAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Schedule of borrowings</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.39151382%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.78%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.62%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"> </b><span style="font-family:'Open Sans';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Innovation credit</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">2,899 </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">2,899 </span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Accrued interest on innovation credit</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">1,901 </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">1,683 </span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">Total borrowings</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">4,800 </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">4,582 </b></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">Current portion</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">4,800 </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">4,582 </span></p></td></tr><tr><td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">Total non-current borrowings</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">&#8212; </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">&#8212; </b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_DeferredIncomeAbstract', window );"><strong>Deferred Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_ScheduleOfDeferredIncomeTableTextBlock', window );">Summary of deferred income</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">&#8364;1</span><i style="color:#262626;font-family:'Open Sans';font-style:italic;">,000</i></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">Payments from Eli Lilly and Company</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">17,367 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">21,501 </span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">Payments from Rett Syndrome Research Trust</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">27 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">441 </span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Current deferred income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">17,394 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">21,942 </b></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';">Payments from Eli Lilly and Company</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">24,125 </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-family:'Open Sans';">29,429 </span></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Non-current deferred income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">24,125 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">29,429 </b></p></td></tr><tr><td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.7%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">Total deferred income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">41,519 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">51,371 </b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_DeferredIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_DeferredIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_ScheduleOfDeferredIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_ScheduleOfDeferredIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory', window );">Schedule of other income</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.34%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">Nine month period </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.34%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;"> </b><span style="font-family:'Open Sans';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#ffffff;font-family:'Open Sans';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><i style="color:#262626;font-family:'Open Sans';font-style:italic;">&#8364;1,000</i></p></td></tr><tr><td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';">Grant income</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">413 </span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><span style="font-family:'Open Sans';">504 </span></p></td></tr><tr><td style="vertical-align:top;width:70.69%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-family:'Open Sans';font-weight:bold;">413 </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="color:#262626;font-family:'Open Sans';font-weight:bold;">504 </b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsHoldingB.v.Member', window );">ProQR Therapeutics Holding B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIB.v.Member', window );">ProQR Therapeutics I B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIiB.v.Member', window );">ProQR Therapeutics II B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIiiB.v.Member', window );">ProQR Therapeutics III B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIvB.v.Member', window );">ProQR Therapeutics IV B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsVB.v.Member', window );">ProQR Therapeutics V B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsViB.v.Member', window );">ProQR Therapeutics VI B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsViiB.v.Member', window );">ProQR Therapeutics VII B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsViiiB.v.Member', window );">ProQR Therapeutics VIII B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIxB.v.Member', window );">ProQR Therapeutics IX B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIInc.Member', window );">ProQR Therapeutics I Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsHoldingB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsHoldingB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIiB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIiB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIiiB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIiiB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIvB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIvB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsVB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsVB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsViB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsViB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsViiB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsViiB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsViiiB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsViiiB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIxB.v.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIxB.v.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_ProqrTherapeuticsIInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information - Revision of comparative figures (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to owners of the Company</a></td>
<td class="nump">&#8364; 57,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 57,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 88,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredIncomeIncludingContractLiabilities', window );">Deferred income</a></td>
<td class="nump">41,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">&#8364; 3,843<span></span>
</td>
<td class="nump">11,218<span></span>
</td>
<td class="nump">&#8364; 14,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result for the period</a></td>
<td class="num">(11,006)<span></span>
</td>
<td class="num">(8,108)<span></span>
</td>
<td class="num">(33,264)<span></span>
</td>
<td class="num">(18,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">57,071<span></span>
</td>
<td class="nump">24,982<span></span>
</td>
<td class="nump">57,071<span></span>
</td>
<td class="nump">24,982<span></span>
</td>
<td class="nump">88,560<span></span>
</td>
<td class="nump">&#8364; 41,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Changes in working capital</a></td>
<td class="nump">3,074<span></span>
</td>
<td class="num">(1,117)<span></span>
</td>
<td class="nump">10,974<span></span>
</td>
<td class="nump">12,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,264)<span></span>
</td>
<td class="num">(18,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="num">&#8364; (458,706)<span></span>
</td>
<td class="num">&#8364; (418,023)<span></span>
</td>
<td class="num">&#8364; (458,706)<span></span>
</td>
<td class="num">&#8364; (418,023)<span></span>
</td>
<td class="num">&#8364; (427,158)<span></span>
</td>
<td class="num">&#8364; (400,850)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsNumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n.a.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsNumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsNumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Critical Accounting Estimates and Judgements (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredIncomeIncludingContractLiabilities', window );">Deferred income</a></td>
<td class="nump">&#8364; 41,519<span></span>
</td>
<td class="nump">&#8364; 51,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember', window );">Eli Lilly and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredIncomeIncludingContractLiabilities', window );">Deferred income</a></td>
<td class="nump">&#8364; 41,492<span></span>
</td>
<td class="nump">&#8364; 50,930<span></span>
</td>
<td class="nump">&#8364; 2,047<span></span>
</td>
<td class="nump">$ 2,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 106,883<span></span>
</td>
<td class="nump">&#8364; 119,765<span></span>
</td>
<td class="nump">&#8364; 149,408<span></span>
</td>
<td class="nump">&#8364; 89,401<span></span>
</td>
<td class="nump">&#8364; 78,970<span></span>
</td>
<td class="nump">&#8364; 118,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepayments and Other Receivables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_PrepaymentsAndOtherReceivablesAbstract', window );"><strong>Prepayments and Other Receivables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Prepayments', window );">Prepayments</a></td>
<td class="nump">&#8364; 1,903<span></span>
</td>
<td class="nump">&#8364; 2,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccruedIncomeIncludingContractAssets', window );">Accrued income from Rett Syndrome Research Trust</a></td>
<td class="nump">502<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_PrepaymentsAndOtherReceivables', window );">Total Prepayments and Other Receivables</a></td>
<td class="nump">&#8364; 3,872<span></span>
</td>
<td class="nump">&#8364; 3,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccruedIncomeIncludingContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing income that has been earned but is not yet a receivable, including contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccruedIncomeIncludingContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Prepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Prepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_PrepaymentsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_PrepaymentsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_PrepaymentsAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_PrepaymentsAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember', window );">Office and laboratory facilities at Zernikedreef in Leiden, the Netherlands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">&#8364; 10,448<span></span>
</td>
<td class="nump">&#8364; 11,433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current Liabilties (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_OtherCurrentLiabilitiesAbstract', window );"><strong>Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">&#8364; 8,550<span></span>
</td>
<td class="nump">&#8364; 8,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_OtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_OtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 12, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsClassesOfWarrantsOrRightsAxisAxis=prqr_PontifaxAndKreosWarrantsMember', window );">Pontifax and Kreos warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_WarrantsEconomicLifetime', window );">Warrants, economic lifetime</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=prqr_InnovationCreditMember', window );">Innovation credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_BorrowingsExcludingAccruedInterest', window );">Borrowings excluding accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPayable', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_CurrentBorrowingsExcludingAccruedInterest', window );">Current borrowings excluding accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_ConditionalWaiverOfDebtTotal', window );">Total conditional waiver of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest recognised as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_BorrowingsExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings excluding accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_BorrowingsExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_ConditionalWaiverOfDebtTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of debt including interest can be waived up on satisfying the conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_ConditionalWaiverOfDebtTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_CurrentBorrowingsExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current borrowings excluding accrued interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_CurrentBorrowingsExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_WarrantsEconomicLifetime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, economic lifetime</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_WarrantsEconomicLifetime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsClassesOfWarrantsOrRightsAxisAxis=prqr_PontifaxAndKreosWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsClassesOfWarrantsOrRightsAxisAxis=prqr_PontifaxAndKreosWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=prqr_InnovationCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=prqr_InnovationCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Liabilities (Details) - Office and laboratory facilities at Zernikedreef in Leiden, the Netherlands<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_AreaOfPropertyUnderLease', window );">Area under lease | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_LeaseTerm', window );">Lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_LeaseExtensionTerm', window );">Lease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_LeaseCurrentExtensionPeriodUnderOption', window );">Lease, current extension period under option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,448<span></span>
</td>
<td class="nump">&#8364; 11,433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_AreaOfPropertyUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of property under lease as per lease terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_AreaOfPropertyUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_LeaseCurrentExtensionPeriodUnderOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, current extension period under option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_LeaseCurrentExtensionPeriodUnderOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_LeaseExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease extension term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_LeaseExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_LeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_LeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Income (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities', window );">Current deferred income</a></td>
<td class="nump">&#8364; 17,394<span></span>
</td>
<td class="nump">&#8364; 21,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities', window );">Non-current deferred income</a></td>
<td class="nump">24,125<span></span>
</td>
<td class="nump">29,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredIncomeIncludingContractLiabilities', window );">Total deferred income</a></td>
<td class="nump">41,519<span></span>
</td>
<td class="nump">51,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember', window );">Eli Lilly and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities', window );">Current deferred income</a></td>
<td class="nump">17,367<span></span>
</td>
<td class="nump">21,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities', window );">Non-current deferred income</a></td>
<td class="nump">24,125<span></span>
</td>
<td class="nump">29,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredIncomeIncludingContractLiabilities', window );">Total deferred income</a></td>
<td class="nump">41,492<span></span>
</td>
<td class="nump">50,930<span></span>
</td>
<td class="nump">&#8364; 2,047<span></span>
</td>
<td class="nump">$ 2,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=prqr_RettSyndromeResearchTrustMember', window );">Rett Syndrome Research Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities', window );">Current deferred income</a></td>
<td class="nump">&#8364; 27<span></span>
</td>
<td class="nump">&#8364; 441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current deferred income including non-current contract liabilities. [Refer: Deferred income including contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=prqr_RettSyndromeResearchTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=prqr_RettSyndromeResearchTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Share capital (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Shareholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_AuthorizedShareCapitalValue', window );">Authorized share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember', window );">Eli Lilly and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Shareholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares (in shares)</a></td>
<td class="nump">9,381,586<span></span>
</td>
<td class="nump">3,989,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Shareholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,710,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares issued and fully paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,345,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates', window );">Treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,365,724<span></span>
</td>
<td class="nump">2,498,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember', window );">Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Shareholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Total for all associates [member]; Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_AuthorizedShareCapitalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of authorized share capital value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_AuthorizedShareCapitalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock shares issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Sale of shares (Details)<br> $ / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 25, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 25, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsSaleOfStockAxis=prqr_ShelfRegistrationStatement2024Member', window );">2024 shelf registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_MaximumOfferingPriceInShelfRegistrationStatement', window );">Maximum offering price in shelf registration statement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsSaleOfStockAxis=prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember', window );">At the market offerings with Cantor Fitzgerald and Co under shelf registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_MaximumOfferingPriceInShelfRegistrationStatement', window );">Maximum offering price in shelf registration statement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement', window );">Percentage of commission payable for gross proceeds from sales agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsSaleOfStockAxis=prqr_October2024UnderwrittenPublicOfferingMember', window );">October 2024 underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsSaleOfStockPricePerShare', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,790,000<span></span>
</td>
<td class="nump">&#8364; 64,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_NetProceedsFromIssuingShares', window );">Net proceeds from issuing shares | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 60,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsSaleOfStockAxis=prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember', window );">Underwriters' option in connection to October 2024 underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares (in shares)</a></td>
<td class="nump">1,940,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_DurationOfUnderwritersOption', window );">Duration of underwriters' option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_NumberOfSharesCallableForOptionsIssued', window );">Number of shares callable for options issued</a></td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsSaleOfStockAxis=prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember', window );">Share purchase agreement with Eli Lilly and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,523,538<span></span>
</td>
<td class="nump">3,523,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="nump">&#8364; 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_PurchasePriceCapSharePurchaseAgreement', window );">Purchase price cap, share purchase agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_DurationOfUnderwritersOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration of underwriters' option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_DurationOfUnderwritersOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsSaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsSaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock shares issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_MaximumOfferingPriceInShelfRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum offering price in shelf registration statement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_MaximumOfferingPriceInShelfRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_NetProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuing shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_NetProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_NumberOfSharesCallableForOptionsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares callable for options issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_NumberOfSharesCallableForOptionsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission payable for gross proceeds from sales agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_PurchasePriceCapSharePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price cap, share purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_PurchasePriceCapSharePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsSaleOfStockAxis=prqr_ShelfRegistrationStatement2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsSaleOfStockAxis=prqr_ShelfRegistrationStatement2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsSaleOfStockAxis=prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsSaleOfStockAxis=prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsSaleOfStockAxis=prqr_October2024UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsSaleOfStockAxis=prqr_October2024UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsSaleOfStockAxis=prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsSaleOfStockAxis=prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsSaleOfStockAxis=prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsSaleOfStockAxis=prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Share options (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Equity-settled share based payments</a></td>
<td class="nump">&#8364; 2,784<span></span>
</td>
<td class="nump">&#8364; 1,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=prqr_IfrsSellingGeneralAndAdministrativeExpensesMember', window );">IFRS General and administrative costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Equity-settled share based payments</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=prqr_IfrsResearchAndDevelopmentExpenseMember', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Equity-settled share based payments</a></td>
<td class="nump">&#8364; 832<span></span>
</td>
<td class="nump">&#8364; 417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=prqr_IfrsSellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=prqr_IfrsSellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=prqr_IfrsResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=prqr_IfrsResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredIncomeIncludingContractLiabilities', window );">Deferred income | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 41,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 51,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember', window );">Eli Lilly and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredIncomeIncludingContractLiabilities', window );">Deferred income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 41,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50,930<span></span>
</td>
<td class="nump">$ 2,429,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,381,586<span></span>
</td>
<td class="nump">9,381,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,989,976<span></span>
</td>
<td class="nump">3,989,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14,122<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,270<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_DiscountOnIssueOfShares', window );">Discount on shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 451<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership', window );">Additional consideration to be received if counterparty exercises option to expand partnership | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_NumberOfPerformanceObligationsInCollaborationAgreement', window );">Number of performance obligations in collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,849<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_ValueOfMilestonesReachedDuringPeriod', window );">Value of milestones reached during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,781<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices', window );">Milestone payments received</a></td>
<td class="nump">&#8364; 56,412<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of goods and rendering of services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 14<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_14_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional consideration to be received if counterparty exercises option to expand partnership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_DiscountOnIssueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discount on issue of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_DiscountOnIssueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock shares issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_NumberOfPerformanceObligationsInCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations in collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_NumberOfPerformanceObligationsInCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_ValueOfMilestonesReachedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of milestones reached during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_ValueOfMilestonesReachedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=prqr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=prqr_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=prqr_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsRevenueFromGrants', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 413<span></span>
</td>
<td class="nump">&#8364; 504<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Total other income</a></td>
<td class="nump">&#8364; 33<span></span>
</td>
<td class="nump">&#8364; 138<span></span>
</td>
<td class="nump">&#8364; 413<span></span>
</td>
<td class="nump">&#8364; 504<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsRevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsRevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income - Narrative (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_OtherIncomeLineItems', window );"><strong>Other Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsRevenueFromGrants', window );">Grant income</a></td>
<td class="nump">&#8364; 413<span></span>
</td>
<td class="nump">&#8364; 504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=prqr_RettSyndromeResearchTrustMember', window );">Rett Syndrome Research Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_OtherIncomeLineItems', window );"><strong>Other Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_IfrsRevenueFromGrants', window );">Grant income</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">&#8364; 504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_MaximumGrantReceivableForInitialPhaseOfProject', window );">Maximum grant receivable for the initial phase of the project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_MaximumGrantReceivableForAdditionalPhaseOfProject', window );">Maximum grant receivable for additional phase of the project | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices', window );">Receipts</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of goods and rendering of services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 14<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_14_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_IfrsRevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_IfrsRevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_MaximumGrantReceivableForAdditionalPhaseOfProject">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum grant receivable for additional phase of the project.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_MaximumGrantReceivableForAdditionalPhaseOfProject</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_MaximumGrantReceivableForInitialPhaseOfProject">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum grant receivable for the initial phase of the project.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_MaximumGrantReceivableForInitialPhaseOfProject</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_OtherIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_OtherIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=prqr_RettSyndromeResearchTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=prqr_RettSyndromeResearchTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Costs (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_ResearchAndDevelopmentCostsAbstract', window );"><strong>Research and Development Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">&#8364; 11,080<span></span>
</td>
<td class="nump">&#8364; 9,414<span></span>
</td>
<td class="nump">&#8364; 34,811<span></span>
</td>
<td class="nump">&#8364; 25,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_ResearchAndDevelopmentCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_ResearchAndDevelopmentCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Costs (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">&#8364; 3,119<span></span>
</td>
<td class="nump">&#8364; 3,283<span></span>
</td>
<td class="nump">&#8364; 11,169<span></span>
</td>
<td class="nump">&#8364; 9,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Financial Assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=prqr_PhoenicisTherapeuticsIncMember', window );">Phoenicis Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems', window );"><strong>Disclosure of Investment in Financial Asset and Gain on Disposal of Associate [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_ProportionOfOwnershipInterest', window );">Proportion of ownership interest</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Financial assets at fair value through other comprehensive income</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=prqr_YarrowBiotechnologyMember', window );">Yarrow Biotechnology, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems', window );"><strong>Disclosure of Investment in Financial Asset and Gain on Disposal of Associate [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prqr_ProportionOfOwnershipInterest', window );">Proportion of ownership interest</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Financial assets at fair value through other comprehensive income</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 44<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 44<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent investment in financial asset and gain on disposal of associate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prqr_ProportionOfOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest that the entity holds in another entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prqr_ProportionOfOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prqr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=prqr_PhoenicisTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=prqr_PhoenicisTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=prqr_YarrowBiotechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=prqr_YarrowBiotechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Current tax liabilities</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax expense (income), continuing operations</a></td>
<td class="nump">&#8364; 18<span></span>
</td>
<td class="num">&#8364; (197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>96</ContextCount>
  <ElementCount>150</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Unaudited Condensed Consolidated Statement of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition</Role>
      <ShortName>Unaudited Condensed Consolidated Statement of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome</Role>
      <ShortName>Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - Unaudited Condensed Consolidated Statement of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity</Role>
      <ShortName>Unaudited Condensed Consolidated Statement of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Unaudited Condensed Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows</Role>
      <ShortName>Unaudited Condensed Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - General Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureGeneralInformation</Role>
      <ShortName>General Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Adoption of New and Revised International Financial Reporting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureAdoptionOfNewAndRevisedInternationalFinancialReportingStandards</Role>
      <ShortName>Adoption of New and Revised International Financial Reporting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Critical Accounting Estimates and Judgments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgments</Role>
      <ShortName>Critical Accounting Estimates and Judgments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureCashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Prepayments and Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivables</Role>
      <ShortName>Prepayments and Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosurePropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureOtherCurrentLiabilities</Role>
      <ShortName>Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureBorrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Lease Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureLeaseLiabilities</Role>
      <ShortName>Lease Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Deferred Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureDeferredIncome</Role>
      <ShortName>Deferred Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureOtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Research and Development Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureResearchAndDevelopmentCosts</Role>
      <ShortName>Research and Development Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11601 - Disclosure - General and Administrative Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCosts</Role>
      <ShortName>General and Administrative Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Investments in Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssets</Role>
      <ShortName>Investments in Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11901 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>12001 - Disclosure - Events After Balance Sheet Date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureEventsAfterBalanceSheetDate</Role>
      <ShortName>Events After Balance Sheet Date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>20302 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Prepayments and Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesTables</Role>
      <ShortName>Prepayments and Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureBorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureBorrowings</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Deferred Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureDeferredIncomeTables</Role>
      <ShortName>Deferred Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureDeferredIncome</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Other Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureOtherIncomeTables</Role>
      <ShortName>Other Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureOtherIncome</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40101 - Disclosure - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureGeneralInformationDetails</Role>
      <ShortName>General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureGeneralInformation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40102 - Disclosure - General Information - Revision of comparative figures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails</Role>
      <ShortName>General Information - Revision of comparative figures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Critical Accounting Estimates and Judgements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails</Role>
      <ShortName>Critical Accounting Estimates and Judgements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureCashAndCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureCashAndCashEquivalents</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Prepayments and Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails</Role>
      <ShortName>Prepayments and Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosurePropertyPlantAndEquipment</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Other Current Liabilties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureOtherCurrentLiabiltiesDetails</Role>
      <ShortName>Other Current Liabilties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureOtherCurrentLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureBorrowingsDetails</Role>
      <ShortName>Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureBorrowingsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails</Role>
      <ShortName>Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureLeaseLiabilities</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Deferred Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureDeferredIncomeDetails</Role>
      <ShortName>Deferred Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureDeferredIncomeTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Shareholders' Equity - Share capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails</Role>
      <ShortName>Shareholders' Equity - Share capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Shareholders' Equity - Sale of shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails</Role>
      <ShortName>Shareholders' Equity - Sale of shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Shareholders' Equity - Share options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails</Role>
      <ShortName>Shareholders' Equity - Share options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureRevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureRevenue</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Other Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureOtherIncomeDetails</Role>
      <ShortName>Other Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureOtherIncomeTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Other Income - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails</Role>
      <ShortName>Other Income - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Research and Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureResearchAndDevelopmentCostsDetails</Role>
      <ShortName>Research and Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureResearchAndDevelopmentCosts</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41601 - Disclosure - General and Administrative Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCostsDetails</Role>
      <ShortName>General and Administrative Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCosts</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Investments in Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails</Role>
      <ShortName>Investments in Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssets</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="prqr-20250930xex99d1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.proqr.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>prqr-20250930.xsd</File>
    <File>prqr-20250930_cal.xml</File>
    <File>prqr-20250930_def.xml</File>
    <File>prqr-20250930_lab.xml</File>
    <File>prqr-20250930_pre.xml</File>
    <File doctype="EX-99.1" isDefinitelyFs="true" isIfrs="true" original="prqr-20250930xex99d1.htm">prqr-20250930xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="364">https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "prqr-20250930xex99d1.htm": {
   "nsprefix": "prqr",
   "nsuri": "http://www.proqr.com/20250930",
   "dts": {
    "schema": {
     "local": [
      "prqr-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "prqr-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "prqr-20250930_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "prqr-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prqr-20250930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "prqr-20250930xex99d1.htm"
     ]
    }
   },
   "keyStandard": 115,
   "keyCustom": 35,
   "axisStandard": 9,
   "axisCustom": 2,
   "memberStandard": 7,
   "memberCustom": 26,
   "hidden": {
    "total": 13,
    "http://www.proqr.com/20250930": 5,
    "http://xbrl.sec.gov/dei/2025": 8
   },
   "contextCount": 96,
   "entityCount": 1,
   "segmentCount": 33,
   "elementCount": 263,
   "unitCount": 8,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 364,
    "http://xbrl.sec.gov/dei/2025": 8
   },
   "report": {
    "R1": {
     "role": "http://www.proqr.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition",
     "longName": "00100 - Statement - Unaudited Condensed Consolidated Statement of Financial Position",
     "shortName": "Unaudited Condensed Consolidated Statement of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome",
     "longName": "00200 - Statement - Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income",
     "shortName": "Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ",
      "name": "ifrs-full:OperatingExpense",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity",
     "longName": "00300 - Statement - Unaudited Condensed Consolidated Statement of Changes in Equity",
     "shortName": "Unaudited Condensed Consolidated Statement of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AcgFrNkamkCvsd1bQi1WLA",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AcgFrNkamkCvsd1bQi1WLA",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows",
     "longName": "00400 - Statement - Unaudited Condensed Consolidated Statement of Cash Flows",
     "shortName": "Unaudited Condensed Consolidated Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ",
      "name": "prqr:AdjustmentsForOtherIncome",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.proqr.com/role/DisclosureGeneralInformation",
     "longName": "10101 - Disclosure - General Information",
     "shortName": "General Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:DisclosureOfGeneralInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:DisclosureOfGeneralInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.proqr.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "10201 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.proqr.com/role/DisclosureAdoptionOfNewAndRevisedInternationalFinancialReportingStandards",
     "longName": "10301 - Disclosure - Adoption of New and Revised International Financial Reporting Standards",
     "shortName": "Adoption of New and Revised International Financial Reporting Standards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgments",
     "longName": "10401 - Disclosure - Critical Accounting Estimates and Judgments",
     "shortName": "Critical Accounting Estimates and Judgments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.proqr.com/role/DisclosureCashAndCashEquivalents",
     "longName": "10501 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivables",
     "longName": "10601 - Disclosure - Prepayments and Other Receivables",
     "shortName": "Prepayments and Other Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.proqr.com/role/DisclosurePropertyPlantAndEquipment",
     "longName": "10701 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.proqr.com/role/DisclosureOtherCurrentLiabilities",
     "longName": "10801 - Disclosure - Other Current Liabilities",
     "shortName": "Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.proqr.com/role/DisclosureBorrowings",
     "longName": "10901 - Disclosure - Borrowings",
     "shortName": "Borrowings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.proqr.com/role/DisclosureLeaseLiabilities",
     "longName": "11001 - Disclosure - Lease Liabilities",
     "shortName": "Lease Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.proqr.com/role/DisclosureDeferredIncome",
     "longName": "11101 - Disclosure - Deferred Income",
     "shortName": "Deferred Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfDeferredIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfDeferredIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.proqr.com/role/DisclosureShareholdersEquity",
     "longName": "11201 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.proqr.com/role/DisclosureRevenue",
     "longName": "11301 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.proqr.com/role/DisclosureOtherIncome",
     "longName": "11401 - Disclosure - Other Income",
     "shortName": "Other Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.proqr.com/role/DisclosureResearchAndDevelopmentCosts",
     "longName": "11501 - Disclosure - Research and Development Costs",
     "shortName": "Research and Development Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCosts",
     "longName": "11601 - Disclosure - General and Administrative Costs",
     "shortName": "General and Administrative Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssets",
     "longName": "11701 - Disclosure - Investments in Financial Assets",
     "shortName": "Investments in Financial Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.proqr.com/role/DisclosureIncomeTaxes",
     "longName": "11801 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.proqr.com/role/DisclosureRelatedPartyTransactions",
     "longName": "11901 - Disclosure - Related-Party Transactions",
     "shortName": "Related-Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.proqr.com/role/DisclosureEventsAfterBalanceSheetDate",
     "longName": "12001 - Disclosure - Events After Balance Sheet Date",
     "shortName": "Events After Balance Sheet Date",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "20302 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesTables",
     "longName": "30603 - Disclosure - Prepayments and Other Receivables (Tables)",
     "shortName": "Prepayments and Other Receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.proqr.com/role/DisclosureBorrowingsTables",
     "longName": "30903 - Disclosure - Borrowings (Tables)",
     "shortName": "Borrowings (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.proqr.com/role/DisclosureDeferredIncomeTables",
     "longName": "31103 - Disclosure - Deferred Income (Tables)",
     "shortName": "Deferred Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:ScheduleOfDeferredIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDeferredIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:ScheduleOfDeferredIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDeferredIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.proqr.com/role/DisclosureOtherIncomeTables",
     "longName": "31403 - Disclosure - Other Income (Tables)",
     "shortName": "Other Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:DisclosureOfOtherIncomeTableTextBlockExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:DisclosureOfOtherIncomeTableTextBlockExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.proqr.com/role/DisclosureGeneralInformationDetails",
     "longName": "40101 - Disclosure - General Information (Details)",
     "shortName": "General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsHoldingBvMember_O8oNddjWmkC-HAijvKH37g",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "prqr:DisclosureOfGeneralInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsHoldingBvMember_O8oNddjWmkC-HAijvKH37g",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "prqr:DisclosureOfGeneralInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
     "longName": "40102 - Disclosure - General Information - Revision of comparative figures (Details)",
     "shortName": "General Information - Revision of comparative figures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:EquityAttributableToOwnersOfParent",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "longName": "40201 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:IfrsNumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_iAZ-erTqcEibFQQvKQuMIg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:IfrsNumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_iAZ-erTqcEibFQQvKQuMIg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails",
     "longName": "40401 - Disclosure - Critical Accounting Estimates and Judgements (Details)",
     "shortName": "Critical Accounting Estimates and Judgements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:DeferredIncomeIncludingContractLiabilities",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "prqr:ScheduleOfDeferredIncomeTableTextBlock",
       "ifrs-full:DisclosureOfDeferredIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.proqr.com/role/DisclosureCashAndCashEquivalentsDetails",
     "longName": "40501 - Disclosure - Cash and Cash Equivalents (Details)",
     "shortName": "Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails",
     "longName": "40601 - Disclosure - Prepayments and Other Receivables (Details)",
     "shortName": "Prepayments and Other Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:Prepayments",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "prqr:DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:Prepayments",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "prqr:DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails",
     "longName": "40701 - Disclosure - Property, Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_Ps4wlpTyCk-CiG6i9mnIJg",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.proqr.com/role/DisclosureOtherCurrentLiabiltiesDetails",
     "longName": "40801 - Disclosure - Other Current Liabilties (Details)",
     "shortName": "Other Current Liabilties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:OtherCurrentLiabilities",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.proqr.com/role/DisclosureBorrowingsDetails",
     "longName": "40901 - Disclosure - Borrowings (Details)",
     "shortName": "Borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:Borrowings",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:Borrowings",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails",
     "longName": "41001 - Disclosure - Lease Liabilities (Details)",
     "shortName": "Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_Ps4wlpTyCk-CiG6i9mnIJg",
      "name": "prqr:AreaOfPropertyUnderLease",
      "unitRef": "Unit_Standard_sqm_Oc_SVpN4d0OQM3FvR-NrfQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_Ps4wlpTyCk-CiG6i9mnIJg",
      "name": "prqr:AreaOfPropertyUnderLease",
      "unitRef": "Unit_Standard_sqm_Oc_SVpN4d0OQM3FvR-NrfQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.proqr.com/role/DisclosureDeferredIncomeDetails",
     "longName": "41101 - Disclosure - Deferred Income (Details)",
     "shortName": "Deferred Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_z_wMRuiDMEqEinzBTRrmJA",
      "name": "ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "prqr:ScheduleOfDeferredIncomeTableTextBlock",
       "ifrs-full:DisclosureOfDeferredIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails",
     "longName": "41201 - Disclosure - Shareholders' Equity - Share capital (Details)",
     "shortName": "Shareholders' Equity - Share capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "prqr:AuthorizedShareCapitalValue",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "prqr:AuthorizedShareCapitalValue",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails",
     "longName": "41202 - Disclosure - Shareholders' Equity - Sale of shares (Details)",
     "shortName": "Shareholders' Equity - Sale of shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_ShelfRegistrationStatement2024Member_ng7Fbf6gFUy4vNzZAU2odA",
      "name": "prqr:MaximumOfferingPriceInShelfRegistrationStatement",
      "unitRef": "Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_ShelfRegistrationStatement2024Member_ng7Fbf6gFUy4vNzZAU2odA",
      "name": "prqr:MaximumOfferingPriceInShelfRegistrationStatement",
      "unitRef": "Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails",
     "longName": "41203 - Disclosure - Shareholders' Equity - Share options (Details)",
     "shortName": "Shareholders' Equity - Share options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.proqr.com/role/DisclosureRevenueDetails",
     "longName": "41301 - Disclosure - Revenue (Details)",
     "shortName": "Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:DeferredIncomeIncludingContractLiabilities",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "prqr:ScheduleOfDeferredIncomeTableTextBlock",
       "ifrs-full:DisclosureOfDeferredIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g",
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.proqr.com/role/DisclosureOtherIncomeDetails",
     "longName": "41401 - Disclosure - Other Income (Details)",
     "shortName": "Other Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:IfrsRevenueFromGrants",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "prqr:DisclosureOfOtherIncomeTableTextBlockExplanatory",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails",
     "longName": "41402 - Disclosure - Other Income - Narrative (Details)",
     "shortName": "Other Income - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw",
      "name": "prqr:IfrsRevenueFromGrants",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "prqr:DisclosureOfOtherIncomeTableTextBlockExplanatory",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_0tkeXgS6dkGzbdukDKq5tg",
      "name": "prqr:IfrsRevenueFromGrants",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.proqr.com/role/DisclosureResearchAndDevelopmentCostsDetails",
     "longName": "41501 - Disclosure - Research and Development Costs (Details)",
     "shortName": "Research and Development Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCostsDetails",
     "longName": "41601 - Disclosure - General and Administrative Costs (Details)",
     "shortName": "General and Administrative Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ",
      "name": "ifrs-full:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails",
     "longName": "41701 - Disclosure - Investments in Financial Assets (Details)",
     "shortName": "Investments in Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_yg5IGweIK0qeV0bYXpRQJg",
      "name": "prqr:ProportionOfOwnershipInterest",
      "unitRef": "Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_yg5IGweIK0qeV0bYXpRQJg",
      "name": "prqr:ProportionOfOwnershipInterest",
      "unitRef": "Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.proqr.com/role/DisclosureIncomeTaxesDetails",
     "longName": "41801 - Disclosure - Income taxes (Details)",
     "shortName": "Income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:CurrentTaxLiabilities",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w",
      "name": "ifrs-full:CurrentTaxLiabilities",
      "unitRef": "Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prqr-20250930xex99d1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ifrs-full_AccruedIncomeIncludingContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccruedIncomeIncludingContractAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails": {
       "parentTag": "prqr_PrepaymentsAndOtherReceivables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued income including contract assets",
        "terseLabel": "Accrued income from Rett Syndrome Research Trust"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing income that has been earned but is not yet a receivable, including contract assets. [Refer: Contract assets]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r169"
     ]
    },
    "prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional consideration to be received if counterparty exercises option to expand partnership",
        "label": "Additional consideration to be received if counterparty exercises option to expand partnership"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share",
        "verboseLabel": "Weighted average number of shares outstanding (diluted)"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation expense",
        "terseLabel": "Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_AdjustmentsForFairValueGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForFairValueGainsLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for fair value losses (gains)",
        "terseLabel": "Results related to financial liabilities measured at fair value through profit or loss"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for finance income (cost)",
        "negatedLabel": "Financial income and expenses"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_AdjustmentsForIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncomeTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for income tax expense",
        "terseLabel": "Income tax expenses"
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "prqr_AdjustmentsForOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "AdjustmentsForOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for other income to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Other Income",
        "negatedLabel": "Other income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments for:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.proqr.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_AreaOfPropertyUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "AreaOfPropertyUnderLease",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of property under lease as per lease terms.",
        "label": "Area Of Property Under Lease",
        "terseLabel": "Area under lease"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r60",
      "r62",
      "r93",
      "r94",
      "r115"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents at the market offerings with Cantor Fitzgerald and Co under the shelf registration statement.",
        "label": "At the market offerings with Cantor Fitzgerald and Co under shelf registration statement [Member]",
        "terseLabel": "At the market offerings with Cantor Fitzgerald and Co under shelf registration statement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r164"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [domain]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r164"
     ]
    },
    "prqr_AuthorizedShareCapitalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "AuthorizedShareCapitalValue",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of authorized share capital value.",
        "label": "Authorized share capital value",
        "terseLabel": "Authorized share capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16"
     ]
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/DisclosureBorrowingsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings.",
        "totalLabel": "Total borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_BorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_BorrowingsByNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsByNameDomain",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings by name [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "prqr_BorrowingsExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "BorrowingsExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings excluding accrued interest.",
        "label": "Borrowings excluding accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureCashAndCashEquivalentsDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "periodStartLabel": "Cash and cash equivalents, at beginning of the period",
        "terseLabel": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r38",
      "r75",
      "r111"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash used in financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r25"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Cash flow from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash (used in) / generated by investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r25"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Cash flow from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r25"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperations",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operations",
        "totalLabel": "Cash used in operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails",
      "http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r81"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails",
      "http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r81"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r100",
      "r125"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r100",
      "r125"
     ]
    },
    "prqr_ClassesOfWarrantsOrRightsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ClassesOfWarrantsOrRightsDomain",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classes of warrants or rights",
        "label": "Classes of warrants or rights [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementConsolidatedStatementOfProfitOrLossAndComprehensiveIncomeCalc2Imported": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r30",
      "r36",
      "r84",
      "r87",
      "r105",
      "r129",
      "r143"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total comprehensive income attributable to"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementConsolidatedStatementOfProfitOrLossAndComprehensiveIncomeCalc2Imported": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to owners of parent",
        "terseLabel": "Owners of the Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r105",
      "r131"
     ]
    },
    "prqr_ConditionalWaiverOfDebtTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ConditionalWaiverOfDebtTotal",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of debt including interest can be waived up on satisfying the conditions.",
        "label": "Conditional Waiver of Debt, Total",
        "terseLabel": "Total conditional waiver of debt"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails",
      "http://www.proqr.com/role/DisclosureDeferredIncomeDetails",
      "http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails",
      "http://www.proqr.com/role/DisclosureRevenueDetails",
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_CounterpartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesDomain",
     "presentation": [
      "http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails",
      "http://www.proqr.com/role/DisclosureDeferredIncomeDetails",
      "http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails",
      "http://www.proqr.com/role/DisclosureRevenueDetails",
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r32",
      "r116",
      "r143"
     ]
    },
    "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.proqr.com/role/DisclosureBorrowingsDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current borrowings and current portion of non-current borrowings",
        "terseLabel": "Borrowings",
        "verboseLabel": "Current portion"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "prqr_CurrentBorrowingsExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "CurrentBorrowingsExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current borrowings excluding accrued interest",
        "label": "Current borrowings excluding accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentDeferredIncomeIncludingCurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureDeferredIncomeDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current deferred income including current contract liabilities",
        "terseLabel": "Deferred income",
        "verboseLabel": "Current deferred income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r169"
     ]
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current derivative financial liabilities",
        "terseLabel": "Derivative financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.proqr.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities.",
        "totalLabel": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r117",
      "r143"
     ]
    },
    "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current payables on social security and taxes other than income tax",
        "terseLabel": "Social securities and other taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current receivables from taxes other than income tax",
        "terseLabel": "Other taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "prqr_DeferredIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "DeferredIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Deferred Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredIncomeIncludingContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredIncomeIncludingContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails",
      "http://www.proqr.com/role/DisclosureDeferredIncomeDetails",
      "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
      "http://www.proqr.com/role/DisclosureRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income including contract liabilities",
        "terseLabel": "Deferred income",
        "totalLabel": "Total deferred income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "verboseLabel": "Revenue"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development expenditures"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations",
     "presentation": [
      "http://www.proqr.com/role/DisclosureAdoptionOfNewAndRevisedInternationalFinancialReportingStandards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of initial application of standards or interpretations [text block]",
        "terseLabel": "Adoption of New and Revised International Financial Reporting Standards"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r77"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16"
     ]
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "Critical Accounting Estimates and Judgments"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBorrowingsExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of borrowings [text block]",
        "terseLabel": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureCashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of cash and cash equivalents [text block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Critical Accounting Estimates and Judgments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails",
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Shareholders Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails",
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r100",
      "r125"
     ]
    },
    "ifrs-full_DisclosureOfDeferredIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDeferredIncomeExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureDeferredIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of deferred income [text block]",
        "verboseLabel": "Deferred Income"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of deferred income. [Refer: Deferred income including contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [text block]",
        "terseLabel": "Schedule of borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails",
      "http://www.proqr.com/role/DisclosureDeferredIncomeDetails",
      "http://www.proqr.com/role/DisclosureRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails",
      "http://www.proqr.com/role/DisclosureDeferredIncomeDetails",
      "http://www.proqr.com/role/DisclosureRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r65"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureEventsAfterBalanceSheetDate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Events After Balance Sheet Date"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [text block]",
        "verboseLabel": "Investments in Financial Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r89"
     ]
    },
    "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of general and administrative expense [text block]",
        "terseLabel": "General and Administrative Costs"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "prqr_DisclosureOfGeneralInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "DisclosureOfGeneralInformationExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of general information about the entity.",
        "label": "Disclosure Of General Information Explanatory",
        "terseLabel": "General Information"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income Taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption of New and Revised International Financial Reporting Standards"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateLineItems",
     "presentation": [
      "http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent investment in financial asset and gain on disposal of associate.",
        "label": "Disclosure of Investment in Financial Asset and Gain on Disposal of Associate [Line items]"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "DisclosureOfInvestmentInFinancialAssetAndGainOnDisposalOfAssociateTable",
     "presentation": [
      "http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to investment in financial asset and gain on disposal of associate.",
        "label": "Disclosure of Investment in Financial Asset and Gain on Disposal of Associate [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Lease Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of material accounting policy information [text block]",
        "terseLabel": "Significant Accounting Policies"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r102",
      "r110"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After Balance Sheet Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other current liabilities [text block]",
        "terseLabel": "Other Current Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "prqr_DisclosureOfOtherIncomeTableTextBlockExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "DisclosureOfOtherIncomeTableTextBlockExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureOtherIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other income.",
        "label": "Disclosure Of Other Income Table Text Block Explanatory",
        "terseLabel": "Schedule of other income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureOtherIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other operating income [text block]",
        "terseLabel": "Other Income"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of prepayments and other assets [text block]",
        "terseLabel": "Prepayments and Other Receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "prqr_DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock",
     "presentation": [
      "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of prepayments and other receivables.",
        "label": "Disclosure Of Prepayments And Other Receivables [Table Text Block]",
        "verboseLabel": "Schedule of prepayments and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosurePropertyPlantAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "terseLabel": "Property, Plant and Equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r81"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r67"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related-Party Transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureResearchAndDevelopmentCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of research and development expense [text block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of revenue [text block]",
        "terseLabel": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "terseLabel": "Shareholders' Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r101",
      "r126"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r14",
      "r40",
      "r92"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r88"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related-Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_DiscountOnIssueOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "DiscountOnIssueOfShares",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discount on issue of shares.",
        "label": "Discount on Issue of Shares",
        "terseLabel": "Discount on shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "DocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.proqr.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.proqr.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.proqr.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.proqr.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_DurationOfUnderwritersOption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "DurationOfUnderwritersOption",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of underwriters' option",
        "label": "Duration of underwriters' option"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share",
        "verboseLabel": "Earnings per share attributable to owners of the Company (Euro per share)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Currency effect cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21"
     ]
    },
    "prqr_EliLillyAndCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "EliLillyAndCompanyMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails",
      "http://www.proqr.com/role/DisclosureDeferredIncomeDetails",
      "http://www.proqr.com/role/DisclosureRevenueDetails",
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly and Company.",
        "label": "Eli Lilly and Company"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.proqr.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.proqr.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r29",
      "r41",
      "r42",
      "r43",
      "r83",
      "r86",
      "r93",
      "r94",
      "r103",
      "r115",
      "r119"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "verboseLabel": "Equity and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent",
        "terseLabel": "Equity attributable to owners of the Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense from equity-settled share-based payment transactions in which goods or services received did not qualify for recognition as assets",
        "terseLabel": "Equity-settled share based payments"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance income (cost)",
        "verboseLabel": "Finance income and expense"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r57",
      "r90"
     ]
    },
    "ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains (losses) on financial liabilities at fair value through profit or loss",
        "terseLabel": "Results related to financial liabilities measured at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r55",
      "r91"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralAndAdministrativeCostsDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedLabel": "General and administrative costs",
        "verboseLabel": "General and administrative expense"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "prqr_GeneralInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "GeneralInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General Information [Abstract]",
        "label": "General Information"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n.a.",
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsClassesOfWarrantsOrRightsAxisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsClassesOfWarrantsOrRightsAxisAxis",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classes Of Warrants Or Rights Axis",
        "label": "IFRS Classes Of Warrants Or Rights Axis [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsNumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsNumberOfReportableSegments",
     "presentation": [
      "http://www.proqr.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Ifrs Number of Reportable Segments",
        "terseLabel": "Number of reportable segment"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsOtherIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsOtherIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsRevenueFromGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsRevenueFromGrants",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/DisclosureOtherIncomeDetails": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureOtherIncomeDetails",
      "http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.",
        "label": "IFRS Revenue From Grants",
        "terseLabel": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsSaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsSaleOfStockAxis",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Ifrs Sale of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsSaleOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsSaleOfStockDomain",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Ifrs Sale of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsSaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsSaleOfStockPricePerShare",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received for each share of common stock issued or sold in the stock transaction.",
        "label": "IFRS Sale Of Stock Price Per Share",
        "terseLabel": "Price per share"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsSellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsSellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "IFRS General and administrative costs",
        "terseLabel": "General and administrative costs"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.proqr.com/role/DisclosureRevenueDetails",
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails",
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock shares issued during the period.",
        "label": "Ifrs Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issue of ordinary shares (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_IfrsStockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "IfrsStockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period through the exercise of options",
        "label": "IFRS Stock Issued During Period Shares Stock Options Exercised",
        "terseLabel": "Share options exercised / RSUs vested (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureIncomeTaxesDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income), continuing operations",
        "negatedLabel": "Income taxes"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r10",
      "r39",
      "r59",
      "r78",
      "r79",
      "r80",
      "r132"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund), classified as operating activities",
        "negatedLabel": "Corporate income tax received / (paid)"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r136"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Net (decrease) / increase in cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r75"
     ]
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInWorkingCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in working capital",
        "negatedLabel": "Changes in working capital",
        "terseLabel": "Changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of options, equity",
        "verboseLabel": "Shares options exercised / RSUs vested"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "verboseLabel": "Recognition of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "prqr_InnovationCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "InnovationCreditMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to innovation credit.",
        "label": "Innovation credit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedLabel": "Interest paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_InterestPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payable",
        "terseLabel": "Accrued interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest recognised as a liability."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "terseLabel": "Interest received"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeDomain",
     "presentation": [
      "http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in equity instruments designated at fair value through other comprehensive income [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Investments in equity instruments designated at fair value through other comprehensive income' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis",
     "presentation": [
      "http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in equity instruments designated at fair value through other comprehensive income [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "prqr_InvestmentsInFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "InvestmentsInFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in financial assets",
        "label": "Investments in Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital",
        "terseLabel": "Share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "prqr_LeaseCurrentExtensionPeriodUnderOption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "LeaseCurrentExtensionPeriodUnderOption",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, current extension period under option",
        "label": "Lease, current extension period under option"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_LeaseExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "LeaseExtensionTerm",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease extension term",
        "label": "Lease extension term"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_LeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "LeaseTerm",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease term",
        "label": "Lease term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r60",
      "r63",
      "r93",
      "r94",
      "r115"
     ]
    },
    "ifrs-full_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_MaximumGrantReceivableForAdditionalPhaseOfProject": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "MaximumGrantReceivableForAdditionalPhaseOfProject",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum grant receivable for additional phase of the project.",
        "label": "Maximum grant receivable for additional phase of the project"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_MaximumGrantReceivableForInitialPhaseOfProject": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "MaximumGrantReceivableForInitialPhaseOfProject",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum grant receivable for the initial phase of the project.",
        "label": "Maximum grant receivable for the initial phase of the project"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_MaximumOfferingPriceInShelfRegistrationStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "MaximumOfferingPriceInShelfRegistrationStatement",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum offering price in shelf registration statement",
        "label": "Maximum offering price in shelf registration statement"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_MilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "MilestonePaymentsMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents milestone payments.",
        "label": "Milestone payments [Member]",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_NetProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "NetProceedsFromIssuingShares",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from issuing shares",
        "label": "Net proceeds from issuing shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r33",
      "r116",
      "r143"
     ]
    },
    "ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureDeferredIncomeDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current deferred income including non-current contract liabilities",
        "terseLabel": "Deferred income",
        "verboseLabel": "Non-current deferred income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current deferred income including non-current contract liabilities. [Refer: Deferred income including contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r169"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r117",
      "r143"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "prqr_NumberOfPerformanceObligationsInCollaborationAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "NumberOfPerformanceObligationsInCollaborationAgreement",
     "presentation": [
      "http://www.proqr.com/role/DisclosureRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of performance obligations in collaboration agreement",
        "label": "Number of performance obligations in collaboration agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares authorised",
        "terseLabel": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r95",
      "r120"
     ]
    },
    "prqr_NumberOfSharesCallableForOptionsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "NumberOfSharesCallableForOptionsIssued",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares callable for options issued.",
        "label": "Number of shares callable for options issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.proqr.com/role/DisclosureRevenueDetails",
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "terseLabel": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued and fully paid",
        "terseLabel": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r96",
      "r121"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r98",
      "r123"
     ]
    },
    "prqr_October2024UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "October2024UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents the October 2024 underwritten public offering.",
        "label": "October 2024 underwritten public offering [Member]",
        "terseLabel": "October 2024 underwritten public offering"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails",
      "http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents the office and laboratory facilities at Zernikedreef in Leiden, the Netherlands.",
        "label": "Office and laboratory facilities at Zernikedreef in Leiden, the Netherlands [Member]",
        "terseLabel": "Office and laboratory facilities at Zernikedreef in Leiden, the Netherlands"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_OfficeAndLaboratoryFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "OfficeAndLaboratoryFacilityMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for office and laboratory space.",
        "label": "Office and Laboratory Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense",
        "negatedTotalLabel": "Total operating costs"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary",
        "terseLabel": "Ordinary"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "verboseLabel": "Other comprehensive income"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r107",
      "r128",
      "r133"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Other comprehensive income (foreign exchange differences on foreign operation)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r133"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureOtherCurrentLiabiltiesDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "prqr_OtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "OtherCurrentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current liabilities.",
        "label": "Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.proqr.com/role/DisclosureOtherIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureOtherIncomeDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income.",
        "totalLabel": "Total other income",
        "verboseLabel": "Other income"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r150",
      "r151"
     ]
    },
    "prqr_OtherIncomeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "OtherIncomeLineItems",
     "presentation": [
      "http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Income [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_OtherIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "OtherIncomeTable",
     "presentation": [
      "http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of other income.",
        "label": "Other Income [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails": {
       "parentTag": "prqr_PrepaymentsAndOtherReceivables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables.",
        "terseLabel": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r153"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r97",
      "r122"
     ]
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedLabel": "Repayment of lease liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission payable for gross proceeds from sales agreement",
        "label": "Percentage of commission payable for gross proceeds from sales agreement"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_PhoenicisTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "PhoenicisTherapeuticsIncMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Phoenicis Therapeutics Inc.",
        "label": "Phoenicis Therapeutics Inc. [Member]",
        "terseLabel": "Phoenicis Therapeutics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_PontifaxAndKreosWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "PontifaxAndKreosWarrantsMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents the Pontifax and Kreos warrants.",
        "label": "Pontifax and Kreos warrants [Member]",
        "terseLabel": "Pontifax and Kreos warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PreferenceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PreferenceSharesMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred",
        "terseLabel": "Preferred"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_Prepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Prepayments",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails": {
       "parentTag": "prqr_PrepaymentsAndOtherReceivables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r153"
     ]
    },
    "prqr_PrepaymentsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "PrepaymentsAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered and other receivables.",
        "label": "Prepayments and other receivables",
        "totalLabel": "Total Prepayments and Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_PrepaymentsAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "PrepaymentsAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Prepayments and Other Receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "verboseLabel": "Proceeds from exercise of share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureRevenueDetails",
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Proceeds from issuance of shares, net of transaction costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities",
        "terseLabel": "Decrease in financial asset - current"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://www.proqr.com/role/DisclosureRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r144",
      "r148"
     ]
    },
    "ifrs-full_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.proqr.com/role/DisclosureRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and services [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r144",
      "r148"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.proqr.com/role/StatementConsolidatedStatementOfProfitOrLossAndComprehensiveIncomeCalc2Imported": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Result for the period",
        "totalLabel": "Result for the period",
        "verboseLabel": "Net result"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r28",
      "r30",
      "r60",
      "r61",
      "r84",
      "r87",
      "r106",
      "r127",
      "r143",
      "r145"
     ]
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to [abstract]",
        "terseLabel": "Result attributable to"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementConsolidatedStatementOfProfitOrLossAndComprehensiveIncomeCalc2Imported": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to owners of parent",
        "terseLabel": "Owners of the Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Result before corporate income taxes"
       }
      }
     },
     "auth_ref": [
      "r54",
      "r146",
      "r147",
      "r150",
      "r151"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating result"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r171"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment including right-of-use assets",
        "periodEndLabel": "Carrying amount at end of period",
        "periodStartLabel": "Carrying amount at beginning of period",
        "terseLabel": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r155",
      "r166"
     ]
    },
    "prqr_ProportionOfOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProportionOfOwnershipInterest",
     "presentation": [
      "http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The proportion of ownership interest that the entity holds in another entity.",
        "label": "Proportion of ownership interest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r31"
     ]
    },
    "prqr_ProqrTherapeuticsHoldingB.v.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProqrTherapeuticsHoldingB.v.Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics Holding B.V. [Member]",
        "label": "ProQR Therapeutics Holding B.V. [Member]",
        "terseLabel": "ProQR Therapeutics Holding B.V."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ProqrTherapeuticsIB.v.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProqrTherapeuticsIB.v.Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics I B.V. [Member]",
        "label": "ProQR Therapeutics I B.V. [Member]",
        "terseLabel": "ProQR Therapeutics I B.V."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ProqrTherapeuticsIInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProqrTherapeuticsIInc.Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics I Inc. [Member]",
        "label": "ProQR Therapeutics I Inc. [Member]",
        "terseLabel": "ProQR Therapeutics I Inc."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ProqrTherapeuticsIiB.v.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProqrTherapeuticsIiB.v.Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics II B.V. [Member]",
        "label": "ProQR Therapeutics II B.V. [Member]",
        "terseLabel": "ProQR Therapeutics II B.V."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ProqrTherapeuticsIiiB.v.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProqrTherapeuticsIiiB.v.Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics III B.V. [Member]",
        "label": "ProQR Therapeutics III B.V. [Member]",
        "terseLabel": "ProQR Therapeutics III B.V."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ProqrTherapeuticsIvB.v.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProqrTherapeuticsIvB.v.Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics IV B.V. [Member]",
        "label": "ProQR Therapeutics IV B.V. [Member]",
        "terseLabel": "ProQR Therapeutics IV B.V."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ProqrTherapeuticsIxB.v.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProqrTherapeuticsIxB.v.Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics IX B.V. [Member]",
        "label": "ProQR Therapeutics IX B.V. [Member]",
        "terseLabel": "ProQR Therapeutics IX B.V."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ProqrTherapeuticsVB.v.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProqrTherapeuticsVB.v.Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics V B.V. [member]",
        "label": "ProQR Therapeutics V B.V. [Member]",
        "terseLabel": "ProQR Therapeutics V B.V."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ProqrTherapeuticsViB.v.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProqrTherapeuticsViB.v.Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics VI B.V. [Member]",
        "label": "ProQR Therapeutics VI B.V. [Member]",
        "terseLabel": "ProQR Therapeutics VI B.V."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ProqrTherapeuticsViiB.v.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProqrTherapeuticsViiB.v.Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics VII B.V. [Member]",
        "label": "ProQR Therapeutics VII B.V. [Member]",
        "terseLabel": "ProQR Therapeutics VII B.V."
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ProqrTherapeuticsViiiB.v.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ProqrTherapeuticsViiiB.v.Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics VIII B.V. [Member]",
        "label": "ProQR Therapeutics VIII B.V. [Member]",
        "terseLabel": "ProQR Therapeutics VIII B.V."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of financial instruments, classified as investing activities",
        "negatedLabel": "Increase in financial asset - current"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "prqr_PurchasePriceCapSharePurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "PurchasePriceCapSharePurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price cap, share purchase agreement.",
        "label": "Purchase price cap, share purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReceiptsFromSalesOfGoodsAndRenderingOfServices",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails",
      "http://www.proqr.com/role/DisclosureRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receipts from sales of goods and rendering of services",
        "terseLabel": "Milestone payments received",
        "verboseLabel": "Receipts"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of goods and rendering of services."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of borrowings, classified as financing activities",
        "terseLabel": "Repayment of borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "prqr_ResearchAndDevelopmentCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ResearchAndDevelopmentCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development costs",
        "label": "Research and Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureResearchAndDevelopmentCostsDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development costs",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r85"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Translation Reserve",
        "terseLabel": "Translation Reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r82",
      "r152"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Settled Employee Benefit Reserve",
        "terseLabel": "Equity Settled Employee Benefit Reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "terseLabel": "Accumulated Deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r152"
     ]
    },
    "prqr_RettSyndromeResearchTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "RettSyndromeResearchTrustMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureDeferredIncomeDetails",
      "http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rett Syndrome Research Trust [Member]",
        "label": "Rett Syndrome Research Trust [Member]",
        "terseLabel": "Rett Syndrome Research Trust"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Revenue"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r65"
     ]
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureLeaseLiabilitiesDetails",
      "http://www.proqr.com/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "terseLabel": "Right-of-use asset"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r66"
     ]
    },
    "prqr_ScheduleOfDeferredIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ScheduleOfDeferredIncomeTableTextBlock",
     "presentation": [
      "http://www.proqr.com/role/DisclosureDeferredIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of deferred income.",
        "label": "Schedule of Deferred Income [Table Text Block]",
        "terseLabel": "Summary of deferred income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Premium",
        "terseLabel": "Share Premium"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "SharePurchaseAgreementWithEliLillyAndCompanyMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents the share purchase agreement with Eli Lilly and Company.",
        "label": "Share purchase agreement with Eli Lilly and Company [Member]",
        "terseLabel": "Share purchase agreement with Eli Lilly and Company"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquityShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares in entity held by entity or by its subsidiaries or associates",
        "terseLabel": "Treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Total for all associates [member]; Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r72",
      "r99",
      "r124"
     ]
    },
    "prqr_SharesOptionsLapsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "SharesOptionsLapsed",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share options lapsing",
        "label": "Shares Options Lapsed",
        "terseLabel": "Share options lapsed"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ShelfRegistrationStatement2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ShelfRegistrationStatement2024Member",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents the 2024 shelf registration statement.",
        "label": "Shelf registration statement, 2024 [Member]",
        "terseLabel": "2024 shelf registration statement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r14",
      "r40",
      "r92"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesDomain",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r14",
      "r40",
      "r92"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Condensed Consolidated Statement of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Condensed Consolidated Statement of Changes in Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Consolidated Statement of Changes in Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.proqr.com/role/DisclosureGeneralInformationRevisionOfComparativeFiguresDetails",
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Condensed Consolidated Statement of Financial Position"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "prqr_TreasurySharesTransferred": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "TreasurySharesTransferred",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares transferred during the period.",
        "label": "Treasury Shares Transferred",
        "negatedLabel": "Treasury shares transferred (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureShareholdersEquitySaleOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents the underwriters' option in connection to the October 2024 underwritten public offering.",
        "label": "Underwriters' option in connection to October 2024 underwritten public offering [Member]",
        "terseLabel": "Underwriters' option in connection to October 2024 underwritten public offering"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_ValueOfMilestonesReachedDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "ValueOfMilestonesReachedDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.proqr.com/role/DisclosureRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of milestones reached during the period.",
        "label": "Value of milestones reached during the period"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_WarrantsEconomicLifetime": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "WarrantsEconomicLifetime",
     "presentation": [
      "http://www.proqr.com/role/DisclosureBorrowingsDetails",
      "http://www.proqr.com/role/DisclosureOtherIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, economic lifetime",
        "label": "Warrants, economic lifetime",
        "terseLabel": "Warrants, economic lifetime"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted average number of shares outstanding (basic)"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract",
     "presentation": [
      "http://www.proqr.com/role/StatementUnauditedCondensedConsolidatedStatementOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average ordinary shares and adjusted weighted average ordinary shares [abstract]",
        "terseLabel": "Share information"
       }
      }
     },
     "auth_ref": []
    },
    "prqr_YarrowBiotechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.proqr.com/20250930",
     "localname": "YarrowBiotechnologyMember",
     "presentation": [
      "http://www.proqr.com/role/DisclosureInvestmentsInFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yarrow Biotechnology.",
        "label": "Yarrow Biotechnology, Inc"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2025-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2025-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2025-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2025-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2025-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2025-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "169",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "176",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "178",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_178&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "192",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "218",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "266",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "43",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "56",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_56_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_ii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_vi&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2026-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "11A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-b&anchor=para_11A_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_r&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "14",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2025-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard",
   "URIDate": "2025-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001104659-25-107349-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-107349-xbrl.zip
M4$L#!!0    (  <X9EM(&Z?UM!$  -N^   1    <')Q<BTR,#(U,#DS,"YX
M<V3M75]SV[@1?[^9?@?6+[W.G"S+3G(73Y(;6[93MW:DL97<M2\9F 0E7"A
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M]U--9 DS+\>M0^D!=L<,T2D6Y_3T:PS=NK7U46!CQ??@H39(4IE'J)=4URE
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M='L2H8P(Z1AHUB G!EV#-J.=%8T1,SKW.A2V82P;,G4,=551]2 &%!%E.54
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M[[)A&J?*@)W+?+;WIXRUX6EP8Y"AL1;S#9S;)-I>DWGVAJ#-&T"3Z'$#:<*
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M9[2*5UGTN*'(@U,LMW>11]?',>!Z<$..N\Z=W; 5+^L(+#@S9+5"87(M1_K
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M(>]06J2:QS[I_*X%QKY3LAW9BA79-,AG_'22:FBSV/_Y_P%02P,$%     @
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M/LC&^3IH-:XJ2\][\'=Z>UV.BEPKA)J]KV2= B0?:Z]>J<LOA$WUUJT4A1?
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M6.!TX?OQ,>+G[N[BD/CJ VQZ-0 SF1[:@KZZBP/G+$WE;7ME]-Z;EGE&QO-
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M*%H1'OA_CL&V[75H0'Y5ZLZ5Q4);GLH@QV&Z?F$F;TE>9F$IM;,9"%N*S]E
M<A,O5)8J_EXT+?-@%.X((3Z8R5B+Y:GV(R-:-_P[JT%G'3W<IX??U74@<XBF
MYH,.N_-.+OZHM-#<0@$T*+>;Q'0HUI$"W16LK-(1X_:)@.PH=D#<#+'J ]3
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M*:><7SCN[EGE_.!'I*J5(4FM%DM/+4C5Q+1:+B6UJ>ZP7ZX@T=#RL1I2SR2
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M&7[']+S84BQB?3Z%^1B26Q*&;V+JLC]X4<>C1%92  \?]E:I+):;B@ ^& P
M- +GRZN*ATP=Y.7ZR&DNTP@)E;+IK5!JZJ7UR<WU8&Z365?>EV @=TS[R7LE
M^^,^'UCN*/'Q*E(O![79S$(&8):UM4C!L:8"@#.L-1Q;?\@:+(.U V\2B5-F
MV@N!X]+H,FTR@";N,#,=ZR1;GF(DWN])(G*E>V\\_^E-3'^D<9+<T=C'.$AN
MF#/Q0Q))P9]M-APN$C").+)7P2D#Y0&G&%?HK&\<%NV+5#^%!N@@51 /5VZY
M$OS!+:$%XC^V.(R8E"/VI!STA1K-W=E&P<J*.\0ZY0'3BPY2U8''6F'@Q*"E
M^H .G$W8LE1"%/N8/.- ]%SL^;OLZZQ[BY&5'_G+KD*P0DD<!GP0%G,_\1T;
M@Z/$$VLGLQYX=&NJU<W]@SSWN,[//8H&^%T(>0]BIJL/H_4-@6[(_7,%1UT?
M99"VWIPN!+:A["D/F*-TD!8<U548.$=IJ6Z=A# 3SCFH;4-A4HJ!A'2 "]:O
MM%]Y89A%3!))>QHOLYJ W=(,?>&@>M6 NZHA"&=7JOVL)1%8R.Z<7ZB<-D@
M: !8F1W8](GWH(291-A(&.0J3E)UZH;.*C")P 1O,S&1JCSD[ H:6MLG*Y*B
M1<^6TP71K]F,@8EW.&CAM#J7YPA(M)5^W.KIW>5A]DMMI.6PU%$8^F"DH[HU
M ^.TL>I"I/SV/!4CCSJ D Y9 \]VZ,3<\,H[M&\5MB[5Z=8$[)9FZ,N%:ZUJ
MP%W5$(3U6))O <O-'=\[G"E/%$P;-P(T *RXL9J"G[_YG8A3 E% 1*B;!=P<
M9) %#!>4,AL))/KO5MI*ADDK(UA/_>2%E5C(,:T[<&X>R."/TB?BC(I?:%',
M ,^%(GQG2!QL\4I58#ZA>9&FE#P=Y6+7Q]<#CA*<7+Y]]E*&]C%^W&%";XZ1
M6.;O?%G30A!T9[6U3=TW3:5 =D5K+/:7Z8H&N8OAK$F>)B<2C68GRPE%FZQ=
MD ]ZFABNYYU/*U%?DJMUO0IJ+N=+<3='>5^L',[^>=&N\PTX9 6W/^*(7Y1E
M8_Y%L"=1=O;K&>?F4!^*MQ$"TT^&V:1^/,)$ O#)JCV> 9OE>YX/<$,B+_)Y
M6JCR!CR;PPEOP)'/CRXGB5B9D>J=H:U44(2-7DW%W,=F.$0QJ>W$R8H?U69H
M6T:>ZG#%I(8PM,% &KW'"684LV.HKO$S#N,#[ZT9I&[RU*L*G#(-\->(4J/>
M NC1!,68I$@B]+(C_DZ<'Z/X$%.>7V_C^3S;RU-\Y$?2I*;"+8)2UYP>T<YC
M#O*$<91E[)MZ1WDJ<]ZK#&%+#D 7 V^-7K4=(ATF0XUD17<+@[=+>R9W.,"9
M%PA#Y0.[,_MYQG!\3U,^A9O@- VSUS"KUGTL#P4GJ^@73OD_QG&0K.D#IL_$
MQXQ"Y='C:Q)\CM-_/WHAV;S=Q)1]'F\C8:R+Y")A#:B)839UH#/)O+]3G7KF
MT04R5\UL$5MRR]261PZP4/P\T[R5TBH7 Y(R\-MR .(F00:AO(00D$"D7?Y=
MPA 'C&@)!'D)?W<%3SP[7/[OUO)3H=I/!2R:O*-Q<&0S C:$Y_;JW')2EX?.
MTSU(&R<1VPM#9KH^E>VGFE*N"*X*(H&XX=-B@9Y]G:X:"^S/7;LTRN(+Z]..
M]EP4O=KYKLHG$N(DC2.<'^55+_^IB\+LBCKXRK05[>6 +^?U:>TXR<\^;ZX(
M%J9=;AL+[J<37#/FX)D.I,-[G23Q^27B=20N%^17;-K@J8L"9I$>?.5%SO9R
MP%FD3VOK<P/R8GF\8;,YV0+BR_[Y2VKRA/JT##(6U.L*P.*IN(?1+AMT,\@4
M(&OO(CI\*B.0:Z->>,7FRR3 \EKL8WR)\VGR:G/%E<#TX-'T[>,KICY)<'81
M]S%F$W,6,MVQ[R)FI!TYM%EHG&8 $]B(=BV?S7#?!G#B'!.Q->D6.O&=AE(I
M?D;K"9<+;(2G]2@U0SA7+<^$RLICH1TZE.I-^U#&?W?S.KCF?X>I>$B2T</Z
M*21;+UN(O(KYG>18*M]Y?<M:$F Z'&:=D[0 9F* D]I 4,-OS1_*AE%<MBQ3
M,U?:GBGSV/+M,_,RJ.#N0UIF95MOQ([(113<8Y[[A$1;%K-F:U[*M3=C,3#Y
M:*A=ZJNH9C(@+ZU:(K$_826;JR;I8[XF=RCY*$WS1L74-6MVILW'B6W3LCR6
MQSEC&. 9TZ<8F GRYMP%:#][(9^:%[9-[GG.O?HC]FW#CV8]F&1GC+P(M70J
M 0^LC"#8=E31"*>H8JV>.ZMH!P6B(7'<]B!:FW;M#1Y^UZ?JGW%T%$="?J1>
M=')6K;,@8'_MQ-8X']\H!=PCNW6V'RN$1(0]&K7U.AEB1'%T3G&>+3@1V<W1
MGO77-^2]>#003\VSR"-[FY[_P_<H?4/\8+R'D@/VR8;X/#?$(>:I(42BX6?"
M*[*9P)9C*6< $R^SCV-8<5LHMRZ7BZ3@>2X(N<<GQ/";#/'>8<[5->MY="6$
MMN7:4)4!3$@J1.5#G(T"P&E(J:Z;H^<D$LL%<DE W*OAEQ$9T_! GGT?\^:S
M;C?Q0YJN@0N!2$I$OS[:YM;H]Z1;Q465KG++\*@39&U>=0OC&HB)9YVJ;-O)
M;HL;&>79F,I%M\S627$EC0_''A*)7MZCQQTK7Y;AQV^/B1SK ^FU^5TX$1?4
M?#=)8M8"OR0GWD:29\&R8SH)"C#30;;&I^HQ17O^F)3WRB+@[*E%J<-<+N[N
M%ZB[N?@]5K8W9+I?AA)#LMQLRG+%KOB);"^\X_FXUIL[&O\=^UWO0NE+ ,P/
M=M9HO@FE61TXIUB"&?KVD0SH:=&@N!'!G9K(9M%!9(CC5\WX3$.V/O'QO 59
M9@*F*+>*!Y!%AY E\D6?3?HI0R5AJ:S1BV<4]_#*8PR >0.D;=R>FLWO*:^B
M9YRDO NMHIL\EA27OBZBX$<6YZTC5OP0)UZXWESDD:!R0N].-&"6<6R_VBE>
M!W*!,Y)KE+:^^,#7YH_,][+Y#U\LK4Y[* [%G(?-84BA)I_EE%,N<1-4[-)N
M/3']X;*$MMQWBWG3]$>-(=BWOABTJIFPT 5=%";\,3/A=<6$A4H#%E5&/%%2
M@DI6D;SBNHJ2E!ZS^Q,>1Q]<I#<>H6*#Z'%'X^-V)^:1_%%ABG<X2L@SEG/*
MSANF(S4&DV>GL7']#,L8+4$^Z3(J7NN]EE(I3A3RBC_[J] +!3@AVTA0LY>B
M#5,./8O-UU2JEZTK^U4%LU5FD+=SNW^&ZP*M_@_1<[EWQ :732;#;6U"*/:M
M+9=4'& &2BS.+TC?[6(<$9\DCZQ1[X"/*?&927WU/>G>&C"]TP!M^;Y)9W'@
M$R!-Y5W<H4Y2%EG+5[**5E&U6;Z9,?&C)N.B[X YX]WJ^4"[(Z3_]"B-7RY)
MG&)_%\5AO'U3<U%78< TU(NQ8"!E2>#DTZ^W;2>4DE%-]+34,BVV,^Y?D!9E
M;[O.AK@5#]B%1["CPP7:VX4<8!D#J=-S+__-EF3=6=/QLNSMH#2QJKD/C?E)
M)/'4R/HENZ.\XI>:F;*M\55/!<!\I86UG/ATE0;.*7JZVT][Q$YIUH(X7YJW
MP;JV;(3-Y+U4[*EFA]MW<1B(Y0 ODI-[^?G$,Z)1[7+78Q-8BZ%U1DST5XF4
M"U)#),*D#8?6JJ]76HN#O" Y')2MY]W4@Y+$>%41EFM>'2D5KUB^WA+OB80D
M)1VWY%6EH;M4)\JZN[06A>P*W0K;=O-,*F*=#(6EW$KG_?.'4A\6+_[VUW_(
M/\F$_/7_ U!+ P04    "  '.&9;Z6UN9Q$L  #N*P, %0   '!R<7(M,C R
M-3 Y,S!?<')E+GAM;.U=7W/;.))_OZK[#KS<P^Y5G1,[CI-X:F:W_'=6NXZE
ML[V3NWM)T20D88<&M2 EV_?I#P IB9( $B!!L4FZMFKCL8$FNON'1J/1:/S\
MYY>GP%D@&N&0_/+NZ/WA.P<1+_0QF?SR;AZ/#[Z^^_.?_O5??OZW@X/_/K^[
M<?S0FS\A$CL>16Z,?.<9QU/G(9S-7.)\0Y3B('#.*?8GR'&.CMXSBN\/G8.#
M/PD2YV[$NH3$$;0^OC]:_N$BI1:2GUBO#Y\^?#S\>.(<_W3XY:>3K\[HV[+=
M-S:R,2YJ&&#R^T_\_Q[9]QS&(8E^>HGP+^^F<3S[Z<.'Y^?G]\_'[T,Z8=T/
MCS[\][>;>V^*GMP#3*+8)1YZY[#V/T7BES>AY\9"/)GN+X\T6!(X_K#ZEK(%
M_Z^#9;,#_JN#HX\'QT?O7R+_73I$_F>-CRR;\[_BG/897I+V._13&1R=GIY^
M$']]]Z=_<9R?:1B@.S1VQ*]^BE]GZ)=W$7Z:!9R4^-V4HO$O[V;TG_2 R__P
M]/B0,_+OERDZEO^>$?^*Q#A^'9!Q2)^$&-\YG/[?[P8;0YG1\)_TO1<^?>!_
M_:!'2/"E);$/%1F[CQD\^4#^3MRYCQE4+T+B(Q*)'Z(PP#['[ZK9<'R-"1,^
M=H-1&&%MOJU\![)81C0<XWA(;\(H8DH=QE-$+\*G&453U@TOT(!9GR=4D["T
MOPY9A!=3ETQ0-"!7_YRS&5&3J':^ EHD;C2]#L+GJ"YAK.GO3PR7./*",)I3
M]"LBB+J!L1'-)= $(_=X0MCZ[;G,HGM>.&<FG4Q&3. >1GJZTZ;5!'MG?CCC
MPAV.;]$SLR]W:($9J 8D1I0(L;O!RE[?H5E(^9@9SHCO4M]4 )6_UH2(+BA;
MI#PW6*OL*HHQPR3B!OFO<W_"9YRI*+2I-L(R,QYL%/P?;DL7;E"&0P61)A@:
M431S7X5$EXOH'?(0&]1C8#R-BX@UPV X0S1^'05NXGHRB<_X$(UY4])I@JW$
MW9E3RD9P@]U''+!98ZPP)94F6#H/*0V?V7PWY2+;L8F!WR!&L+P2=KLWP<0E
M&K,=/U]RM'UV=>=&_)&IRUS_,/ 1C0R\Z7P"33#"UGY$YJ8J6/5JS!J50LY&
MSV:D'2&7>GQ!OF0B#$)AU"_"R'A9SZ74X%:#C>?,?\($1S%EKN0"E6&N@%83
M[ W( D6Q\#8&9.4<GT41,N8NGU0SS/$I\>"^&"\G&SV;F5$!WW*/7.8M/5"7
M1*['-S#FTTE%I@FFKA;"JQVS_=BY&_!0[/T4H?B2#=&0KUQ*X#;R=6SHF]W8
MYV]2'NSO>QX:W/VL7>-2C.UV;]XU+<6(G$3#KE(I3B3]880Q+U'LXJ"D7R&C
M X,M$8D3D3E^N. F7L\UGK#&D2V6M;X!;FDHQ[T>29CA3'&"4))O8^IPPILE
M&<ZG!6_I+\>F)DU0H<^RG!:1@Q$(C4O;I@):S3IPY5B2](<0(BW'C))*\UYI
M.884-&"$3\5O+MP9CMV@Y%JO1Q,(NVR!&H[%[\NZ-GHT@;#+?S,4A\[VV)71
M;#"$7HZO[<X-[Q(K+&4 S$IF'+<N378VE3G:I03LY* L\(H)@CM'J+0'+B )
M[52A'*]:%!L^8RC+V2X!4T;$6)?<R+Z>[7Z:C("@"3\:N'$?4?"N4 0R6@&E
M&Z1X%O<IS^(^^BR$M/F%RB-]8$LDJG^XV<]4'W/(?+0]C#GSF63,,^8LL<DB
M(F,W[!OIES@M"VGF&4[02XR(C_S5;W',/W'(QGGH'#A+0MD?7>(["56G7 (F
MYY#K)?0VAA+P>PDA+9J[_#<_\A@\>^26U(N7A (NV%_>Z77Y8#(XSFK$>!5\
M1LA[/PD7'WR$Q24._H,8N1@U^X_5H!\8Q:W!;?_YQ^?CKZ=?OGX^^?SE\\G'
MDZ^'G[^LQY8%QQG='"=;.Y>DV8\[>-G42-KBP\SEN_T#;XJ#%1#&-'S2%5HZ
M@%"3CY R=_F7=T?OG'G$AI=D?;K!?H0_0A2'C!D_/6Q4:6&C71?44<Q0JI>/
M>]5+&FJZ9@NJ&_P/\_W4JE$U;;-VC'A*%72\5P4EK-RAB7!027SK/LF4(VO6
M9L5H\Y,JY5,CUFR-FVOVFRC'GFVU;+-J3%A*M7/2H'82PZNGGTS;[FBHB*E4
M1Y\;,&L7;)#B'-I'+W]#KTJ[MM6NS;K19RC5RY>]ZN6,\>,+[ 3N1**/C;^W
M60_%C*3R_RJ7_\\?MC>)57:.=B[JZFPLCP[YQG)%B/V\^J2S^J:3_6BF<3AV
M5M]U2MP0+@U</*:1H!>[+R$)GUX%? \.CP\^?ODPG@?!#]YB_=.!%](?ZR8"
MWN+WHD6>&!7;5[TNY6>F70:3R)Z"%54S*+/91#M\-AOQH]S\,@:3@]";1$I*
M!L3HXTR8:\:65\J,CG!"H2! F2DQ(%XPY_4X[O!D&H=C)H95DKD<)>:DH"#)
M"!DR0%EBO5;0'<$!W6U(O&1#70"I[8:= 8P68\I CR$<,F%KD'!07C*6@T+>
MO#/0,&!/&6@R TA0%1N*Z'_A'>NL?C5ZM%S%93E41J[VK.4Z+4!B"S.2N&:2
M%J>U0D0/4Y>L3G#5AL&$2LO!9)-K9?"M8V['A9;/<=%)AZ.8*V5XKV/>1H'Z
M.Z;W8H7OQ@UM*!S0%C=)^&2K;28=NS#DD=<)"CC*!T",N;.T%5D@^AA*%HG/
MX-"BB0]@B*B@X1R8O,7)5J*(8XH?YS%WLQ["X3-APQZ.1T(?15#)Z0H6/B4!
M8\IJK2 "9UL*@-(Q,.P_LG4*1^$F'@=@1\/RLK)GIP/\OG0=#);45RL*C&]W
M@8>9*E QY+-_!RB;US)7QTWK!A<A$2(W0U49LEU%GC59U&K//D)$IZ$IZSZ6
M-"%2]40'?! N#4>NK_SS$Z_D=R->,%J4EUY);:-J:F[4UIA@MX!F50J6SIW
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M4ST/4-,8\@G=[9POH:E_'PWG<12[A-?)5L)#V:/;B#%CVY(IR0,1H(RZ5E[
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M,GHFJ*XWZ. ":_EL3>:)&UUL2;KV$%ZZ4JCA7D(+EL3M5TPTL;7=K7^XTI*
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MFCNA.9D IP]\5Q,E!U3ON)N"*.NF[NNJE_''JFOKAJJXJCHIVS55!Y:@H?H
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MZU0G;WX]E#C1RR^-!_(Q'LB/XF%B&%G+4OHBUZV4%)&PASR/0#R\$@_DZ_%
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M.=.;V<VR)"1\E#_'_8K7@+_2_VH6)G[#'A01OCBF_0XGMTA]EO 0*P[^5RS
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MO5"BW[S]H7E]"88FZN/^L?P6:Z%^V>YR"[U*C9>MR1;I/W15B7[PN+)&8*D
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MX@0(R^YHPQ<W_08W,//37J<G#,5\)BQZ5.NHM,ZU6X(SYG.DYO:HJ4U.6="
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M\PJE>!9=\$EB9)Y.=\MJ>&K9GS:6O$&H3^<^C]-Y#AG$TEE$&)DU"$0(Q)>
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M@WF"@F^J0:68-RR]PI;2%J5G$2UD7ACGW5+,:^[R_.Z&'Z9PP12N>.JA:S@
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M?\TM0\)S5]ZX.S\'SUR!BNEKG EQE33^9]53>5J:S\:-DL-U T6C.(9JU7K
M[D<'LQ'$+4:\>!X$M/J07'$DUW5R^9]E5XT1ZG,BN_)Y7;?E<=O+Y'N=B%W
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MKQ;L["P]<*KV9ZCG0&MT.P!#L3_DPK%/I>W@)NIQ>5M=<X/<AL]I8Z]E*9J
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M^55PW#T\YV!8'<6+\LSGH/FV'R)07:NNK(.O#T>ZI9QYJ'6\E.Z%J =8ELU
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MH3A$R,].Y!X%X]Y#ZEN*/+U:TWO^J&9&-F5;46.R'VNK<Q\E"<*[BF@B'OX
MXY&/HWG7&B!X]2:GOZ8?]WPA>7BOTUG(\]5Q@9L*M+^CRI?WI+IVOK+>5*I4
M)I++;45,]!,].R=R*R7'_TU9[T-POA; 1T?U(%X]\#VX3K"W)\IW!451+,TI
M%459WG+W%5<ISEA>(BE8OLLQ<8I)Q6GBU0[.UXKBSU#6'U(I&-_7E$C[='"_
M._$6OOM4,55",A):Q?&)37O>&&K&NJW2*PADYM<?.DZGB MB^/8M[B\#\557
MNOPT$)\HD!Y8A:0E6Y0ALI5AH;2B:"47K"Z$X1H=]!U>+1DZRU(%OS6P[052
MQNRO/PQ)QPDVC5&,48Q1_,&"Z$Z!K=V;BQ1#9/OW@=Y*6YU1Y4**N9!J#E9R
M8LP9^I;.]DMFN>(H2#'#*N=DG$MBS8PQC3']1DP+:V4JVQ,UIVN:ZJJV CQ<
M&UW/8:(:N CAZZW6%^Q2.B<$0C>0\E8N%0070GBZ-<W7[?5H)1:,8GN;+*CY
M>VD"$4X2O_ZDR$MZSQC?WQ/?GQ&O/?>1I@_!^V2%^6JAE\R:WLV*;(MKT7EE
MQ2K9,QG?SQY+TKT@W6FF_21AS=.JFB;&^FB K'!82,Z07)R@Z%-GDS"DOQK2
MN+3\TBI[0J4=>NBD>".169NK)==7ZMS':LF?U:ML(<L2*7XL"(LF$_1GY9'@
M<B$0&6 Z,_$T1^%B\2O,+-]T4!\7BV.&^ZYTP@R'BXQP6=M-$A)S'.8XS'%7
M22C,<9CC,,?=)"$QQ]U(<.W:"'E+<:6O+04OR78@NYL8&8]1!)6\C;I17/W]
M@V+A[Z[^)BF))L]2(5HL)NK+"3U0#'FF%EMC=[@=EC^Q_+OHE<;E-<//!*MH
M)[.#KKSA8>J:@>7?))&*IT@BGKYH!AM'[C"@OS2Y]9EH/E]RK'R?$WNT/&,$
MV5LIQ:#.C7R'A\AE?OUAXC3!X:J3:TQ17W75R8]#\8F";Z?I3C,MREF+\KQB
M;RI!D7<7%\IPW^M2-Z&V9FN![<^X_H(N!OD2 C$L^.;H.$>^FN'&,,8P_NDP
M?KWBNU5*%H&2]'L"V\Y-W/:F+?G4A5!==DDM1=\;-9&5]"R1:3!^V5M!5,.*
M;S9.,5@W8U!C4)^YY#O=S+?6*K?01,M?U9M2WMNXPH5.:B5:"=?GE24CJLQJ
M.3+KTP$;0AR6?)-Q&A_JP!#_047??XOPTWW%+5=+M*3^@-ALQ0)7M\NN<:YC
MT\]6?8\3HW8B2$PML:!71WZ+GZ],#47"4-4WE8J3R6.UC:N^KP#3N.K[XFJ;
MI0S7[KGJPNCU5EU=IG/K^OQ"D2V+S,JUUBRHBYM F,WJZJPW(Y%3#,N^.2Z>
M9%]5KM\J/?=Q:/[Z XRIP/3A#L7\J1J;HYL>;Z8 ]]5TW,<+OA\2<#\E9']+
M-^?@)!'F.'Q7TW6RW%6[5)CE,,MAEL,LAUD.LQQFN1]_RV[R\&:TY!EBE45O
M/9[.R[6,V)LE;7G=7R:WN>:' B,-U]%TO^)X+UZ>*PM";YNH9E6BL!!7V75Y
MG6^R38E,HG@E3<<IEL$7Z%X'D*\Z0/DM@ PVKZPX[:5$+)+Z-#\M5\G>]&.Y
MO[?!,)F4J+;>U";&0JNM"MJB89=Y'L&0>0<,<;SR"?_4_:GJ @ZPYJXZ56U/
M7ZHQW0:_JS<35L)!RQ]NZ>*@)>8X[%M=)\M=M6^%60ZS'&8YS'+?F^4NXSC$
MKCF$]+Z"UO&DOB"(%I\4-UL_J#7S5L>K?JSH!KE5V4.OJHB<JI=<W&TF[_?D
MUFHI6DPIG\YFTW(*WDK 1K6N1.KX>"@.-&&\8Q7S$U@.QS9O,+;Y-VK &[E$
M3JUQA&!YJC@*JG1FP89J@'F[&L"!SJ/"3,69 +:!?.1H,=2+(H%.L,7FT1&V
MFXE)X8CG#U>;..*).0X;:M?)<M@WP"R'6>[R+'?]X:=GFR1L.<LM2?TV1=3'
M5K,5Y/W>U/Z8IP'\"E<%K\JIX;^=J>L$D^G1%%#T*Z28=\+YF!&]JIN5YH2A
M3VHC69MP!#-N2F0*M52(I[CC(@N,>8QYK&8PRV&6PRSWLZ*>IXZ<WYYE<X&P
MYYF,D76+61<]KUT65*)0RW>"B=V'%P2FPGO)WFB-X$CH$_;JP#T)W$T8 _5B
M/MP%375=]78.JN.KR7Y$9N<='://Y[^=ZCB;; CB1K<+M&%-[RMMLU'J2F3S
M;_I'S]V%^WL'P;!U=.<!@"=:1]_3\R(E"+V>6"_V3:Z7'O85"TA!#K6.IJDX
MRR8O6Q=PPTC&T69L(']KEL,^&68YS'*8Y3#+89;#+(=9#K/<[;+<CPQV/LMR
M.&[WA%(H6!!SYBA<&C/EN8<#=CA@=\NJX88Y#@>6;I+CL#&"[5_,<ICE;BT1
M]JVK&%%*++I%-;1N*\BX?>F4E-+M3&R.22^)GM I2D$]T2P9O$2F8:$B&4_2
MQ_>YX;.R&-58D6"6^Z8L=\6:Y+(=/5]0'T^U!K$5G,9PH@U%*\>,5RF3V>;N
M)U!KP&:>I]4&QC .AN)@Z'4'0]6UZBHZ/,O]WUBK+7JQI>KY.#J*HZ-7IGR_
M:SUC$;RL[3N*$;X+S!WL:0/=?14J9O1AI)V%'5A/%#MZTO!^RY1*IM%3ZJ:6
M'8E&A>3!DE\J=L0Q:1R3QG[=#V Y[-==DU^')'O#52T]L"*U$C1$F=*E5-4(
M\IMYBRFFZS/Q8[<T/'.6:*=$ZEJD54YX>X7F;%U-U)6YL.C1V^6DL*A,<RNH
M3-A??]@4]O0PJG'8_XJ;%YS"^+,)@?8J(58LMF$9Y<W&K-]G:\FLCRQ'F! X
M<5(0IP,PVK'9B%GNF[+<%6N8S[K@ZP.F8Z+1G4^&9E8C FO!9H;9WKQD-Z$V
M08D"W ;G6K#](],$W[5!Q%N0R0T$)3VMEIM$0MWD$UZ.W63("4(F\T:O[HS)
ME(NSV&=@%?V^4B'W LB9X\\!+^Z1>WUA5<1MG^T.?P=N^TXJ%7/@A3@06W4W
MX;%A%L0LB%D0LR!F0<R"F 6O.+QRF=Q<Z-.=V[/#3'<C,;VKEWL?CE[!-^[(
M25$RDQY]93'PZ,RQJU]_,K(IVXH:D_U86YW[*+T0PIDFXN$/,*[Y?_\=G2VP
M\)44?C70]=<4YIZC\$XXGH6 )R,.G\ZC[PWCGY]MSU]"S'M273M?S7"[.JJ4
MQS33(LK:?5!EW+FJFY._J1E^2 34 OCHJ-K$JP>^!]<)]O9$;?#4+9*U@=OH
M"VVY/=AZ?$MJ<Q.)HE!M,)&*IT@BGB:/;\>+?1>H?]]D !8"[Q(";\WL?;H$
M>'<F,'SWB3S?-*F4E'R@)82-U\DZY;GE]Y(([<RO/TR<)K@+XAS:ZACHG^93
M8J!_(=!/E'&ONQ6KN4P1OF%U>FY?W Z->^=C%Z(_BW-CK%3U+D\W";;=:9>W
MU6F^9#8ASEF <XZ.<ZDT1CI&.D;ZAY'^>FUWSJMV$X-<QA;+*;9;;$QT@TA<
M"/C)FMRKDD'W7I"=H5ANTH13K",%#Z^:2\7IBUKR&/<8]S\.]\):F<KV1,WI
MFJ:ZJJT E]M&MX^8J  PD@+=5;=1Z[3*,T.6@OFVQF17%?5C!7_/2H',ME5M
M#0)?% .R3P3K.9LN=%=0"I $% ,G"VVQ#, RX.RYH_-+@'.?\OJ0"#A9="][
MH^S65!958U--KJ@!W6B-%A\KNM\C_=F36L4IL=HVV-78H$;^J%M>B8DAQR/(
M4\#D3W+Q%'&L^O^#87\+L#_.W5T5[+^%ZE^(0R*G:JXB;/J+Q+(P$ <!=R']
MG'3+A;:Y8?N$2DGK'-5@9YEBJ)^97W^2J3B1(E]3T2AC^5]?'IGJF=!C EF6
MF(8T)^_(]"%'/<'/Z]M('CTPF8P>N&=BXNU)VNM;8/JZ%LB=9WV__G2F:DQ6
M%*#[9'L#A$C,=GS5B\'&4.#K.@#0Q)7-V%QV_9BCQ?PIL(,!%N5@#.37& UP
M=0M"#:P5-H\"/R%!)<./-=V6;04L"DP$_ &YR7=GW^B/,N[?"OKO,?FQ[LU-
M>0.%C_K/NU9RR( ?70KQ$84[UI=__@_\9Z^$3%5VH::=/H$H#5\3V3 $\3\7
ML$1.KGR_6>]:$/KO_SM<UTA6C(GK!/8X$>G9J!'=P8*C_:"073!1$R-7E8V$
MK &<_I;-E;SQ(@)P>S/C][Z3':1/C/N?6/0O7,P1<2UYG3@@861\)$Q5 V*(
M0$[+[F]N*)NB/SJ>#C7;;U>%GO)2A4]_]%RT4[XS_TV1=RRD*O@U6@Y#WJ62
ME]X[9$72Q(-5(\>F+C0>_M6I9T_N*_QY9[X=<F_T)R!>H<*&@C,+;1$@_?;;
M+)]'AJ0?TXED[MY2>T6]:"<3A"S+)/BPP1>$_=&_EP8RYQ2+[UX2F("XUTC9
MO2;*'FJB_%X3M?>:Z'Q"_.7)/2+=9^J6\T_K95'[6#"<PKN,;&(IS:HIC1B3
M4EI-$1+#I@DI+:<8258U-LF,DB1!)G^%( F_L=\TR=&DK.Q-I;SIK+QHS%F(
M=:1]GL?,Z!TJFGS.P6FTZLU6K',OM/B&(':*V7:L=M>]0V;_65[P?R/WOW_.
M][A7(;;?(R3OP![%T![M_9AH[Y4TJQ CF9!D;I26F!1)2%R*I265TRB&&"7'
MG,8^VGO@05627&[4J:\#L4R.K/5\[&[UY@2>M'XZ,JO08E;E2EM!3B^]_'3*
M=)HE./+HF<4Z-QXD&Y6R( >%BNLSC)*? J_L^)F\MNH:B68U(UHBDZ.RZ17;
M*/$2=?S,>K5>LXJL1AO9M;7R1<THSY*\1!\_4]M*DVY]TRF)B7*#R"S["SIQ
MWP0CF:<CYT*.96OY45+LS3KCY#1!-Y,-./+H[?=<(^\E2J6\P9(^W^<6/7J^
M68&1W-.1=#E)<+6.7"7JB?QR4A[9?<V:2,SQ/-L+)6OFC*0EU+5U>C4?LRD7
MO)TYGF=BOO(6@<E20GW1M0B_/!P(<QZ,/)JGV)[+>K:FT )5Z4E:/9<OVS(<
M>33/;;V2%')^82(DQER]G^A)=&[,2TF)>#J2*(T+]"0_+XEEEW-D1UU($[XI
ML<<C2\U)935,;JMBVYTDB\V<+W'@[:GCD=5BC=C0>B,GUCLE/C',2K/)K"EQ
MQR,#=M[?5@I^GEC(I<Q&&<M6=;@"(\FG(W.)F9*9C:8TH3:YM*"-NM0(/?.(
MGB1?[EK-;G%%4$Z-S.JYTFCDPF<>4:GET^:F[J1:QF8PWBKS-44N<TTI?3S/
M5(<>9'MFDA(HE4BT%I(O#S--"4#P:.CZOFBGJ[YDB$'@3RJ][C;06#3T:$VC
M%4N2^67/,%2_5*Q:;,E+B !SY/%3!YF,ZE54;DX4IJU<J\793; %$DD=#V6M
MW%)L3W,545Y27<<3*C6# 4/IXZ%,K9UTE'2.$-J*VDA5>4F>+'@X]&BN[CI%
MMWU-%$76*A*D6VM/[@=HZ!'K%_M35^YH]32A%NQ$8:+1O.^LX-"CO5HU$FS%
M+N7'Q(9*3:Q&R1MQ94"!$XQJ%EG=:R9*33%;KGGYPJ:ICSM@ B<XM;RR:;7J
MI.M$0->,T:(^\@I4$]Y:?S2TGC4+6E>L5 1K7BK/5(88)MJKZ(+[)Q*23R4Z
MPGA0(@K502[!U@WE'C[U!+LX+LD,1;$W$E7#Z+?YM*AV6Z@?V#%GV8-^@6@L
M-F)6'CE6;N/Y(Q/%N(Z&KF:FDYX)R0Y!K1:=A2 G<V/8GY8Y'BJX W94Z2WF
MAMZL<'/7X[;W+'CJ";I6Q[D5ER3LK*!GZ$Q7)=/E3!H-/:* VQ)Z=7;$=H1-
M/R>,<O=FE89MSI+'&YO.]YB>N16' DM;V58FMYD16_34(ZDVF17=9#-1\0@J
M,%<5G9#[[0QXZHF-S2E\A5],JUNQ,+ &]]UJ=S9)3.#0H[F*]L!/6\OE1J"6
M6D%F"U*-DIMPZ-$$S KO%M64G1;D^5!R=:NEE9-@KB<D6R4OUN;%+C$Q5())
M+,K%C;?(@J$G>( L^IN47JZZHKI.Z&)ST/$V0%70)\ =;,;IECKL)8WRLE_(
M3K3<PA" _CG! ]MQ*SO8*';"Z*76F:6<:'0*8%E@Z!%BS6#43M%&6A MTNZF
M9O5Q1N<G<.@1L5J!+AK")-$2%^M$(Y,22<.AP= 3(H/*9KE4H;59":K #J;S
MT8 H W#3)T3&(M\J:ES )H2"6"[*TWM^+ $10Y]@PLY<&Y2K0K,IR)PJK<2Z
M,B@,P01.;(%!-GO.E,LHPJ;4 BR6$PIN#@P]L07U,D_GG>9@2^B31271:7;K
M:A_HX!,P).I^QB\YZZFP26J3=&,S75KM"1QZM*Q&4-"+M4F2$\L#LIH0&*E6
M],!3'W8+19OWL8<P(P$\/W1KYN_=#X>V(W3:(Z\-.@-*Z/,^#A$<)"RB^ #R
M5."K$J:\<0+_MQSXSH.G?Y>FD;/ON[NI[!S#T!A_-=."'L10=RGZI<-C!S[-
MP?,=\$P-6+$[IVCW>V+ERO/?86QE!2CS:G0C"D"A%^^&RB-@/ >^^@E1C>=S
M8Q\-4'TPW47=I5]L*H*WY4NVA:3NDBF\+]>W+W=,$F_+]6T+=<>P>%^N;U\P
M7*YR6S!<KG-?,%RN<ELP7"ZY+Z\W@SCE23[DXG__2T/_VQ7MP0SVH[OB4)+T
M6FHAK[OZ,70';Y6V45H\FO+KE.;.0&?P3OA'5&_XES1G[YCT-1']20&JHL(B
MLS<6GG^@XK0S=54U;,MA@4^GX8]S= /;6;MUA&KV>NC]0YB<YJZ)Z%_$Y#7=
M?@^/GULW7GWW[QM5C]="OIL5#B]KP*]OW/=9\D&UQ["4YYF>7Y=6@-=)SO<R
M];/$?8:(GZ#=, -_C7;[^HO"ST'3\"P25I/G[-%X+FER_-]S">DP!8AERJ\_
M9VUU^>FJ[SL9P%$H%#,E8DKFIS#EF60F9E$L-['<Q$S)?#LWX#OQZJT$N?ZF
MQT5X8A2V@]653T,^,N._U$/]HONB:9;YA]R14C_W]OWZ$P>4^[__ZC]"O]T:
MTS,O7<&'F1XS/69ZS/28Z3'38Z9_.]._Y]ZD:W23/B5;@EH?P$)++Z:YCA5S
MYBJ\&]Z>Q&!KMZ7NZZIWIJC(U;M*;R7CI[I"U\:1?W]3VGO$Q65NY+MR779M
M_/?>(!SF/\Q_F/\P_V'^^\[\]^W-ZK^C64WU8Z[J!:;_@Y(+UX;8'VLQG_OF
M@5S@H@M"I!3L6P=[D'><@X;D@\JH;AEDAR=THI/J-:Q!C70_=HU PW4TW:\X
MGO?R50)E3U:-=%4,G&1*W2X'M<1V):%>1"09)T[?(X U*-:@WPN/S"$>&:G%
M-!.)?*(Q,MAM/9GEVZ6:'7SL@H"WX9%L-LF"T6.R0I9+Y>ZMB>#4NQ"/S*\_
M7)P\<6<GAB.&X_>!(WE2/8(M+"M.>RD1BZ0^S4_+5;(W_0PX6DE^G:]8WLPH
M=X2)MY:H&<%#.+*__M!TG&*/;]?">,1X_'9X?*(>TQ8M9?0%WR5Z^K"J#'.^
MG$U^[!KKM^&Q6VAKN8S=O2?417_!\AFZH-*PT2\'S%4NSB3?HA^QPWV2A_CQ
M+/!\U!L?;MUO['9CM_L1.2\OR#Z'OEBKWKA6Q=R(N1%S(^;&+Z<6YL:WT!?;
MV\_5\%$D]4^L[D]5-Z;;BF.IY[:YK^K\UCD*'TGF>QO:-Q\PN'!^:^XNW-\'
MGFK><1%^B@@^)R(&JZS7-LI\RB'4U5B::6QBP@KP(AT*1O!P] [KTLM5=[]?
M%V#NP]SW;53!A7,Y[U8%\WK>5'+99D%,K(H%A]%=D^[Q0!6PO_XP)-8%&(W7
MK0NP'_4BO7+JW 42 LD>G+O N8O/1^Z-^E0/2=C'VO004,)Z#B_]/:%5[[T,
M,UC[(U9,!(-VO4(NQO)@ N8)'"PV11YI56SC8JWZ_;!Y^?K!O\$FH;2-$55:
MI@36K&>R-:6P[E<A-AF 3>ZX5@)C$V/S&V'STXH)_P:;RT5UJS/=>M;8+)S<
M=KZZG[DMB$W@C5)QU*8,HQ.C\]NC\_*EA7^#SO9T,15*LVS2V*S7]<W&O>^Q
MO168)X?0F2;>@$[LK[_HK[>GLJLF1K*GPB;X%MR)B_CNWR\'2F&'_;I%VQ<Y
M[ A1"% ->8/^>$*RB=/[*I]>;Y;"(ML(ZHO,=L67)Q))H"-_<9),8<,#&QX_
M )V?[;*_"9V<EYI(C$VK0CDE%Y8MRT\.581.Z+)#R8^Q>5W8Q$"\-?_\34#T
M5GVV32RUJJA*0ZO VY4RP:P@$)%_GN*P?WYU4,1J\AOXYV]")T,L;+Z59_M$
MO>NZ]WJVUBQVD)J$!P'CZ=1QVPKLG[_3/\_KMFPK8#)1;7(,,%),#2,FWNTG
MV#_@N%^;\+LY#_[J2]>^R($/(:>&%6Q9Q_-/=>P1D[10GO<,,=L6A-76Z;C+
M#!!])/3?*>XX,(G+V+!9\NV0^=G.^YN0.1WV^GZY4Q46Q4HFN]PJ3IE8060"
MWYUATQB9UX9,#,,;<]W? L,"PXFS+KEPA()T[P?9K)IPDTT(0^"YIZGC\#:&
M(5:0WPZ9G^VVOP69PY:J4,N5-3 "*B=82\.8IPP>(A-Y[4SJ+<8K]MI?]-I;
MJ&6N%W-54_;5<<QW8MK>D3=U&8%:5[V8I<I>X((1LA_39-V-+64S4&/^%!!J
M,HW-43^FF./&3,?#[OXUR<R;<_>O/];Y5?X^P%T7PJX@Z[8'FY^IIZ*=5FHQ
M"7PN,10++7&UKM:;)0.Z_!1R^7$>XHJPB>V9[^+PGX;FLYT)$]VU5W)KJZ)0
MH#M6-]O.E9WD"F(4./\DC9W_JT,IAN2M.?_OA&0_4:='Z_EF)@360&_F1A25
MSO,0DBR Y(D4(88D5IS?#J6?'@AX)TK]MN7G4HE-2; 2G9SNLQ0WGR'%"4OM
MV;>@%(<$7@P)A#&9F"^OOT?Z_H-E]^\HM.>PWX[[&V$%B[D/<]^W]KBN/T#Y
M12Y7:#ITY/7S)R6%62=-,-6"2*CCJFGTY4&/RDXDDD9>%NXQ<'4HO"4=@)VL
M-^/R60=+JSLILYYH&T*VVY[-Z<V<3L&3##3*NJ;?4@]QZP[6#:,6YTN_G]]U
MA3W:?[(.9G^V#L;<>%7<^,,M0LR-F!LQ-[Y WUNWQ2^4[,A.97NB>C'=CJT<
MUP 3CBGR7/=E$]OB5X3PJ[/%;SX"\6FEBT5;<5794W-J^&_1[H5 RX8X.Q%Z
M*#?G7%G,$KX(&&LYJF44==N?2&02W;X2)U+X^N1K N?5J=_;C]M_6O7B&]#Y
M;(1PD&GFN0+%R80^20VT<:-3JO(K"%,&MP3#,/W^.O33LFM_H4,#+U-GVID%
M*U LT=-F3+JS*/(0G#"_1L336(EB=/X$=%X^Q_87Z'2,W'!$MV>RV',7F3:5
M%M2%AU0G3*Y1\11U? /&]\NOO>K3Z^]EI_!W^)W?D/*Z EU\V9O& M@N&#CY
MSEP-V<,#],7._3N)B=W]-PO#L[#N[7O_$'QYTUEY>=>Q1 #"HEW?0_ EYZ(A
MBE*9;9@;0IX,M5F38A(\ ^P7%O4;IN(L<?+FO;-@&ALO/\]XN0F\7CX>\-=X
MY9U[L==34PNQ["2MKLW/Q_?<"N(5=B".4^F31QDQ7*]#X6( 7QC GQ8J^&L
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M"K6)YU@,7@S>;PS>3^O/<!'P%@6G7#6%#4&PY84_X?N)M#;@(7AA]_@T[M>
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M?" 0P_8[P_;3TG9GAFVNR^F,535+HEP9UGN)9,GMC"<0MF$G3Y; P,7 _?[
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MX/G@#Q9DI[M'\F:L+__\'_C/;N:*J<HN%#33)]2FX3(C,4,0_W,!T7N2B.'
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M( ^' :BI#.-?<V=G5:%.3W8H>TU]&\F)OU,-<200/#CVI/1]:&"D!1!&<(?
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M2$@S4'?<XJH 2&K\D:,@CX!&>C(>;9<J U6J ,O10YD"*!>1Q[4W%6]W W8
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M%P,&F@?P LP:VS"F89I ]4:5 O+$51'? !/VQK LW\6*8UC%KSVQ8!Y5CHS
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MC*<)^MDJ0 RSB-.NU>N[89C=8.WMRS"S>CFOU&7N5X+NSF<C4C*V3156 C+
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M91O:A$PDF0P#L?:86R!<<%ER=)/YHRHA3F%'5-.BR>ATLF"=+GL_&ZK20[.
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MIM2WBIN\6LOFB$N6-.A1<M8KU[E D3\"& %M;S&=?B!,TTO B@2/,*AKT,_
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M*FX'J4ZNO<YV^NG6]+PD2X9,,1,?(P8R/^AD%P$&P[V/J6LP\G8H'JHJ.@>
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M+#8?S--@T%)%9IVH3#MI)GQ(W>\Y!X";"H\"%"%!J*< H=@945<47 I!N8C
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M6:E<>]5&PVT$CT04 7.:0-N33KQLM&"248&OB@PU7*A.#H_,)ECC/QW?/17
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M*_BSH12'% 8$=\[[*5: 6QW1- I<T4)RMWZN<5>#@&]#QD'#B A>".".FP1
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MQV+#@ES-/E751[@33229,%,=DHDB8'>D%3K]Y-#05 .@0Z9 V\A!P@.?/Y7
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M.?PW\5W1%/ <ZA*"-W+(.1GZ-EK@KOC0)=WKR^2A:$U).PM\,?2B.BK#P1/
M_%N@<S<#>/<@^;3 1+!=/XP[N,>=2N@]L'#<0]_<WLWM'8WY#FMDG_M ;^P3
MW#$@/A!%TXASQ*E9TW*11;E C:P(W&I;;=> Y7Z/^M.OIC?\8V9R'AUX*CZ@
M0NK#25"Z5QP4.22GR"W!!T,-A+\ZNUXMTSLJ0Y8D.*CJ>"&PJTF0:>A9V/1)
M.(R=0Q+!^T+EG^+GX3]!^P!Y#!T_C\P1J@DV3+A+<^].L&80 7A;M<ENURL<
M#M85XVHV9#ITGK<-N%PW^+6AT3#0:T(B<::I\V3XMF_B_7??3X1+9@ P"U<P
MFSI41^&."G2A'VMF(Z&U@0(>^!@!EQGA!WG]=*X+P1V(G$K6K6L* 3GWW<45
M47 G):]0#9^JN//: E_ <\D#?]JU >+5!$GBGGI@CZXXB*IN>R!:[25;X)L!
M_AX#7/7:#_;3-+[$F[X2H+9IRH+DB%"VVX -Y6YA0P4'UEQWHS<HLWBBN7ET
MM/%!N+@+0EW)7?@P].AZ'$=0<]W&O=5XEB6Q_IRQTW\R7]U[L+#W)0-9?O=:
M]#T%QDOD.22T$OSX[Q7E.'Y(P+BL(1G)J\GYY="9#";!'-H5S%0<WWO!JU]<
M><O*W0R$&Z&]X/[11E$XYNA?<?!D-]']'TY=_%,,; F15X0B(+MX>6[B#CT3
M'QR@#]T-D+\Y),$6:A SR9 (L(&!()IPBU>&LRFFC:OV15L)"+B[KW7- EX1
M"OWP"OQ]9R!W^)+%TOSF+-\1!WNX<-.F+FED1PK%9!<M'*6:6VL07 ,_E\#*
M38<>Q&'P/222^-Q%$!?LX6\:?)D:O)O5\2Q(O4)U/%$-C[WZ#]?"FQ)^7W[_
MZ!XN\CSA2:+37>I10OU@>_A5Y+LH2%=0I$W2%J]O$(,*<30 #.8O=_TU?Y*+
MW<@Y$,2[7<LOZ"+I;M/1AWB]P%P@Z/(5626E(.]'MJ1P\:22[A6=N>3P^X5"
MEI?#[^(N%'K_:/+G>S,2504S!#A[@6_\(>#Q,[9*?/U1S_L&NN"3GB&GH.IZ
MOXC6[!+:!AO?CI[K%%=5D&K<K^OT2)*:CE7LEV293!CXF=W?7\_&4RI./\S'
M6:R>F$_R@):EIZ5-C\MQ3B\B>)=(.A-*^X1[N/9L;-AN>@1T/X%,QM%I$0';
MC>F+AT5PN\2,\!&3\L9 RUMQZZVX]5;<>B'%K?%;<>NMN/4\Q:VH7/70^G/D
MF_R$+A1FZ>E\-F.A!\E$>Z-.U^RL42SP!]$R_\I1,EZHS):]J6P_C8I\QYPU
ME&@.M4(]O[+Q.&UTI_'*1.::3CJCMP>JX,PF\<,K9VI9:B_'96?0VZ9CXWBA
MSVVE-;PR\?S*EM:H\#V04.C4.%N6AC5%; YFD\3A/>/*)O%8$WO,H%6/)W-Z
MDYTR? Y>>7#/?JO>,?ITO\@6'KG<8AQOLL-99Y*:T.Z57SKTN86:E%H>XA&9
MBW5L O1Z76[E^A5G)<?4H3K/*T^R,%E_TTSGL <X)^XH3 >*O+\_Q?E,G/!;
M<?>80)Z-?4\?/B:OZ+Q\C!/1IZ4Y*282ALSQL^VC9$R;$NH(#ID3Q,WN##I]
M]][HB7Y_]'1"VHHL"D48[H*0X>*)@]Z/9^A=CL8-9@ZR49QMZ<_"$LOPUN%)
MFIN&\E,ZS[)%)$[U(C3Z+I7];Y \SQ)  >,;N#_*DHB*OO:(Y/T>13FG7R0>
M1)6$;\9A@2R<?RDWA8[4ML 7Q%]0.)*O9"P^$50_SZN]P(2]A!T.X]R7OLLF
M;VRY/+;$[C(W=;E OMPE8S>V7!Y;8G=9YL:7<_$%GPKL'S>]P]?O,CR__B/B
M_[D9&G*,L-A0>!]+>1ONE[GW#31[]?@I<RP(?R]Q0W#7UTI9-\'B+OF$8[Y/
MT!D^$WWX__^(__%!FL?2=_'$)1$]LY\#X3%@R^M<^,BNKWF0T_;W?6>Q"EZY
MRHZ2B13ZYV+$]RH-PZ40[X?J_C<([1>I_[,#+'*V':<CWB'WUYH"]W#HO%0-
MG8;$8K[;AOP.5B/[;CJ?8#'VJ4XD]/#?^S+[V;WY[V@34.XV+"KBG?0%.ZR+
M]O9DO_N;BF#BQSF?'R295Q*'QE+HGU/B4%(6X2*#?I66G^IHOB1,>JT.(W:7
M.""_]!':!ZF-:8N*\KS*L-_" 9TJJ9EOE=13_='O)ZDW/W549&]NZ?T]#[^M
MV[EBP;MP+W-)M+I +_+=Q'S;:>!^K(OU&&^FU4Z/>/[XMVQP9#8-KD6[^8B;
MC_AHP'>)S3TOU49^K$,'(8MU2<,*P@_ JK/#"(C_X57=9E2#S^F+06'0DM?Q
M\JI1+C!]5'4;^^/?!*J$?]:.0]U\Y,U'7KGB)8**EYADU?@D+RUS0WHDC1O\
MN&AQA>2'H83>JWASJ<!P9K$]'(P>VYEM<UK.MWLSJ'@)!*B0>(?BG25&N$/,
M<B4H%N,2V>E-'4^OQ_D1U SC*/[,8<:7TO<M>Q</Y:#C2H..71=-H&GCB-F[
M3SAY<V#D>;;77CW-M*ULE.W9)/U*O''><\?KT=@/)X8O]YSR6O3W!-)_J3:?
M*Y)YKS8K':GX5!JGABRDQJ81R_:2@KR&VOQR$'-PA.N-'7F.]Q2*<KW2(O<Q
MA[A_PV3RV-"M+VJ*S>[+<YC8\C5.0_"1>'1!8G\:"C[?QW-VT:"J("*$/WNU
MV^OVR71*4>=M-$];]\:PH9&P!X/*=9$":*8U&BD,7T77;%X!NB6A <0>,#O;
M:IH^,CN9AQE8U0% NP7XN0:5=N;X6.TN=KSW33S[@3<D,KL;S<S4#:H!K+FC
M4(5%F9I*FD P)'0+2!H5\Y?28 OMV!ZN/*\;!AJX R]7;8OSIW-+F%:F=4<-
MCDVEP'3BUM   &&/QO8"3:APCY1.&X#AECR%:W8(\AWCXK8FWC&'I LLJ^=H
M MP!@:X[7;AO0 EUQY'$1":K]C?#*<W)[72\QTWT7N?#>ZX&MY%4F^RU".(=
M,BDEW7"GK;;GG E:8MO0T4SUHX-)VD*LUNLRCUFZ-=>B&;MJ,TD:H2]': *E
M_=D!,RY\JSMH>893F=[D?W^Z$UJG/[>5K)8HTAK/'W&A6]T!)(@5=U0+72V9
M[ATO$*GSN*OZO AMQLR@/J_I#=;>Y+CI.CU-"TKG/-OVH*24TZO$8%.::P-G
MG-S$JJPVKXXP"F(B##EQ.>U/#S/W6K _-'P&6G!DI2Y7-DX><_26;-"6#!YF
MO90@E[=3P9:+]672.E-*)R@;34C.>R;:KPQ242X*,B6G8?9S>&<3AFR\(A>>
M*3EA(A$>8S?E%#Q,SA,[PYUJ7@3NB$CW_L@#0DG"@G0PS^B"(YDB-)KXM8]$
M,ACTU)WRY.'/XB"&!#"Z-^8=ASD^QNI%S'MS/7(L1)=LM%<3IFV.%=FI/_2F
MJ6J=&T4_/"'L19>\ ZM]AU>>&94*GYC$F[)3%M>.E%T5<QFH3YD(DPQE[!L4
M:]$F@9Z/'.-QW[07"]T@$"V<L$)JXH6K>-8Z4."R <9X$?!<'G<.*P_W"&BS
M#$-,J #F'94ST5340PV\\EESH1OA%S"B0D7$'I62Y7@JS4SD)5U2QDG#F<W*
M,,[3]$\'>'@FI$G-N14TJP#^R0_8O)ET:+CM#NW$G6X+WU;&\-D(Y<(!EHMM
MQP,A=!O[)0/OB7O$H"P!?P453<?^2O+]"0$L4('GJ.!'@9FK>-:JX$\NYW7S
MX*:OPD5_Z;0@3_RA( :06-C- LWN.C:L!KY!U&[$G]IL.<ML)&:N1CN;GS(V
M"(86W2 H61"<IH#XZ&>!KD:HNR^!K+ER2=!L=IOVBS;M9TCZOZH 1PUQ/Y4K
MPAUW;<465M9,[J3&&7L!#7$\$<DP88P"_4!(3/WY_CW5KPO>3YT_+7PZO^]I
MD(K&'I9164IM,UNGDFTT[CM__!M+1M*),#(L?_D8L6A\MH'!9A#2BJ+H/'8E
M0%THN@. J[,DN,>037/X+7>4MP>9Y:& HBOA71#2#8[F\$-<N#UHT/%(>EM%
ML2W\BFY;IFX;&-K/1]J(^,/&,7@BY)J" D<;Y7L,'4H9!DK#5@0-\<9.<K=H
M_)=G]O30_L!W,0!>_W.PGF<.EB26)*@9#KQ?!+Z7A%"^!-O'1WN>4=W=.O!V
M[\"<])YVJ%&0G%C9"#F\NR.Q(G !/I\0EM *"A(*)[SD:ZG/>JG7RW'_90"W
MCYP"E2$GJ##X1R %:%S,*P% +B/92WJ9Y0:]1:;0G:^:4E</?UK=]P0 J3O*
M)0EF\CY1KC4$"+X1M_]&MR  J\0;:G#4+4RRB[BZ+0QJ@U%J4<PY9KXVLJ%;
M@"$ D\K>PH#+#@,^Q'%GN-HVZF5Y$.VO5MU>!S!,*??'OUD8!V3"B ,NQR_X
M8YISI@DL\Y@?J*X3?4'6UX!ME<H/0B^S4B?WN1_B!])W5%5; =,B**0P(M@-
MKB8DN3XWL'LAG#STWX?#[^/!X^ZPF9]'4\%OM^<ZT"1>,E$JWH#\MN$[FBCE
M?N<'//XU>R?.CU"3]#65E_3 2??>]\@51V.EJZ$U0:>=0VE"AZ=GL:T+J*B3
MC" OQ>9@NI9'W:TLU1Z,.9OM',NX'\N/!D2\JK$8^;B*<*IL_%$#AK?P&4+.
M*G&2@8$S^G-#MV=S?'Z#!,0 <V@MH=DD9RV[#*O/^Z!XP(O<!*LS2U;+:U"M
MTTLPI*>/#XMNI[9GT$](V$-:HVPW)%5+;*W=XY"J6\#@&_)H+'@26K2R;8NW
M)X/"I+BUQ31;88HSN(6_RQ[8\/^>G)@G3]Y3DY=3Z1'W'-W7+B\;^]$Z"NHL
M)117)CZGYN>?^;OWK_EHH+ :SP0FGU?SLL-H"\U2Z'J41:EZ2?DTVH]_+!AG
MGL5QER F1\_UODU.VIM,.LX9I2KM;-;9_K1^7^.KK^T4OEA.:B6U,=4;S:C<
M2B=RBWCA<2LE0Y&3O^X"+AK#UF/4!G2<89DO)T'TA8OWB,*"74(D4+JQM#D#
M ;V]M*NXHV[^^@K]-8FY]H(R5X>RN;S9%GDCSXYF]TIFT(CUEKDO=-7:<*ZE
M:AVQ1)=ET)MEQLG$TR,J6KIC0G75A )O^6D14I9:(=)Z<;(;SSX+IUTO3K*9
M%V2?KT>JOM<RSU9#N]"+#R6VKC*CQ,,*V+U.[N;!OU!$F-3H?K5.9&6YT'RB
MA^-<ZCYG7Y"(9!2QWRMDNQ.YM]!:U41'*27I63C.^[4\T%=@YIVON^Z&%GA#
M"PR_]>R&%O@1M,#$#2WPAA;X3K3 KSMZ\%#3-L<.'5+15JN5,M9/@V5!Y<W[
MK)DHB#^E^BR#SQ0^\M4[K]@=D@U<X=$$JN?G;<, _I0DRN(VE")Q1+J/)$6_
M]XCZ^6YJ.1C312 :/.L\+*.K\N/@T<Y\*M-4(.2 #+UWJ2"]4!BLY)KW8Z E
M;%HRHLU!N;2I1D/:JQPO_GYE!W,)7 GL8%(QV=!&!EC*H]%Z*''QXJ:U>*TS
M($2V"*R^%O/&*L%&*WVSIE7[:G\05G*OJ5.H(542H?JBR@V@+G2#,QQ*D$01
M&*@(VZ3 !IWG38&U1C7=',\C'4*)/%S #?7+ *:MD"(MJ-!; @4+XQ[!:Z%!
M%[G'@RB/"!8H[8?RA*CYP(+FFH)^1(.W-".4),+[.B1-8DFJ]QRWM@3>E91(
MHS(W&R[/L#A)NZ-R/.K<@1<KSGZ/2["N/-@]!/]TN#R_Z!K:!]V#/J6@1S&!
M>9T'B'UD_O#ZO7*T)D"[4^@1!9-2.0?RE>*AG$FH DTW4"\NO!*2!K5D L6Y
MHRKZ&JR 0<BJBR*B$V2#>]>UI"CH'@IDE47*W#EJ!AV^A@OL*&X&^6.2'A)1
M,DR_0Y-B*+A>Q145R (<+2\,792L.ZJ$:E;V/D-W!ALHCR9)F4E>O5'$6PIZ
M&QT5\TW]=9(^XB3]7_\[Y!;(T?D=31$H2#:*&:$J104@V%"9T'/]M!X@Q1R?
MH-<I5)I#B8 V$1<)XG5S A('(J=!@D 2^;2\HX/4#"0DD1,\?Q[@DJ<,?'$?
M!#8@;<ZPG&.!I\T-MZO9=-ACEXUH=G#?>9JU!S^EZC&+/ !^_R@F -5'(P:(
M;SIS-!E*Z.CY#$$'Q&G@3B;TB15X$=(AZ7D*MRG,+5NVYO!9J (9V@OB!E$3
M)71[>1T9"A6'.^9-'[],']D5VNOG4"ZL"_"9D39KXX+&8]JY=2JE?A0AQ;>>
M-+62;"K)6.N'; MC]!U%J$%A<E!YM_&Y-P?00Q6A-%_?AJ^I:]_KW3ZT[C=4
MZU"/GL^1HNE;6OR4M+C[[L$TM?O17I8ZD(6.TT>SZ2M=$HXGT_UL^=]377#@
M?^:6JOS[OU!+ 0(4 Q0    (  <X9EM(&Z?UM!$  -N^   1
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9:'1M4$L%!@     &  8 D0$  $N- 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>prqr-20250930xex99d1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:prqr="http://www.proqr.com/20250930"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="prqr-20250930.xsd" xlink:type="simple"/>
    <context id="Duration_9_1_2022_To_9_30_2022_prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_prqr_PontifaxAndKreosWarrantsMember_QDqtNs1aIEi1heNwMkeeNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="prqr:IfrsClassesOfWarrantsOrRightsAxisAxis">prqr:PontifaxAndKreosWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_b5MiuBOLvkiPnH8dj15XoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:SharePurchaseAgreementWithEliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-25</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_dbgoR6vcMUqTMO3jvVhl5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_iVCbzNhSAkCnatzraPCD8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_ShelfRegistrationStatement2024Member_ng7Fbf6gFUy4vNzZAU2odA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:ShelfRegistrationStatement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_sHnEGchkcEymfM1vdGke-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_2f19mTxVb0akP73Sa_oSQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:RettSyndromeResearchTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_7_1_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember__5Hj4Avi-0abIwNa79N03w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">prqr:OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_mQAGEX8GEkW-yeLTTQ4VGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">prqr:OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_DDyp30oG70y9MAT2AAkBnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">prqr:OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_5PEUyinG3kmhHLSlPJV_1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_fkkBmmdVaESJHda3nXUU-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_31_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_SQEbr7EQSkStP6J8wDVlYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_prqr_IfrsSaleOfStockAxis_prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_PGd6rcr3S0i-F2HTv9iGJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_xZ1UKhJoMEuxAabw7b7dlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:RettSyndromeResearchTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_flCTEjbcz066k8F4PCLrew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2025_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_PoXgbyj0VEimJfqnnq8vXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_2suHy2Uqqkq-b7CLFUL2lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_YJJKCH6_f0CGHWEK670wpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_Ps4wlpTyCk-CiG6i9mnIJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">prqr:OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_pMfe7-CYZkSkMiFKJi9Z7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">prqr:OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_wm8LBrxXCkyzFCS9TM0Eaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_0tkeXgS6dkGzbdukDKq5tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:RettSyndromeResearchTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2023_To_2_28_2023_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_ifrs-full_ProductsAndServicesAxis_prqr_MilestonePaymentsMember_8ueA1NVJtEa4bfujUxBP3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">prqr:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GmQU-y9rwk-z-77kvpEtVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViiiBvMember_VdFaX-IgmUWXDhT8Sj91cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsViiiB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViiBvMember_vOqWyc0GxkKVzCAG4aDgJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsViiB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViBvMember_Eg_4tvfBoUCuq-QPluHQsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsViB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsVBvMember_XAFpvyId2k2r7a7zNVEohA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsVB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIxBvMember_8b6o2YoKLUWPL-vDhftrUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIxB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIvBvMember_TGiLF5LfiUGZLR-qDsOFtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIvB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIIncMember_ECpwoHs8RUyCW8sNiNEueg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIiiBvMember_fK1FbaT8-k-4CxcnPUyGNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIiiB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIiBvMember_0sZHnPkpQUib6ZcDTeKIPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIiB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIBvMember_rEz99sZOpEOeeXyEDeM7bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsIB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsHoldingBvMember_O8oNddjWmkC-HAijvKH37g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">prqr:ProqrTherapeuticsHoldingB.v.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_25_2024_To_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_1SV3IDfQekeRE9nHK-mnpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:SharePurchaseAgreementWithEliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-25</startDate>
            <endDate>2024-10-25</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2021_To_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_m4ViI6b7i0S1NobB07mbHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="prqr:IfrsSaleOfStockAxis">prqr:October2024UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_dgOq00RA5UyztuNQFmTsMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_G4ICZ7yXkk65BgEHTs4AlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_-bqBRBYnMkqbwyTudO1CSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_MWf62Mctg0SEca73DdSQSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_10_12_2018_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_lbY8fExZj0i3II_9Pf9fhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-12</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_Jm0ycghQx06aKQaV-XaMYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_U0bIiWfTwUK2UDFOYXKvcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">prqr:InnovationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_uPUa2i_7MkuFypR4I9OjUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_IsxdhpKNBUWj5naxXv5zDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_z8mrJ_XS20OdmQRuFtWhnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_iwf40QnTJ0m4Vo8mAlujCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_08ltvoMrCUOhqccsXSmSpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_D3VJA-2yEka_L4CJUP1bwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_YarrowBiotechnologyMember_9ABsPfcrBEWgLl8UM2SqAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">prqr:YarrowBiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_yg5IGweIK0qeV0bYXpRQJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">prqr:PhoenicisTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_YarrowBiotechnologyMember_16WLvw49kkCNj0VZA6LAug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">prqr:YarrowBiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_Px873arFI0yxw9TbKLJcIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">prqr:PhoenicisTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_NBruH9iPUEO1qm4ppbYCPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">prqr:IfrsSellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsResearchAndDevelopmentExpenseMember_tcUIS9w0g0CCeSma1Lfl1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">prqr:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_JxIfwdbS8kWh6YPJlU9p3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">prqr:IfrsSellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsResearchAndDevelopmentExpenseMember_cdQDW243CEmqV7EBFQBmvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">prqr:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_xVLmQv70tkmTWrXUzZkHoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_asbCzlcqMkyM5w2Y3PRbqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_DsMV-YDBnUK76VIPgik0-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_VwVPNTRKjka_upzN4CwLew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_SMbLKd34R0KfHuM4rpeilg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_oQrhBR2oxUapLnyLuIArqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_0mrf-R_XY0yzUG8OnKrkDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_RJ5IIuOtWE6SDgrSyS_t2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_9QFRxe8qfUmtwOQ_FsyrEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_II-Ovg3YckajeIRdrZzZKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_YmG5mam2kU6LZGJw23cDuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_wqiJlNiVCU6R8R3Fcw6cCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_TG6NHlq740CXHuiR9mTbLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_xzfXEnJ9DEuEVu_FmD7uuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_77JK05vzLU-X-WnDU8wcDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_e5T6UVKy1ki9ZfWxfnjDhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_7CEaesH_rUeFoouKWkTtcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_4xDxWcNmjEeMIATjnOIb_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_OFftNnWG-UGZ6tREcP4ijw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AcgFrNkamkCvsd1bQi1WLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_hWA0MWK6lUqB0UHEeVamnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_EeQqadGBPU6ffQXEFmCknA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:RettSyndromeResearchTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_z_wMRuiDMEqEinzBTRrmJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_rPv_1PsZlkyKXSb6IKaW-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:RettSyndromeResearchTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_N0cWD2q4NkeY3A32UZEFqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">prqr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_i0u4-QQ5ZU-UjEoLiyQsHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_g29o3Zo7Ak-Bxlwv8XcO8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ZHbkuA8ZZEC6p9HbY3sb1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_7SqLUGM3Ck68Fx8rYXnMKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612940</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_sqm_Oc_SVpN4d0OQM3FvR-NrfQ">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="Unit_Standard_segment_iAZ-erTqcEibFQQvKQuMIg">
        <measure>prqr:segment</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_q_6SzVvYpE-NdnoAmmu_UA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tc_zSjLbJXv_UGKsGIyg1Sl8Q_2_1">0001612940</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tc_Hs17U_KiTUWAbGefjwv2UA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tc_lxzQgqV3jk2T4MMt8-5VBw_4_1">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tc_XUy2uYK_XUeMZVs26cUJPw_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tc_LOOGAOmpqUaYvPCN3O-boA_6_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tc_ejJZIjULsEy8Qa81jJfomw_7_1">ProQR Therapeutics N.V.</dei:EntityRegistrantName>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tc_5PiMSMYdFUu8w54GRgDWpg_8_1">6-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tc_ntZAHLvz5kC47rW3vwiIqw_9_1">2025-09-30</dei:DocumentPeriodEndDate>
    <prqr:LeaseTerm
      contextRef="Duration_7_1_2020_To_7_1_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember__5Hj4Avi-0abIwNa79N03w"
      id="Hidden_1k_9dkbIBE6F9vmNuzcVIw">P10Y</prqr:LeaseTerm>
    <prqr:LeaseTerm
      contextRef="Duration_7_1_2020_To_7_1_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember__5Hj4Avi-0abIwNa79N03w"
      id="Hidden_9sghCigMRE-91luzw8kAXw">P10Y</prqr:LeaseTerm>
    <prqr:LeaseTerm
      contextRef="Duration_12_1_2020_To_12_31_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_mQAGEX8GEkW-yeLTTQ4VGA"
      id="Hidden_zMWif57Oekmju6l1QF4dVQ">P11Y</prqr:LeaseTerm>
    <prqr:LeaseCurrentExtensionPeriodUnderOption
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_DDyp30oG70y9MAT2AAkBnw"
      id="Hidden__Ne-iWIfzU6QAPw9QT7ObQ">P5Y</prqr:LeaseCurrentExtensionPeriodUnderOption>
    <prqr:DurationOfUnderwritersOption
      contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_flCTEjbcz066k8F4PCLrew"
      id="Hidden_SBfXi-xh50yWDW8Jo_eMMQ">P30D</prqr:DurationOfUnderwritersOption>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_0pgaWSl4KUCGGVm1sBTiMg_5_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">13018000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_Tg3x4fq8e0OYlBc9YCTiYA_5_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">14113000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_0oPXqRJjYE2cYsGEByIUTQ_7_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">13018000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_AKdpOnCdGEGrgKl-me1Mrg_7_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">14113000</ifrs-full:NoncurrentAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_YiCxvqodUUK8GkQy5WXW2A_9_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">106883000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_7Rhmvia_Gk2bf2N3zrk1Zg_9_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">149408000</ifrs-full:CashAndCashEquivalents>
    <prqr:PrepaymentsAndOtherReceivables
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_85BMUdXt2EmYCZSKGewjXA_10_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">3872000</prqr:PrepaymentsAndOtherReceivables>
    <prqr:PrepaymentsAndOtherReceivables
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_vBg3eucyvkqBP_WAu5VjiQ_10_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">3747000</prqr:PrepaymentsAndOtherReceivables>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_3k-QXim_tEuV0ZFqfy2CWQ_11_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">576000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_PNruGeuZU0SH6u1jLIYM4g_11_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">690000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_kk1LGuHUwEWvZJeSw7lkeA_12_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">111331000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_4boPl6vnuEuUfhXK4SPfpg_12_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">153845000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_qYmvhGR2OUOkq6Riw6OjUg_13_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">124349000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_Z5_i61FU7E2TpcQoVc8NGw_13_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">167958000</ifrs-full:Assets>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_-Ur3mNlm5UmcNTKD_6QSbg_17_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">57071000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_iK-pywS7MEaEPCg311a7BQ_17_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">88560000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_lHrj6vMBME2sYjI36I-psw_18_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">57071000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_zFO5viT5ZUa9WwsSP0GiDw_18_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">88560000</ifrs-full:Equity>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_5WDQAtBf3EWhQL-_N8y4Bg_22_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">10017000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_WFwAeu12r0Gh3XCnmezWIw_22_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">11067000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_z4fg8Pq-KUGrMEnj4ki1Lg_23_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">24125000</ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities>
    <ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_OgZ1O9P1LEif43374A6Q0Q_23_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">29429000</ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_zbuIevT22UOaUsXhSGENvw_24_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">34142000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_AkgXlbfDl0KkJQodF4PQFQ_24_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">40496000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_w67wqrIAZUWlWOgV2iFvbQ_26_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">4800000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc__d2yKuJGDkmiJ9H7m5iB-g_26_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">4582000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_dBhbX5BEfUOXzEdxguPRgg_27_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1674000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_R4vuqgbV50KIfxLDN3T0sg_27_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1567000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_MZajUUXzZUmtFt2OCMjk0Q_28_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">292000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_KwOKN1aDFUWgIV_c1TGITA_28_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">468000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_5y9zHIbFiEKbyvPqp09g0g_29_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">305000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_r8EP-60fzECQxi2hW7nAEg_29_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">16000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_8hjzLiJ3mUW70ofSowyUFA_30_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">121000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_8da4kROD60aTEibZBQpc6w_30_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1478000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_fWZrIG141EOK8SVtisEEHg_31_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">17394000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_DGz-IyNRA0m2wmRgqHFyzw_31_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">21942000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_UZ20Sd6p2UeAD9Us2F10Dg_32_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">8550000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_lZ5g5l_u4UeGdmY-8rZXzQ_32_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">8849000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_IhHpjZNHoESudg5E85PLTg_33_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">33136000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_L8_Mp3BwtUiincZQsADTRg_33_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">38902000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_u9uJyYQ9YkSG3Ls23dF_MA_34_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">67278000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_j4nsN_jJG0Cc-K-YUQdd3g_34_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">79398000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_9tonhQf2KUKdGuTUpnBtMw_36_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">124349000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_3xVuYuL8Gkq3WTTOhVWYpw_36_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">167958000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_Cc3YEeJXAUalR-8gmHSp2Q_5_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2882000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_dd7twKMQBk-bP9CKLpvPdA_5_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">3843000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_be_RpEAnkUWod96xjNMrlA_5_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">11218000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_U6hRy0j7a0am7m1R__vcQQ_5_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">14598000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:OtherIncome
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_QUqHLJaDK02_9SgXftNaag_7_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">33000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_BgLSgk3WQEW9-pNQyaXWow_7_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">138000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_FzP_HaBUQEu0AJi2ikSuWQ_7_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">413000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_rwB5KNR45k643bDeLyeiqA_7_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">504000</ifrs-full:OtherIncome>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_U8Yt8yIFqkSDIB3pFt7tOQ_9_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">11080000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_JFLi3ESIS0KTbAc7j3jLYg_9_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">9414000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_kVURblW8UUaj9HPWRBULKg_9_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">34811000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_ZoyxkFgHDUqANEWbVjGpmA_9_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">25745000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_VSzYmMB8lkGZ8WKTQ_1vMQ_10_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">3119000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_W719dD_Mmka2JP2jvU7LAg_10_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">3283000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_J5xq8fXJB0ykZ8URO3qszQ_10_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">11169000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_VO32mfozqEWcrZ6yINa8SQ_10_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">9748000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_PmxHEnb4zUWoyOYnDXOpeQ_11_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">14199000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_Ajuci-UEUUqYrozezoNJHA_11_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">12697000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_4D47HJRIRk6bRB9Ve9CtbA_11_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">45980000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_SYgxHEtEU0qULnU8SQC7Qw_11_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">35493000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_TClTMgmf4U-IMgDrfKqFRA_13_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-11284000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_FeHmKYhEckeKCxfZCR-u9Q_13_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-8716000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_w-50RnqiqEa2pXCwciPM4w_13_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-34349000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_jS5G6R15-Em_2B2ygfHpFw_13_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-20391000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_4RJW6BfpsUOWre3AF4Ao7Q_14_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">280000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_Omh00bfUw0-KGCE6J5L7vQ_14_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">469000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_yJ6A6Ulj_E69H72hJMqXvA_14_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">927000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_glC8gP9rlU61Z5j8ffrcAQ_14_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1470000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_vjjvkpFio0uxlaeWHhUj8Q_15_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-2000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_arzRHAKL_02UJrm1xtYw3g_15_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">139000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_wmz19EesYkOHKpR1M7e8AA_15_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">176000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_55OOLg8cnUiGiM_OINca1g_15_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">266000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_FBEf4oZGek69C0itCrez-g_17_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-11006000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_0fshqAQID0-OH6gOkJ5CJA_17_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-8108000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_uliJsEgDIk2wHH4mINVc3A_17_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-33246000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_T04kNAqHukCKVi5hErT6jQ_17_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-18655000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_2l0sEDnexEWCyUCgZsPmdg_18_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">18000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_WceuaASur0uA3zHb9R1GsQ_18_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-197000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_Fbob8BPeV0eawfpmjEJcGw_20_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-11006000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_GXAtEFN8yEa22vI2D92fYg_20_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-8108000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_xw5dvWGGS0iDZqnkJ9b-rQ_20_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-33264000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_N2io_dhaE0GPM0sfXJsa3g_20_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-18458000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_aZ5SkRnQYkGHaBjGKmkAHw_21_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-23000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_NqlZanWDn0K61Tm2rP5jBg_21_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-377000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_zRgBO2xCRUu34uxsg6fXEQ_21_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-1076000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_L4Rt_upC8UaOg1tMNi6neA_21_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-101000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_iyhiw44JF0epZcOZthxV1w_23_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-11029000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_wkrEwP_qi0C1yyVW8MGnjQ_23_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-8485000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_KF50k3XnRUy4KXefB9G_cA_23_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-34340000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_aIkLipgoq0CrlhrOZSHc5A_23_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-18559000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_PAJK4pi4RkOlTdlepCzoEA_26_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-11006000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_uIQDrLB8jUuj5hBTk_574Q_26_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-8108000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_AgqYYsb-FUulg0YyHGvWeQ_26_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-33264000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_aKt9qMMDE0-vKF_jt7_C-Q_26_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-18458000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLoss
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_7T_IDaGZNkeYySp8XkZ7Sg_28_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-11006000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_DFGobGCEcEy2zPWevbJ_Ww_28_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-8108000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_CK2szqKB_k238v-bkYGNvQ_28_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-33264000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_0monkrYtsECmiQ-Y5eVJJA_28_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-18458000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_EXXErGI56kmdxXd0Q2MwXw_30_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-11029000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_kvQyNv6mTkyIKiaOFj8Hcg_30_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-8485000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc__yC6XH-ddk659Iman2hvaw_30_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-34340000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_ZTEG0gBXvUa0kW4DkiAf-Q_30_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-18559000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_uFfcqbUvjU6HNj7_GNMY4g_32_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-11029000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_WLfKNDfzQEmD2312dbUzqw_32_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-8485000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_wSytm9UPL024WWnqbay-Iw_32_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-34340000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_5WV_Y-6jGEKyr0BttWyJIw_32_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-18559000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="0"
      id="Tc_4OyBA5NKzE-knRZJUAf3Dg_35_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">105344996</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="INF"
      id="Tc_4OyBA5NKzE-knRZJUAf3Dg_35_2_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">105344996</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="0"
      id="Tc_dz8HPvqgH0SMB3BaCxeXZg_35_4"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">81682296</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="INF"
      id="Tc_dz8HPvqgH0SMB3BaCxeXZg_35_4_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">81682296</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="0"
      id="Tc_6mdFNphE1kOtUlwBgZLI_w_35_6"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">105328752</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="INF"
      id="Tc_6mdFNphE1kOtUlwBgZLI_w_35_6_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">105328752</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="0"
      id="Tc_8_yNxwVA80GtQtAVy9Qlig_35_8"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">81639533</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="INF"
      id="Tc_8_yNxwVA80GtQtAVy9Qlig_35_8_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">81639533</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="2"
      id="Tc_TX_OmuqLh0S8PKxDqpOTOA_38_2"
      unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg">-0.1</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="2"
      id="Tc_pJYcw-P9VUK36cFJsz2OXw_38_4"
      unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg">-0.1</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="2"
      id="Tc_s4p3Rj1sNEei8rE1UMUcwg_38_6"
      unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg">-0.32</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="2"
      id="Tc_gDmQDSG3yE2YgRihCX1JZQ_38_8"
      unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg">-0.23</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="2"
      id="Tc_3xdgtgdroEqBdaprFuW2zw_39_2"
      unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg">-0.1</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="2"
      id="Tc_6LEmXJeSm0qw3i_R36LS0w_39_4"
      unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg">-0.1</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="2"
      id="Tc_rAltVSr5REaA_gZkXcxqmw_39_6"
      unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg">-0.32</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="2"
      id="Tc_s9xCNhJU7UyUXkbd8wzU2A_39_8"
      unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg">-0.23</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AcgFrNkamkCvsd1bQi1WLA"
      decimals="INF"
      id="Tc_Z_57e2awz0GwZjT9pXw4Wg_4_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">84248384</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_AcgFrNkamkCvsd1bQi1WLA"
      decimals="-3"
      id="Tc_noOSBe3LRk-_RDE8Pb48nA_4_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">3370000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_e5T6UVKy1ki9ZfWxfnjDhQ"
      decimals="-3"
      id="Tc_Ajh4IBsFBEi1-XMJV02uPA_4_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">412894000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_4xDxWcNmjEeMIATjnOIb_A"
      decimals="-3"
      id="Tc_I7cYIVejqUCS8Ga-AxQZTA_4_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">25159000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_OFftNnWG-UGZ6tREcP4ijw"
      decimals="-3"
      id="Tc_KMIChVf7ykOBIs7BwBuh1w_4_10"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">817000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_7CEaesH_rUeFoouKWkTtcA"
      decimals="-3"
      id="Tc_bc2RjtMIW0Cf-Z1XJSsmYg_4_12"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-400850000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_7SqLUGM3Ck68Fx8rYXnMKQ"
      decimals="-3"
      id="Tc_DqX7B3N8xUmsFYIXwdWL6Q_4_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">41390000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_08ltvoMrCUOhqccsXSmSpg"
      decimals="-3"
      id="Tc_1gGHV1VXtke2It3WsVaY_A_5_12"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-18458000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_K3VirHnyWESgPU-G8sc9IA_5_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-18458000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_G4ICZ7yXkk65BgEHTs4AlQ"
      decimals="-3"
      id="Tc_Wb7LfKJQPkqwatnfuG-78w_6_10"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-101000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_Zassv3eoLE-jcLeMEAO3NA_6_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-101000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_D3VJA-2yEka_L4CJUP1bwA"
      decimals="-3"
      id="Tc_AeN0i3Dhw067cvny-ujjew_7_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1976000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_oUO5rbqmIEaJTtlOcES5Rw_7_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1976000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <prqr:TreasurySharesTransferred
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_fkkBmmdVaESJHda3nXUU-Q"
      decimals="INF"
      id="Tc_lwqoaCo270qKOQum_HQd3g_8_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">329675</prqr:TreasurySharesTransferred>
    <prqr:SharesOptionsLapsed
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_D3VJA-2yEka_L4CJUP1bwA"
      decimals="-3"
      id="Tc_R7qKPkU1B0aC54ETrCQO6A_9_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-994000</prqr:SharesOptionsLapsed>
    <prqr:SharesOptionsLapsed
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_08ltvoMrCUOhqccsXSmSpg"
      decimals="-3"
      id="Tc_MppEoaShukyeNudqi7Flow_9_12"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">994000</prqr:SharesOptionsLapsed>
    <prqr:IfrsStockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_fkkBmmdVaESJHda3nXUU-Q"
      decimals="INF"
      id="Tc_6NMfn5oufUWZFokvxR0PDw_10_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">328597</prqr:IfrsStockIssuedDuringPeriodSharesStockOptionsExercised>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_iwf40QnTJ0m4Vo8mAlujCg"
      decimals="-3"
      id="Tc_RhuIOZlPPkCgNNpldFVXTg_10_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">175000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_D3VJA-2yEka_L4CJUP1bwA"
      decimals="-3"
      id="Tc_sO-C2uhOBUex46Vgwhc1ow_10_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-291000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_08ltvoMrCUOhqccsXSmSpg"
      decimals="-3"
      id="Tc_8I7lgYwYo0qjTuL506h7tA_10_12"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">291000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_lMnfIn9NPEiI-WxaX_CKyg_10_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">175000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_77JK05vzLU-X-WnDU8wcDA"
      decimals="INF"
      id="Tc_EcccmfoJIUaaz8HLrcIj6A_12_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">84247306</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_77JK05vzLU-X-WnDU8wcDA"
      decimals="-3"
      id="Tc_s-_k-fLot0ySpPZfkxSe3w_12_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">3370000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_YmG5mam2kU6LZGJw23cDuw"
      decimals="-3"
      id="Tc_sN3uXoAeJki662GtRYnnqA_12_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">413069000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_TG6NHlq740CXHuiR9mTbLA"
      decimals="-3"
      id="Tc_G7QYwa-d8kiz3CXJlKLocw_12_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">25850000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_xzfXEnJ9DEuEVu_FmD7uuA"
      decimals="-3"
      id="Tc_9RhFOnxbwUGkISz5GeFH_g_12_10"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">716000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_wqiJlNiVCU6R8R3Fcw6cCw"
      decimals="-3"
      id="Tc_isu9TQ9t50mp9ee90dibYA_12_12"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-418023000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2024_g29o3Zo7Ak-Bxlwv8XcO8g"
      decimals="-3"
      id="Tc_6GC607AdEEqQ4uXjKbEr8A_12_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">24982000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_II-Ovg3YckajeIRdrZzZKA"
      decimals="INF"
      id="Tc_IsJdKx4AjEmIn5CYVayA_g_14_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">107710916</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_II-Ovg3YckajeIRdrZzZKA"
      decimals="-3"
      id="Tc_KHDUW3aj4EaswcIuO8btoA_14_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">4308000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_oQrhBR2oxUapLnyLuIArqg"
      decimals="-3"
      id="Tc_Hi_V-eRjxE6Xj8Xq3IuFJA_14_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">483812000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_RJ5IIuOtWE6SDgrSyS_t2g"
      decimals="-3"
      id="Tc_Kr1f73HkNU6_iC0BP4tKsw_14_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">26248000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_9QFRxe8qfUmtwOQ_FsyrEw"
      decimals="-3"
      id="Tc_-R-rtAcv4Ue4wvblOhY6sw_14_10"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1350000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_0mrf-R_XY0yzUG8OnKrkDA"
      decimals="-3"
      id="Tc_d-bS-u-hmUGiMbtRApwlfg_14_12"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-427158000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_m1CaNRjuOUyuEjjOejWj1A_14_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">88560000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_IsxdhpKNBUWj5naxXv5zDQ"
      decimals="-3"
      id="Tc_aEEWz-MCe0GqUwCxKxFQ6Q_15_12"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-33264000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_55_2SiQfgkqfNwGfqPnKAA_15_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-33264000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_dgOq00RA5UyztuNQFmTsMA"
      decimals="-3"
      id="Tc_zBFtWaRwvUm4JF9CC9a7qA_16_10"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-1076000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_sbr0DeN80EmseUbuM3Bq6A_16_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-1076000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_z8mrJ_XS20OdmQRuFtWhnw"
      decimals="-3"
      id="Tc_j0WMrC_p0kigNbafg804dQ_17_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2784000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_xR4xIssSKEe0GNFTugnXYA_17_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2784000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <prqr:TreasurySharesTransferred
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_5PEUyinG3kmhHLSlPJV_1Q"
      decimals="INF"
      id="Tc_H3pI2EEWWUOIXl8W9ZXcmA_18_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">132665</prqr:TreasurySharesTransferred>
    <prqr:SharesOptionsLapsed
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_z8mrJ_XS20OdmQRuFtWhnw"
      decimals="-3"
      id="Tc_cVTgn849v0WETI_uO-QJkA_19_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-1532000</prqr:SharesOptionsLapsed>
    <prqr:SharesOptionsLapsed
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_IsxdhpKNBUWj5naxXv5zDQ"
      decimals="-3"
      id="Tc_0zEoPZgfZUmD4dw7l4zDHg_19_12"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1532000</prqr:SharesOptionsLapsed>
    <prqr:IfrsStockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_5PEUyinG3kmhHLSlPJV_1Q"
      decimals="INF"
      id="Tc_s_ZHz4JJlkWcOlfCbUkL1A_20_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">132665</prqr:IfrsStockIssuedDuringPeriodSharesStockOptionsExercised>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_uPUa2i_7MkuFypR4I9OjUQ"
      decimals="-3"
      id="Tc_GQjxM-OcpEqW3zvgGqLhDw_20_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">67000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_z8mrJ_XS20OdmQRuFtWhnw"
      decimals="-3"
      id="Tc_Sw-ULm6PmkKyylOHCN5CtA_20_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-184000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_IsxdhpKNBUWj5naxXv5zDQ"
      decimals="-3"
      id="Tc_-PVpgZlCf0umq6BZCWpJnQ_20_12"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">184000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_8YEc9hMKQ0-eyF-sD6yB1g_20_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">67000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_SMbLKd34R0KfHuM4rpeilg"
      decimals="INF"
      id="Tc_hrI1NYrPXESaSYzsAR_S8g_22_2"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">107710916</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_SMbLKd34R0KfHuM4rpeilg"
      decimals="-3"
      id="Tc_h5cJcFuf-EysTCoKpmtW5g_22_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">4308000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_xVLmQv70tkmTWrXUzZkHoA"
      decimals="-3"
      id="Tc_kdcMiVA3Q06STSKzMhFJlQ_22_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">483879000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfSharebasedPaymentsMember_DsMV-YDBnUK76VIPgik0-A"
      decimals="-3"
      id="Tc_5NaWM1uVHEaoZUKQ30oIOg_22_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">27316000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_VwVPNTRKjka_upzN4CwLew"
      decimals="-3"
      id="Tc_BzRMRYutUUu1X0uxp69GVw_22_10"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">274000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_asbCzlcqMkyM5w2Y3PRbqQ"
      decimals="-3"
      id="Tc_Ih0wzP6wdk2btbVKwU-Z8A_22_12"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-458706000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_5rKGSly6X0e2_xD2P6jBIw_22_14"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">57071000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_IhKsaek9MUuo57ezvYN-zw_6_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-11006000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_1QQ1GkW4CEC87DHmgEoOVw_6_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-8108000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_m5AxFLmsjkKTEgsx_2j0Aw_6_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-33264000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_VGSfDBnVH0eqXq6AB3Ge3Q_6_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-18458000</ifrs-full:ProfitLoss>
    <prqr:AdjustmentsForOtherIncome
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_wCsSkKA7o0ewd_jf6-g6Ew_8_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">33000</prqr:AdjustmentsForOtherIncome>
    <prqr:AdjustmentsForOtherIncome
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_pOFlcDCQGU-wIGo4irl3WA_8_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">413000</prqr:AdjustmentsForOtherIncome>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_HsB4Yxtb6U-uYSOL1qdaYg_9_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">671000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_0cSkb2Jv7E6lOBCNcGxXMg_9_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">688000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_vqMzi4VOCkyqoDzpwHjrRg_9_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2024000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_ShqhEJjC5kyxxOyyrHW6Ww_9_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2090000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_UhHMA9xyvEqCPuOqBzwAKg_10_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1117000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_8s7g_4n3eEK7aGvRmt5Zeg_10_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">612000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_swX6S0vfMUe_ZmGAnLK04w_10_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2784000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_40qnARF6X0OVrrHiCNQITg_10_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1976000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFinanceIncomeCost
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_IU53EKpWkUCSEEwzoTrvBg_11_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">280000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_IhZWXtKTMEqILBCvzcoK0w_11_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">469000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_G48UjV1qoEG_HtuCCe-r5Q_11_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">927000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_ZRec2vwmYku2DEmvkkp7kA_11_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1470000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_m7qgut8-ZUGRUwxMOQJkBg_12_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_-VxsJrNwIEG3TmVCSDKo5w_12_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-139000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_X-O3bxpyjEumYiQDb229FA_12_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-176000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_tSmtD7-yJEm-TDit628pjw_12_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-266000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_EjT904MGU0edMlkXaYW2Cg_13_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">18000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_fOo7lO-SkECVSjp3yp374w_13_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-197000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_KQp8KUC0tUityvbNBcezXg_15_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">3074000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_YBQF8G28a0ig7YfdPTJMAw_15_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-1117000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_usBO4SBq6E260Wfj49TqIA_15_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">10974000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_okDZb3SjaUWrqBS29Eeqsw_15_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">12721000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_PUU_K6Ply0agZfjQ24-A4A_16_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-12603000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_AoHUWWe7qUKo5mVnApdH8w_16_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-6299000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_hHvoFrifz0CuJlgUIYjusw_16_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-40928000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc__SkHCE3zIkeRBkTcfoxe2w_16_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-29046000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_-IQg7xbKp06nGwHnn4tzJg_18_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-1000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_furFCQcvt0y8TOP3PMBofw_18_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">18000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_qe-AHTguTkmsTL5DBT9ALQ_18_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-197000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_iJqNhWyizkaXCqPwm-NMyg_19_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">519000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_4lhTUjCmrkyuCzig5PgAZw_19_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">860000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_afD9b_1DRUKSxrvFrOiu4g_19_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1924000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_Le_WxfLzyEu0M0_rD8k6Cg_19_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2402000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_C-6MdZJwL0OOKGupQEsOsw_20_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">151000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_TuHOnD1yCE2NWjecIFI5Hg_20_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">219000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_J4kSvC_LFkSN0qRRhrsslA_20_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">412000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_XnysXJ2dGE-oE2jpZwTpOA_20_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">598000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_UsDuY_KP30SKRAYekSwGaQ_22_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-12235000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_S-yyfWda30y9bOgNk2BuYw_22_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-5657000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_xhmO-wdPeEO2ZBfhtEQzaA_22_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-39434000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_sSmVjy0mdkGoQscYntsvXw_22_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-27045000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_miAaBzlAMUaesKynVEiokA_25_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">17000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_kdpVHv47rEecL0qQEm83lg_26_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">17000000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_tsbAUHCsJ0Sy0f6_7o2gTw_26_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">17000000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_E5GLhWfeS0aVi986_D2YNg_27_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">169000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_KY6ai4MQvUGe3Ij4NSfkXw_27_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">286000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_IEoKMlEy006KqtgAX-9fYA_27_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">494000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_KQ0ccQymZ0KiuadyNx05JQ_27_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1285000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_H35S8fJEk0y8eL8lNu0-ng_29_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-169000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_lsS_yTWCb02jkdmXZhffqQ_29_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">16714000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_EEWVU0oiKESPtC9-KyvCbA_29_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-494000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_cN3QEiRgkkqRRzXRTlGa8A_29_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-1285000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_jILzXyvxw0SUA9IfOrlEQw_32_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_5ssSshEvu02ivC0aK8-FWg_32_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">67000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_AfIhGXHoT0WICTYj3ZaaUw_32_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">175000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_BRSz4XUz0ka_dfhyOfhdIg_33_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">444000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_OA0fTb3uC06ky6YW73lCDw_33_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">454000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_CnVPB3SOOEqleh2WIRfbbw_33_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1304000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_o0YhTijGpU-V1QMji4VYPA_33_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1329000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_AzbukifYRESHbUfxQGcTPg_35_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-444000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_vT_BJGEqB0GDbolBLHBhhQ_35_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-453000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_Il_65MclHUudq-pgEhsKkw_35_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-1237000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_aaPJlzt9WE2PIih6hQeH0Q_35_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-1154000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_pEgR_dmdI0-rHcYeDj5VkQ_37_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-12848000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_pNsm8E_ArUmdsdqgaalNqQ_37_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">10604000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_a0CJVrCETEyRsoehOo6qKw_37_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-41165000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_CSgTBmSKnUy2poopYbXD5w_37_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-29484000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_7_1_2025_To_9_30_2025_YLbOmk1TA0i0T7WPmYN1rQ"
      decimals="-3"
      id="Tc_3djnP4fU0EON4Dno96n9fQ_39_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-34000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_7_1_2024_To_9_30_2024_R4Q--F-Pbk6zO5CASJNnuw"
      decimals="-3"
      id="Tc_Ac3dVEmo_UqmiKfomWA7WQ_39_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-173000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_DV8i4mMlJUaLZOW-5JrTdg_39_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-1360000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_dWTixVZD-Eukv7zShVMwIg_39_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">-40000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2025_i0u4-QQ5ZU-UjEoLiyQsHw"
      decimals="-3"
      id="Tc_UkI9YNi0FkC8DwklGJNiJw_40_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">119765000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2024_ZHbkuA8ZZEC6p9HbY3sb1w"
      decimals="-3"
      id="Tc_KKldtCjEUEWbfrw_J2s2Aw_40_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">78970000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_lS0MFWoTq02CvzpMClo17g_40_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">149408000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2023_7SqLUGM3Ck68Fx8rYXnMKQ"
      decimals="-3"
      id="Tc_-hZvpzqtc0CNiR27QIqX2A_40_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">118925000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_w11-nWDPkkazz5OjXx5_og_42_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">106883000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_9_30_2024_g29o3Zo7Ak-Bxlwv8XcO8g"
      decimals="-3"
      id="Tc_pzTADizJ1k2NUdHKC5fIhA_42_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">89401000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_ayTatYf16k-ScXCYOAWAEQ_42_6"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">106883000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_9_30_2024_g29o3Zo7Ak-Bxlwv8XcO8g"
      decimals="-3"
      id="Tc_7cR-1YrPRUCYRa3PYNyH8A_42_8"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">89401000</ifrs-full:CashAndCashEquivalents>
    <prqr:DisclosureOfGeneralInformationExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_wWzC2AkKMkmRvMSxJo9Igg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;1. General Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;ProQR Therapeutics N.V., or &#x201c;ProQR&#x201d; or the &#x201c;Company&#x201d;, is a biotechnology company domiciled in the Netherlands that primarily focuses on the discovery and development of novel therapeutic medicines.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Since September 18, 2014, the Company&#x2019;s ordinary shares have been listed on Nasdaq. They are currently trading at Nasdaq Capital Market under ticker symbol PRQR. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The Company was incorporated in the Netherlands, on February&#160;21, 2012 (Chamber of Commerce no. 54600790) and was reorganized from a private company with limited liability to a public company with limited liability on September&#160;23, 2014. The Company has its statutory seat in Leiden, the Netherlands. The address of its headquarters and registered office is Zernikedreef 9, 2333 CK Leiden, the Netherlands.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;ProQR Therapeutics N.V. is the ultimate parent company of the following entities:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;ProQR Therapeutics Holding B.V. (&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;ProQR Therapeutics I B.V. (&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;ProQR Therapeutics II B.V. (&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;ProQR Therapeutics III B.V. (&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;ProQR Therapeutics IV B.V. (&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;ProQR Therapeutics V B.V. (&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;ProQR Therapeutics VI B.V. (&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;ProQR Therapeutics VII B.V. (&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;ProQR Therapeutics VIII B.V. (&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;ProQR Therapeutics IX B.V. (&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;ProQR Therapeutics I&#160;Inc. (&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;ProQR Therapeutics N.V. is also statutory director of Stichting Bewaarneming Aandelen ProQR (&#x201c;ESOP Foundation&#x201d;) and has full control over this entity. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;As used in these condensed consolidated financial statements, unless the context indicates otherwise, all references to &#x201c;ProQR&#x201d; or the &#x201c;Company&#x201d; refer to ProQR Therapeutics N.V. including its subsidiaries and the ESOP Foundation.&lt;/span&gt;&lt;/p&gt;</prqr:DisclosureOfGeneralInformationExplanatory>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsHoldingBvMember_O8oNddjWmkC-HAijvKH37g"
      decimals="INF"
      id="Narr__xTuVq-8T0OkTFXa1vflZg"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIBvMember_rEz99sZOpEOeeXyEDeM7bQ"
      decimals="INF"
      id="Narr_9mm9jNR9j0-l7uA3fYjdNg"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIiBvMember_0sZHnPkpQUib6ZcDTeKIPA"
      decimals="INF"
      id="Narr_bx0wu18qckqxpgBwn_rBew"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIiiBvMember_fK1FbaT8-k-4CxcnPUyGNw"
      decimals="INF"
      id="Narr_lL4qnBJYwEamL8_w0AYa1Q"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIvBvMember_TGiLF5LfiUGZLR-qDsOFtQ"
      decimals="INF"
      id="Narr_1k2uohSVA0GGkxCKPiGd_Q"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsVBvMember_XAFpvyId2k2r7a7zNVEohA"
      decimals="INF"
      id="Narr_I9A9RmOfsEekFfiayHKiuQ"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViBvMember_Eg_4tvfBoUCuq-QPluHQsQ"
      decimals="INF"
      id="Narr_tWke656V2E-rBYfnM4XcTA"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViiBvMember_vOqWyc0GxkKVzCAG4aDgJQ"
      decimals="INF"
      id="Narr_XgeWOQAZDky0-SQGt9KSMw"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsViiiBvMember_VdFaX-IgmUWXDhT8Sj91cg"
      decimals="INF"
      id="Narr_LemBnAFMy06cBShKVxXvTQ"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIxBvMember_8b6o2YoKLUWPL-vDhftrUQ"
      decimals="INF"
      id="Narr_ta2cSAbmaU6QGZFVZdCtAw"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_prqr_ProqrTherapeuticsIIncMember_ECpwoHs8RUyCW8sNiNEueg"
      decimals="INF"
      id="Narr_U9KoLsaF-UG3bNBQq025SQ"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_4VcKChri-kOXA66XYSvUiA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2. Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;These interim condensed consolidated financial statements for the three and nine month periods ended September 30, 2025, have been prepared in accordance with IAS 34 Interim Financial Statements. They should be read in conjunction with the Company&#x2019;s annual financial statements for the year ended December 31, 2024. These interim condensed consolidated financial statements do not include all information required for a complete set of financial statements prepared in accordance with IFRS Standards. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company&#x2019;s financial position and performance since the last annual financial statements. In the opinion of management, all events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period are disclosed in these interim condensed consolidated financial statements. The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those applied in the preparation of the Company&#x2019;s annual financial statements for the year ended December 31, 2024. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;During the nine month period ended September 30, 2024, the Company invested in financial assets in the form of a deposit with an original maturity of longer than three months but shorter than twelve months which are measured at amortized cost as they give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. The deposit matured on September 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The Company&#x2019;s financial results have varied substantially, and are expected to continue to vary, from period to period. The Company believes that its ordinary activities are not linked to any particular seasonal factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The management of ProQR has, upon preparing and finalizing these interim condensed consolidated financial statements, assessed the Company&#x2019;s ability to fund its operations for a period of at least one year after the date of signing these interim condensed consolidated financial statements. Management expects the Company to continue as a going concern based on its existing funding, taking into account the Company&#x2019;s current cash position and the projected cash flows based on the activities under execution on the basis of ProQR&#x2019;s business plan and budget. Thus, we continue to adopt the going concern basis of accounting in preparing the interim condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The carrying amount of all financial assets and financial liabilities is a reasonable approximation of the fair value and therefore, information about the fair values of each class has not been disclosed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The Company operates in &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;one&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; reportable segment, which comprises the discovery and development of innovative, RNA based therapeutics.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <prqr:IfrsNumberOfReportableSegments
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="INF"
      id="Narr_lRm-LsImMkqi8Eg027mqdg"
      unitRef="Unit_Standard_segment_iAZ-erTqcEibFQQvKQuMIg">1</prqr:IfrsNumberOfReportableSegments>
    <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_3ZMAXfmTMkObXgmRjXSewA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;3. Adoption of New and Revised International Financial Reporting Standards&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;New Standards and Interpretations, which became effective as of January&#160;1, 2025, did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_M7TfTwmnnkC06e7mvY9rAA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;4. Critical Accounting Estimates and Judgements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;In the application of the Company&#x2019;s accounting policies, management is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The significant judgements made by management in applying the Company&#x2019;s accounting policies and the key sources of estimation uncertainty were the same as those described in the Company&#x2019;s annual financial statements for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-family:'Open Sans';font-style:italic;"&gt;(i) Revenue recognition for the Eli Lilly and Company research and collaboration agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;a. Identification of the performance obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;As further described in Note 13 the identification of the performance obligations for the Company&#x2019;s original research and collaboration agreement with Eli Lilly and Company (&#x201c;Lilly&#x201d;), and the amended and restated research and collaboration agreement (collectively, the &#x201c;Collaboration agreement&#x201d;) involves significant judgement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;A key judgement was made in determining that the license granted to Lilly is not distinct from the associated research and development (&#x201c;R&amp;amp;D&#x201d;) services, due to the lack of stand-alone value of the license without the Company&#x2019;s involvement and the significant interdependencies between the license and the R&amp;amp;D services to be provided by the Company. As a result, the license and the R&amp;amp;D services are accounted for together as a single combined performance obligation consisting of multiple activities that are not distinct.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;b. Determining the timing of satisfaction of performance obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;As further described in Note 13, before the handover of a compound to Lilly, the Company recognizes revenue over time, using an input method that estimates the satisfaction of the performance obligation as the percentage of labor hours incurred compared to the total estimated labor hours required to complete the promised services. As the Company&#x2019;s estimate of the total labor hours required is dependent on the evolution of the research and development activities, it may be subject to change. If the progression and/or outcome of certain research and development activities would be different from the assumptions that were made during the preparation of these financial statements, this could lead to material adjustments to the total estimated labor hours, which might result in a reallocation of revenue between current and future periods. Our total deferred revenue balance related to this Lilly performance obligation amounts to &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;41,492,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; at September 30, 2025 (December 31, 2024: &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;50,930,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;c. Determining the transaction price&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The Company applied judgement to determine whether the equity investments made by Lilly in ProQR are part of the transaction price for the Collaboration agreement. The Company concluded that the differences between the prices that Lilly paid for the shares and the ProQR stock closing prices on the days of entering into the equity investment agreements arose because of the Company&#x2019;s existing obligations to deliver research and development services to Lilly under the terms of the Collaboration agreement. Therefore, the above differences between the closing share prices on the agreement effective dates and the equity investment prices paid by Lilly are considered to be part of the transaction price of the contract and are initially allocated to deferred revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The contract also includes variable consideration, but no variable consideration was included in the initial transaction price at the inception, as it was not highly probable that a significant reversal in the amount of cumulative revenue recognized would not occur. The Company includes such variable consideration in the transaction price when the uncertainty associated with the variable consideration is resolved. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The Collaboration agreement includes variable consideration in the form of development milestones, commercial milestones, and sales-based royalties based on the level of sales. As further described in Note 13, during 2025, the Company achieved development milestones during the ProQR research program under the agreement, which were added to the transaction price and recognized partially as revenue during 2025 based on the status of completion (satisfied part) of the single combined performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-family:'Open Sans';font-style:italic;"&gt;(ii) Research and development expenditures&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Research expenditures are reflected in the income statement. Development expenses are currently also reflected in the income statement because the criteria for capitalization are not met. At each balance sheet date, the Company estimates the level of service performed by the vendors and the associated costs incurred for the services performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Although we do not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_RfU_Fsdc20OWzTokcX7_UA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-family:'Open Sans';font-style:italic;"&gt;(i) Revenue recognition for the Eli Lilly and Company research and collaboration agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;a. Identification of the performance obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;As further described in Note 13 the identification of the performance obligations for the Company&#x2019;s original research and collaboration agreement with Eli Lilly and Company (&#x201c;Lilly&#x201d;), and the amended and restated research and collaboration agreement (collectively, the &#x201c;Collaboration agreement&#x201d;) involves significant judgement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;A key judgement was made in determining that the license granted to Lilly is not distinct from the associated research and development (&#x201c;R&amp;amp;D&#x201d;) services, due to the lack of stand-alone value of the license without the Company&#x2019;s involvement and the significant interdependencies between the license and the R&amp;amp;D services to be provided by the Company. As a result, the license and the R&amp;amp;D services are accounted for together as a single combined performance obligation consisting of multiple activities that are not distinct.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;b. Determining the timing of satisfaction of performance obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;As further described in Note 13, before the handover of a compound to Lilly, the Company recognizes revenue over time, using an input method that estimates the satisfaction of the performance obligation as the percentage of labor hours incurred compared to the total estimated labor hours required to complete the promised services. As the Company&#x2019;s estimate of the total labor hours required is dependent on the evolution of the research and development activities, it may be subject to change. If the progression and/or outcome of certain research and development activities would be different from the assumptions that were made during the preparation of these financial statements, this could lead to material adjustments to the total estimated labor hours, which might result in a reallocation of revenue between current and future periods. Our total deferred revenue balance related to this Lilly performance obligation amounts to &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;41,492,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; at September 30, 2025 (December 31, 2024: &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;50,930,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;c. Determining the transaction price&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The Company applied judgement to determine whether the equity investments made by Lilly in ProQR are part of the transaction price for the Collaboration agreement. The Company concluded that the differences between the prices that Lilly paid for the shares and the ProQR stock closing prices on the days of entering into the equity investment agreements arose because of the Company&#x2019;s existing obligations to deliver research and development services to Lilly under the terms of the Collaboration agreement. Therefore, the above differences between the closing share prices on the agreement effective dates and the equity investment prices paid by Lilly are considered to be part of the transaction price of the contract and are initially allocated to deferred revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The contract also includes variable consideration, but no variable consideration was included in the initial transaction price at the inception, as it was not highly probable that a significant reversal in the amount of cumulative revenue recognized would not occur. The Company includes such variable consideration in the transaction price when the uncertainty associated with the variable consideration is resolved. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The Collaboration agreement includes variable consideration in the form of development milestones, commercial milestones, and sales-based royalties based on the level of sales. As further described in Note 13, during 2025, the Company achieved development milestones during the ProQR research program under the agreement, which were added to the transaction price and recognized partially as revenue during 2025 based on the status of completion (satisfied part) of the single combined performance obligation.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities
      contextRef="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_z_wMRuiDMEqEinzBTRrmJA"
      decimals="-3"
      id="Narr_VOVheS1Qh02s7WDUqe1OqA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">41492000</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities
      contextRef="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_N0cWD2q4NkeY3A32UZEFqg"
      decimals="-3"
      id="Narr_3Uyr96w3A0yM-y17vmJrNw"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">50930000</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_lHv1HCh5iU2OpXOwcNcC-Q">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-family:'Open Sans';font-style:italic;"&gt;(ii) Research and development expenditures&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Research expenditures are reflected in the income statement. Development expenses are currently also reflected in the income statement because the criteria for capitalization are not met. At each balance sheet date, the Company estimates the level of service performed by the vendors and the associated costs incurred for the services performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Although we do not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_ChgAjryzyECElOtwsik-mQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;5. Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;At September 30, 2025, the Company&#x2019;s cash and cash equivalents were &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;106,883,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; compared to &#x20ac;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;&#160;149,408,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; at December&#160;31, 2024. The cash balances are held at banks with investment grade credit ratings. Short-term credit ratings must be rated A-1/P-1/F1 at a minimum by at least one of the Nationally Recognized Statistical Rating Organizations (&#x201c;NRSROs&#x201d;) specifically Moody&#x2019;s, Standard &amp;amp; Poor&#x2019;s or Fitch. The cash at banks is at full disposal of the Company. Included in cash and cash equivalents are deposits fixed for at most 3-month periods at a time.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Narr_CDQCzr5pyUC3BoGvweVStA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">106883000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Narr_n65XTa3lQ06GJ4PqRN6CsA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">149408000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_DwP1V_FtU0K_fG7PpoIgAw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.55;margin:0pt 0pt 4pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;6. Prepayments and Other Receivables&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;September&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;&#x20ac;1&lt;/span&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;&#x20ac;1&lt;/span&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Prepayments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt; 1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;2,410 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt; 1,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;835 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Accrued income from Rett Syndrome Research Trust&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt; 502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;502 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.52%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;3,872 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;3,747 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;All receivables are considered short-term and due within one year. At September 30, 2025 and December 31, 2024 prepayments consisted principally of payments made by the Company for services not yet provided by vendors. At September 30, 2025 other receivables consisted principally of amounts receivable from research collaboration partners, accrued income and deposits. At December 31, 2024 other receivables consisted principally of accrued grant income and deposits. As at September 30, 2025 and December 31, 2024 the accrued grant income relating to Rett Syndrome Research Trust (&#x201c;RSRT&#x201d;) includes the initial fair value of the warrants issued to RSRT that was accounted for as a reduction of the transaction price. The RSRT agreement is described in Note 14. Other Income.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory>
    <prqr:DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_5FzAFasx5E6vBTT8QyuM4g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;September&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;&#x20ac;1&lt;/span&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;&#x20ac;1&lt;/span&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Prepayments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt; 1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;2,410 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt; 1,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;835 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.52%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Accrued income from Rett Syndrome Research Trust&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt; 502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;502 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.52%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.87%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;3,872 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;3,747 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</prqr:DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock>
    <ifrs-full:Prepayments
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_BBpTqlIuS0eIcu378-yRJQ_4_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1903000</ifrs-full:Prepayments>
    <ifrs-full:Prepayments
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_mWDsJV4HwEirpjb1_kzQew_4_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2410000</ifrs-full:Prepayments>
    <ifrs-full:OtherReceivables
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_PygbQL_qpUSYltYiiJgtDQ_5_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1467000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_1OEiaaxHaEKOvbvVzKhhLg_5_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">835000</ifrs-full:OtherReceivables>
    <ifrs-full:AccruedIncomeIncludingContractAssets
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_2J5jBjjt60-ebFVQLXvG5Q_6_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">502000</ifrs-full:AccruedIncomeIncludingContractAssets>
    <ifrs-full:AccruedIncomeIncludingContractAssets
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_6y-wzenrv0Ogv2_KuN_a2A_6_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">502000</ifrs-full:AccruedIncomeIncludingContractAssets>
    <prqr:PrepaymentsAndOtherReceivables
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_FQj9U1yRtUif5Xp9-pfTDw_7_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">3872000</prqr:PrepaymentsAndOtherReceivables>
    <prqr:PrepaymentsAndOtherReceivables
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_H16DXKHYvkW1VsXtvJwWUA_7_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">3747000</prqr:PrepaymentsAndOtherReceivables>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_aJUY1185c0yicVx68Rupmg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.55;margin:0pt 0pt 4pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;7. Property, Plant and Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;At September 30, 2025, and December 31, 2024, property plant and equipment consisted of buildings and leasehold improvements, laboratory equipment and other assets. Buildings and leasehold improvements include a right-of-use asset relating to the lease of our Leiden office and laboratory space, with a carrying amount of &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;10,448,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; at September&#160;30,&#160;2025 (December 31, 2024: &#x20ac;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;&#160;11,433,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;).&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_Ps4wlpTyCk-CiG6i9mnIJg"
      decimals="-3"
      id="Narr_DkL2cj1yZkGTbVZfYBCMag"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">10448000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_pMfe7-CYZkSkMiFKJi9Z7Q"
      decimals="-3"
      id="Narr_gaZdwmjC60e792oYazRriQ"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">11433000</ifrs-full:RightofuseAssets>
    <ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_q4ptrGKyckeBrWjw31JzYQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.55;margin:0pt 0pt 4pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;8. Other Current Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;At September 30, 2025, other current liabilities amount to &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;8,550,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (December 31, 2024:&#160;&#x20ac; &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;8,849,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;). At September 30, 2025 and December&#160;31, 2024, other current liabilities consisted principally of accruals for services provided by vendors not yet billed, payroll related accruals and other miscellaneous liabilities.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Narr_8IyuMVPts02cln8TCxOGuQ"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">8550000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Narr_-nn-5-b_pEyRELgVmiXNCQ"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">8849000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:DisclosureOfBorrowingsExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_jMkQc_PXPk-jTqIFcy701A">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;9&lt;/b&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;. Borrowings&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.39151382%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.78%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.62%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-family:'Open Sans';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#ffffff;font-family:'Open Sans';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;&#x20ac;1,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;&#x20ac;1,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Innovation credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;2,899 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;2,899 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Accrued interest on innovation credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;1,901 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;1,683 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;Total borrowings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;4,800 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;4,582 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;4,800 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;4,582 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;Total non-current borrowings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;&#x2014; &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;&#x2014; &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;In December 2018, ProQR was awarded an Innovation credit for the sepofarsen program. Amounts were drawn under this facility from 2018 through 2022. The credit of &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;3,907,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; was used to conduct the Phase 2/3 clinical study and efforts to obtain regulatory and ethical market approval (New Drug Applications (&#x201c;NDA&#x201d;) / Marketing Authorization Applications (&#x201c;MAA&#x201d;)) of sepofarsen for LCA10. In the fourth quarter of 2023, ProQR made a partial repayment of the principal, amounting to &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;1,008,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;. The remaining amount payable of &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;2,899,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; is recognized under current borrowings as at September 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;In December 2023, ProQR received a waiver for the remaining balance of the Innovation credit including accrued interest. As a result, the repayment of the total loan of &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;4,292,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;, including accrued interest, could be waived if conditions are met, subject to annual review. In January 2025, the waiver for the principal and interest was again extended until December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;In September 2022, ProQR extinguished its debt with Pontifax and Kreos by repaying all outstanding principal amounts. However, the Pontifax&#x2019; and Kreos&#x2019; warrants, classified as derivative financial instruments on the balance sheet, remain in place until their &lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;five-year&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; economic life expires in 2025 and 2026. These warrants are accounted for as embedded derivatives and were recognized separately from the host contract as derivative financial liabilities at fair value through profit or loss. During Q3 2025, the original Pontifax warrants expiring in July 2025 and the Kreos warrants expiring in August 2025 expired and were derecognized. &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfBorrowingsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_d9-2gdHIAkC6zR7jKi00Yw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.39151382%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.78%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.62%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;border-bottom:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-family:'Open Sans';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#ffffff;font-family:'Open Sans';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;&#x20ac;1,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;&#x20ac;1,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Innovation credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;2,899 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;2,899 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Accrued interest on innovation credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;1,901 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;1,683 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;Total borrowings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;4,800 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;4,582 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;4,800 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;4,582 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.62%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;Total non-current borrowings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.94%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;&#x2014; &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.92%;background:#ffffff;border-bottom:1.5pt solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;&#x2014; &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <prqr:BorrowingsExcludingAccruedInterest
      contextRef="As_Of_9_30_2025_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_Jm0ycghQx06aKQaV-XaMYg"
      decimals="-3"
      id="Tc_pU_mLJN_9EyUELoSWJXCOQ_4_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2899000</prqr:BorrowingsExcludingAccruedInterest>
    <prqr:BorrowingsExcludingAccruedInterest
      contextRef="As_Of_12_31_2024_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_U0bIiWfTwUK2UDFOYXKvcg"
      decimals="-3"
      id="Tc_nrsCRAzqi0-s8MgXRT6yKw_4_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2899000</prqr:BorrowingsExcludingAccruedInterest>
    <ifrs-full:InterestPayable
      contextRef="As_Of_9_30_2025_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_Jm0ycghQx06aKQaV-XaMYg"
      decimals="-3"
      id="Tc_keiNtv9s4E6YeEqBTWVYPw_5_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1901000</ifrs-full:InterestPayable>
    <ifrs-full:InterestPayable
      contextRef="As_Of_12_31_2024_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_U0bIiWfTwUK2UDFOYXKvcg"
      decimals="-3"
      id="Tc_FhiqUVNRSUiYYRMWPhWcgg_5_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1683000</ifrs-full:InterestPayable>
    <ifrs-full:Borrowings
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_UzMtNS93lkeMuaQSysapQg_7_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">4800000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_Bt7fgqU85kWeojlonQL6yA_7_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">4582000</ifrs-full:Borrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_wdRqE2Eef0O7uTHtcVfHqg_8_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">4800000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_tZqb77hm1kalkhTVVNwtMQ_8_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">4582000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_10_12_2018_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_lbY8fExZj0i3II_9Pf9fhw"
      decimals="-3"
      id="Narr_1V4qG17pJUi1ZfhbYqZLvw"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">3907000</ifrs-full:NotionalAmount>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_10_1_2023_To_12_31_2023_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_wm8LBrxXCkyzFCS9TM0Eaw"
      decimals="-3"
      id="Narr_Mi2-VXmMF0Sz5oHTk-Jgkw"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1008000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <prqr:CurrentBorrowingsExcludingAccruedInterest
      contextRef="As_Of_6_30_2025_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_PoXgbyj0VEimJfqnnq8vXw"
      decimals="-3"
      id="Narr_VFYPTbGozEWwAu3T2MbN5w"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2899000</prqr:CurrentBorrowingsExcludingAccruedInterest>
    <prqr:ConditionalWaiverOfDebtTotal
      contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_prqr_InnovationCreditMember_2suHy2Uqqkq-b7CLFUL2lg"
      decimals="-3"
      id="Narr_Ll1Nd4RN_0uncXx6JshItw"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">4292000</prqr:ConditionalWaiverOfDebtTotal>
    <prqr:WarrantsEconomicLifetime
      contextRef="Duration_9_1_2022_To_9_30_2022_prqr_IfrsClassesOfWarrantsOrRightsAxisAxis_prqr_PontifaxAndKreosWarrantsMember_QDqtNs1aIEi1heNwMkeeNg"
      id="Narr_okaQb4dpRkmceeuaur0azA">P5Y</prqr:WarrantsEconomicLifetime>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_gN9OWDFK60G1FTtDxBmJ9A">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;10. Lease Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;At September 30, 2025 and December 31, 2024, lease liabilities primarily consisted of the Company&#x2019;s lease of office and laboratory facilities at Zernikedreef in Leiden, the Netherlands. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The Company leases office and laboratory facilities of &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;4,818&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; square meters at Zernikedreef in Leiden, the Netherlands, where our headquarters and our laboratories are located. The current lease agreement for these facilities terminates &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;on June 30, 2031. The lease agreement contains no significant dismantling requirements. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;The initial &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_1k_9dkbIBE6F9vmNuzcVIw;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; lease agreement for the Leiden office and laboratory facilities was accounted for as of commencement date July 1, 2020. This &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_9sghCigMRE-91luzw8kAXw;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; period was extended by &lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;1 year&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; to an &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_zMWif57Oekmju6l1QF4dVQ;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;11-year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; period in December 2020. The lease contract may be extended for subsequent &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden__Ne-iWIfzU6QAPw9QT7ObQ;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;5-year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; periods. As the Company is not reasonably certain to exercise these extension options, these are not included in the lease term. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The carrying amount of the right-of-use asset is disclosed in Note 7.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <prqr:AreaOfPropertyUnderLease
      contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_Ps4wlpTyCk-CiG6i9mnIJg"
      decimals="0"
      id="Narr_vX-H8cAKYUWzkT74Q5izcw"
      unitRef="Unit_Standard_sqm_Oc_SVpN4d0OQM3FvR-NrfQ">4818</prqr:AreaOfPropertyUnderLease>
    <prqr:LeaseExtensionTerm
      contextRef="Duration_12_1_2020_To_12_31_2020_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_prqr_OfficeAndLaboratoryFacilitiesAtZernikedreefInLeidenNetherlandsMember_mQAGEX8GEkW-yeLTTQ4VGA"
      id="Narr_B4DRHiXTR06onj0Q0qdXvQ">P1Y</prqr:LeaseExtensionTerm>
    <ifrs-full:DisclosureOfDeferredIncomeExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_fLg2hUh7eUOmf1w4HbQ71w">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;11. Deferred Income&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The following table summarizes details of deferred income at September 30, 2025 and December 31, 2024. The nature of the deferred income is described in Note 13 and 14.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;&#x20ac;1&lt;/span&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;&#x20ac;1&lt;/span&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Payments from Eli Lilly and Company&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;17,367 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;21,501 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Payments from Rett Syndrome Research Trust&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;27 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;441 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;Current deferred income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;17,394 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;21,942 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Payments from Eli Lilly and Company&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;24,125 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;29,429 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;Non-current deferred income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;24,125 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;29,429 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.7%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;Total deferred income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;41,519 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;51,371 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';"&gt;c&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfDeferredIncomeExplanatory>
    <prqr:ScheduleOfDeferredIncomeTableTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_rRV0BxIlCE-pVGS08tAslA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;&#x20ac;1&lt;/span&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;&#x20ac;1&lt;/span&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Payments from Eli Lilly and Company&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;17,367 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;21,501 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Payments from Rett Syndrome Research Trust&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;27 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;441 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;Current deferred income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;17,394 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;21,942 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Payments from Eli Lilly and Company&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;24,125 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;29,429 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;Non-current deferred income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;24,125 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;29,429 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.7%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.7%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;Total deferred income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;41,519 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;51,371 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</prqr:ScheduleOfDeferredIncomeTableTextBlock>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_z_wMRuiDMEqEinzBTRrmJA"
      decimals="-3"
      id="Tc_ijR2YHA9wUm9TVlbkJWn3A_4_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">17367000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_N0cWD2q4NkeY3A32UZEFqg"
      decimals="-3"
      id="Tc_MlZ8js4Ns0KirngWbvs27Q_4_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">21501000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_EeQqadGBPU6ffQXEFmCknA"
      decimals="-3"
      id="Tc_ZFjOrvA0NkWPjVzkIhm6JQ_5_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">27000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_rPv_1PsZlkyKXSb6IKaW-A"
      decimals="-3"
      id="Tc_PXu582gMHUysNzHfHojVOg_5_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">441000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_0BJltPkgGUeNVtj0WIkVqg_6_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">17394000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_tWvKzUmbHkq4HWgWoY9QoQ_6_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">21942000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities
      contextRef="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_z_wMRuiDMEqEinzBTRrmJA"
      decimals="-3"
      id="Tc_KcrTIq2O5ESNOtMwoSMRsg_8_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">24125000</ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities>
    <ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities
      contextRef="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_N0cWD2q4NkeY3A32UZEFqg"
      decimals="-3"
      id="Tc_dgxwrtPto0aTu_sXXOOyVA_8_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">29429000</ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities>
    <ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_41H9ajUsA0igU4Yu_qIeUg_9_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">24125000</ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities>
    <ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_6LrKfxvD_0S_kkcZw4lb_A_9_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">29429000</ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Tc_ODxF5HgCD0q4dDxCmmfWnA_11_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">41519000</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Tc_Mw5HUlJkuUWta-RcoQQ0vw_11_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">51371000</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_cyDyVCgfcUG6oNFak0LbrA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;12. Shareholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The authorized share capital of the Company amounting to &#x20ac;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; 13,600,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; consists of &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;170,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; ordinary shares and &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;170,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; preference shares with a par value of &#x20ac;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; 0.04&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;&#160;per share. At September 30, 2025, &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;107,710,916&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; ordinary shares were issued, &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;105,345,192&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; ordinary shares were fully paid and &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;2,365,724&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; ordinary shares were held by the Company as treasury shares (December 31, 2024: &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;2,498,389&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;In September 2024, the Company filed a shelf registration statement on Form F-3, which permitted: (a) the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;300,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; of its ordinary shares, warrants and/or units; and (b) as part of the $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;300,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;, the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;75,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; of its ordinary shares that may be issued and sold under a sales agreement (the &#x201c;sales agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;) in one or more at-the-market (&#x201c;ATM&#x201d;) offerings. The Company will pay Cantor a commission equal to &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;3%&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; of the gross proceeds of the sales price of all ordinary shares sold through it as sales agent under the sale agreement. As of September 30, 2025, &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;no&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; shares have been issued pursuant to this ATM facility.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;In October 2024, the Company consummated an underwritten public offering of &lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;18,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; ordinary shares (the &#x201c;offering&#x201d;) at a public offering price of $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;3.50&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; per share (the &#x201c;public offering price&#x201d;). In addition, the Company granted the underwriters a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_SBfXi-xh50yWDW8Jo_eMMQ;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;30-day&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; option to purchase up to &lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;2,700,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; additional ordinary shares at the public offering price, less underwriting discounts and commissions. The option was partially exercised on October 31, 2024, resulting in the issuance of &lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;1,940,072&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; shares. The gross proceeds from the Offering and subsequent partial exercise of the underwriters&#x2019; option, amounted to $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;69,790,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt; (&#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;64,600,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;) while the transaction costs amounted to approximately &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;4,365,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;, resulting in net proceeds of approximately &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;60,235,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Concurrently with the Offering, the Company entered into a share purchase agreement with Lilly in a separately negotiated transaction (the &#x201c;concurrent private placement&#x201d;), pursuant to which the Company agreed to offer and sell, and Lilly agreed to purchase, &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;3,523,538&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; ordinary shares at a price per share equal to the public offering price, for total gross proceeds of approximately $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;12,300,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;, subject to a purchase price cap of $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;15,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;, the consummation of the Offering and the satisfaction of other customary closing conditions. The proceeds of $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;12,300,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (&#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;11,400,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;) from the concurrent private placement were received on October 25, 2024. The ordinary shares purchased in the concurrent private placement are not subject to any underwriting discounts or commissions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-family:'Open Sans';font-style:italic;"&gt;Translation reserve&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-family:'Open Sans';font-style:italic;"&gt;Share options&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The Company operates an equity-settled share-based compensation plan, which was introduced in 2013. Options and Restricted Stock Units (&#x201c;RSUs&#x201d;) may be granted to employees, members of the Board and consultants. The compensation expenses included in operating costs for this plan in the nine month period ended September 30, 2025 were &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;2,784,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (nine month period ended September 30, 2024: &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;1,976,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;), of which &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;1,952,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; was recorded in general and administrative costs (nine month period ended September 30, 2024: &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;1,559,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;) and &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;832,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; was recorded in research and development costs (nine month period ended September 30, 2024: &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;417,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;).&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <prqr:AuthorizedShareCapitalValue
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Narr_diUxTsC5yk69Vd9CrL2pOg"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">13600000</prqr:AuthorizedShareCapitalValue>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_MWf62Mctg0SEca73DdSQSA"
      decimals="INF"
      id="Narr_7uN0ZbqfsEqUn0yiFqvDFQ"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">170000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_-bqBRBYnMkqbwyTudO1CSg"
      decimals="INF"
      id="Narr_AzPCc2C8oky3V_7aK_5Utg"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">170000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="INF"
      id="Narr_Vod3mhiWN0KAgmuIusZn-g"
      unitRef="Unit_Divide_EUR_shares_Uz1P0tInSEqiK5ZvPfz-Vg">0.04</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_MWf62Mctg0SEca73DdSQSA"
      decimals="INF"
      id="Narr_0wEDROJwOkmEi7Me7tLOCg"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">107710916</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_MWf62Mctg0SEca73DdSQSA"
      decimals="INF"
      id="Narr_2TxHfKrTWEiNfX54bhZUYQ"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">105345192</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates
      contextRef="As_Of_9_30_2025_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_MWf62Mctg0SEca73DdSQSA"
      decimals="INF"
      id="Narr_GEZ3W7N8i0Ge4NGuGC9Gfg"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">2365724</ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates>
    <ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates
      contextRef="As_Of_12_31_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_YJJKCH6_f0CGHWEK670wpw"
      decimals="INF"
      id="Narr_yhHCpl3Gykq3hzFPsbcUBQ"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">2498389</ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates>
    <prqr:MaximumOfferingPriceInShelfRegistrationStatement
      contextRef="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_ShelfRegistrationStatement2024Member_ng7Fbf6gFUy4vNzZAU2odA"
      decimals="INF"
      id="Narr_n-EEwDtggkqxVW7vr6w-_Q"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">300000000</prqr:MaximumOfferingPriceInShelfRegistrationStatement>
    <prqr:MaximumOfferingPriceInShelfRegistrationStatement
      contextRef="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_ShelfRegistrationStatement2024Member_ng7Fbf6gFUy4vNzZAU2odA"
      decimals="INF"
      id="Narr_rb_n4I7qdE2aiVRnogItuQ"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">300000000</prqr:MaximumOfferingPriceInShelfRegistrationStatement>
    <prqr:MaximumOfferingPriceInShelfRegistrationStatement
      contextRef="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_sHnEGchkcEymfM1vdGke-g"
      decimals="INF"
      id="Narr_yQ6AK1Lx-EufAkBBuiaf3g"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">75000000</prqr:MaximumOfferingPriceInShelfRegistrationStatement>
    <prqr:PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement
      contextRef="As_Of_9_30_2024_prqr_IfrsSaleOfStockAxis_prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_sHnEGchkcEymfM1vdGke-g"
      decimals="2"
      id="Narr_0J2QTWp1vk6nyp9wdcnJiQ"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">0.03</prqr:PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement>
    <prqr:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_prqr_IfrsSaleOfStockAxis_prqr_AtMarketOfferingsWithCantorFitzgeraldAndCoUnderShelfRegistrationStatementMember_PGd6rcr3S0i-F2HTv9iGJg"
      decimals="INF"
      id="Narr_CeV78P9rq0KA1OMCZ9ZWXQ"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">0</prqr:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <prqr:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA"
      decimals="INF"
      id="Narr_55jRqgcBrkqJvBTM0VLoOg"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">18000000</prqr:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <prqr:IfrsSaleOfStockPricePerShare
      contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA"
      decimals="2"
      id="Narr_5TV9dKK-OkK4JQSdynBT5Q"
      unitRef="Unit_Divide_USD_shares_q_6SzVvYpE-NdnoAmmu_UA">3.5</prqr:IfrsSaleOfStockPricePerShare>
    <prqr:NumberOfSharesCallableForOptionsIssued
      contextRef="As_Of_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_dbgoR6vcMUqTMO3jvVhl5g"
      decimals="INF"
      id="Narr_STqEDCfXaEuJlRjcCVkl6g"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">2700000</prqr:NumberOfSharesCallableForOptionsIssued>
    <prqr:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_31_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_UnderwritersOptionInConnectionToOctober2024UnderwrittenPublicOfferingMember_SQEbr7EQSkStP6J8wDVlYQ"
      decimals="INF"
      id="Narr_SbiJHTTzyEaQE-uDVbtxqQ"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">1940072</prqr:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA"
      decimals="-3"
      id="Narr_AnXN3GFZ_0m2IeGJOeyURA"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">69790000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA"
      decimals="-3"
      id="Narr_1ZxUpkhnVE6Snc19GyGbCg"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">64600000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA"
      decimals="-3"
      id="Narr_VTno_8wWx0KsBpGdq7YsZQ"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">4365000</ifrs-full:PaymentsForShareIssueCosts>
    <prqr:NetProceedsFromIssuingShares
      contextRef="Duration_10_1_2024_To_10_31_2024_prqr_IfrsSaleOfStockAxis_prqr_October2024UnderwrittenPublicOfferingMember_hJmC9kzIVka8J5MBGfU7rA"
      decimals="-3"
      id="Narr_mhEr6BpOpEerF6VrGjTMHA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">60235000</prqr:NetProceedsFromIssuingShares>
    <prqr:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_25_2024_To_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_1SV3IDfQekeRE9nHK-mnpw"
      decimals="INF"
      id="Narr_-_b786Sy9k2SwPjnLv_0OA"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">3523538</prqr:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_10_25_2024_To_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_1SV3IDfQekeRE9nHK-mnpw"
      decimals="-3"
      id="Narr_vwJqSs5UZU2wMeiq8wqZAA"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">12300000</ifrs-full:ProceedsFromIssuingShares>
    <prqr:PurchasePriceCapSharePurchaseAgreement
      contextRef="As_Of_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_b5MiuBOLvkiPnH8dj15XoQ"
      decimals="INF"
      id="Narr_380FeGJDA0Kogow3Y5Gh0A"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">15000000</prqr:PurchasePriceCapSharePurchaseAgreement>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_10_25_2024_To_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_1SV3IDfQekeRE9nHK-mnpw"
      decimals="-3"
      id="Narr_Q27qrXEFNUKbMb5duVf89w"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">12300000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_10_25_2024_To_10_25_2024_prqr_IfrsSaleOfStockAxis_prqr_SharePurchaseAgreementWithEliLillyAndCompanyMember_1SV3IDfQekeRE9nHK-mnpw"
      decimals="-3"
      id="Narr_GRD9dVc0mkCnNlm7dXHuNA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">11400000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Narr_lCbwnsJ_y0-p1Hiiekyx7g"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2784000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Narr_S-L7AOC3gkWTRRyWV9ToVg"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1976000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_NBruH9iPUEO1qm4ppbYCPA"
      decimals="-3"
      id="Narr_0I6pAeW_hEqZc8w1a6OgKw"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1952000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsSellingGeneralAndAdministrativeExpensesMember_JxIfwdbS8kWh6YPJlU9p3w"
      decimals="-3"
      id="Narr_xD0rA6EYyECnO1AJMli6Qg"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1559000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsResearchAndDevelopmentExpenseMember_tcUIS9w0g0CCeSma1Lfl1Q"
      decimals="-3"
      id="Narr_g7KNz4-r2k-CgX_cQ_xRRg"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">832000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_prqr_IfrsResearchAndDevelopmentExpenseMember_cdQDW243CEmqV7EBFQBmvQ"
      decimals="-3"
      id="Narr_E-KwUP1dxkSNPeE2hH7Qbw"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">417000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:DisclosureOfRevenueExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_eLS7qS-_sU-oZvJsYdQmHg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;13. Revenue&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-family:'Open Sans';font-style:italic;"&gt;Eli Lilly and Company collaboration&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;In September 2021, the Company entered into a global licensing and research collaboration with Lilly focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR and Lilly will use ProQR&#x2019;s proprietary Axiomer&lt;/span&gt;&lt;span style="font-size:11pt;"&gt;&#x2122;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; RNA editing platform to progress new drug targets toward clinical development and commercialization.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Under the terms of the agreement, ProQR received an upfront payment and equity consideration, and is eligible to receive milestone payments and royalties on the net sales of any resulting products. In September 2021, the Company issued &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;3,989,976&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; shares to Lilly, resulting in gross proceeds of &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;$&#160;30,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (&#x20ac;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;&#160;25,270,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;). These shares were issued at a premium of $ &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;2,429,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (&#x20ac; &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;2,047,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;), which was determined to be part of the transaction price and as such was initially recognized as deferred revenue. An up-front payment of $&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;&#160;20,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (&#x20ac; &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;16,849,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;) was received in October 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;In December 2022, the Company and Lilly amended their research and collaboration agreement described above, which expanded the collaboration. Under the amended and restated research and collaboration agreement, Lilly will gain access to additional targets in the central nervous system (&#x201c;CNS&#x201d;) and peripheral nervous system (&#x201c;PNS&#x201d;) with ProQR&#x2019;s Axiomer platform.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;As described under Note 12, pursuant to the amended and restated agreement, the Company issued &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;9,381,586&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; shares to Lilly in December 2022, resulting in gross proceeds of $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;15,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (&#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;14,122,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;). These shares were issued at a discount of $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;480,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (&#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;451,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;), which is accounted for as a reduction of the transaction price. In February 2023, ProQR also received an upfront payment of $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;60,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (&#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;56,412,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;). Lilly has the ability to exercise an option to further expand the partnership for a consideration of $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;50,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;With regard to the original and amended and restated research and collaboration agreements with Lilly, the Company concluded as follows:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;The amended and restated research and collaboration agreement is accounted for as a separate contract under IFRS 15 given the group of promises to be delivered are distinct and are priced commensurate with stand-alone selling prices.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;For each of the agreements, the company identified &lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt; performance obligation under IFRS 15, for the transfer of a license combined with the performance of research and development activities. The Company concluded that the license is not capable of being distinct and is not distinct in the context of the contract. ProQR&#x2019;s services are evaluated as predominant at inception of the contract and the compounds resulting from the collaboration do not represent a series of distinct promises because they were not predetermined at the inception of the contract and can be terminated or replaced at the discretion of Lilly subject to the terms and conditions of the Collaboration agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;The transaction price of the agreement includes fixed components, consisting of an up-front fee and an equity component (premium or discount). The agreement also contains variable parts, notably milestones, which are included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Development milestone payments to be reached during the ProQR research program will only be included to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the milestones is subsequently resolved. Sales-based milestones and sales-based royalties will be included as the underlying sales occur.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Initially, the Company recognizes revenue over time, using an input method that estimates the satisfaction of the performance obligation as the percentage of labor hours incurred compared to the total estimated labor hours required to complete the promised services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;After the handover of a compound to Lilly:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;The variable consideration for development milestones to be reached during the Lilly R&amp;amp;D activities is linked to a separable right to use the license which comes into existence for each successful compound transferred to Lilly. This license is a separate performance obligation and revenue will be recognized at a point in time when the development milestone for a license is achieved and the variable constraint is resolved. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;The variable consideration for commercial milestones is linked to a separable right to use the license which comes into existence for each successful compound transferred to Lilly. This license is a separate performance obligation and will be recognized at a point in time when the commercial milestone for a license is achieved and the variable constraint is resolved. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-style:normal;font-weight:normal;"&gt;For sales-based royalties, the license is the predominant item to which the royalty relates. The sales-based royalties will be recognized after the handover of the compound to Lilly (after completion of the initial performance obligation) and once the respective sale level occurs. &#160; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;During the nine month period ended September 30, 2025, the Company reached milestones amounting to $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;2,000,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (&#x20ac; &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;1,781,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;) under the agreement, which was added to the transaction price and recognized partially as revenue during the nine month period ended September 30, 2025.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <prqr:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_1_2021_To_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_m4ViI6b7i0S1NobB07mbHQ"
      decimals="INF"
      id="Narr_Wo5xoSEZBEKdHJtr9OZ3yA"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">3989976</prqr:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_9_1_2021_To_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_m4ViI6b7i0S1NobB07mbHQ"
      decimals="0"
      id="Narr_NgIapWR0nEi525SfM3bkRw"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">30000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_9_1_2021_To_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_m4ViI6b7i0S1NobB07mbHQ"
      decimals="-3"
      id="Narr_L8qhLvtr1E6PCoaPd2ekYg"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">25270000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities
      contextRef="As_Of_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_hWA0MWK6lUqB0UHEeVamnw"
      decimals="-3"
      id="Narr_Xt8xNRYywUSmjTWnPAxtpg"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">2429000</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities
      contextRef="As_Of_9_30_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_hWA0MWK6lUqB0UHEeVamnw"
      decimals="-3"
      id="Narr_x25xtSRj-Uad8_I8xky5Ew"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">2047000</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices
      contextRef="Duration_10_1_2021_To_10_31_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GmQU-y9rwk-z-77kvpEtVw"
      decimals="-3"
      id="Narr_34lOyA_BsEWsPhppx9HLnA"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">20000000</ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices>
    <ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices
      contextRef="Duration_10_1_2021_To_10_31_2021_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GmQU-y9rwk-z-77kvpEtVw"
      decimals="-3"
      id="Narr_wuPYktp-dUO9HHH7ps_rvQ"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">16849000</ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices>
    <prqr:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g"
      decimals="INF"
      id="Narr_5AdN7w_p1UimFpNPHKo3hQ"
      unitRef="Unit_Standard_shares_h2ALirYfWEGQgGVg-g5pbA">9381586</prqr:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g"
      decimals="-3"
      id="Narr_1u4QR43Xfk-gwBDdlEweKQ"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">15000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g"
      decimals="-3"
      id="Narr_6Pg85B_yr0KKLMGnwiwdKw"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">14122000</ifrs-full:ProceedsFromIssuingShares>
    <prqr:DiscountOnIssueOfShares
      contextRef="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g"
      decimals="-3"
      id="Narr_oCLhZz3-jkuklcw7b4lQHQ"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">480000</prqr:DiscountOnIssueOfShares>
    <prqr:DiscountOnIssueOfShares
      contextRef="Duration_12_1_2022_To_12_31_2022_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_GEOsj1VzTEONJYUNO32Z7g"
      decimals="-3"
      id="Narr_CZUAuQjwvk22VCkI9jImYA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">451000</prqr:DiscountOnIssueOfShares>
    <ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices
      contextRef="Duration_2_1_2023_To_2_28_2023_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_ifrs-full_ProductsAndServicesAxis_prqr_MilestonePaymentsMember_8ueA1NVJtEa4bfujUxBP3g"
      decimals="-3"
      id="Narr_oj-Edp89uECsk0Nv1XsAUA"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">60000000</ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices>
    <ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices
      contextRef="Duration_2_1_2023_To_2_28_2023_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_ifrs-full_ProductsAndServicesAxis_prqr_MilestonePaymentsMember_8ueA1NVJtEa4bfujUxBP3g"
      decimals="-3"
      id="Narr_KdZjxwqm5kCXQ0LuX_3nTw"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">56412000</ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices>
    <prqr:AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership
      contextRef="As_Of_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_z_wMRuiDMEqEinzBTRrmJA"
      decimals="-3"
      id="Narr_9bsWcbRyq0S7I1QG6PHAYA"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">50000000</prqr:AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership>
    <prqr:NumberOfPerformanceObligationsInCollaborationAgreement
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_iVCbzNhSAkCnatzraPCD8A"
      decimals="INF"
      id="Narr_FdrWjPocPEq8gxjHxFGIfg"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">1</prqr:NumberOfPerformanceObligationsInCollaborationAgreement>
    <prqr:ValueOfMilestonesReachedDuringPeriod
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_iVCbzNhSAkCnatzraPCD8A"
      decimals="0"
      id="Narr_DvIe6MLwK0WiiNytDTFkkw"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">2000000</prqr:ValueOfMilestonesReachedDuringPeriod>
    <prqr:ValueOfMilestonesReachedDuringPeriod
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_EliLillyAndCompanyMember_iVCbzNhSAkCnatzraPCD8A"
      decimals="-3"
      id="Narr_g2K4h_Be0kijqu0ZG3aoDA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1781000</prqr:ValueOfMilestonesReachedDuringPeriod>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_wwGOATHyvk2mVmhBljkd_w">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;14. Other Income&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.34%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;Nine month period &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.34%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-family:'Open Sans';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#ffffff;font-family:'Open Sans';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;&#x20ac;1,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;&#x20ac;1,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Grant income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;413 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;504 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.69%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;413 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;504 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;line-height:1.55;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;In January, 2024, the Company entered into an agreement with the RSRT that focuses on the design and development of editing oligonucleotides (&#x201c;EONs&#x201d;) using the Company&#x2019;s Axiomer technology platform targeting the transcription factor Methyl CpG binding protein 2 (&#x201c;MECP2&#x201d;) and correcting mutations of interest. Under the agreement, RSRT awarded the Company up to &#x20ac;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;&#160;1,015,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; as a research grant for the initial phase of the project that was received during 2024. Of this grant &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;504,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; was recognized as Other Income during the nine month period ended September 30, 2024, and &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;413,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; recognized as Other Income for the nine month period ended September 30, 2025. The balance was recorded as Deferred Income in 2024 and 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;In December 2024, the Company expanded partnership with RSRT to include an additional $&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;8,150,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; in funding from the RSRT to support the advancement of the selected candidates into clinical trials. As at September 30, 2025 &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;no&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; amounts have been received under this agreement and the work has not yet commenced.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Grants are recognized in other income in the same period in which the related R&amp;amp;D costs are recognized.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory>
    <prqr:DisclosureOfOtherIncomeTableTextBlockExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_-jqs_D44rkacgzYirbNi7g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.34%;background:#ffffff;border-top:1px solid #00aaa1;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;Nine month period &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.34%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-family:'Open Sans';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#ffffff;font-family:'Open Sans';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #464646;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:9pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;&#x20ac;1,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;i style="color:#262626;font-family:'Open Sans';font-style:italic;"&gt;&#x20ac;1,000&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.69%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';"&gt;Grant income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;413 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;504 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.69%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.89%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;413 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:12.91%;background:#ffffff;border-bottom:1.5pt solid #22a49b;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="color:#262626;font-family:'Open Sans';font-weight:bold;"&gt;504 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</prqr:DisclosureOfOtherIncomeTableTextBlockExplanatory>
    <prqr:IfrsRevenueFromGrants
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_8mrcAopUCUOkw3GvMGC1TQ_6_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">413000</prqr:IfrsRevenueFromGrants>
    <prqr:IfrsRevenueFromGrants
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_hiC1asDPVUWYP8zNbGBPSg_6_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">504000</prqr:IfrsRevenueFromGrants>
    <ifrs-full:OtherIncome
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Tc_L4yBsUrBcESPvjgnzkrGug_7_2"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">413000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Tc_lQiDjFZ6VEamixM29S5dkw_7_4"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">504000</ifrs-full:OtherIncome>
    <prqr:MaximumGrantReceivableForInitialPhaseOfProject
      contextRef="As_Of_1_31_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_2f19mTxVb0akP73Sa_oSQg"
      decimals="-3"
      id="Narr_Pd2JSR1Y90Ohn-8uIu150w"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">1015000</prqr:MaximumGrantReceivableForInitialPhaseOfProject>
    <prqr:IfrsRevenueFromGrants
      contextRef="Duration_1_1_2024_To_9_30_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_xZ1UKhJoMEuxAabw7b7dlQ"
      decimals="-3"
      id="Narr_G7v4UxFhnUyZ5x2IEnhIWA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">504000</prqr:IfrsRevenueFromGrants>
    <prqr:IfrsRevenueFromGrants
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_0tkeXgS6dkGzbdukDKq5tg"
      decimals="-3"
      id="Narr_NspaL1-THU6-a-e8FyMsTA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">413000</prqr:IfrsRevenueFromGrants>
    <prqr:MaximumGrantReceivableForAdditionalPhaseOfProject
      contextRef="As_Of_12_31_2024_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_rPv_1PsZlkyKXSb6IKaW-A"
      decimals="-3"
      id="Narr_grHHc4_3NkyGfwyi9vDA8A"
      unitRef="Unit_Standard_USD_hAE_x2CczUeEXAIEkvofUg">8150000</prqr:MaximumGrantReceivableForAdditionalPhaseOfProject>
    <ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices
      contextRef="Duration_1_1_2025_To_9_30_2025_ifrs-full_CounterpartiesAxis_prqr_RettSyndromeResearchTrustMember_0tkeXgS6dkGzbdukDKq5tg"
      decimals="-3"
      id="Narr_WF5G3671_kq0FlZ5ryggGw"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">0</ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices>
    <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_ogn-uM3jPEG91xi1hm-Qxw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;15. Research and Development Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Research and development costs amount to &#x20ac; &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;34,811,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; for the nine month period ended September 30, 2025 (nine month period ended September 30, 2024: &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;25,745,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;) and are comprised of allocated employee costs including share-based payments, the costs of materials and laboratory consumables, outsourced activities, license and intellectual property costs and other allocated costs. Research and development costs increased compared to the same period in the prior year, mainly due to the Company&#x2019;s increased outsourced research and development activities in the nine month period of 2025 and increased full time employee equivalents (&#x201c;FTE&#x201d;).&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Narr_T6ADJSRJvECvtgkQ6Z8upw"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">34811000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Narr_L0e6-2Xq-ki6z8zyH9MMLQ"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">25745000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_A8iuq0q9aUSp8CRhvNiRog">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;16. General and Administrative Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;General and administrative costs amount to &#x20ac; &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;11,169,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; for the nine month period ended September 30, 2025 (nine month period ended September 30, 2024: &#x20ac;&#160;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;9,748,000&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;).&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      decimals="-3"
      id="Narr__9p3mzCUJUW6pDAysBJWuQ"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">11169000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_9m3_BiqAV0WiZMcZDtaC5g"
      decimals="-3"
      id="Narr__yVvzMKGkU-TvvRSQe11FA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">9748000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_Iw4TdkoweEOFGXdS8vm_LA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;17. Investments in Financial Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Investment in financial assets consist of the Company&#x2019;s investment in Phoenicis Therapeutics Inc. (&#x201c;Phoenicis&#x201d;) and Yarrow Biotechnology Inc. (&#x201c;Yarrow&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;ProQR holds a &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;3.9%&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; interest in Phoenicis. As at September 30, 2025, the investment amounts to &#x20ac;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; nil&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (December 31, 2024: &#x20ac;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; nil&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;). Phoenicis discontinued its research and development operational activities during the quarter ended September 30, 2024. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;ProQR holds a &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;5.1%&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; interest in Yarrow. As at September 30, 2025, the fair value of the Yarrow financial asset amounted to &#x20ac;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; nil&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; (December 31, 2024: &#x20ac;&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; nil&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;).&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <prqr:ProportionOfOwnershipInterest
      contextRef="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_yg5IGweIK0qeV0bYXpRQJg"
      decimals="3"
      id="Narr_GDt9Ptcu_UC_Dzuf7EH1Dg"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">0.039</prqr:ProportionOfOwnershipInterest>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_yg5IGweIK0qeV0bYXpRQJg"
      decimals="-3"
      id="Narr_vZgd1BBmBky1npntl0K-Ew"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">0</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="As_Of_12_31_2024_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_PhoenicisTherapeuticsIncMember_Px873arFI0yxw9TbKLJcIw"
      decimals="-3"
      id="Narr_JFmMboMN-kO74Ap3CYzi5w"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">0</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <prqr:ProportionOfOwnershipInterest
      contextRef="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_YarrowBiotechnologyMember_9ABsPfcrBEWgLl8UM2SqAg"
      decimals="3"
      id="Narr_nVhn6JQfF0GkeSg8Z54jYA"
      unitRef="Unit_Standard_pure_8dkqfNUbwkWRzkiJXrhE9Q">0.051</prqr:ProportionOfOwnershipInterest>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="As_Of_9_30_2025_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_YarrowBiotechnologyMember_9ABsPfcrBEWgLl8UM2SqAg"
      decimals="-3"
      id="Narr_gvVuCS3ViEKm1W4XveuSQA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">0</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="As_Of_12_31_2024_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_prqr_YarrowBiotechnologyMember_16WLvw49kkCNj0VZA6LAug"
      decimals="-3"
      id="Narr_8lfTSC9R_kSpnOI4QlF50g"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">0</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_6-OOO6rwjUqCmcsL9s4Cfw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;18&lt;/b&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The current income tax liability amounts to &#x20ac; &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;nil&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt; at September 30, 2025 (December 31, 2024: &#x20ac; &lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;nil&lt;/span&gt;&lt;span style="font-family:'Open Sans';"&gt;). No significant temporary differences exist between accounting and tax results. Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which are uncertain. Accordingly, the Company has not yet recognized any deferred tax asset related to operating losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;Tax losses in the Netherlands may be carried forward indefinitely. However, the offset of losses will be limited in a given year against the first &#x20ac; 1 million of taxable profit. For taxable profit in excess of this amount, losses may only be offset up to 50% of this excess. In addition, unused non-deductible interest expenses may be carried forward indefinitely. However, the offset will be limited in a given year against the higher of 20% of adjusted taxable profit or &#x20ac; 1.0 million of interest income.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="As_Of_9_30_2025_qUZ0DefrcEyXq-vGYUYu8w"
      decimals="-3"
      id="Narr_lANLZen4u0ir-NUGFxI-QA"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">0</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="As_Of_12_31_2024_62krnWreqkWWwVia3DxOpA"
      decimals="-3"
      id="Narr_dEowfBrv4E-HTsJnITmTUw"
      unitRef="Unit_Standard_EUR_Wo1r15ChuUOVqHZuOPjfWg">0</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_uaVzvgbVSEqM-9ULQjgPUg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;19. Related-Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;The Company does not have any transactions with related parties other than compensation to its Board members.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="Duration_1_1_2025_To_9_30_2025_ddeKcoSv_0q5ihFhKM1Whw"
      id="Tb_zyHFT-3H_kOjnmH5Nl52Ow">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-family:'Open Sans';font-weight:bold;"&gt;20. Events After Balance Sheet Date&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Open Sans';"&gt;None.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_gDmQDSG3yE2YgRihCX1JZQ_38_8"
          xlink:label="Tc_gDmQDSG3yE2YgRihCX1JZQ_38_8"
          xlink:type="locator"/>
        <link:footnote id="_6bcb422b_dd88_4484_a93e_66423de002bd" xlink:label="_6bcb422b_dd88_4484_a93e_66423de002bd" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:normal;font-weight:normal;">For these periods the potential exercise of share options is not included in the diluted earnings per share as the Company was loss-making. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal</xhtml:span><xhtml:span style="color:#262626;font-family:'Open Sans';font-size:8pt;font-style:normal;font-weight:normal;">. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gDmQDSG3yE2YgRihCX1JZQ_38_8"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_pJYcw-P9VUK36cFJsz2OXw_38_4"
          xlink:label="Tc_pJYcw-P9VUK36cFJsz2OXw_38_4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_pJYcw-P9VUK36cFJsz2OXw_38_4"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_s4p3Rj1sNEei8rE1UMUcwg_38_6"
          xlink:label="Tc_s4p3Rj1sNEei8rE1UMUcwg_38_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_s4p3Rj1sNEei8rE1UMUcwg_38_6"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_TX_OmuqLh0S8PKxDqpOTOA_38_2"
          xlink:label="Tc_TX_OmuqLh0S8PKxDqpOTOA_38_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_TX_OmuqLh0S8PKxDqpOTOA_38_2"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_s9xCNhJU7UyUXkbd8wzU2A_39_8"
          xlink:label="Tc_s9xCNhJU7UyUXkbd8wzU2A_39_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_s9xCNhJU7UyUXkbd8wzU2A_39_8"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_6LEmXJeSm0qw3i_R36LS0w_39_4"
          xlink:label="Tc_6LEmXJeSm0qw3i_R36LS0w_39_4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_6LEmXJeSm0qw3i_R36LS0w_39_4"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_rAltVSr5REaA_gZkXcxqmw_39_6"
          xlink:label="Tc_rAltVSr5REaA_gZkXcxqmw_39_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_rAltVSr5REaA_gZkXcxqmw_39_6"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_3xdgtgdroEqBdaprFuW2zw_39_2"
          xlink:label="Tc_3xdgtgdroEqBdaprFuW2zw_39_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_3xdgtgdroEqBdaprFuW2zw_39_2"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_8_yNxwVA80GtQtAVy9Qlig_35_8"
          xlink:label="Tc_8_yNxwVA80GtQtAVy9Qlig_35_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_8_yNxwVA80GtQtAVy9Qlig_35_8"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_dz8HPvqgH0SMB3BaCxeXZg_35_4"
          xlink:label="Tc_dz8HPvqgH0SMB3BaCxeXZg_35_4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_dz8HPvqgH0SMB3BaCxeXZg_35_4"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_6mdFNphE1kOtUlwBgZLI_w_35_6"
          xlink:label="Tc_6mdFNphE1kOtUlwBgZLI_w_35_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_6mdFNphE1kOtUlwBgZLI_w_35_6"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_4OyBA5NKzE-knRZJUAf3Dg_35_2"
          xlink:label="Tc_4OyBA5NKzE-knRZJUAf3Dg_35_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_4OyBA5NKzE-knRZJUAf3Dg_35_2"
          xlink:to="_6bcb422b_dd88_4484_a93e_66423de002bd"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
